{"docstore/data": {"9d4fc53e-3c13-46e0-9782-a90f84a5c1ce": {"__data__": {"id_": "9d4fc53e-3c13-46e0-9782-a90f84a5c1ce", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.   (MCK ) \nQ1 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "699dc1f6-bb15-4f76-9596-032d9c39cc28", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c857b8c4d720a605b8419e81773259c2b65c535cec0df1fbe649cf86aaaf205a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77136ac7-589c-443f-96f9-408ba599318b", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.   (MCK ) \nQ1 2023 Earnings Call    ", "original_text": "(MCK ) \nQ1 2023 Earnings Call    "}, "hash": "2445477bf281fc54bd0015648ec10e4aa2f97e5283cc5cf135b36a5fb0e29b11", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77136ac7-589c-443f-96f9-408ba599318b": {"__data__": {"id_": "77136ac7-589c-443f-96f9-408ba599318b", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.   (MCK ) \nQ1 2023 Earnings Call    ", "original_text": "(MCK ) \nQ1 2023 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "699dc1f6-bb15-4f76-9596-032d9c39cc28", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c857b8c4d720a605b8419e81773259c2b65c535cec0df1fbe649cf86aaaf205a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d4fc53e-3c13-46e0-9782-a90f84a5c1ce", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.   (MCK ) \nQ1 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae3630d726d51e2db068ab7e7c61008a29b4bd4fd05b3da4038ea33d8f31c132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf1f2fd1-4861-44b9-bbef-b7590a1e9984", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  "}, "hash": "57fe2de0d94720c64056ed031dc5cdc84ed551ca317ade5cbd801fc6f79f8a08", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf1f2fd1-4861-44b9-bbef-b7590a1e9984": {"__data__": {"id_": "cf1f2fd1-4861-44b9-bbef-b7590a1e9984", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77136ac7-589c-443f-96f9-408ba599318b", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.   (MCK ) \nQ1 2023 Earnings Call    ", "original_text": "(MCK ) \nQ1 2023 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03109078aa3cba534280368282026cd94784b39cbc9e137c1f6d9e6fefb9bcb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd3740d-040a-4bda-b9f5-045f9755491a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "8878b849119ff0a0eba4b369b67d59dffaf96a2c23f2fe0135358119bcb6eb86", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd3740d-040a-4bda-b9f5-045f9755491a": {"__data__": {"id_": "cbd3740d-040a-4bda-b9f5-045f9755491a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf1f2fd1-4861-44b9-bbef-b7590a1e9984", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "052feb0c4fb96a647d0c427d7065f4abea57610744e27025eafe8da66cecd367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9485fb9e-8ec8-420d-a88d-6c7cd1a5bf9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "a3b79e0731b39d53a65f1d408a97bca7236bf297db0fe1a0bc0c54de1c92f145", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9485fb9e-8ec8-420d-a88d-6c7cd1a5bf9f": {"__data__": {"id_": "9485fb9e-8ec8-420d-a88d-6c7cd1a5bf9f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd3740d-040a-4bda-b9f5-045f9755491a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9370f6eb4fb44c5ed1f1a667fffe2e338c1f376314142070853358e22978af67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9147c473-bbdd-4656-a290-0f8f9cf6897f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "f9bfe9662e698121a3f1796b632a6ad744dfa286c2a0122f33f01d3da8abc235", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 341, "end_char_idx": 428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9147c473-bbdd-4656-a290-0f8f9cf6897f": {"__data__": {"id_": "9147c473-bbdd-4656-a290-0f8f9cf6897f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9485fb9e-8ec8-420d-a88d-6c7cd1a5bf9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "105c5a314b2f5a4dc07d52e2d517e259c56caef6c354cd7850c5b88069cbc8e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e348e8c-4782-4360-bb9f-6feba1216947", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . "}, "hash": "393f8a66dfc95f28fd60c5899c7bfc92e55e120fd2a34dde33c5bb2c762da44e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 428, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e348e8c-4782-4360-bb9f-6feba1216947": {"__data__": {"id_": "5e348e8c-4782-4360-bb9f-6feba1216947", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9147c473-bbdd-4656-a290-0f8f9cf6897f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "466a2d701bb9765907e6e5e28c439316eac3ab4a2129c2c0380c9cb9a6a3f2b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93dd1fe7-5ee6-4d9a-b7db-e73e08a3ca2f", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. ", "original_text": "Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "1ce41b8f8af68e76368c2558dfb49f919d2938f1de4d44f2f8a974647756ecad", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . ", "start_char_idx": 825, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93dd1fe7-5ee6-4d9a-b7db-e73e08a3ca2f": {"__data__": {"id_": "93dd1fe7-5ee6-4d9a-b7db-e73e08a3ca2f", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. ", "original_text": "Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e348e8c-4782-4360-bb9f-6feba1216947", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R . ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8af8f6014c6c8bd9f3ce6a3cff2d0ff78dcb78276fde04529f4fc0c782ef25ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ee80233-7a3d-48d1-863b-77289928fcb7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded. ", "original_text": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "bd61b0392c2e83be44296fe3cd5a3e21d2171dc2eaf8cbf17244aa647877675d", "class_name": "RelatedNodeInfo"}}, "text": "Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 938, "end_char_idx": 981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ee80233-7a3d-48d1-863b-77289928fcb7": {"__data__": {"id_": "7ee80233-7a3d-48d1-863b-77289928fcb7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded. ", "original_text": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93dd1fe7-5ee6-4d9a-b7db-e73e08a3ca2f", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. ", "original_text": "Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18214eee6d06483af7477d922bca31d4466ea552392cc10b4465e68502fe8ca3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b4430a-09df-4785-91bb-1ca7d2d97133", "node_type": "1", "metadata": {"window": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. ", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "51316c92982e0701a17914884bb76c6db708886cf97937d44b09fd8294bb57f5", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 981, "end_char_idx": 1094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b4430a-09df-4785-91bb-1ca7d2d97133": {"__data__": {"id_": "68b4430a-09df-4785-91bb-1ca7d2d97133", "embedding": null, "metadata": {"window": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. ", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ee80233-7a3d-48d1-863b-77289928fcb7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded. ", "original_text": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "316d9272b8b9932def2f03d57c43694ce4b25878b0ca65ca74c5a4e3e8290381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab165856-0427-4286-bcaf-b129280bcf6b", "node_type": "1", "metadata": {"window": "Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n ", "original_text": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. "}, "hash": "d1fa08467776f110577cb83983ac10b264c47ae7bb842b589603023bd8ac4ae9", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1094, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab165856-0427-4286-bcaf-b129280bcf6b": {"__data__": {"id_": "ab165856-0427-4286-bcaf-b129280bcf6b", "embedding": null, "metadata": {"window": "Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n ", "original_text": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b4430a-09df-4785-91bb-1ca7d2d97133", "node_type": "1", "metadata": {"window": "Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric Percher  \nAnalyst, Nephron Research LLC  \nRicky R .  Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. ", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f316d5e86943036b0a049bc9778b306e2aa713e37fa66ea41333eb7aa671249c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7fc95fc-df68-40ad-9960-8d30256d96b8", "node_type": "1", "metadata": {"window": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "original_text": "Please be advised that \ntoday's conference is being recorded. "}, "hash": "34c22e678597e1a716c75ff33dac31d101c4486294d8896ba02da6509a8fe105", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. ", "start_char_idx": 1131, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7fc95fc-df68-40ad-9960-8d30256d96b8": {"__data__": {"id_": "c7fc95fc-df68-40ad-9960-8d30256d96b8", "embedding": null, "metadata": {"window": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "original_text": "Please be advised that \ntoday's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab165856-0427-4286-bcaf-b129280bcf6b", "node_type": "1", "metadata": {"window": "Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n ", "original_text": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08cba5b5a82955401b3bdba81860941242d5100823723ffcec7a8fe2b686c485", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80fcf69b-e66b-48b3-8a84-0324ff9c947a", "node_type": "1", "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. ", "original_text": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. "}, "hash": "5a404df573d8521ed242673ef612ac0b30edc7c581c3fc1775ea8781c6500d84", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that \ntoday's conference is being recorded. ", "start_char_idx": 1575, "end_char_idx": 1637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80fcf69b-e66b-48b3-8a84-0324ff9c947a": {"__data__": {"id_": "80fcf69b-e66b-48b3-8a84-0324ff9c947a", "embedding": null, "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. ", "original_text": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7fc95fc-df68-40ad-9960-8d30256d96b8", "node_type": "1", "metadata": {"window": "LLC  Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "original_text": "Please be advised that \ntoday's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6ae263c2a1d80f6ff75c04b728605c00666362df59d616eb0ad8c8c020d4bea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed2e32d-a66c-4510-ac2c-91fabe5509f8", "node_type": "1", "metadata": {"window": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "Please go ahead.  \n "}, "hash": "81b53768fc35a28a134d66ecaf0d04327ab20fc7125827e9a067b47b7d3f34db", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. ", "start_char_idx": 1637, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed2e32d-a66c-4510-ac2c-91fabe5509f8": {"__data__": {"id_": "fed2e32d-a66c-4510-ac2c-91fabe5509f8", "embedding": null, "metadata": {"window": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80fcf69b-e66b-48b3-8a84-0324ff9c947a", "node_type": "1", "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. ", "original_text": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d73a7c097c777cd7446459f5ea66e30999b9f7e71592b631e2e4abbe7a98e17d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f611f65-a3e7-475b-b1da-27785f85f965", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. "}, "hash": "a10a3c07e5a482cf69fb1837e1fc2b02e795915fe5a0083252e774af01c7c6d9", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1735, "end_char_idx": 1755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f611f65-a3e7-475b-b1da-27785f85f965": {"__data__": {"id_": "3f611f65-a3e7-475b-b1da-27785f85f965", "embedding": null, "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed2e32d-a66c-4510-ac2c-91fabe5509f8", "node_type": "1", "metadata": {"window": "LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's First Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "280b8a43ff6165e76afc5bb6e7339e261ada084e0d8bda28c4ac88871c626a52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdb043cc-acae-4bf3-ae61-1002785768f5", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. "}, "hash": "7157d760e702d37c02e6d7a174d0ee18ada99e49d31936750c3b25e5a4097ff8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "start_char_idx": 1755, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdb043cc-acae-4bf3-ae61-1002785768f5": {"__data__": {"id_": "bdb043cc-acae-4bf3-ae61-1002785768f5", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f611f65-a3e7-475b-b1da-27785f85f965", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cea1fbf992d2a684b9ad330b2936bf2d0e34cb6005c7f5d2867a9fb585da7285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1ef161e-f04e-4b59-888a-b3fc1322f02a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "7970e0e64cfae61fa2f561d4cf7b54dacb71282b50af6c184e742f5ecb633337", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. ", "start_char_idx": 2111, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1ef161e-f04e-4b59-888a-b3fc1322f02a": {"__data__": {"id_": "e1ef161e-f04e-4b59-888a-b3fc1322f02a", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdb043cc-acae-4bf3-ae61-1002785768f5", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel  Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0761c078c733f69dfa2fe9f91e0c9784d71f0833beb3e6fab0a8e812f338499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399256c1-cb60-4c23-88fa-0463a6b8a707", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "f14df5a550a23ade3231743936f51d0946b7923ba5ec3cda52551b15e6b0c08e", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 2206, "end_char_idx": 2318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399256c1-cb60-4c23-88fa-0463a6b8a707": {"__data__": {"id_": "399256c1-cb60-4c23-88fa-0463a6b8a707", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1ef161e-f04e-4b59-888a-b3fc1322f02a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4dcd3b2b337f20bf1effa0572061f7cfd596512b4b4511283ded2da2b8a276d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bf3fdae-5d3f-4b82-851b-a16f389407c4", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. "}, "hash": "379bd56513343e9b92e99e3aa5c8ed784ff17ed54aa6beb82715af0a6907db1d", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 2318, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bf3fdae-5d3f-4b82-851b-a16f389407c4": {"__data__": {"id_": "6bf3fdae-5d3f-4b82-851b-a16f389407c4", "embedding": null, "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399256c1-cb60-4c23-88fa-0463a6b8a707", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2da60aa7a07f6e3f4512a92488e8bff95f471afd1f0f3ff4a353a51a65eb7f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbc009a4-7521-48c7-ab5b-49c26eca61bf", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n"}, "hash": "2470420f1c6df907fe227b568c9c2b910bccbee3a6090d65a5935d9e02398cdc", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. ", "start_char_idx": 2419, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbc009a4-7521-48c7-ab5b-49c26eca61bf": {"__data__": {"id_": "bbc009a4-7521-48c7-ab5b-49c26eca61bf", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bf3fdae-5d3f-4b82-851b-a16f389407c4", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8a08c006b68c90b33718e4cf7353d6df3bebce41c77741f70bcd1455d867b13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8931bbfb-2721-4e70-b72d-d5e35c3692e0", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation "}, "hash": "2b82010ba15a4dfe72719a0bc746b7912b67350350dcf73a6eba5344a8423867", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "start_char_idx": 2547, "end_char_idx": 2914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8931bbfb-2721-4e70-b72d-d5e35c3692e0": {"__data__": {"id_": "8931bbfb-2721-4e70-b72d-d5e35c3692e0", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "befcd309-db1e-435f-b504-7c23466eec88", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8082c41fd30656e5430df21c3ed339bb09245ca34ebc474c576ec0fb649cb9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbc009a4-7521-48c7-ab5b-49c26eca61bf", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef992ceaa50f0f5a4a8211b47483af186e23c00c2cd3bf60d2f177cc731d27ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11f55e55-b28a-410b-90b7-0227853b6d3f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "McKesson Corp.  "}, "hash": "303ede011bc5e31d79159c69dcd7106e8696b05250cd7b9a3be8df7bf53cbb34", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "start_char_idx": 2914, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11f55e55-b28a-410b-90b7-0227853b6d3f": {"__data__": {"id_": "11f55e55-b28a-410b-90b7-0227853b6d3f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8931bbfb-2721-4e70-b72d-d5e35c3692e0", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson 's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional inf ormation concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eee8ff1aef3969693b2cecfa2bec893d572aa7676e6097c1a6ff47fc16dcc5f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19114e22-1a19-4c3d-be4f-f5e2a0bbf8c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides. "}, "hash": "7cc1a669877b51360902d4c125e99bf9dcf77e284eba9c11f7ad7409fd78d69d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19114e22-1a19-4c3d-be4f-f5e2a0bbf8c6": {"__data__": {"id_": "19114e22-1a19-4c3d-be4f-f5e2a0bbf8c6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11f55e55-b28a-410b-90b7-0227853b6d3f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1ded761053bcbf169c1871d10623fb1ac618ee95e7d73f36bb94e0f65dfb911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc403d46-426f-445a-a7f9-098ef6674364", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel. ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n"}, "hash": "81ce7c49203a5bf044b86aa265724c64fea5047aa64d73c5019e415c72c81cde", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides. ", "start_char_idx": 16, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc403d46-426f-445a-a7f9-098ef6674364": {"__data__": {"id_": "bc403d46-426f-445a-a7f9-098ef6674364", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel. ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19114e22-1a19-4c3d-be4f-f5e2a0bbf8c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca0d99845c1fb2331561b627457b357aff4191c240b3a74ae7acbdb34eec794e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e67d6c5a-170c-4c1d-9c1b-d2f241e054b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "522706e2fb5967f57dfa84f6408d62d9e8da933c5da7ad79ad6e3a00247d7690", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n", "start_char_idx": 188, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e67d6c5a-170c-4c1d-9c1b-d2f241e054b4": {"__data__": {"id_": "e67d6c5a-170c-4c1d-9c1b-d2f241e054b4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc403d46-426f-445a-a7f9-098ef6674364", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel. ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a96eabd297cd89ecd7ff6e57f625fa996b15a8388bf3f62e902388e872b424ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "837c9bf5-2e5e-4cc6-9852-6875b53b87fb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "c0027fcfad0c8fd7a72303678d7a808881657bc43d6deae571b78a4cac47f139", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 305, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "837c9bf5-2e5e-4cc6-9852-6875b53b87fb": {"__data__": {"id_": "837c9bf5-2e5e-4cc6-9852-6875b53b87fb", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e67d6c5a-170c-4c1d-9c1b-d2f241e054b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9e0bbbcc9388b3b7a1723f7a8931ee3904d0a951d9899861cca9ed7ad260fa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44af2634-1c56-4852-99bd-2d777e66cb1a", "node_type": "1", "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n", "original_text": "Thanks, Rachel. "}, "hash": "bdc99ba668fea840e15f8c6090d46cef97c989de8ceda6c7c61342e6e4dc9076", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 349, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44af2634-1c56-4852-99bd-2d777e66cb1a": {"__data__": {"id_": "44af2634-1c56-4852-99bd-2d777e66cb1a", "embedding": null, "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n", "original_text": "Thanks, Rachel. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "837c9bf5-2e5e-4cc6-9852-6875b53b87fb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9016b03c8b08bf9c7803eee88cec66612864787e5e5db36b22c3ec5e1fb57cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "185d9c6c-0e72-42dd-a86e-3f82994d4992", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. ", "original_text": "And thanks to everyone joining us on our call this afternoon.  \n \n"}, "hash": "1d53b2fbc77d8139b74cfb713f04f686b8fe4f09e578c9c8c175dc15a81c0489", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Rachel. ", "start_char_idx": 691, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "185d9c6c-0e72-42dd-a86e-3f82994d4992": {"__data__": {"id_": "185d9c6c-0e72-42dd-a86e-3f82994d4992", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. ", "original_text": "And thanks to everyone joining us on our call this afternoon.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44af2634-1c56-4852-99bd-2d777e66cb1a", "node_type": "1", "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n", "original_text": "Thanks, Rachel. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30a8092a7d1c417490a997da803dc457ace4a85bd646f80da130fca1103d919b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68514a8d-6d59-4538-a280-0785e612e1e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n", "original_text": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. "}, "hash": "315e3d0ff461d1dbdabba0945bcbfb80c2771996aa8f11d655968316f0191248", "class_name": "RelatedNodeInfo"}}, "text": "And thanks to everyone joining us on our call this afternoon.  \n \n", "start_char_idx": 707, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68514a8d-6d59-4538-a280-0785e612e1e9": {"__data__": {"id_": "68514a8d-6d59-4538-a280-0785e612e1e9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n", "original_text": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "185d9c6c-0e72-42dd-a86e-3f82994d4992", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. ", "original_text": "And thanks to everyone joining us on our call this afternoon.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70d82cd2998dd63c439afd9ac6598daead5c9853a15662db21efa02c68715557", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3db40648-6700-4b59-8e9d-c8ae7703b506", "node_type": "1", "metadata": {"window": "Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. ", "original_text": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n"}, "hash": "b232cd7c981dd2f1909783f81acf52995dbcda2301bc1901754a524d0eeebeb2", "class_name": "RelatedNodeInfo"}}, "text": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. ", "start_char_idx": 773, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3db40648-6700-4b59-8e9d-c8ae7703b506": {"__data__": {"id_": "3db40648-6700-4b59-8e9d-c8ae7703b506", "embedding": null, "metadata": {"window": "Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. ", "original_text": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68514a8d-6d59-4538-a280-0785e612e1e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n", "original_text": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "496b43b0a29ef033bac65d0936e0df273beafee046bdc3efa7eff1efdd06aaa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80f25cc6-56cf-48af-aa49-59448247f9b1", "node_type": "1", "metadata": {"window": "And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. ", "original_text": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. "}, "hash": "36334e725905a74afbb18ba4de8586607419db6af7bc0eb86e0f5becedbe819d", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n", "start_char_idx": 953, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80f25cc6-56cf-48af-aa49-59448247f9b1": {"__data__": {"id_": "80f25cc6-56cf-48af-aa49-59448247f9b1", "embedding": null, "metadata": {"window": "And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. ", "original_text": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3db40648-6700-4b59-8e9d-c8ae7703b506", "node_type": "1", "metadata": {"window": "Thanks, Rachel.  And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. ", "original_text": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26047f89d1519cd48f7cb65b93e6e99f42c03bfe7c2989963e23dff8a1ad603a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb61f033-a0d2-4a75-9af4-43d583124139", "node_type": "1", "metadata": {"window": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n", "original_text": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n"}, "hash": "b3cb95609cc5486e75ae8534f06bc0c91bb5492739f6c37ff017a3a675bd5f91", "class_name": "RelatedNodeInfo"}}, "text": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. ", "start_char_idx": 1214, "end_char_idx": 1566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb61f033-a0d2-4a75-9af4-43d583124139": {"__data__": {"id_": "fb61f033-a0d2-4a75-9af4-43d583124139", "embedding": null, "metadata": {"window": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n", "original_text": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80f25cc6-56cf-48af-aa49-59448247f9b1", "node_type": "1", "metadata": {"window": "And thanks to everyone joining us on our call this afternoon.  \n \n Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. ", "original_text": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "654e7b7b0be9e6228db114a1fa5d688d1ed682cb7140de7f64078fafd660a5ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a75a7b6c-4c88-4e17-8267-c4eff571078b", "node_type": "1", "metadata": {"window": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. ", "original_text": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. "}, "hash": "f7a0bc15da2f6429cf46416318f0abd994625ee846ee3cee142775ead7d0a304", "class_name": "RelatedNodeInfo"}}, "text": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n", "start_char_idx": 1566, "end_char_idx": 1775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a75a7b6c-4c88-4e17-8267-c4eff571078b": {"__data__": {"id_": "a75a7b6c-4c88-4e17-8267-c4eff571078b", "embedding": null, "metadata": {"window": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. ", "original_text": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb61f033-a0d2-4a75-9af4-43d583124139", "node_type": "1", "metadata": {"window": "Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue an d \nadjusted operating profit across the North American businesses.  As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n", "original_text": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15f53612ef930f17714afaa73b4aeab42fec1c8b4b14cdccfc546feaf301e8ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5b6ecec-f02e-4111-8dee-43791015d65b", "node_type": "1", "metadata": {"window": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. ", "original_text": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. "}, "hash": "21d22e18559ad1579f6b62efc6989cc5bb947641a3de15bd7e52646246967dab", "class_name": "RelatedNodeInfo"}}, "text": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. ", "start_char_idx": 1775, "end_char_idx": 1950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5b6ecec-f02e-4111-8dee-43791015d65b": {"__data__": {"id_": "e5b6ecec-f02e-4111-8dee-43791015d65b", "embedding": null, "metadata": {"window": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. ", "original_text": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a75a7b6c-4c88-4e17-8267-c4eff571078b", "node_type": "1", "metadata": {"window": "As a result of our first quarter performance and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2023 \nadjusted earnings per diluted s hare from $22.90 to $23.60 to a new range of $23.95 to $24.65.  \n \n Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. ", "original_text": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c32e6a2e17683a99b7a27ce5742fd29d45db7384eb6839df3b2efc486664ba22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d547a3b3-37ed-430e-a3ed-0652f7de5987", "node_type": "1", "metadata": {"window": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n", "original_text": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n"}, "hash": "52af137e8c539d34cae2f1c039d72b87806cf4c45bec3cd08da88c6778b2cc93", "class_name": "RelatedNodeInfo"}}, "text": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. ", "start_char_idx": 1950, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d547a3b3-37ed-430e-a3ed-0652f7de5987": {"__data__": {"id_": "d547a3b3-37ed-430e-a3ed-0652f7de5987", "embedding": null, "metadata": {"window": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n", "original_text": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5b6ecec-f02e-4111-8dee-43791015d65b", "node_type": "1", "metadata": {"window": "Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, \nstreamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what \nunderpin our fiscal 2023 outlook and our long -term growth framework, so I wanted to center my remarks today \naround those themes.  And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. ", "original_text": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f55a5b5849b9b24f41e5656a7d34bb1982e4de2280763e998e8391667c81b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6123132d-dd7e-4933-b9ee-912cc0d1a9c0", "node_type": "1", "metadata": {"window": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. ", "original_text": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. "}, "hash": "b4ff647b696938d64929cf70c9f9fda6b8b97515bd40122686602ed0b53e97f4", "class_name": "RelatedNodeInfo"}}, "text": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n", "start_char_idx": 2068, "end_char_idx": 2253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6123132d-dd7e-4933-b9ee-912cc0d1a9c0": {"__data__": {"id_": "6123132d-dd7e-4933-b9ee-912cc0d1a9c0", "embedding": null, "metadata": {"window": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. ", "original_text": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d547a3b3-37ed-430e-a3ed-0652f7de5987", "node_type": "1", "metadata": {"window": "And I thought I would start maybe with a highlight of the progress we've made against our \ncompany pr iorities, and then I will wrap up with a few brief comments on the performance in the business itself.  \n \n Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n", "original_text": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "454a6e97f7eec6b4e076ec8275a8fa0bb0d7fe273d1edbd696ccd10316930cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ba592a0-2f9d-459c-b59b-424118ac9456", "node_type": "1", "metadata": {"window": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n", "original_text": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. "}, "hash": "67c164819315ee13f11fc39f2a9c3f91df4b99e92b20931fe79b92787c6a9c93", "class_name": "RelatedNodeInfo"}}, "text": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. ", "start_char_idx": 2253, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ba592a0-2f9d-459c-b59b-424118ac9456": {"__data__": {"id_": "7ba592a0-2f9d-459c-b59b-424118ac9456", "embedding": null, "metadata": {"window": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n", "original_text": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6123132d-dd7e-4933-b9ee-912cc0d1a9c0", "node_type": "1", "metadata": {"window": "Foundational to our company, foundational to our company's history, quite frankly, and our strategy, are really the \ncore Pharmaceutical and Medical Dist ribution businesses.  As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. ", "original_text": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ce2d361e04c485e4298df919bfc3b1b2a138e1278728b8fe11d470131c86e7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a5523cb-3158-4c3b-ae53-09e230663013", "node_type": "1", "metadata": {"window": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n", "original_text": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n"}, "hash": "8d7800c5f429ca3a86ea5359d63ae8915ce4aedbcdebee399a014fc062af17aa", "class_name": "RelatedNodeInfo"}}, "text": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. ", "start_char_idx": 2403, "end_char_idx": 2551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a5523cb-3158-4c3b-ae53-09e230663013": {"__data__": {"id_": "1a5523cb-3158-4c3b-ae53-09e230663013", "embedding": null, "metadata": {"window": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n", "original_text": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ba592a0-2f9d-459c-b59b-424118ac9456", "node_type": "1", "metadata": {"window": "As we expand the reach of our services, we remain \nfocused on generating sustainable growth in these core businesses.  Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n", "original_text": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ab2e9e719088951c973e041825417e55ee5d07b1cd9af46f1135913ea3963c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f35672-2e6f-42c0-b433-69df81107a10", "node_type": "1", "metadata": {"window": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. ", "original_text": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. "}, "hash": "2a23e7dafe16f2da3aba480163b5abe41d45a59ff00280af624255e6f34a5e7a", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n", "start_char_idx": 2551, "end_char_idx": 2649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f35672-2e6f-42c0-b433-69df81107a10": {"__data__": {"id_": "65f35672-2e6f-42c0-b433-69df81107a10", "embedding": null, "metadata": {"window": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. ", "original_text": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a5523cb-3158-4c3b-ae53-09e230663013", "node_type": "1", "metadata": {"window": "Our operational excellence and ability to \nleverage our scale with global suppliers is one of the many reasons why McKe sson continues to be a partner of \nchoice for our customers.  \n \n Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n", "original_text": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b331b5c1349f5bdff01c1ec7248658c808935a9e591584f2d5dc3d54f15d2380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "533b090b-7cc2-44ac-b4a6-6127c9c19858", "node_type": "1", "metadata": {"window": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n", "original_text": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n"}, "hash": "1f135ee25505cd2686015928f6b699960d817a00b1c67438197ad919f414791c", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. ", "start_char_idx": 2649, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "533b090b-7cc2-44ac-b4a6-6127c9c19858": {"__data__": {"id_": "533b090b-7cc2-44ac-b4a6-6127c9c19858", "embedding": null, "metadata": {"window": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n", "original_text": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f35672-2e6f-42c0-b433-69df81107a10", "node_type": "1", "metadata": {"window": "Over the past two years, you're well aware we've been working closely with the US government to distribute the \nCOVID -19 vaccine and ancillary kits.  As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. ", "original_text": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e46f4db421e57e3606bb333ef85b85ca3062855d9de45cb07a59f65645238086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63ac8c72-5510-4295-81c2-2bd1344ed2f2", "node_type": "1", "metadata": {"window": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n"}, "hash": "ce042a2d378acf246772b427552d4486c643a6d0e7134ef600d72369d83fbc47", "class_name": "RelatedNodeInfo"}}, "text": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n", "start_char_idx": 2815, "end_char_idx": 3025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63ac8c72-5510-4295-81c2-2bd1344ed2f2": {"__data__": {"id_": "63ac8c72-5510-4295-81c2-2bd1344ed2f2", "embedding": null, "metadata": {"window": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "533b090b-7cc2-44ac-b4a6-6127c9c19858", "node_type": "1", "metadata": {"window": "As requested by the US government, our contract  to serve as the \ncentralized distributor for COVID -19 vaccines was extended through July of 2023.  Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n", "original_text": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6699ad8fd52e5d7c61ddbb142534e3282441dd0be2cfcebc5fe21a1b111729e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a84099e-db3b-4dc1-92c7-46aec4b80118", "node_type": "1", "metadata": {"window": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. "}, "hash": "32d3cd956187898684746b8b2bd78aad060049a37e66adafb67bb26a04e10c6c", "class_name": "RelatedNodeInfo"}}, "text": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n", "start_char_idx": 3025, "end_char_idx": 3256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a84099e-db3b-4dc1-92c7-46aec4b80118": {"__data__": {"id_": "8a84099e-db3b-4dc1-92c7-46aec4b80118", "embedding": null, "metadata": {"window": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63ac8c72-5510-4295-81c2-2bd1344ed2f2", "node_type": "1", "metadata": {"window": "Similarly, the contract for \nancillary kits and storage was extended through January of 2023.  \n \n We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3294c1e4db0c9c99a1d9112edbde3c03b212aaa1bea21f2859f9402c7579467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9dc5178-5548-46a3-8da3-153882d73f23", "node_type": "1", "metadata": {"window": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n"}, "hash": "215fae3631720f87ff08ac2ce80eeaeecca8b2ce5f818d9f61bfe4cbb4e35c5b", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. ", "start_char_idx": 3256, "end_char_idx": 3441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9dc5178-5548-46a3-8da3-153882d73f23": {"__data__": {"id_": "d9dc5178-5548-46a3-8da3-153882d73f23", "embedding": null, "metadata": {"window": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a84099e-db3b-4dc1-92c7-46aec4b80118", "node_type": "1", "metadata": {"window": "We continue to be honored and privileged to be able to leverage our distribution scale and expertise and to \ncontinue to support this important public health effort.  Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute. ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78513922d96aaa23957fac361ebf5c29d010ca61287a649d948f20ab4f1f87da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68a624e7-2e93-479e-a194-bf74799a2af4", "node_type": "1", "metadata": {"window": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical "}, "hash": "389feda4466b368f5ce47f43a363229d02260c48572eb1a252eb2baf102ca836", "class_name": "RelatedNodeInfo"}}, "text": "This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n", "start_char_idx": 3441, "end_char_idx": 3614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68a624e7-2e93-479e-a194-bf74799a2af4": {"__data__": {"id_": "68a624e7-2e93-479e-a194-bf74799a2af4", "embedding": null, "metadata": {"window": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b36129abd3400cc8d7eca0421768b76df00c5c80b38b7a42f36a08111e565cc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9dc5178-5548-46a3-8da3-153882d73f23", "node_type": "1", "metadata": {"window": "Britt will comment a little more specifically on the financial \nimpact of these contract extensions, but we continue to look forward to serving the US gover nment for several \nmore months in this capacity.  \n \n Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b627ac433aa483bf7bcc75cb115d805d7bb89c72f8d3b94e77197f27aa7162a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "023b6cb2-bfa5-4bf1-8f79-a9761ec0682f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "original_text": "McKesson Corp.  "}, "hash": "59243fff8080076237653dc4da7752c7bf9d053d89a9d3bd9b6b9d2b8dab4ceb", "class_name": "RelatedNodeInfo"}}, "text": "By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "start_char_idx": 3614, "end_char_idx": 3951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "023b6cb2-bfa5-4bf1-8f79-a9761ec0682f": {"__data__": {"id_": "023b6cb2-bfa5-4bf1-8f79-a9761ec0682f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68a624e7-2e93-479e-a194-bf74799a2af4", "node_type": "1", "metadata": {"window": "Building upon the success of the core distribution businesses, we'd like to say we're tackling some of the most \ncomplicated problems in healthcare through the expansion of our oncology and our biopharma serv ices \necosystems.  \n \n In the first quarter, we were really excited to announce the formation of a joint venture between McKesson's US \nOncology Research and HCA Healthcare's Sarah Cannon Research Institute.  This transaction marks a really \nimportant alliance bet ween these two companies, and we expect it will accelerate our strategic advancement of \nthe oncology ecosystem.  \n \n By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "original_text": "By combining the resources and the expertise of these two organizations, we're creating an expanded clinical \nresearch network, and that really means a broader portfolio of clinical trial offerings, expanded patient reach, \naccess to a broader set of data, and more advanced analytics capabilities to better match patients with clinical ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d4c83b72c1aab1580fb7266d3b95ac299a18b0525930a2a7d359d85659c9c4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0e62999-b7fe-42ff-a87f-c4e75aeba6b8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials. "}, "hash": "d376fafbc5be068d1acb70a598108777b82a0fdef56fdf56a5b4bfbac495586b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0e62999-b7fe-42ff-a87f-c4e75aeba6b8": {"__data__": {"id_": "d0e62999-b7fe-42ff-a87f-c4e75aeba6b8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "023b6cb2-bfa5-4bf1-8f79-a9761ec0682f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31fd19207d084493cbbdfb8a597843f1bc632a86f46fa0a45793184128932e66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36e2ef85-0b32-49c3-a5f3-3220904da5df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n", "original_text": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n"}, "hash": "41d3c3e90335127ddd5c5e0a0dba8344df6ce3d1808098d7058e102b6350678a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials. ", "start_char_idx": 16, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36e2ef85-0b32-49c3-a5f3-3220904da5df": {"__data__": {"id_": "36e2ef85-0b32-49c3-a5f3-3220904da5df", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n", "original_text": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0e62999-b7fe-42ff-a87f-c4e75aeba6b8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6124691341bc0142e14b8b28208e1622a9c0a42a5154f29d753183ac3e36140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c366bf7a-fb37-47e9-a3e5-1f5f86df74bf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n", "original_text": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. "}, "hash": "15133492bf64e1ad55ebb60bf5dad821f8b05f5b3dd209ab27ddb581e7f3459d", "class_name": "RelatedNodeInfo"}}, "text": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n", "start_char_idx": 188, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c366bf7a-fb37-47e9-a3e5-1f5f86df74bf": {"__data__": {"id_": "c366bf7a-fb37-47e9-a3e5-1f5f86df74bf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n", "original_text": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36e2ef85-0b32-49c3-a5f3-3220904da5df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n", "original_text": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9fe3ebc64d69970c77e433f243c85a582c59de71e9ce525e11a1cdefa9c5300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75895686-a0bc-4dbf-bdce-20e23786592f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem. ", "original_text": "It is also purposeful. "}, "hash": "20170d3facaf8f1af15a77c5ff59c130c3b78e039a15f53f83ba7448e9967d39", "class_name": "RelatedNodeInfo"}}, "text": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "start_char_idx": 429, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75895686-a0bc-4dbf-bdce-20e23786592f": {"__data__": {"id_": "75895686-a0bc-4dbf-bdce-20e23786592f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem. ", "original_text": "It is also purposeful. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c366bf7a-fb37-47e9-a3e5-1f5f86df74bf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n", "original_text": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9ade177b70167f51a972fa10eb1354c3d76b65abb5d5c04915c155c5264bac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c6022db-b147-4a01-9339-2f0313b7e4f5", "node_type": "1", "metadata": {"window": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. ", "original_text": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n"}, "hash": "64343068299050d11a41ea9f89297b86a0a295e716cc8f481e1e050680b503ba", "class_name": "RelatedNodeInfo"}}, "text": "It is also purposeful. ", "start_char_idx": 589, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c6022db-b147-4a01-9339-2f0313b7e4f5": {"__data__": {"id_": "9c6022db-b147-4a01-9339-2f0313b7e4f5", "embedding": null, "metadata": {"window": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. ", "original_text": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75895686-a0bc-4dbf-bdce-20e23786592f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem. ", "original_text": "It is also purposeful. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e1a88bf8cc290de81504e47303eb7633f1aa226ae06cc6837a013370f147bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efa1d6f0-2da9-43be-97b5-2f88390806bd", "node_type": "1", "metadata": {"window": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n", "original_text": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n"}, "hash": "ec2ea5dd94ee0dc9e135ef24adcf71710669fd937877063045e9027cc978c636", "class_name": "RelatedNodeInfo"}}, "text": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n", "start_char_idx": 612, "end_char_idx": 695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efa1d6f0-2da9-43be-97b5-2f88390806bd": {"__data__": {"id_": "efa1d6f0-2da9-43be-97b5-2f88390806bd", "embedding": null, "metadata": {"window": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n", "original_text": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c6022db-b147-4a01-9339-2f0313b7e4f5", "node_type": "1", "metadata": {"window": "The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. ", "original_text": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dc7813806853e453b036c23331d822323040ad9b348117c89c0093e473ce404", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8965e000-ea66-4421-a02b-d5162cbd34f3", "node_type": "1", "metadata": {"window": "It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. ", "original_text": "We're also making meaningful progress on expanding our biopharma services ecosystem. "}, "hash": "7714e39191da1f9f5b3ae4cc764f50f009e2371fcb4516a7b9ab6709ebadab78", "class_name": "RelatedNodeInfo"}}, "text": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n", "start_char_idx": 695, "end_char_idx": 902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8965e000-ea66-4421-a02b-d5162cbd34f3": {"__data__": {"id_": "8965e000-ea66-4421-a02b-d5162cbd34f3", "embedding": null, "metadata": {"window": "It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. ", "original_text": "We're also making meaningful progress on expanding our biopharma services ecosystem. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efa1d6f0-2da9-43be-97b5-2f88390806bd", "node_type": "1", "metadata": {"window": "This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle.  It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n", "original_text": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf4d92be2ce56f66f3825187c2a1391fcfef945fb6f74adc99eb013f266c3c87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "306ae602-2cfc-41bb-980b-16609204522c", "node_type": "1", "metadata": {"window": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. ", "original_text": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. "}, "hash": "8ea77f5582aa17ef3f12ac3e42ec803a0fe90a78ac599be0d2b56d453746ce34", "class_name": "RelatedNodeInfo"}}, "text": "We're also making meaningful progress on expanding our biopharma services ecosystem. ", "start_char_idx": 902, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "306ae602-2cfc-41bb-980b-16609204522c": {"__data__": {"id_": "306ae602-2cfc-41bb-980b-16609204522c", "embedding": null, "metadata": {"window": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. ", "original_text": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8965e000-ea66-4421-a02b-d5162cbd34f3", "node_type": "1", "metadata": {"window": "It is also purposeful.  It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. ", "original_text": "We're also making meaningful progress on expanding our biopharma services ecosystem. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3279b187d72451f92d2fd575b97a9cad19d6fe3f04cebaa33685d5a1160f9f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd337223-95ad-48d6-9ef7-42ec1b9d0ba7", "node_type": "1", "metadata": {"window": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. ", "original_text": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n"}, "hash": "c3091b1712834fa13152476115b3abcfea8bb28633dc00f6e9fff583503cb243", "class_name": "RelatedNodeInfo"}}, "text": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. ", "start_char_idx": 987, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd337223-95ad-48d6-9ef7-42ec1b9d0ba7": {"__data__": {"id_": "fd337223-95ad-48d6-9ef7-42ec1b9d0ba7", "embedding": null, "metadata": {"window": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. ", "original_text": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "306ae602-2cfc-41bb-980b-16609204522c", "node_type": "1", "metadata": {"window": "It reinforces our commitment as a \ncompany to advance health outcomes for all.  \n \n We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. ", "original_text": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2774b0ee25c48e54ee22394d7778316516b2e69d8adea29bb33a7435ef044e9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad4eda19-6634-43e2-bae7-e775bbf01cad", "node_type": "1", "metadata": {"window": "We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n", "original_text": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. "}, "hash": "1d484be2423cc3cf3eb4165755ab360a87daf36658a55dafb3dc965f99d75c1b", "class_name": "RelatedNodeInfo"}}, "text": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n", "start_char_idx": 1187, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad4eda19-6634-43e2-bae7-e775bbf01cad": {"__data__": {"id_": "ad4eda19-6634-43e2-bae7-e775bbf01cad", "embedding": null, "metadata": {"window": "We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n", "original_text": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd337223-95ad-48d6-9ef7-42ec1b9d0ba7", "node_type": "1", "metadata": {"window": "We expect to close the transaction by the end of calendar year 2022, and  we look forward to the partnership, the \ncollaboration, and greater outcomes we can bring to the patients we collectively serve.  \n \n We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. ", "original_text": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfaa6c7e5fc9893a402b8e080bb286eb1210a3502cc48a069a44b3e1b3325923", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c79061c9-477d-4427-bab9-6c91d84173df", "node_type": "1", "metadata": {"window": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. ", "original_text": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. "}, "hash": "7d57ac2e4d3f9b6220e433d62d79dd60ad14da36f25594c03d780049d593782f", "class_name": "RelatedNodeInfo"}}, "text": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. ", "start_char_idx": 1402, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c79061c9-477d-4427-bab9-6c91d84173df": {"__data__": {"id_": "c79061c9-477d-4427-bab9-6c91d84173df", "embedding": null, "metadata": {"window": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. ", "original_text": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad4eda19-6634-43e2-bae7-e775bbf01cad", "node_type": "1", "metadata": {"window": "We're also making meaningful progress on expanding our biopharma services ecosystem.  Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n", "original_text": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5359496d3d3694741bb2a084533d170808f8ec73fcd9c5dc81435c230e1cbc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb33b505-d82b-4c55-990c-7d153cb9f477", "node_type": "1", "metadata": {"window": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. ", "original_text": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. "}, "hash": "84ea583039508919463d1c0d13ac54076fced4a868ddc9c713f9513a66d45635", "class_name": "RelatedNodeInfo"}}, "text": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. ", "start_char_idx": 1538, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb33b505-d82b-4c55-990c-7d153cb9f477": {"__data__": {"id_": "eb33b505-d82b-4c55-990c-7d153cb9f477", "embedding": null, "metadata": {"window": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. ", "original_text": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c79061c9-477d-4427-bab9-6c91d84173df", "node_type": "1", "metadata": {"window": "Through years of \nintentional investment, we've built a suite of innovative biopharma solutions that supports really every phase of \nthe medication lifecycle across nearly all therapeutic categories.  We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. ", "original_text": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a698d8258474cc476c3c68b2ed4bd5a11e006eef7643959d85faefbff942ccb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "670c85c1-1615-497c-869f-81dc26bffa1a", "node_type": "1", "metadata": {"window": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n", "original_text": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n"}, "hash": "c47e9edcae0328239478ccfc70711d9ac0d25f7dcf286fc9ff9525939684f56d", "class_name": "RelatedNodeInfo"}}, "text": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. ", "start_char_idx": 1645, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "670c85c1-1615-497c-869f-81dc26bffa1a": {"__data__": {"id_": "670c85c1-1615-497c-869f-81dc26bffa1a", "embedding": null, "metadata": {"window": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n", "original_text": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb33b505-d82b-4c55-990c-7d153cb9f477", "node_type": "1", "metadata": {"window": "We're reinventing how biopharma companies, \nproviders, and payers can connect to each other through technology with the ultimate goal of really helping \npatients access, afford, and adhere to their medications.  \n \n Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. ", "original_text": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89864f360b82d9ee5b1368755e4bb9ccf3dd3a169b51c3b3da8e64013a31ab1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a85679b1-cccf-42c8-8a8f-b0bbc095260f", "node_type": "1", "metadata": {"window": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. ", "original_text": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. "}, "hash": "654cdac58ff23f66572ce3022582e619e8a0ff6803b05fd4c4463520f019c705", "class_name": "RelatedNodeInfo"}}, "text": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n", "start_char_idx": 1781, "end_char_idx": 1867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a85679b1-cccf-42c8-8a8f-b0bbc095260f": {"__data__": {"id_": "a85679b1-cccf-42c8-8a8f-b0bbc095260f", "embedding": null, "metadata": {"window": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. ", "original_text": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "670c85c1-1615-497c-869f-81dc26bffa1a", "node_type": "1", "metadata": {"window": "Today, I thought I might share a few examples around our affordability efforts and how these efforts fit into our \nbiopharma ecosystem.  A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n", "original_text": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a264dede33884f3d1cbb134bf4425e22826eaa9e8540382b6ddc0793d492a10d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "019d0934-aa0a-4015-be8b-db21b9a28d8f", "node_type": "1", "metadata": {"window": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. ", "original_text": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. "}, "hash": "b9c6503816b9f452e5441c701a4767af12c107d7a15c44c0cb8643e13effb2bc", "class_name": "RelatedNodeInfo"}}, "text": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. ", "start_char_idx": 1867, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019d0934-aa0a-4015-be8b-db21b9a28d8f": {"__data__": {"id_": "019d0934-aa0a-4015-be8b-db21b9a28d8f", "embedding": null, "metadata": {"window": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. ", "original_text": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a85679b1-cccf-42c8-8a8f-b0bbc095260f", "node_type": "1", "metadata": {"window": "A key piec e of our innovative medication affordability product suite is our automatic \ncouponing program.  This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. ", "original_text": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597eb3e04d96e72fc1f9c5db00644ab726e9bae6c85ea88711b7793bef5a64d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2167ffd-37ad-423f-a863-6f87c8b80486", "node_type": "1", "metadata": {"window": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n", "original_text": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n"}, "hash": "ffdf597e1f7747c5f0c0207b9cf46cef30388297a2330d9f291caf256e304886", "class_name": "RelatedNodeInfo"}}, "text": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. ", "start_char_idx": 2062, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2167ffd-37ad-423f-a863-6f87c8b80486": {"__data__": {"id_": "f2167ffd-37ad-423f-a863-6f87c8b80486", "embedding": null, "metadata": {"window": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n", "original_text": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019d0934-aa0a-4015-be8b-db21b9a28d8f", "node_type": "1", "metadata": {"window": "This automatic couponing program really applies co -pay offsets or savings for qualified \nmedications right at the point of dispensing.  Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. ", "original_text": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3501bc8bb018e1572df6c55c369e07b43bfd16335f0da5ab9fc6150cf3bc091a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d67204fa-54cf-4452-8124-301c0327151e", "node_type": "1", "metadata": {"window": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. ", "original_text": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. "}, "hash": "bb5683708128f48cfe4c2d0c7190ec904dec00141cfd0690e63be3f242564706", "class_name": "RelatedNodeInfo"}}, "text": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n", "start_char_idx": 2180, "end_char_idx": 2431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d67204fa-54cf-4452-8124-301c0327151e": {"__data__": {"id_": "d67204fa-54cf-4452-8124-301c0327151e", "embedding": null, "metadata": {"window": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. ", "original_text": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2167ffd-37ad-423f-a863-6f87c8b80486", "node_type": "1", "metadata": {"window": "Using our technologies, it' s seamlessly integrated into the pharmacy \nwork flow.  \n \n We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n", "original_text": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79b28743a5d197a0f86fa59f1313d1d4db05e4c1e500c44967f091ce210f1069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98467f6b-e6a1-45c6-ad80-42ec5cf474c1", "node_type": "1", "metadata": {"window": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n", "original_text": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. "}, "hash": "f3a03531822a55073d81254a23ccf4fe3a4001ec5a6f2783e6215bff649df65b", "class_name": "RelatedNodeInfo"}}, "text": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. ", "start_char_idx": 2431, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98467f6b-e6a1-45c6-ad80-42ec5cf474c1": {"__data__": {"id_": "98467f6b-e6a1-45c6-ad80-42ec5cf474c1", "embedding": null, "metadata": {"window": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n", "original_text": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d67204fa-54cf-4452-8124-301c0327151e", "node_type": "1", "metadata": {"window": "We further help patients stay on their trusted brands through multi -channel support options like activity inform \nmessaging about other discounts, real -time support, and educational materials.  We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. ", "original_text": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e768593a0fb6933ab4b058d13cb6e873720bdbe869bf03768d4e7684996dcf03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6f6d21f-12ea-40d7-9a22-3b182b08a4f5", "node_type": "1", "metadata": {"window": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio. ", "original_text": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n"}, "hash": "42f704469830ccf2ce20140a8ec65aaef6504075bc186d1935b9f5c6567da4b5", "class_name": "RelatedNodeInfo"}}, "text": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. ", "start_char_idx": 2624, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6f6d21f-12ea-40d7-9a22-3b182b08a4f5": {"__data__": {"id_": "b6f6d21f-12ea-40d7-9a22-3b182b08a4f5", "embedding": null, "metadata": {"window": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio. ", "original_text": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98467f6b-e6a1-45c6-ad80-42ec5cf474c1", "node_type": "1", "metadata": {"window": "We also fa cilitate patient \nassistance programs, which are a critical financial safety net for millions of patients.  We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n", "original_text": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b2d1e5ac3f004d262b338dbf931a282d62190fa02561993ecf4f4d6a2df3544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78a6bb53-5c9c-40ac-ad5b-94a6a019ac8c", "node_type": "1", "metadata": {"window": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. ", "original_text": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. "}, "hash": "b227bd4bdbd956efde151e2dcbac63adffde2b3e3155928ac161894655686b6b", "class_name": "RelatedNodeInfo"}}, "text": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n", "start_char_idx": 2711, "end_char_idx": 2907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78a6bb53-5c9c-40ac-ad5b-94a6a019ac8c": {"__data__": {"id_": "78a6bb53-5c9c-40ac-ad5b-94a6a019ac8c", "embedding": null, "metadata": {"window": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. ", "original_text": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6f6d21f-12ea-40d7-9a22-3b182b08a4f5", "node_type": "1", "metadata": {"window": "We implement and administer \ncomprehensive patient assistant programs through program pharmacies, which enable access to free medication \nprograms to el igible patients treated at hospitals, in community care settings, and sometimes even at home.  \n \n Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio. ", "original_text": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f19be960efb42b42b4955f90c3a884ab0c718443223c7486e271ff60fddde5fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73182dc2-7644-42a0-9654-d3f1cbc43100", "node_type": "1", "metadata": {"window": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n", "original_text": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n"}, "hash": "23a56822615e8bbf0421645efbcdf8dad3e89536f0f165e74ab0dac5d47e8f15", "class_name": "RelatedNodeInfo"}}, "text": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. ", "start_char_idx": 2907, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73182dc2-7644-42a0-9654-d3f1cbc43100": {"__data__": {"id_": "73182dc2-7644-42a0-9654-d3f1cbc43100", "embedding": null, "metadata": {"window": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n", "original_text": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78a6bb53-5c9c-40ac-ad5b-94a6a019ac8c", "node_type": "1", "metadata": {"window": "Both of these solutions leverage the reach of our technology network, and in fiscal year 2022, our solutions \nenabled patients to save more than $6 billion on bra nd and specialty medications.  And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. ", "original_text": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "150904a9860aa59bd13296ef84b5f52a16ba9595890c2f939de2f1c56ce1143b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cba4d94a-df3a-41b8-b33c-e108217cae72", "node_type": "1", "metadata": {"window": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. ", "original_text": "I want to talk a bit about our next priority, which is streamline the portfolio. "}, "hash": "36409bfe78ab25c29da98223f503839cda49e1c1dfcc5e57724d79dff1feca5e", "class_name": "RelatedNodeInfo"}}, "text": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n", "start_char_idx": 3076, "end_char_idx": 3260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cba4d94a-df3a-41b8-b33c-e108217cae72": {"__data__": {"id_": "cba4d94a-df3a-41b8-b33c-e108217cae72", "embedding": null, "metadata": {"window": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. ", "original_text": "I want to talk a bit about our next priority, which is streamline the portfolio. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73182dc2-7644-42a0-9654-d3f1cbc43100", "node_type": "1", "metadata": {"window": "And importantly, we prevented \nmore than 9 million prescriptions from being abandoned.  By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n", "original_text": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d2c227ff353e329a38cad9bf06ea4034bb77ca3ab611055c3c3f34b7ef26ae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc232171-0890-4b7d-8134-d3ee6e05b419", "node_type": "1", "metadata": {"window": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. "}, "hash": "08d4e666edfab824875034fbf6e7ab22f56fe2154640dd865933a62379cb50f7", "class_name": "RelatedNodeInfo"}}, "text": "I want to talk a bit about our next priority, which is streamline the portfolio. ", "start_char_idx": 3260, "end_char_idx": 3341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc232171-0890-4b7d-8134-d3ee6e05b419": {"__data__": {"id_": "cc232171-0890-4b7d-8134-d3ee6e05b419", "embedding": null, "metadata": {"window": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cba4d94a-df3a-41b8-b33c-e108217cae72", "node_type": "1", "metadata": {"window": "By improving affordability of prescriptions, in many \ninstances these solutions also improve adherence, helping patients stay on the treatmen t longer, which leads to \nbetter health outcomes.  \n \n As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. ", "original_text": "I want to talk a bit about our next priority, which is streamline the portfolio. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6917c7f7080df8244c8592f5509f73c3f6fe98c245c27e8646745022e23f6aed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a62a0587-b65a-4ad4-9abd-f1042605b8ec", "node_type": "1", "metadata": {"window": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "This includes the \nprogress we're making towards fully  exiting the European region.  \n \n"}, "hash": "a88688274f1255ed239ef765ab6a5873f8660d4caeb95679277f93b2c94c4add", "class_name": "RelatedNodeInfo"}}, "text": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. ", "start_char_idx": 3341, "end_char_idx": 3581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a62a0587-b65a-4ad4-9abd-f1042605b8ec": {"__data__": {"id_": "a62a0587-b65a-4ad4-9abd-f1042605b8ec", "embedding": null, "metadata": {"window": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "This includes the \nprogress we're making towards fully  exiting the European region.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc232171-0890-4b7d-8134-d3ee6e05b419", "node_type": "1", "metadata": {"window": "As we look ahead, we continue to be proud of our differentiated assets and capabilities, and we're excited to bring \ninnovative solutions to more partners and patients.  Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6199b713a4a70be24c34b373e410f8f9c8751c9a41f864e9a335d76a07d9638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "174b2df9-e099-4211-ace4-ba57daa0e9f5", "node_type": "1", "metadata": {"window": "I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. "}, "hash": "3554b5e15e69cea89b99f3f5e8fb9d45cae93ce90ceb7c2ca9de2bb4aa9ad813", "class_name": "RelatedNodeInfo"}}, "text": "This includes the \nprogress we're making towards fully  exiting the European region.  \n \n", "start_char_idx": 3581, "end_char_idx": 3670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "174b2df9-e099-4211-ace4-ba57daa0e9f5": {"__data__": {"id_": "174b2df9-e099-4211-ace4-ba57daa0e9f5", "embedding": null, "metadata": {"window": "I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a62a0587-b65a-4ad4-9abd-f1042605b8ec", "node_type": "1", "metadata": {"window": "Oncology and biopharma services both r epresent large, \ncomplex, and growing markets for McKesson, and we're strategically positioned to continue to enhance value in \nthese areas.  \n \n I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "This includes the \nprogress we're making towards fully  exiting the European region.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dab07e15c795eda9420b6ca05cb90f68ee43d16ee9a36667c37dfada11f060d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5eb6739c-bf4a-4707-b49e-50870f38bc5f", "node_type": "1", "metadata": {"window": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and "}, "hash": "b6ae97c63c73a2dbedf7b632dc2a0426e3f23e7661e9f9a72f05efe274a27c19", "class_name": "RelatedNodeInfo"}}, "text": "We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. ", "start_char_idx": 3670, "end_char_idx": 3774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5eb6739c-bf4a-4707-b49e-50870f38bc5f": {"__data__": {"id_": "5eb6739c-bf4a-4707-b49e-50870f38bc5f", "embedding": null, "metadata": {"window": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44679b1d7fd431c7c7b99d5d3024bcb5d466791f703d12035300ad4b8ca90b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "174b2df9-e099-4211-ace4-ba57daa0e9f5", "node_type": "1", "metadata": {"window": "I want to talk a bit about our next priority, which is streamline the portfolio.  It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022. ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aeb03609c29b8adf43c046f1fd830f64c61cf40b86f2da906d337cf0dd755db8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "828bcf49-3c8f-4eb8-99b6-3b811d87ec7e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "original_text": "McKesson Corp.  "}, "hash": "15ae8c0f92e91f070f8d982184359a6080eb67d7b2c43b7dd892318148a4d198", "class_name": "RelatedNodeInfo"}}, "text": "The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "start_char_idx": 3774, "end_char_idx": 3888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "828bcf49-3c8f-4eb8-99b6-3b811d87ec7e": {"__data__": {"id_": "828bcf49-3c8f-4eb8-99b6-3b811d87ec7e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5eb6739c-bf4a-4707-b49e-50870f38bc5f", "node_type": "1", "metadata": {"window": "It's absolutely imperative that we \ncontinue to focus our human and our financial capital into the highest growth and highest margin areas of the \ncompany, and part of that is a continuous estimate of our portfolio for strategic alignment.  This includes the \nprogress we're making towards fully  exiting the European region.  \n \n We recently entered into an agreement to sell Denmark, and the transaction was closed on July 29, 2022.  The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "original_text": "The \npending transaction with the PHOENIX Group is progressing well, and we would characterize it as on track and ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ccf2fdd46280360761ac7dbac87dc20573f39feb6d418b60d6f765818abf78b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9683624b-4fec-4f16-88e0-da107bce3540", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023. "}, "hash": "9dcae84de75b093c904bc4691b36ca00a05f03f92ebe461600f67b9fbd0ec546", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9683624b-4fec-4f16-88e0-da107bce3540": {"__data__": {"id_": "9683624b-4fec-4f16-88e0-da107bce3540", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "828bcf49-3c8f-4eb8-99b6-3b811d87ec7e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdfbedc505c7550ae962efb376092cd5d9dc14376353e147d9ecbbeef2cb91fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fb117ce-5126-480c-9022-a36eb13d954e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n", "original_text": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n"}, "hash": "e4bcddbb7a93580df07a0075626da735d386ce6fe503bfd1f6830f0cfd61a626", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023. ", "start_char_idx": 16, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fb117ce-5126-480c-9022-a36eb13d954e": {"__data__": {"id_": "5fb117ce-5126-480c-9022-a36eb13d954e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n", "original_text": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9683624b-4fec-4f16-88e0-da107bce3540", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10555fb3a5416334182cf6d935fb5d6daab705fbbaba6a12e5c6b89a23de451e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09d53872-5256-47f5-b048-c7ef6bf74d70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. ", "original_text": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. "}, "hash": "e83bbc6353492331ffcf75d8f1d1726c5fad630a56125ef2890336d572aa34ec", "class_name": "RelatedNodeInfo"}}, "text": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n", "start_char_idx": 242, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09d53872-5256-47f5-b048-c7ef6bf74d70": {"__data__": {"id_": "09d53872-5256-47f5-b048-c7ef6bf74d70", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. ", "original_text": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fb117ce-5126-480c-9022-a36eb13d954e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n", "original_text": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faed3c1abae9a129ac0aef5eb908870ee19883d2be4be046ed2b3b13ac1891c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eaba3b9-009d-4cce-b7b1-12eccdcdb052", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention. ", "original_text": "So I'm really pleased with the execution of this important initiative. "}, "hash": "e227a69d27e4a937335a278db4e215144a465f2676ed9ba31e8de470d3352393", "class_name": "RelatedNodeInfo"}}, "text": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "start_char_idx": 339, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eaba3b9-009d-4cce-b7b1-12eccdcdb052": {"__data__": {"id_": "9eaba3b9-009d-4cce-b7b1-12eccdcdb052", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention. ", "original_text": "So I'm really pleased with the execution of this important initiative. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09d53872-5256-47f5-b048-c7ef6bf74d70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. ", "original_text": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03ec083da695cd1601781f966fcefeba5a59df0ec1cf16bf6d4cee8811637e87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe4af4a8-24db-456b-81d8-61fdd1fdae34", "node_type": "1", "metadata": {"window": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. ", "original_text": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n"}, "hash": "e1ac272ff81b5c5d190413d49fddb89c613153250631f765081142a14c81a92f", "class_name": "RelatedNodeInfo"}}, "text": "So I'm really pleased with the execution of this important initiative. ", "start_char_idx": 570, "end_char_idx": 641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe4af4a8-24db-456b-81d8-61fdd1fdae34": {"__data__": {"id_": "fe4af4a8-24db-456b-81d8-61fdd1fdae34", "embedding": null, "metadata": {"window": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. ", "original_text": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eaba3b9-009d-4cce-b7b1-12eccdcdb052", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention. ", "original_text": "So I'm really pleased with the execution of this important initiative. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7580cf4ba5baeb6c1fc10e37a3c521513aa72f0a42082f8da9513f9089d4e8bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05e95049-ed59-486f-a7e6-44cea189deab", "node_type": "1", "metadata": {"window": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n", "original_text": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. "}, "hash": "1515c0de835bcf0dd1b7878f397d8a3c88d84371a442b943590b24fd443891c6", "class_name": "RelatedNodeInfo"}}, "text": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n", "start_char_idx": 641, "end_char_idx": 721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05e95049-ed59-486f-a7e6-44cea189deab": {"__data__": {"id_": "05e95049-ed59-486f-a7e6-44cea189deab", "embedding": null, "metadata": {"window": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n", "original_text": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe4af4a8-24db-456b-81d8-61fdd1fdae34", "node_type": "1", "metadata": {"window": "Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. ", "original_text": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8243d6104c4f9456746b41b6d36f12232d614ccfbf08e1068ae26f5a12438032", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "622434c9-071e-4ff9-aa2b-da3b4230aea7", "node_type": "1", "metadata": {"window": "So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. ", "original_text": "In fact, it's \ntypically the first priority we mention. "}, "hash": "abfa5212bcc030d273d5077a92ea33c93123d47243065bc525fd14d15da1e434", "class_name": "RelatedNodeInfo"}}, "text": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. ", "start_char_idx": 721, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "622434c9-071e-4ff9-aa2b-da3b4230aea7": {"__data__": {"id_": "622434c9-071e-4ff9-aa2b-da3b4230aea7", "embedding": null, "metadata": {"window": "So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. ", "original_text": "In fact, it's \ntypically the first priority we mention. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05e95049-ed59-486f-a7e6-44cea189deab", "node_type": "1", "metadata": {"window": "So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope.  So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n", "original_text": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "149231fb633988a7ad44eecde9bf6db7455a87a8d60ed67d05b555d274326743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47e0b962-1ff1-4969-a911-4db2cba6f4be", "node_type": "1", "metadata": {"window": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. ", "original_text": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. "}, "hash": "b49872b0e009ddd5f413c9697e8aa8e4e6c3dd70e4cdc38a5d58d4a2c904a668", "class_name": "RelatedNodeInfo"}}, "text": "In fact, it's \ntypically the first priority we mention. ", "start_char_idx": 825, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47e0b962-1ff1-4969-a911-4db2cba6f4be": {"__data__": {"id_": "47e0b962-1ff1-4969-a911-4db2cba6f4be", "embedding": null, "metadata": {"window": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. ", "original_text": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "622434c9-071e-4ff9-aa2b-da3b4230aea7", "node_type": "1", "metadata": {"window": "So I'm really pleased with the execution of this important initiative.  I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. ", "original_text": "In fact, it's \ntypically the first priority we mention. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c732c76136156eba1dda106d28c06b8983b5789efd4c0fb678dcf3d4fe989f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "297848d1-8949-4952-808c-65a70d8ed085", "node_type": "1", "metadata": {"window": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n", "original_text": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n"}, "hash": "6b46f18bcc30d0cc4bf860f277fdef9ec3e08c3855096d538228f4c496e56bd3", "class_name": "RelatedNodeInfo"}}, "text": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. ", "start_char_idx": 881, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "297848d1-8949-4952-808c-65a70d8ed085": {"__data__": {"id_": "297848d1-8949-4952-808c-65a70d8ed085", "embedding": null, "metadata": {"window": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n", "original_text": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47e0b962-1ff1-4969-a911-4db2cba6f4be", "node_type": "1", "metadata": {"window": "I think the teams have got after it with \nremarkable speed and effic iency.  \n \n I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. ", "original_text": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c878e45d7339dad66581ef38cfb162745abec1f04e3800f0f4822e6dc052303", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dbe34db-b60a-42d5-bf46-a053eb10be66", "node_type": "1", "metadata": {"window": "In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n", "original_text": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. "}, "hash": "e0f288cb6111d84886c7a7bf9197b0af5b82649c41416012a31cccd50a67704c", "class_name": "RelatedNodeInfo"}}, "text": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n", "start_char_idx": 998, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dbe34db-b60a-42d5-bf46-a053eb10be66": {"__data__": {"id_": "0dbe34db-b60a-42d5-bf46-a053eb10be66", "embedding": null, "metadata": {"window": "In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n", "original_text": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "297848d1-8949-4952-808c-65a70d8ed085", "node_type": "1", "metadata": {"window": "I want to wrap up my review of our company's priorities by reaffirming our focus on people and culture.  In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n", "original_text": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5822620e6b99b7fb1587d481cd637c90e4af3e1c7f544672f3a9c8dd2dd46c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4dfa8ed-5f14-411e-b586-46e2b512f948", "node_type": "1", "metadata": {"window": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n", "original_text": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. "}, "hash": "fb8d9a4ce36c95c357456a0a16999afcd716ee0902fef172057185696bc9a23e", "class_name": "RelatedNodeInfo"}}, "text": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. ", "start_char_idx": 1192, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4dfa8ed-5f14-411e-b586-46e2b512f948": {"__data__": {"id_": "d4dfa8ed-5f14-411e-b586-46e2b512f948", "embedding": null, "metadata": {"window": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n", "original_text": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dbe34db-b60a-42d5-bf46-a053eb10be66", "node_type": "1", "metadata": {"window": "In fact, it's \ntypically the first priority we mention.  We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n", "original_text": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cdc7d56c6d1088c4b39959a7f7526f7298b979edce74fea01d89343ac5094e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a77c429a-ba69-4a81-994c-8ccb146bbfa5", "node_type": "1", "metadata": {"window": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. ", "original_text": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n"}, "hash": "7d925d8dfb61509dcd1e0b7ddf59f67a1e64f09d509dcadf9651a0e6592f6a61", "class_name": "RelatedNodeInfo"}}, "text": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. ", "start_char_idx": 1389, "end_char_idx": 1529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a77c429a-ba69-4a81-994c-8ccb146bbfa5": {"__data__": {"id_": "a77c429a-ba69-4a81-994c-8ccb146bbfa5", "embedding": null, "metadata": {"window": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. ", "original_text": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4dfa8ed-5f14-411e-b586-46e2b512f948", "node_type": "1", "metadata": {"window": "We believe that talent can truly be differentiating, and we continue to invest \nin the development of our employees.  We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n", "original_text": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e64defd4ccc396ca0c9811a2ddea26d004ab8c759021cf6c515247650c04e3b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8685035-4f3f-41ac-a5a1-43418f5aa75e", "node_type": "1", "metadata": {"window": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. ", "original_text": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n"}, "hash": "33de7781a6061f36b3ee6c83a588f8f54afe94a5465b7c6269df5d59f6d546b3", "class_name": "RelatedNodeInfo"}}, "text": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n", "start_char_idx": 1529, "end_char_idx": 1754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8685035-4f3f-41ac-a5a1-43418f5aa75e": {"__data__": {"id_": "e8685035-4f3f-41ac-a5a1-43418f5aa75e", "embedding": null, "metadata": {"window": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. ", "original_text": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a77c429a-ba69-4a81-994c-8ccb146bbfa5", "node_type": "1", "metadata": {"window": "We provide our employees not only competitive compensation and \ncompetitive benefits, but also the resources and support they need to grow into the next generation of leaders for \nMcKesson.  \n \n As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. ", "original_text": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9575ea19d65dd5eafc9a0bead829a054eb729ee9369998fc494148adc3400ec1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcc51e60-cc80-4d48-b946-a790aa65938a", "node_type": "1", "metadata": {"window": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n", "original_text": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n"}, "hash": "a6536a6714cb7e60098fadd8b11bff97390dcb6166641752dee2a14628d2c964", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n", "start_char_idx": 1754, "end_char_idx": 1964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcc51e60-cc80-4d48-b946-a790aa65938a": {"__data__": {"id_": "fcc51e60-cc80-4d48-b946-a790aa65938a", "embedding": null, "metadata": {"window": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n", "original_text": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8685035-4f3f-41ac-a5a1-43418f5aa75e", "node_type": "1", "metadata": {"window": "As an organization, we're committed t o advancing diversity, equity, and inclusion, and we continue to increase \nleadership representation for women in North America and people of color in the US.  In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. ", "original_text": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "033f4a5ef6804240a0391ba811e33c73dc7e1ff24057c95c2c5d7954c80fd83f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab097267-e0b3-4830-8467-6405848d9600", "node_type": "1", "metadata": {"window": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n", "original_text": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. "}, "hash": "183e34d95699f2b1edcefd1974443f5635c083e6fdd9d385fd5aeab064a65957", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n", "start_char_idx": 1964, "end_char_idx": 2109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab097267-e0b3-4830-8467-6405848d9600": {"__data__": {"id_": "ab097267-e0b3-4830-8467-6405848d9600", "embedding": null, "metadata": {"window": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n", "original_text": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcc51e60-cc80-4d48-b946-a790aa65938a", "node_type": "1", "metadata": {"window": "In fact, just recently \nMcKesson was recognized by Forbes as one of the Best Employers for Women, a chieving an industry -leading \nranking.  This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n", "original_text": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed06b90967cf17f61c60792d03ac602f09ab6746f1bc74e6e85ddc02174a2885", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b07528-d3a7-4fe1-b182-404cf9a42398", "node_type": "1", "metadata": {"window": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n", "original_text": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. "}, "hash": "29dc377bb9e68b8c7bb9b7549258933ce02e43cd2666d7dcc1a85443fc74fdbb", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. ", "start_char_idx": 2109, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b07528-d3a7-4fe1-b182-404cf9a42398": {"__data__": {"id_": "d8b07528-d3a7-4fe1-b182-404cf9a42398", "embedding": null, "metadata": {"window": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n", "original_text": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab097267-e0b3-4830-8467-6405848d9600", "node_type": "1", "metadata": {"window": "This is a demonstration of our outstanding progress in promoting equity and diversity in the workplace \nand really in my view reflects our deep commitment to support all employees at McKesson, all employees at \nMcKesson.  \n \n Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n", "original_text": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7668503f3c6dd7760f6dff6e9e5fba3b1c7d74380d1ed05f1bbddf9708c77ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "836a9f1d-fe94-4d59-8585-5e5b86007088", "node_type": "1", "metadata": {"window": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. ", "original_text": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n"}, "hash": "79c2dcf450a736538401333a1bd54e4b1775ad8bdad8bea4473a1742082ed083", "class_name": "RelatedNodeInfo"}}, "text": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. ", "start_char_idx": 2270, "end_char_idx": 2381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "836a9f1d-fe94-4d59-8585-5e5b86007088": {"__data__": {"id_": "836a9f1d-fe94-4d59-8585-5e5b86007088", "embedding": null, "metadata": {"window": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. ", "original_text": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b07528-d3a7-4fe1-b182-404cf9a42398", "node_type": "1", "metadata": {"window": "Additionally, for the seventh consecutive year, McKesson was named the Best Place to Work for Disability \nInclusion, which includes earning a top ranking score of 100 on the 2022 Disability Equality Index.  \n \n I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n", "original_text": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a86f9b7172ffa06c513d56288382614d943fca4fdd6ef284f229084539311d12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "117fc85c-f11a-4c3f-9519-3e20486cbfd0", "node_type": "1", "metadata": {"window": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n", "original_text": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n"}, "hash": "f5d07ac3825a3f12e0fab806fa89b936243f15edfcde444ae1137bb02324a370", "class_name": "RelatedNodeInfo"}}, "text": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n", "start_char_idx": 2381, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "117fc85c-f11a-4c3f-9519-3e20486cbfd0": {"__data__": {"id_": "117fc85c-f11a-4c3f-9519-3e20486cbfd0", "embedding": null, "metadata": {"window": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n", "original_text": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "836a9f1d-fe94-4d59-8585-5e5b86007088", "node_type": "1", "metadata": {"window": "I'm proud of the progress that we've made on all  our company's priorities, and we can clearly see it helping \nadvance our long term growth.  \n \n Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. ", "original_text": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7761efd6dc77a06859b446c066a340f85dac406092b56f3eaa91935555d70d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "278d2b06-10e4-4389-b25e-348cfbbb28d1", "node_type": "1", "metadata": {"window": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over. ", "original_text": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n"}, "hash": "a1e7884ddf653d243d3b7a1623c535cfdb30ef1627ee95f8795bd579fa29828a", "class_name": "RelatedNodeInfo"}}, "text": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n", "start_char_idx": 2571, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "278d2b06-10e4-4389-b25e-348cfbbb28d1": {"__data__": {"id_": "278d2b06-10e4-4389-b25e-348cfbbb28d1", "embedding": null, "metadata": {"window": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over. ", "original_text": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "117fc85c-f11a-4c3f-9519-3e20486cbfd0", "node_type": "1", "metadata": {"window": "Before I turn my attention to our first quarter results, I did want to just provide everyone a quick update on the \nprogress of the opioid -related litigations.  This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n", "original_text": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94d6c7595a3d9b3791b4557b4b41cee6f94ba4756c8d380e4135bdb875c15d64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb91b59-3e23-4a17-b475-c8f52ad7a3ab", "node_type": "1", "metadata": {"window": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n", "original_text": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. "}, "hash": "0c0c5af35bb648932d9fddd05c507c10c864f5ef3327e478e9ce7f05a47b7680", "class_name": "RelatedNodeInfo"}}, "text": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n", "start_char_idx": 2686, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb91b59-3e23-4a17-b475-c8f52ad7a3ab": {"__data__": {"id_": "dcb91b59-3e23-4a17-b475-c8f52ad7a3ab", "embedding": null, "metadata": {"window": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n", "original_text": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "278d2b06-10e4-4389-b25e-348cfbbb28d1", "node_type": "1", "metadata": {"window": "This past quarter, we reached agreements in principle with the State of \nWashington and the State of Oklahoma.  With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over. ", "original_text": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "420c8c31888063bec46c0cb636a5c4a361259199f417a27483313af05e66a31b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5025615-6ff1-4be4-b5be-68c0c57a9975", "node_type": "1", "metadata": {"window": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance. ", "original_text": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n"}, "hash": "6b2b4812cf0b794e031df027ccb9e8950e8aa0e542aa85c94cfb79bee55f2897", "class_name": "RelatedNodeInfo"}}, "text": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. ", "start_char_idx": 2827, "end_char_idx": 3025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5025615-6ff1-4be4-b5be-68c0c57a9975": {"__data__": {"id_": "f5025615-6ff1-4be4-b5be-68c0c57a9975", "embedding": null, "metadata": {"window": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance. ", "original_text": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb91b59-3e23-4a17-b475-c8f52ad7a3ab", "node_type": "1", "metadata": {"window": "With the recent developments, we have settled or we have reached \nagreements to settle the opioid -related claims of all 50 states, the District of Colum bia, and all eligible territories. \n The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n", "original_text": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87b2f683007ba899db141f9d9789b7c166c8f6ed43f2d04e1e6452b86ed0f76c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790d32c0-a7c5-4250-bb1f-c80f44129cff", "node_type": "1", "metadata": {"window": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n", "original_text": "As we move forward, our role in combating opioid abuse is not over. "}, "hash": "0b97c37f0e00a962f5f0709aec8e6fcb837c6d547e7564fe7365d6bee961b395", "class_name": "RelatedNodeInfo"}}, "text": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n", "start_char_idx": 3025, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790d32c0-a7c5-4250-bb1f-c80f44129cff": {"__data__": {"id_": "790d32c0-a7c5-4250-bb1f-c80f44129cff", "embedding": null, "metadata": {"window": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n", "original_text": "As we move forward, our role in combating opioid abuse is not over. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5025615-6ff1-4be4-b5be-68c0c57a9975", "node_type": "1", "metadata": {"window": "The majority of the payments that we'll fund as part of these settlements will be used on opioid relief programs. \n We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance. ", "original_text": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4d08f244d1858d5343a16945070ce7aa73e15be7940481fd35035e1c7de8d73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fad3459-1921-4838-8d6c-02b1d09bde6c", "node_type": "1", "metadata": {"window": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n", "original_text": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n"}, "hash": "5458ee79b84543f60ecc2060cffffbda3da1d1366106deec7e094484768933c5", "class_name": "RelatedNodeInfo"}}, "text": "As we move forward, our role in combating opioid abuse is not over. ", "start_char_idx": 3157, "end_char_idx": 3225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fad3459-1921-4838-8d6c-02b1d09bde6c": {"__data__": {"id_": "7fad3459-1921-4838-8d6c-02b1d09bde6c", "embedding": null, "metadata": {"window": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n", "original_text": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790d32c0-a7c5-4250-bb1f-c80f44129cff", "node_type": "1", "metadata": {"window": "We're particularly proud of that, and we'll support a wide variety of strategies in local communities to he lp fight the \nopioid crisis.  \n \n In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n", "original_text": "As we move forward, our role in combating opioid abuse is not over. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a259d593efa8204babbbdd566b6876e071f942df5968d13502fa226d5349470b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d98624-dd10-4f13-b0da-b0080978e474", "node_type": "1", "metadata": {"window": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "Let's move on to business performance. "}, "hash": "201dccd39973c5c677dfee347300dddb094e768c20e14a17f0bb3e8d08701747", "class_name": "RelatedNodeInfo"}}, "text": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n", "start_char_idx": 3225, "end_char_idx": 3392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d98624-dd10-4f13-b0da-b0080978e474": {"__data__": {"id_": "38d98624-dd10-4f13-b0da-b0080978e474", "embedding": null, "metadata": {"window": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "Let's move on to business performance. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fad3459-1921-4838-8d6c-02b1d09bde6c", "node_type": "1", "metadata": {"window": "In July, after a full trial, a federal judge ruled that McKesson along with two other distributors could not be held \nliable to two West Virginia subdivisions for contributing to the opioid crisis.  This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n", "original_text": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0324b5af4d8e90dd0b03e5da405359b3ab833d4b0a0d3c331b12f96e71bb74fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd59befa-21b0-4735-8786-09c9cd8b29cb", "node_type": "1", "metadata": {"window": "As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n"}, "hash": "21e652f3ae6c6b9243494151f8573ee8fb7dcf19ea3853c6876444d02bc6702c", "class_name": "RelatedNodeInfo"}}, "text": "Let's move on to business performance. ", "start_char_idx": 3392, "end_char_idx": 3431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd59befa-21b0-4735-8786-09c9cd8b29cb": {"__data__": {"id_": "cd59befa-21b0-4735-8786-09c9cd8b29cb", "embedding": null, "metadata": {"window": "As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d98624-dd10-4f13-b0da-b0080978e474", "node_type": "1", "metadata": {"window": "This ruling is significant, as  the court \nconfirmed that McKesson did not cause an oversupply of opioids in these communities.  \n \n As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "Let's move on to business performance. ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4518e1f575da921b21c795c125600cc4478c92c1b49599f5cc2b24143e2258ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d47f5d-ba6e-4777-9a5a-a4c88896eb95", "node_type": "1", "metadata": {"window": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n"}, "hash": "4f5c86b597892844fdee539419eb647881c3cd30b8892528283b9c71eab754d0", "class_name": "RelatedNodeInfo"}}, "text": "I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n", "start_char_idx": 3431, "end_char_idx": 3607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d47f5d-ba6e-4777-9a5a-a4c88896eb95": {"__data__": {"id_": "c7d47f5d-ba6e-4777-9a5a-a4c88896eb95", "embedding": null, "metadata": {"window": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd59befa-21b0-4735-8786-09c9cd8b29cb", "node_type": "1", "metadata": {"window": "As we move forward, our role in combating opioid abuse is not over.  McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8626e41eca88fca11aa8b176890d1b6a4c751530c6fb4070baac8a7a0572c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3b452bc-227b-4dea-b57c-5bb7b75045ea", "node_type": "1", "metadata": {"window": "Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient "}, "hash": "e38a6e4db503fe6c95b6cdbde0f928d094b5b37a9192110b092f0d0dec232ada", "class_name": "RelatedNodeInfo"}}, "text": "In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n", "start_char_idx": 3607, "end_char_idx": 3717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b452bc-227b-4dea-b57c-5bb7b75045ea": {"__data__": {"id_": "c3b452bc-227b-4dea-b57c-5bb7b75045ea", "embedding": null, "metadata": {"window": "Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdffb3050e5c18fa4d2774a399e3303615ee8194aa6bf3c982d3a8886e61b592", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d47f5d-ba6e-4777-9a5a-a4c88896eb95", "node_type": "1", "metadata": {"window": "McKesson will remain part of the solution \nwhen it comes to relief across the country and in  preventing opioid diversion within the pharmaceutical supply \nchain.  \n \n Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26f78003157e0898c5fe69d0ca8e3091697452047e5cf21f1d04d506693423df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f2aa3e8-3e65-4e17-9207-e3bc2c298fc8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment. ", "original_text": "McKesson Corp.  "}, "hash": "b45bda520a696ec7d99c3ffb343f51780d8959e5f008be906209922074c8a75f", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "start_char_idx": 3717, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f2aa3e8-3e65-4e17-9207-e3bc2c298fc8": {"__data__": {"id_": "9f2aa3e8-3e65-4e17-9207-e3bc2c298fc8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3b452bc-227b-4dea-b57c-5bb7b75045ea", "node_type": "1", "metadata": {"window": "Let's move on to business performance.  I want to start by just providing a few comments on the macroeconomic \ntrends and environment that we're seeing and what the potential impacts are o n McKesson's business.  \n \n In the past quarter, we have observed positive prescription volumes and positive patient utilization trends. \n Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "original_text": "Additionally, as the macroeconomic environment continues to evolve, our business model has remained resilient ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4221ee389c158f2893670b40e9170516ef522c1b3c0a5b380392edab683a57ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e734cdfa-1023-4e61-8af1-13e8d1c442be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption. "}, "hash": "1d2b89f6b768e0a155dc7b42728f2f41594e874746aa56ced958323a06d2e62d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e734cdfa-1023-4e61-8af1-13e8d1c442be": {"__data__": {"id_": "e734cdfa-1023-4e61-8af1-13e8d1c442be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f2aa3e8-3e65-4e17-9207-e3bc2c298fc8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2d89c709501e61ca6757fba2f13a4868b9c44e310ad736ab514ca30feffa76f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8247678-97a0-4131-ac6b-3e54d9b0f0f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n", "original_text": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n"}, "hash": "ba02ab7a5ab38c2bc8dcc8ef5a5ec0110fed24332681ce352014d79888f004e1", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption. ", "start_char_idx": 16, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8247678-97a0-4131-ac6b-3e54d9b0f0f2": {"__data__": {"id_": "b8247678-97a0-4131-ac6b-3e54d9b0f0f2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n", "original_text": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e734cdfa-1023-4e61-8af1-13e8d1c442be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90d404b0ccebdfce389d8a846d2e05fc40278ceac470a9efc2afb209397937f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2b8040e-9f23-4302-acc3-dae612791244", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical. ", "original_text": "We remain confi dent in our ability to navigate a dynamic economic environment. "}, "hash": "6fe5e99c8cebb10ce5fe465220ef57781fc1acfa14392987cc375a73a4692057", "class_name": "RelatedNodeInfo"}}, "text": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n", "start_char_idx": 247, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2b8040e-9f23-4302-acc3-dae612791244": {"__data__": {"id_": "e2b8040e-9f23-4302-acc3-dae612791244", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical. ", "original_text": "We remain confi dent in our ability to navigate a dynamic economic environment. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8247678-97a0-4131-ac6b-3e54d9b0f0f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n", "original_text": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcec5579978cb10797e109af494bff02486a8dc88096233a58df0388d99b6915", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46e48568-a4b0-43f2-9ba3-0773c11c520f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n", "original_text": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n"}, "hash": "ec4b695145b6804a1491d05b25dc9f0d79a898cd9fe395d2b110b4a827e0808b", "class_name": "RelatedNodeInfo"}}, "text": "We remain confi dent in our ability to navigate a dynamic economic environment. ", "start_char_idx": 440, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46e48568-a4b0-43f2-9ba3-0773c11c520f": {"__data__": {"id_": "46e48568-a4b0-43f2-9ba3-0773c11c520f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n", "original_text": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2b8040e-9f23-4302-acc3-dae612791244", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical. ", "original_text": "We remain confi dent in our ability to navigate a dynamic economic environment. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2eedf80adb71dc1cf73a0449ab148d1f7bc6132de3d42292e4eb9409a3558ed1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b034b5e0-870f-4ac9-b6f5-7ce038427953", "node_type": "1", "metadata": {"window": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. ", "original_text": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n"}, "hash": "b81c02214af6573cea8efdb59d44779a97e96afd337b06a5abd0ca3dee84780b", "class_name": "RelatedNodeInfo"}}, "text": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n", "start_char_idx": 520, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b034b5e0-870f-4ac9-b6f5-7ce038427953": {"__data__": {"id_": "b034b5e0-870f-4ac9-b6f5-7ce038427953", "embedding": null, "metadata": {"window": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. ", "original_text": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46e48568-a4b0-43f2-9ba3-0773c11c520f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n", "original_text": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c592a3fefc512e9efe84f37a9160befaba3aae5391609ed362469bc221ccd8ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59c9c593-2b1a-4576-b8b2-972b04762429", "node_type": "1", "metadata": {"window": "We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n", "original_text": "I want to start with US Pharmaceutical. "}, "hash": "db40eb32bfca96cb51513b3b9462fb82d75950ecf38fd4662ce3cb84c82d7bf0", "class_name": "RelatedNodeInfo"}}, "text": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n", "start_char_idx": 823, "end_char_idx": 976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59c9c593-2b1a-4576-b8b2-972b04762429": {"__data__": {"id_": "59c9c593-2b1a-4576-b8b2-972b04762429", "embedding": null, "metadata": {"window": "We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n", "original_text": "I want to start with US Pharmaceutical. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b034b5e0-870f-4ac9-b6f5-7ce038427953", "node_type": "1", "metadata": {"window": "The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. ", "original_text": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9205ffa5462b3dd69880cd4765831aec236b0302d7e7f2b531106140095ee18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "235b920b-2d50-48dc-a44f-be7d700bb772", "node_type": "1", "metadata": {"window": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. ", "original_text": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n"}, "hash": "9150597dd7db1a381612be83dde03b5081d3322c9630c294119b9493a7c2b278", "class_name": "RelatedNodeInfo"}}, "text": "I want to start with US Pharmaceutical. ", "start_char_idx": 976, "end_char_idx": 1016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "235b920b-2d50-48dc-a44f-be7d700bb772": {"__data__": {"id_": "235b920b-2d50-48dc-a44f-be7d700bb772", "embedding": null, "metadata": {"window": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. ", "original_text": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59c9c593-2b1a-4576-b8b2-972b04762429", "node_type": "1", "metadata": {"window": "We remain confi dent in our ability to navigate a dynamic economic environment.  We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n", "original_text": "I want to start with US Pharmaceutical. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8d98801341bed3e4a266dbfddfe1dd75dcffadffeff41448ceeab37e40fdf58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "699c2272-1739-4cfd-bbdb-fcaa7b650556", "node_type": "1", "metadata": {"window": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. ", "original_text": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. "}, "hash": "2206ebde8f216438482b3fe1ef1f4971dcda3ae7b8786d35799ebf328247ca1d", "class_name": "RelatedNodeInfo"}}, "text": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n", "start_char_idx": 1016, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "699c2272-1739-4cfd-bbdb-fcaa7b650556": {"__data__": {"id_": "699c2272-1739-4cfd-bbdb-fcaa7b650556", "embedding": null, "metadata": {"window": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. ", "original_text": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "235b920b-2d50-48dc-a44f-be7d700bb772", "node_type": "1", "metadata": {"window": "We have a diverse set of \nproducts and solutions that allow us to follow the market demand and capture evolving opportunities, and we \nremain committed to supporting our customers and partners b y delivering innovative products and solutions and \nmaking quality care more accessible and affordable.  \n \n Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. ", "original_text": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d928335c4bc8b5e951e0182da340b42ab7475c75be2fa4ed159cc13a53bfcfb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5986007f-b30c-4e11-880d-1d7ac8581cb2", "node_type": "1", "metadata": {"window": "I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n", "original_text": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n"}, "hash": "a12cb01495ac33848f2f6d7c994eecdf1bdbc28c8b52715b124a6dc445df2a12", "class_name": "RelatedNodeInfo"}}, "text": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. ", "start_char_idx": 1193, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5986007f-b30c-4e11-880d-1d7ac8581cb2": {"__data__": {"id_": "5986007f-b30c-4e11-880d-1d7ac8581cb2", "embedding": null, "metadata": {"window": "I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n", "original_text": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "699c2272-1739-4cfd-bbdb-fcaa7b650556", "node_type": "1", "metadata": {"window": "Let me quickly summarize the first quarter performance, and then I'm going to turn it over to Britt, who will provide \nadditional financial details.  \n \n I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. ", "original_text": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29a39977fcf525d3baf5f77f8e933bea8950db169cb027ce2bc7974712dc63c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b4deed6-de40-4e1d-a4bd-1e55e7b162b0", "node_type": "1", "metadata": {"window": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. ", "original_text": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. "}, "hash": "683d071e629985dbf5a33616728195e93b6a98540cff5fa1a97c7ded091c227f", "class_name": "RelatedNodeInfo"}}, "text": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n", "start_char_idx": 1327, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b4deed6-de40-4e1d-a4bd-1e55e7b162b0": {"__data__": {"id_": "4b4deed6-de40-4e1d-a4bd-1e55e7b162b0", "embedding": null, "metadata": {"window": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. ", "original_text": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5986007f-b30c-4e11-880d-1d7ac8581cb2", "node_type": "1", "metadata": {"window": "I want to start with US Pharmaceutical.  We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n", "original_text": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c88995a97e276204b7d9677a19c2104e274a9a378ad2e2860554d7bce751748", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f7e3cc9-4ccd-468e-997b-b6176907d07b", "node_type": "1", "metadata": {"window": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. ", "original_text": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. "}, "hash": "e65558c02936880e2c411ed8d59c884435a9850db7fe302ac47c0ffcd1cec145", "class_name": "RelatedNodeInfo"}}, "text": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. ", "start_char_idx": 1460, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f7e3cc9-4ccd-468e-997b-b6176907d07b": {"__data__": {"id_": "1f7e3cc9-4ccd-468e-997b-b6176907d07b", "embedding": null, "metadata": {"window": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. ", "original_text": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b4deed6-de40-4e1d-a4bd-1e55e7b162b0", "node_type": "1", "metadata": {"window": "We delivered solid first quarter performance in core pharmaceutical \ndistribution, led really by our differentiated value proposition and exceptional service to our customers. \n Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. ", "original_text": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6afb08c7e1c3eee237c2eed2b0ca221311a1b8de243b8a676d9cc379b372a63b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bccbeeb9-17fb-4022-ae6f-98b74369c773", "node_type": "1", "metadata": {"window": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. ", "original_text": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n"}, "hash": "2fcb069d47e66de2d50ae77c7b97557433bc965e724465c7073a4062ea825cfa", "class_name": "RelatedNodeInfo"}}, "text": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. ", "start_char_idx": 1579, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bccbeeb9-17fb-4022-ae6f-98b74369c773": {"__data__": {"id_": "bccbeeb9-17fb-4022-ae6f-98b74369c773", "embedding": null, "metadata": {"window": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. ", "original_text": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f7e3cc9-4ccd-468e-997b-b6176907d07b", "node_type": "1", "metadata": {"window": "Throughout the quarter, we saw year -over-year growth in prescription volume with positive trends in both branded \nand generic drugs.  Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. ", "original_text": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bd4963f573f5f5a62cf02475a9bd738b57cc9c092a0211f59f9b5b69e641d09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d1d55f3-dfee-414e-884e-f2299638372f", "node_type": "1", "metadata": {"window": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n", "original_text": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. "}, "hash": "b8c6d7d094a7aa10b18eabcc05b7c8f1809692b2f533041fbdeb730d54c8f02c", "class_name": "RelatedNodeInfo"}}, "text": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n", "start_char_idx": 1872, "end_char_idx": 2036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d1d55f3-dfee-414e-884e-f2299638372f": {"__data__": {"id_": "6d1d55f3-dfee-414e-884e-f2299638372f", "embedding": null, "metadata": {"window": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n", "original_text": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bccbeeb9-17fb-4022-ae6f-98b74369c773", "node_type": "1", "metadata": {"window": "Our distribution expertise is reflected in the breadth of product offerings, delivery accuracy, \nand reliability of our service.  \n \n We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. ", "original_text": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ccd160f69ef3401cad8720a6234869abe1c9cd0c12f7ccaca89260bf7298e35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26265ea8-e69b-4e6d-9383-4611c27120fa", "node_type": "1", "metadata": {"window": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. ", "original_text": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. "}, "hash": "cd2f11188eab54f552bc3294e68c8da28b31e12a7691a277d167256dd7cbd395", "class_name": "RelatedNodeInfo"}}, "text": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. ", "start_char_idx": 2036, "end_char_idx": 2191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26265ea8-e69b-4e6d-9383-4611c27120fa": {"__data__": {"id_": "26265ea8-e69b-4e6d-9383-4611c27120fa", "embedding": null, "metadata": {"window": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. ", "original_text": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d1d55f3-dfee-414e-884e-f2299638372f", "node_type": "1", "metadata": {"window": "We also remain focused on expanding the  oncology ecosystem to strengthen our already differentiated market \nposition.  The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n", "original_text": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08f825f97144d761ff0f7cf4c82d72e8c5762ad3c1f9f9c9ae94f7c94ac1dc91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c10f8c20-f4d4-474e-a917-ecb9eeff97e9", "node_type": "1", "metadata": {"window": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. ", "original_text": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. "}, "hash": "9983a84a7a17ecfe01946637d7eea5f9c5236e59f5afc68b9b29aa0538e3258c", "class_name": "RelatedNodeInfo"}}, "text": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. ", "start_char_idx": 2191, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c10f8c20-f4d4-474e-a917-ecb9eeff97e9": {"__data__": {"id_": "c10f8c20-f4d4-474e-a917-ecb9eeff97e9", "embedding": null, "metadata": {"window": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. ", "original_text": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26265ea8-e69b-4e6d-9383-4611c27120fa", "node_type": "1", "metadata": {"window": "The advancements not only reflected in financial performance and its increasing contribution to the \nsegment growth, but also demonstrated by the research we published, the insigh ts we generated and the \npartnerships we formed, all focused on empowering innovation and advancing cancer care.  Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. ", "original_text": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dd6f62d991ad6399e81916c3ebf769ec6e92655dc487e7e5a7d7835f825b6f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe7f705-527b-421b-8d3f-0caf05317b60", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n", "original_text": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n"}, "hash": "d1ae36b3fe3e333f5fa9f188814e21e6e009042021c49689f231558228493425", "class_name": "RelatedNodeInfo"}}, "text": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. ", "start_char_idx": 2324, "end_char_idx": 2464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe7f705-527b-421b-8d3f-0caf05317b60": {"__data__": {"id_": "ebe7f705-527b-421b-8d3f-0caf05317b60", "embedding": null, "metadata": {"window": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n", "original_text": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c10f8c20-f4d4-474e-a917-ecb9eeff97e9", "node_type": "1", "metadata": {"window": "Our oncology \nbusiness has proven to be resilient throughout the pandemic, and we saw stable demand in patient visit trends \nwithin our US Oncolog y practices.  \n \n In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. ", "original_text": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80c2604fda68acdef5dc030c6e9d8799fce25b37fa05e809ec93cfeaa2889763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "612fc3a8-afb1-4675-a25c-c66a0c8c1510", "node_type": "1", "metadata": {"window": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets. ", "original_text": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. "}, "hash": "9addd70a524fe79c472bf807a324113152bf3f9b9c8f6a8a6d1a57471155ba6a", "class_name": "RelatedNodeInfo"}}, "text": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n", "start_char_idx": 2464, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "612fc3a8-afb1-4675-a25c-c66a0c8c1510": {"__data__": {"id_": "612fc3a8-afb1-4675-a25c-c66a0c8c1510", "embedding": null, "metadata": {"window": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets. ", "original_text": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe7f705-527b-421b-8d3f-0caf05317b60", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, we're pleased with the growth momentum in the first quarter driven by \naccess affordability and adherence solutions.  The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n", "original_text": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4280c78520ed89bb19471d3bb92bd50afd49ee4ea5cb7ba19c0b116b9e21aa91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79ca684a-7c3d-4f50-bed5-a61dc90ff398", "node_type": "1", "metadata": {"window": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. ", "original_text": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. "}, "hash": "6f58a6ad80c8fb4c5b527d645569ab2a3fb243b256f31f612de161f1e43bb51c", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. ", "start_char_idx": 2562, "end_char_idx": 2689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79ca684a-7c3d-4f50-bed5-a61dc90ff398": {"__data__": {"id_": "79ca684a-7c3d-4f50-bed5-a61dc90ff398", "embedding": null, "metadata": {"window": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. ", "original_text": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "612fc3a8-afb1-4675-a25c-c66a0c8c1510", "node_type": "1", "metadata": {"window": "The market demand for our products and solutions remain strong, \ncontributing to the orga nic growth in the core product categories.  The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets. ", "original_text": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05f9d39e5dad85da359b4e8c5bd0aedce6bb9e0333a80741f2c370589086064e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65b7502b-036d-46f7-a832-84ad3be1086a", "node_type": "1", "metadata": {"window": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n", "original_text": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n"}, "hash": "bbf00711f66abaab312d941b7edee77b45f7bda540dec14c79da74ad2f52db82", "class_name": "RelatedNodeInfo"}}, "text": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. ", "start_char_idx": 2689, "end_char_idx": 2833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65b7502b-036d-46f7-a832-84ad3be1086a": {"__data__": {"id_": "65b7502b-036d-46f7-a832-84ad3be1086a", "embedding": null, "metadata": {"window": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n", "original_text": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79ca684a-7c3d-4f50-bed5-a61dc90ff398", "node_type": "1", "metadata": {"window": "The strong financial performance also allows us \nto reinvest into the business and to expand the reach of our biopharma services ecosystem.  The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. ", "original_text": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec62640838a6f812d3da3d2f542b450f6a7a1d424f967f7a2567adf0c3e44c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59ff8e31-a4f7-48b1-912b-5198e4f3e73e", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together. ", "original_text": "And in the International segment, we're progressing well with the divestiture of our European  assets. "}, "hash": "8aa3d2dd5d273dc6b521c20ef371af99b9003b79ad4e326251f9772c34dd5214", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n", "start_char_idx": 2833, "end_char_idx": 2970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59ff8e31-a4f7-48b1-912b-5198e4f3e73e": {"__data__": {"id_": "59ff8e31-a4f7-48b1-912b-5198e4f3e73e", "embedding": null, "metadata": {"window": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together. ", "original_text": "And in the International segment, we're progressing well with the divestiture of our European  assets. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65b7502b-036d-46f7-a832-84ad3be1086a", "node_type": "1", "metadata": {"window": "The continued \ninvestment in innovation is critical to the long term growth  of the business.  \n \n In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n", "original_text": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5655ccc352800c46032083f993750407310da2dc3a2ccc5dc72b657a40bf682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "277644bc-5d78-4391-979b-90f89aa3c32c", "node_type": "1", "metadata": {"window": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023. ", "original_text": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. "}, "hash": "ee2c0ca53c810dabfc511832459d3f3b5dbe8f75ae703df661997a38ea63c40a", "class_name": "RelatedNodeInfo"}}, "text": "And in the International segment, we're progressing well with the divestiture of our European  assets. ", "start_char_idx": 2970, "end_char_idx": 3073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "277644bc-5d78-4391-979b-90f89aa3c32c": {"__data__": {"id_": "277644bc-5d78-4391-979b-90f89aa3c32c", "embedding": null, "metadata": {"window": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023. ", "original_text": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59ff8e31-a4f7-48b1-912b-5198e4f3e73e", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we again had strong performance, led by strength in the primary care \nmarketplace.  The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together. ", "original_text": "And in the International segment, we're progressing well with the divestiture of our European  assets. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4e3fe6f35d52a3e63cd6fcbee21153d0a94481d1d9f17ae4ea72162a334885f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f09b6d7b-16cb-4fb9-9034-7b861fb31d25", "node_type": "1", "metadata": {"window": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. ", "original_text": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n"}, "hash": "8c6a996ac045fcf298dbb05fdc5293dd8d37bebe740836a719ea3a0e794de5f7", "class_name": "RelatedNodeInfo"}}, "text": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. ", "start_char_idx": 3073, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f09b6d7b-16cb-4fb9-9034-7b861fb31d25": {"__data__": {"id_": "f09b6d7b-16cb-4fb9-9034-7b861fb31d25", "embedding": null, "metadata": {"window": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. ", "original_text": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "277644bc-5d78-4391-979b-90f89aa3c32c", "node_type": "1", "metadata": {"window": "The demand for COVID tests during the quarter was higher than anticipated, but I would also say \ngenerally in lin e with the COVID case counts.  We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023. ", "original_text": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f258b0ede6e48022f18d1330d9f2566d2e9d23b39c2c513f258684bb56fe42b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff858c9f-ecb4-4584-86ab-0525c7273aff", "node_type": "1", "metadata": {"window": "And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n", "original_text": "Let me try to pull everything together. "}, "hash": "7285d1993ab3a17b8e0af6916f65e0f989573e4363364ec5f1d2a2db89251cbe", "class_name": "RelatedNodeInfo"}}, "text": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n", "start_char_idx": 3224, "end_char_idx": 3405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff858c9f-ecb4-4584-86ab-0525c7273aff": {"__data__": {"id_": "ff858c9f-ecb4-4584-86ab-0525c7273aff", "embedding": null, "metadata": {"window": "And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n", "original_text": "Let me try to pull everything together. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09b6d7b-16cb-4fb9-9034-7b861fb31d25", "node_type": "1", "metadata": {"window": "We continue to expand the breadth of our products and services to \nstrengthen our leading capabilities in the alternate site market.  \n \n And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. ", "original_text": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de9520a38d948767e2fb1b1e5392f8e1c19d288dbfa46f9f33283290f8b24d9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d04067ce-1aff-4a6a-9726-1019a9b4a05c", "node_type": "1", "metadata": {"window": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson. ", "original_text": "McKesson reported solid first quarter in fiscal 2023. "}, "hash": "70eb506fbcb89cbd082023820821d79a1be894ca94787f13d8eab88b58570770", "class_name": "RelatedNodeInfo"}}, "text": "Let me try to pull everything together. ", "start_char_idx": 3405, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d04067ce-1aff-4a6a-9726-1019a9b4a05c": {"__data__": {"id_": "d04067ce-1aff-4a6a-9726-1019a9b4a05c", "embedding": null, "metadata": {"window": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson. ", "original_text": "McKesson reported solid first quarter in fiscal 2023. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff858c9f-ecb4-4584-86ab-0525c7273aff", "node_type": "1", "metadata": {"window": "And in the International segment, we're progressing well with the divestiture of our European  assets.  As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n", "original_text": "Let me try to pull everything together. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fb293243b48420ed7133d1577762c312e902ca3434390dd3a5135fe27f28b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1256cb6e-bb0e-44da-86d5-5a2a3186f545", "node_type": "1", "metadata": {"window": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam. ", "original_text": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. "}, "hash": "5ecd5df0c70c69a19c4e20d5850387d85bb0d2b1c5a4f9e50a564f380152cfc4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson reported solid first quarter in fiscal 2023. ", "start_char_idx": 3445, "end_char_idx": 3499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1256cb6e-bb0e-44da-86d5-5a2a3186f545": {"__data__": {"id_": "1256cb6e-bb0e-44da-86d5-5a2a3186f545", "embedding": null, "metadata": {"window": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam. ", "original_text": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d04067ce-1aff-4a6a-9726-1019a9b4a05c", "node_type": "1", "metadata": {"window": "As it relates \nto our Canadian business, we remain committed to our strategy in the Canadian market, where we have scale \nand a diverse set of assets.  The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson. ", "original_text": "McKesson reported solid first quarter in fiscal 2023. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a5177e693750b44aad2e3be769e573cc5195dc513c880e43370642000c1d67c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6de39b9-d334-42d4-9164-72259947c89e", "node_type": "1", "metadata": {"window": "Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners. ", "original_text": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n"}, "hash": "d8462e374abf6bd3442c3090bb451870d8c284e4cfb4ebf93054094bf7265759", "class_name": "RelatedNodeInfo"}}, "text": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. ", "start_char_idx": 3499, "end_char_idx": 3636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6de39b9-d334-42d4-9164-72259947c89e": {"__data__": {"id_": "e6de39b9-d334-42d4-9164-72259947c89e", "embedding": null, "metadata": {"window": "Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners. ", "original_text": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1256cb6e-bb0e-44da-86d5-5a2a3186f545", "node_type": "1", "metadata": {"window": "The distribution and retail businesses remain stable and the team is doing great work \ndriving grow th through improved sourcing economics and expanding customer relationships.  \n \n Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam. ", "original_text": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdfc13b3aa4ed95aa6975552f0301ed20f52ff2e8fbe4086ad5c82e55ec1a8a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc1c4220-7f1e-4715-8e64-ee7d7918840e", "node_type": "1", "metadata": {"window": "McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "Last, I want to be sure to th ank my teammates and the employees of McKesson. "}, "hash": "d06e2dccd163fd54e352e3b5d9794bb31e81b70da7ab2861486257d80dd8d0ba", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n", "start_char_idx": 3636, "end_char_idx": 3817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc1c4220-7f1e-4715-8e64-ee7d7918840e": {"__data__": {"id_": "fc1c4220-7f1e-4715-8e64-ee7d7918840e", "embedding": null, "metadata": {"window": "McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "Last, I want to be sure to th ank my teammates and the employees of McKesson. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6de39b9-d334-42d4-9164-72259947c89e", "node_type": "1", "metadata": {"window": "Let me try to pull everything together.  McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners. ", "original_text": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "416a1e01e1003bf3e8c0e90ff8188e8b9f18cf18f5eac81798e9ea106af4df8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a0ce581-819b-43a9-a2a2-0c4cd91e4710", "node_type": "1", "metadata": {"window": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "I'm proud to lead this amazing \nteam. "}, "hash": "cc3ca8f1538eb1ea7145228563297d6e0647672ad88493840ff2bceab4a35661", "class_name": "RelatedNodeInfo"}}, "text": "Last, I want to be sure to th ank my teammates and the employees of McKesson. ", "start_char_idx": 3817, "end_char_idx": 3895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a0ce581-819b-43a9-a2a2-0c4cd91e4710": {"__data__": {"id_": "1a0ce581-819b-43a9-a2a2-0c4cd91e4710", "embedding": null, "metadata": {"window": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "I'm proud to lead this amazing \nteam. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc1c4220-7f1e-4715-8e64-ee7d7918840e", "node_type": "1", "metadata": {"window": "McKesson reported solid first quarter in fiscal 2023.  The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "Last, I want to be sure to th ank my teammates and the employees of McKesson. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a03d240283d20dc737a6bc80e9fc12c7c7ac867c0a03ecb349ee4a0cd1e15a5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19ac5f6d-f606-418b-a870-68adf754ea4d", "node_type": "1", "metadata": {"window": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "You're all innovative problem solvers that bring positive change to our customers and partners. "}, "hash": "d63c7bcf7f713ca4d4dac2178ff99e73e39f8eb6aa6c1a8b69edb9036d62969c", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud to lead this amazing \nteam. ", "start_char_idx": 3895, "end_char_idx": 3933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19ac5f6d-f606-418b-a870-68adf754ea4d": {"__data__": {"id_": "19ac5f6d-f606-418b-a870-68adf754ea4d", "embedding": null, "metadata": {"window": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "You're all innovative problem solvers that bring positive change to our customers and partners. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a0ce581-819b-43a9-a2a2-0c4cd91e4710", "node_type": "1", "metadata": {"window": "The fundamentals of \nour business are stable, and I'm excited about the meaningful pr ogress we've made against our company \npriorities.  Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "I'm proud to lead this amazing \nteam. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58f40e8956fd43b20ce116c4ed3f4100c8744969a182f5d5e2576bb0965cfed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a3ebcac-9b94-42cd-a516-221d8f33eb81", "node_type": "1", "metadata": {"window": "Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "It's the "}, "hash": "9d5a8e034b812c7c50199e970432a53caa930007db0d7ea600d5c0ae6b81a17c", "class_name": "RelatedNodeInfo"}}, "text": "You're all innovative problem solvers that bring positive change to our customers and partners. ", "start_char_idx": 3933, "end_char_idx": 4029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a3ebcac-9b94-42cd-a516-221d8f33eb81": {"__data__": {"id_": "7a3ebcac-9b94-42cd-a516-221d8f33eb81", "embedding": null, "metadata": {"window": "Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "It's the ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde2f17be1144a33944672d9747998b200896ad31d68df852c3db503c72ee780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19ac5f6d-f606-418b-a870-68adf754ea4d", "node_type": "1", "metadata": {"window": "Our updated outlook for fiscal 2023 aligns with the long term growth targets of the business and \ndemonstrates our commitment to deliver sustainable growth across all segments.  \n \n Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "You're all innovative problem solvers that bring positive change to our customers and partners. ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e086def8e27446fe295eabc185a0ab06f5f58bca8c1e85f1c4a07232b17b2d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1899a560-4162-4a44-98f7-cb46072067f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "McKesson Corp.  "}, "hash": "f602d8d2db43d1cbfe88e3dea72a2ad9b9737ca9ee7367babd08cac972f87584", "class_name": "RelatedNodeInfo"}}, "text": "It's the ", "start_char_idx": 4029, "end_char_idx": 4038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1899a560-4162-4a44-98f7-cb46072067f5": {"__data__": {"id_": "1899a560-4162-4a44-98f7-cb46072067f5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a3ebcac-9b94-42cd-a516-221d8f33eb81", "node_type": "1", "metadata": {"window": "Last, I want to be sure to th ank my teammates and the employees of McKesson.  I'm proud to lead this amazing \nteam.  You're all innovative problem solvers that bring positive change to our customers and partners.  It's the ", "original_text": "It's the ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1110a1e03eb3cfe1e382697c54a5268502c38a44707211e02bd7f3c64f1f7e5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cb24a6d-3b71-4b91-b4d2-bc6e13d914a6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n"}, "hash": "2d54227f7bf171fa1a9fb0622cb3b5ddd5e394cbd7c40fdb596e83d4abd0fc13", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cb24a6d-3b71-4b91-b4d2-bc6e13d914a6": {"__data__": {"id_": "2cb24a6d-3b71-4b91-b4d2-bc6e13d914a6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1899a560-4162-4a44-98f7-cb46072067f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "575d8a984a2157e1e29d62aa6f40ba391236f72b67d3719c1d23e32cd1fdd2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9892b113-5b2d-407a-a55a-c1b8d8151464", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. ", "original_text": "With that, Britt, why don't you provide some additional color and comments?  \n "}, "hash": "ead08cd7a0cda8ec3e3fcefffb6c5ce7e73e11f9811c5264b6b848b741bfe1bb", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n", "start_char_idx": 16, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9892b113-5b2d-407a-a55a-c1b8d8151464": {"__data__": {"id_": "9892b113-5b2d-407a-a55a-c1b8d8151464", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. ", "original_text": "With that, Britt, why don't you provide some additional color and comments?  \n ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cb24a6d-3b71-4b91-b4d2-bc6e13d914a6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca58f5fae9e0a55d37d60399f9814822df4b50a23ee943d556de728bca64c595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82156ea0-0724-4dd8-8422-e993de036909", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "44d021f05ad2deb10dea94f34322f6f9c1e7a39796ab2d95ca397cb3787e2848", "class_name": "RelatedNodeInfo"}}, "text": "With that, Britt, why don't you provide some additional color and comments?  \n ", "start_char_idx": 344, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82156ea0-0724-4dd8-8422-e993de036909": {"__data__": {"id_": "82156ea0-0724-4dd8-8422-e993de036909", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9892b113-5b2d-407a-a55a-c1b8d8151464", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. ", "original_text": "With that, Britt, why don't you provide some additional color and comments?  \n ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bea597f3a6eef3fe483feeac0dda01d17e1d025ca357578c12bdce72c832c442", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc14f00-422f-4934-ae8a-6ed026c6f38f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results. ", "original_text": "Well, thank you, Brian, and good afternoon.  \n \n"}, "hash": "313aa2711ce3e6f20364818bee292f3747db5db0c1944d734a14ae5369361757", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 423, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc14f00-422f-4934-ae8a-6ed026c6f38f": {"__data__": {"id_": "acc14f00-422f-4934-ae8a-6ed026c6f38f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results. ", "original_text": "Well, thank you, Brian, and good afternoon.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82156ea0-0724-4dd8-8422-e993de036909", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85b85d00ad03b15c63b87040138e4697223f46fd0758ed4ee874c4e94b42a31e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1d3e2e4-9adc-4b2e-a844-1c0f72d06ee5", "node_type": "1", "metadata": {"window": "With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n", "original_text": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. "}, "hash": "a19bbdd9bcf614ce69e0a7ba7122710e19b00ab1585f925bc04490c88ec44c11", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, Brian, and good afternoon.  \n \n", "start_char_idx": 781, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1d3e2e4-9adc-4b2e-a844-1c0f72d06ee5": {"__data__": {"id_": "a1d3e2e4-9adc-4b2e-a844-1c0f72d06ee5", "embedding": null, "metadata": {"window": "With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n", "original_text": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc14f00-422f-4934-ae8a-6ed026c6f38f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results. ", "original_text": "Well, thank you, Brian, and good afternoon.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dcc4f73d62a21ac1e0ecc67819e5a4cf135fcd3993b86a12415eaf66bb15911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f742c09d-4812-435a-8e9b-acccbdfa3c15", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. ", "original_text": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n"}, "hash": "72c3350903cf6a9ed926780903455be48aaa432d85c8a99658428147f43d0f96", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. ", "start_char_idx": 829, "end_char_idx": 1020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f742c09d-4812-435a-8e9b-acccbdfa3c15": {"__data__": {"id_": "f742c09d-4812-435a-8e9b-acccbdfa3c15", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. ", "original_text": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1d3e2e4-9adc-4b2e-a844-1c0f72d06ee5", "node_type": "1", "metadata": {"window": "With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n", "original_text": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0d5cf9fb5474b3296e696ff3384aeee7c42381809ffb14389e9d2cb05860704", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6eebea9-638e-409d-886d-68725f159695", "node_type": "1", "metadata": {"window": "Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n", "original_text": "Let me begin today with a few company updates before reviewing our first quarter results. "}, "hash": "62198440b69424704063e2e814d88e91f50c8382bfe04793ecc1b5c41eda99cf", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n", "start_char_idx": 1020, "end_char_idx": 1200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6eebea9-638e-409d-886d-68725f159695": {"__data__": {"id_": "e6eebea9-638e-409d-886d-68725f159695", "embedding": null, "metadata": {"window": "Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n", "original_text": "Let me begin today with a few company updates before reviewing our first quarter results. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f742c09d-4812-435a-8e9b-acccbdfa3c15", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. ", "original_text": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd4677cd4ca55e09bc39244832c4dd4c24593d35568f1932db012a0e6b54bcae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75d5c319-ce35-4fee-9c2e-ae1e32ede272", "node_type": "1", "metadata": {"window": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. ", "original_text": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n"}, "hash": "c91d4f829668ccc82d3d6512a451e9a5c8abff88082107612e905481ab7074ed", "class_name": "RelatedNodeInfo"}}, "text": "Let me begin today with a few company updates before reviewing our first quarter results. ", "start_char_idx": 1200, "end_char_idx": 1290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75d5c319-ce35-4fee-9c2e-ae1e32ede272": {"__data__": {"id_": "75d5c319-ce35-4fee-9c2e-ae1e32ede272", "embedding": null, "metadata": {"window": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. ", "original_text": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6eebea9-638e-409d-886d-68725f159695", "node_type": "1", "metadata": {"window": "Well, thank you, Brian, and good afternoon.  \n \n We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n", "original_text": "Let me begin today with a few company updates before reviewing our first quarter results. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf908706e4e545bb2d4393cb298c78f70195ac6ce84604083bae98bdc358a3cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f10a455d-7792-486f-b65b-0b4f8d5bd831", "node_type": "1", "metadata": {"window": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n", "original_text": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. "}, "hash": "adbf6961723d0f3597306158b78601eb5d2754959082411c44999afa3522cc83", "class_name": "RelatedNodeInfo"}}, "text": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n", "start_char_idx": 1290, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f10a455d-7792-486f-b65b-0b4f8d5bd831": {"__data__": {"id_": "f10a455d-7792-486f-b65b-0b4f8d5bd831", "embedding": null, "metadata": {"window": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n", "original_text": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75d5c319-ce35-4fee-9c2e-ae1e32ede272", "node_type": "1", "metadata": {"window": "We are pleased to report June quarter financial results that continue to demonstrate our ability to grow our \nbusinesses and execute effectively as a diversified healthcare services company.  Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. ", "original_text": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27a5ace098d37f65067badca353a13701c29afa6c0a0200cba541c4f6fefcebc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c627d022-4964-4c72-a9b4-a37048394f38", "node_type": "1", "metadata": {"window": "Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. ", "original_text": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n"}, "hash": "b1de94741d95a3d387a99280358bb0304bc4eb2d68cd8b38548a33678303c149", "class_name": "RelatedNodeInfo"}}, "text": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. ", "start_char_idx": 1375, "end_char_idx": 1638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c627d022-4964-4c72-a9b4-a37048394f38": {"__data__": {"id_": "c627d022-4964-4c72-a9b4-a37048394f38", "embedding": null, "metadata": {"window": "Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. ", "original_text": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f10a455d-7792-486f-b65b-0b4f8d5bd831", "node_type": "1", "metadata": {"window": "Our fiscal first quarter results \nare ahead of our expectations, reflecting progress against our strategic priorities, demonstrating the continued \nstrength of our operations.  \n \n Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n", "original_text": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c12c5f8473ca34b4d769745f3c3e5298af73af48afa0d90431a82a6a1db76d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da845238-27c1-456e-89d6-e3dec2cf38e9", "node_type": "1", "metadata": {"window": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations. ", "original_text": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. "}, "hash": "0ce266c66461e2837651cfc61ad714f52e6ac10dbc196f5a324317d27630990b", "class_name": "RelatedNodeInfo"}}, "text": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n", "start_char_idx": 1638, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da845238-27c1-456e-89d6-e3dec2cf38e9": {"__data__": {"id_": "da845238-27c1-456e-89d6-e3dec2cf38e9", "embedding": null, "metadata": {"window": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations. ", "original_text": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c627d022-4964-4c72-a9b4-a37048394f38", "node_type": "1", "metadata": {"window": "Let me begin today with a few company updates before reviewing our first quarter results.  I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. ", "original_text": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d346efa7b49f0c0be7b03aaad98e9f7617535f75342795e9965504ce30ab4f32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7acd228b-f625-43f5-9521-f954c691a534", "node_type": "1", "metadata": {"window": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business. ", "original_text": "To date, we've successfully closed the following transactions.  \n \n"}, "hash": "259c14007b40bf86b278ae11d34506e34b78667252e578950005b9ff98e278a2", "class_name": "RelatedNodeInfo"}}, "text": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. ", "start_char_idx": 1733, "end_char_idx": 1869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7acd228b-f625-43f5-9521-f954c691a534": {"__data__": {"id_": "7acd228b-f625-43f5-9521-f954c691a534", "embedding": null, "metadata": {"window": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business. ", "original_text": "To date, we've successfully closed the following transactions.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da845238-27c1-456e-89d6-e3dec2cf38e9", "node_type": "1", "metadata": {"window": "I want t o start with \nEurope and our ongoing focus to streamline our portfolio.  \n \n Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations. ", "original_text": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f57b0a40575cfe6f69d05f173d462f82abb937a6cd0710f0ca99c91294fc7038", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6756821-2c34-449b-a6f2-6ccb5cdb43bf", "node_type": "1", "metadata": {"window": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. ", "original_text": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. "}, "hash": "1eac8fb2eb0563be45c51247cb05ef3523c21ae0e19d5b1da899ce073aa23e2c", "class_name": "RelatedNodeInfo"}}, "text": "To date, we've successfully closed the following transactions.  \n \n", "start_char_idx": 1869, "end_char_idx": 1936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6756821-2c34-449b-a6f2-6ccb5cdb43bf": {"__data__": {"id_": "b6756821-2c34-449b-a6f2-6ccb5cdb43bf", "embedding": null, "metadata": {"window": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. ", "original_text": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7acd228b-f625-43f5-9521-f954c691a534", "node_type": "1", "metadata": {"window": "Over the past few years, we've taken deliberate actions to streamline the business and deploy capital more \neffectively, ensuring the organization is operationally efficient and delivering solutions that are focused on solving \nour customers' biggest challenges.  This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business. ", "original_text": "To date, we've successfully closed the following transactions.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c7d69de740775c893545b43a39bf594e12719ff03de08c2605e41b98dc44c60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bf47647-ee3d-4d88-80f6-0aaec72b1991", "node_type": "1", "metadata": {"window": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n", "original_text": "In April of 2022, we completed the sale of our UK retail and wholesale operations. "}, "hash": "df49ab6faf003dd9565346b03d57a83a389624fa7d094512289db2b24a8241db", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. ", "start_char_idx": 1936, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bf47647-ee3d-4d88-80f6-0aaec72b1991": {"__data__": {"id_": "6bf47647-ee3d-4d88-80f6-0aaec72b1991", "embedding": null, "metadata": {"window": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n", "original_text": "In April of 2022, we completed the sale of our UK retail and wholesale operations. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6756821-2c34-449b-a6f2-6ccb5cdb43bf", "node_type": "1", "metadata": {"window": "This is exemplified by our actions to exit the European region announced in \nJuly of 2021.  \n \n Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. ", "original_text": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25dc325bfb4042c137c48eaa7defc963ca2a6181b8423108d0029f90b97091e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70a9bf8e-6e3a-4d96-859e-b0c224a8400d", "node_type": "1", "metadata": {"window": "To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n", "original_text": "And \nin July of 2022, we completed the sale of our Denmark business. "}, "hash": "af56773b2f93e9adb6d776e2e02e46767809d8e4533e0f13d490457028e1d51b", "class_name": "RelatedNodeInfo"}}, "text": "In April of 2022, we completed the sale of our UK retail and wholesale operations. ", "start_char_idx": 2076, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70a9bf8e-6e3a-4d96-859e-b0c224a8400d": {"__data__": {"id_": "70a9bf8e-6e3a-4d96-859e-b0c224a8400d", "embedding": null, "metadata": {"window": "To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n", "original_text": "And \nin July of 2022, we completed the sale of our Denmark business. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bf47647-ee3d-4d88-80f6-0aaec72b1991", "node_type": "1", "metadata": {"window": "Since that time, we've divested or entered into agreements to sell business opera tions in 11 of the 12 countries in \nwhich we operate.  To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n", "original_text": "In April of 2022, we completed the sale of our UK retail and wholesale operations. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "300a9805394b423560cdc638470018b8697384444483ec5ab1290097c3071b7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b2a8a11-1844-4e40-99ae-d630baa9c981", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n", "original_text": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. "}, "hash": "f1bdc3363f6c30918d1b128cd217dfe3d0561ba093941cb90ec4dc6f9688339e", "class_name": "RelatedNodeInfo"}}, "text": "And \nin July of 2022, we completed the sale of our Denmark business. ", "start_char_idx": 2159, "end_char_idx": 2228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b2a8a11-1844-4e40-99ae-d630baa9c981": {"__data__": {"id_": "3b2a8a11-1844-4e40-99ae-d630baa9c981", "embedding": null, "metadata": {"window": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n", "original_text": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70a9bf8e-6e3a-4d96-859e-b0c224a8400d", "node_type": "1", "metadata": {"window": "To date, we've successfully closed the following transactions.  \n \n In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n", "original_text": "And \nin July of 2022, we completed the sale of our Denmark business. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ee18f8957b0b23228554123c100820b3e406b4cf4c101f4dc2620e7757045c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e393ee25-ac0b-48cd-9aa4-add91df17604", "node_type": "1", "metadata": {"window": "In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n", "original_text": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n"}, "hash": "ddfd281b657248f59cdc48eeb2f0f0f04bd92dd796fa034336874451426218fc", "class_name": "RelatedNodeInfo"}}, "text": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. ", "start_char_idx": 2228, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e393ee25-ac0b-48cd-9aa4-add91df17604": {"__data__": {"id_": "e393ee25-ac0b-48cd-9aa4-add91df17604", "embedding": null, "metadata": {"window": "In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n", "original_text": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b2a8a11-1844-4e40-99ae-d630baa9c981", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, we completed the sales of our Austrian business and the remaining share of \nour German joint venture.  In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n", "original_text": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3210fd89aedd5231de00fb7abc779c0ad5ef19890408bd4bb8ba90a1cc9703d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "524a8b8d-2afa-41bf-98c3-9581ad5e4800", "node_type": "1", "metadata": {"window": "And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. ", "original_text": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n"}, "hash": "bbef6a356b2e32b69eec10c5c86f863f7dc9055b6aee0a0745eeb89b69fb416b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n", "start_char_idx": 2368, "end_char_idx": 2467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "524a8b8d-2afa-41bf-98c3-9581ad5e4800": {"__data__": {"id_": "524a8b8d-2afa-41bf-98c3-9581ad5e4800", "embedding": null, "metadata": {"window": "And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. ", "original_text": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e393ee25-ac0b-48cd-9aa4-add91df17604", "node_type": "1", "metadata": {"window": "In April of 2022, we completed the sale of our UK retail and wholesale operations.  And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n", "original_text": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ddbb85af0bee8e8134a3071fc6aea15612a493e9fc48cc7a56e58daf5c72b46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37fa92ce-943a-45ef-8c6c-a89d901819ab", "node_type": "1", "metadata": {"window": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n"}, "hash": "c1dc2376ccf9b23ea9b6053376d28aee6437bbc5882f21e2f29cece1f809d8bc", "class_name": "RelatedNodeInfo"}}, "text": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n", "start_char_idx": 2467, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37fa92ce-943a-45ef-8c6c-a89d901819ab": {"__data__": {"id_": "37fa92ce-943a-45ef-8c6c-a89d901819ab", "embedding": null, "metadata": {"window": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "524a8b8d-2afa-41bf-98c3-9581ad5e4800", "node_type": "1", "metadata": {"window": "And \nin July of 2022, we completed the sale of our Denmark business.  The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. ", "original_text": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f256e771a95edbcf2da1b04e09bd1ff38327a99d20b781a48890faaf00a16f96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8778d622-64dc-420a-8558-db6b9df538fe", "node_type": "1", "metadata": {"window": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n"}, "hash": "f04ab6087e719678bb32f9e60f8174643ae3c8d68305ab06fc8309e5613df2c5", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n", "start_char_idx": 2630, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8778d622-64dc-420a-8558-db6b9df538fe": {"__data__": {"id_": "8778d622-64dc-420a-8558-db6b9df538fe", "embedding": null, "metadata": {"window": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37fa92ce-943a-45ef-8c6c-a89d901819ab", "node_type": "1", "metadata": {"window": "The transaction with the PHOENIX Group to sell \noperations and other certain assets in several European co untries is also proceeding well.  We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "960f99484270e83ecb8669933489f083435d5b4a9989714bc822096feab537d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc10eb1-252f-436a-baa5-6026d39e4b2a", "node_type": "1", "metadata": {"window": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. "}, "hash": "00cf8d5ec621694a22abc2672a3bd930c788e5ba39af5bfcf0ba8719f0b5a155", "class_name": "RelatedNodeInfo"}}, "text": "As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n", "start_char_idx": 2909, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc10eb1-252f-436a-baa5-6026d39e4b2a": {"__data__": {"id_": "dfc10eb1-252f-436a-baa5-6026d39e4b2a", "embedding": null, "metadata": {"window": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8778d622-64dc-420a-8558-db6b9df538fe", "node_type": "1", "metadata": {"window": "We anticipate it will \nclose in the second half of fiscal 2023, subject to regulatory reviews.  \n \n We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99653493fd43d273ae8096c1434679fca401c97a8031b7610d85edae73e35057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "937b3715-4164-44d6-83a0-542ffb9a3f05", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n "}, "hash": "140dadcbddafa324f6217291933ed9a6df0ae83df1fc813768202482278f493f", "class_name": "RelatedNodeInfo"}}, "text": "Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. ", "start_char_idx": 3071, "end_char_idx": 3290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "937b3715-4164-44d6-83a0-542ffb9a3f05": {"__data__": {"id_": "937b3715-4164-44d6-83a0-542ffb9a3f05", "embedding": null, "metadata": {"window": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acdd98c6-6563-4a6e-b066-86f581f11c88", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de430aedd49f7e42a410cd1923ea1e40be03d6fd5916e7bf8748c8d29620b1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc10eb1-252f-436a-baa5-6026d39e4b2a", "node_type": "1", "metadata": {"window": "We continue to explore strategic alternatives to exit remaining operations in Norway, the only country that we've \nnot yet entere d into an agreement to sell.  \n \n For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem. ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1511e50c982b8a15998f8e831aea5c9825277bf8149bbdac25ebb6d727f5e2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f2b410a-b583-4eb1-ada4-38f690166acd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "original_text": "McKesson Corp.  "}, "hash": "bb808c4c9ddc1230793c2b1b5c1cbaa72d9ad23d95a234e92811706c88767c1f", "class_name": "RelatedNodeInfo"}}, "text": "In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "start_char_idx": 3290, "end_char_idx": 3538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f2b410a-b583-4eb1-ada4-38f690166acd": {"__data__": {"id_": "9f2b410a-b583-4eb1-ada4-38f690166acd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "937b3715-4164-44d6-83a0-542ffb9a3f05", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our remaining European operations will contribute adjusted operating profit of \napproximately $0.85 to $1.15 per diluted share, which includes accretion resulting from the held -for-sale \naccounting  and the transaction with the PHOENIX Group.  \n \n As discussed at our December Investor Day, we intend to deploy capital to share repurchases to offset the \ndilution resulting from the European divestitures.  \n \n Exiting operations in Europe allows us to focus on a nother important strategic priority, expanding our oncology \nand biopharma services ecosystems, and we took an important step this quarter in our oncology ecosystem.  In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "original_text": "In \nJune, we announced an agreement to form a joint venture combining McKesson's US Oncology  Research and \nHCA Healthcare's Sarah Cannon Research Institute including the acquisition of Genospace, Sarah Cannon's \npersonalized medicine platform.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e12f54dbd09d8130f167b2218eede3f66763c512a0940b9222480e2fafc0cc3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2a12234-ff10-4715-9e93-e682a8019f96", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations. "}, "hash": "0fade3f2aeb815c95e739e02770f6efc0ffeaeee7944771b76763416f7e62056", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2a12234-ff10-4715-9e93-e682a8019f96": {"__data__": {"id_": "b2a12234-ff10-4715-9e93-e682a8019f96", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f2b410a-b583-4eb1-ada4-38f690166acd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2257d1c9d7edf5e9f9c6cc9eaf9167f83c665b39105a9590aa9d78c97f02d98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8a35de9-ecf4-4e4a-960d-cb8a24669ca6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. ", "original_text": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting. "}, "hash": "6ea116bf84c234e14b450ca1c34b3b85bfe23ffeae8dcd6baf02662791224f88", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations. ", "start_char_idx": 16, "end_char_idx": 249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8a35de9-ecf4-4e4a-960d-cb8a24669ca6": {"__data__": {"id_": "a8a35de9-ecf4-4e4a-960d-cb8a24669ca6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. ", "original_text": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2a12234-ff10-4715-9e93-e682a8019f96", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba1442227492d3b545a98824949c4fc5acdb403d5dae89687a7a78fe242259cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efce78af-7fbe-4f52-b86d-5326fff03f29", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n", "original_text": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. "}, "hash": "e9ee3ebc29ea8b553a6c689e67d34c5a16e7b9b16b2f2969bb4c75efd5567b1a", "class_name": "RelatedNodeInfo"}}, "text": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting. ", "start_char_idx": 249, "end_char_idx": 358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efce78af-7fbe-4f52-b86d-5326fff03f29": {"__data__": {"id_": "efce78af-7fbe-4f52-b86d-5326fff03f29", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n", "original_text": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8a35de9-ecf4-4e4a-960d-cb8a24669ca6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. ", "original_text": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1afa3dcb20994065193d2e1954d91cc7334ad2e04a4708451e03a13940e698ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845d4e4f-72cb-4b19-813b-e0b6df9cb377", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. ", "original_text": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n"}, "hash": "cfb2c57f5b41211dbcdb6b3a0565edb0bd665f8ceea65f519d3de11a9c9fdcc9", "class_name": "RelatedNodeInfo"}}, "text": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "start_char_idx": 358, "end_char_idx": 482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845d4e4f-72cb-4b19-813b-e0b6df9cb377": {"__data__": {"id_": "845d4e4f-72cb-4b19-813b-e0b6df9cb377", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. ", "original_text": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efce78af-7fbe-4f52-b86d-5326fff03f29", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n", "original_text": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95f5188205170531b289bcd311feacf771ed9dbaf252acf6b4131dd8c6b3fb4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d7a094f-1ef7-4fb1-86cf-29dfb09fad97", "node_type": "1", "metadata": {"window": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. ", "original_text": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. "}, "hash": "acc86b0d2c62b52fce1c72185aea3fc2c19b49eceb108a1c89dcb9668328edd6", "class_name": "RelatedNodeInfo"}}, "text": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n", "start_char_idx": 482, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d7a094f-1ef7-4fb1-86cf-29dfb09fad97": {"__data__": {"id_": "0d7a094f-1ef7-4fb1-86cf-29dfb09fad97", "embedding": null, "metadata": {"window": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. ", "original_text": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845d4e4f-72cb-4b19-813b-e0b6df9cb377", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. ", "original_text": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a101b436cfb1b2ac48903b2736b39156ff2ad20af3aa53abaacb1e830f34cf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "435d3427-9414-49d2-a646-a4ca1853d51d", "node_type": "1", "metadata": {"window": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n", "original_text": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n"}, "hash": "258d9894e807074eb531fd0d227702ab0e5bb5532d402bb4b61ee921dab195fc", "class_name": "RelatedNodeInfo"}}, "text": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. ", "start_char_idx": 610, "end_char_idx": 895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "435d3427-9414-49d2-a646-a4ca1853d51d": {"__data__": {"id_": "435d3427-9414-49d2-a646-a4ca1853d51d", "embedding": null, "metadata": {"window": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n", "original_text": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d7a094f-1ef7-4fb1-86cf-29dfb09fad97", "node_type": "1", "metadata": {"window": "It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. ", "original_text": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "068948aeb0724d5137928dfd78673544eb15ef320e4a93f1fdd68e7836ef6426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "197fca61-c016-4809-b584-5b63291c9e86", "node_type": "1", "metadata": {"window": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n", "original_text": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. "}, "hash": "aed8f08db8afc67e3352eb6c8be4b76736b1290c086f3f17096e7451e98662b5", "class_name": "RelatedNodeInfo"}}, "text": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n", "start_char_idx": 895, "end_char_idx": 969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "197fca61-c016-4809-b584-5b63291c9e86": {"__data__": {"id_": "197fca61-c016-4809-b584-5b63291c9e86", "embedding": null, "metadata": {"window": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n", "original_text": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "435d3427-9414-49d2-a646-a4ca1853d51d", "node_type": "1", "metadata": {"window": "The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval.  We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n", "original_text": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2243cac61c068647a6654553b06090bfc41c6f7600692fbf92c6a32f8a5ad2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57ab07d1-cad1-4552-bde7-729c07500c6c", "node_type": "1", "metadata": {"window": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n", "original_text": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. "}, "hash": "927107c4806d98e35de95704f54a4919f005c62d2bba1ab5bb29d025083e9eda", "class_name": "RelatedNodeInfo"}}, "text": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. ", "start_char_idx": 969, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57ab07d1-cad1-4552-bde7-729c07500c6c": {"__data__": {"id_": "57ab07d1-cad1-4552-bde7-729c07500c6c", "embedding": null, "metadata": {"window": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n", "original_text": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "197fca61-c016-4809-b584-5b63291c9e86", "node_type": "1", "metadata": {"window": "We do not anticipate this transaction will \nhave a material imp act on our fiscal 2023 adjusted earnings per share outlook.  \n \n Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n", "original_text": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae17ee096788816a7e39daeae7fbbc1234051b43afd272d5c8d2344b29eb409b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "216de203-dc90-402c-9045-57c1be875ffb", "node_type": "1", "metadata": {"window": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%. ", "original_text": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n"}, "hash": "e5ca5db5aa34f6cafdda6813b2bcc2abeb3366074d2cb6003ab5da078a6334e6", "class_name": "RelatedNodeInfo"}}, "text": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. ", "start_char_idx": 1081, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "216de203-dc90-402c-9045-57c1be875ffb": {"__data__": {"id_": "216de203-dc90-402c-9045-57c1be875ffb", "embedding": null, "metadata": {"window": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%. ", "original_text": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57ab07d1-cad1-4552-bde7-729c07500c6c", "node_type": "1", "metadata": {"window": "Next, as Brian mentioned earlier, our contract with the US government to serve as the centralized distributor for \nCOVID -19 vaccines was recently extended through July of 2023, and the contract fo r the kitting and storage of \nancillary supplies was extended through January of 2023.  I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n", "original_text": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7536242e3c85cf92e402bf583c4421f84c46485509ca7deb1b07aedc9cc36a1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0950528-60c1-4172-a17c-fae3513f111b", "node_type": "1", "metadata": {"window": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. ", "original_text": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n"}, "hash": "78d3511e3f2e46aed7c4117fb924affabb8a7a480bf88875d0e04781b1c116e0", "class_name": "RelatedNodeInfo"}}, "text": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n", "start_char_idx": 1190, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0950528-60c1-4172-a17c-fae3513f111b": {"__data__": {"id_": "f0950528-60c1-4172-a17c-fae3513f111b", "embedding": null, "metadata": {"window": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. ", "original_text": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "216de203-dc90-402c-9045-57c1be875ffb", "node_type": "1", "metadata": {"window": "I'll discuss the impact of fiscal 2023 guidance later in \nmy remarks.  \n \n Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%. ", "original_text": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f634f495be36228e551dc6e21f239d35e96ac61e0a7381dc3a2b9455b6c50919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfe07f87-6403-45fb-9ae0-080a27672c62", "node_type": "1", "metadata": {"window": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n", "original_text": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n"}, "hash": "c3c427016f03b0515d1fa0a1a1d8951c1dd6d170c6c640c19d3a10c8066e9611", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n", "start_char_idx": 1274, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfe07f87-6403-45fb-9ae0-080a27672c62": {"__data__": {"id_": "dfe07f87-6403-45fb-9ae0-080a27672c62", "embedding": null, "metadata": {"window": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n", "original_text": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0950528-60c1-4172-a17c-fae3513f111b", "node_type": "1", "metadata": {"window": "Finally, I want to point out one additional item that will impact our fiscal second quarter GAAP -only results.  In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. ", "original_text": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e8cea0e7bd6bc41b83a799585179786b5ebe61035db4512a1a6d9809eb27f94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2055d0d8-be83-41ff-a4de-1b0f0aa5e6fb", "node_type": "1", "metadata": {"window": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. ", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 4%. "}, "hash": "2337f472564f924677f8232e58e5d6d58424f7dac9618090b9dfaee7bf1eff90", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n", "start_char_idx": 1451, "end_char_idx": 1674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2055d0d8-be83-41ff-a4de-1b0f0aa5e6fb": {"__data__": {"id_": "2055d0d8-be83-41ff-a4de-1b0f0aa5e6fb", "embedding": null, "metadata": {"window": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. ", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 4%. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfe07f87-6403-45fb-9ae0-080a27672c62", "node_type": "1", "metadata": {"window": "In July \nof 2022, McKesson exited one of its investments in equity securities with proceeds of $179 million.  We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n", "original_text": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c8d9f05c0ccb0acf0b30340e5d133c4e1603808cd799dae930b84419068169e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d19dcd6-46e5-4217-af45-ef122418c549", "node_type": "1", "metadata": {"window": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n", "original_text": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. "}, "hash": "851c8b21aaa7a460002ba0cb759680a4caa7495ebe9ea2e5a684e6d332ec22a8", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3 billion for the quarter, a decrease of 4%. ", "start_char_idx": 1674, "end_char_idx": 1737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d19dcd6-46e5-4217-af45-ef122418c549": {"__data__": {"id_": "4d19dcd6-46e5-4217-af45-ef122418c549", "embedding": null, "metadata": {"window": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n", "original_text": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2055d0d8-be83-41ff-a4de-1b0f0aa5e6fb", "node_type": "1", "metadata": {"window": "We will \nrecognize a GAAP -only gain within other income in the second quarter.  \n \n Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. ", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 4%. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18a974389b1ff1f00d94dbdee534ac310fa397716212ad6ea954f639bffa4469", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a77dc1f1-6b0f-4562-8837-bd27d8814d45", "node_type": "1", "metadata": {"window": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n", "original_text": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n"}, "hash": "5dd00fe9af4e1795ae3860ed5f17553a39e85a72d722fc13d6af1d08f0b9b049", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. ", "start_char_idx": 1737, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a77dc1f1-6b0f-4562-8837-bd27d8814d45": {"__data__": {"id_": "a77dc1f1-6b0f-4562-8837-bd27d8814d45", "embedding": null, "metadata": {"window": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n", "original_text": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d19dcd6-46e5-4217-af45-ef122418c549", "node_type": "1", "metadata": {"window": "Moving now to a review of our first quarter fiscal 2023 re sults, my comments today will refer to our adjusted \nresults on a year -over-year basis unless I state otherwise.  \n \n Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n", "original_text": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c5067d9222748502a0212e8d18ae1813dd99d52e8c6304a8e8fe4e4139a9793", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f563057-2ded-48e7-8892-0339e4355ef3", "node_type": "1", "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. ", "original_text": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. "}, "hash": "0032d395234773d62cbe5774df8d073908f273102dca67e6b2ea09e1f00d15aa", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n", "start_char_idx": 2058, "end_char_idx": 2175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f563057-2ded-48e7-8892-0339e4355ef3": {"__data__": {"id_": "0f563057-2ded-48e7-8892-0339e4355ef3", "embedding": null, "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. ", "original_text": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a77dc1f1-6b0f-4562-8837-bd27d8814d45", "node_type": "1", "metadata": {"window": "Consolidated revenues of $67.2 billion increased 7%, reflecting growth in the US Pharmaceutical segment, \npartially offset by lower revenues in the International segment as a result of the European divestiture process.  \n \n Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n", "original_text": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30d6e6b787bbe778e1ccb5e692c92c72678824051bd1b1c08b7812fab95fe8c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34dbd582-5ad7-4716-8417-7ed83bbf7acb", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n", "original_text": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n"}, "hash": "0e1e62c9685047916f26db10308b3f0018ae15c0930ec37045e90d89c508f931", "class_name": "RelatedNodeInfo"}}, "text": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. ", "start_char_idx": 2175, "end_char_idx": 2390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34dbd582-5ad7-4716-8417-7ed83bbf7acb": {"__data__": {"id_": "34dbd582-5ad7-4716-8417-7ed83bbf7acb", "embedding": null, "metadata": {"window": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n", "original_text": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f563057-2ded-48e7-8892-0339e4355ef3", "node_type": "1", "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 4%.  Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. ", "original_text": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa315a172e189a02c505f988df2389c43fb78151c6b657aeb3395f64bcc67f73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a8b53c3-3d2f-40b6-99fa-b25c0be218b8", "node_type": "1", "metadata": {"window": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n", "original_text": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n"}, "hash": "9350fd790614bcffca227b6faebdb8016cfb50b1849b35f180b1011e98812265", "class_name": "RelatedNodeInfo"}}, "text": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n", "start_char_idx": 2390, "end_char_idx": 2617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a8b53c3-3d2f-40b6-99fa-b25c0be218b8": {"__data__": {"id_": "7a8b53c3-3d2f-40b6-99fa-b25c0be218b8", "embedding": null, "metadata": {"window": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n", "original_text": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34dbd582-5ad7-4716-8417-7ed83bbf7acb", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business \noperations and completed divestitures, gross profit increased 9%, a res ult of organic growth in our Medical -\nSurgical Solutions segment, increased volume in specialty products in our US Pharmaceutical segment, and \ngrowth in the Prescription Technology Solutions segment.  Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n", "original_text": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e23ab125874091c4d99929862bb2aec3a67c42140612de71961e3a3a76d52b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5f3ec4f-e172-408f-9de5-c2476d3b3034", "node_type": "1", "metadata": {"window": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical. ", "original_text": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. "}, "hash": "e4b41e0878e9d10dc3556fc271cdf8ed5040fbf1a9740abe75c4da5ecb754df7", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n", "start_char_idx": 2617, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5f3ec4f-e172-408f-9de5-c2476d3b3034": {"__data__": {"id_": "b5f3ec4f-e172-408f-9de5-c2476d3b3034", "embedding": null, "metadata": {"window": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical. ", "original_text": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a8b53c3-3d2f-40b6-99fa-b25c0be218b8", "node_type": "1", "metadata": {"window": "Operating expenses decreased by 10% in the quarter \ndue to  completed divestitures in the International segment.  \n \n As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n", "original_text": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d8b911d772d1b7696769b1b5b39d43c32b03bf82a431fae4f32999b300d6406", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a539cf1-12ee-4a83-9693-309d5cd4ad5c", "node_type": "1", "metadata": {"window": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n", "original_text": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n"}, "hash": "4954c9373915cab5ab634aa1fb1bca2bed188947f6e81b04a8c8a6d64ffb7f66", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. ", "start_char_idx": 2788, "end_char_idx": 3034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a539cf1-12ee-4a83-9693-309d5cd4ad5c": {"__data__": {"id_": "8a539cf1-12ee-4a83-9693-309d5cd4ad5c", "embedding": null, "metadata": {"window": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n", "original_text": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5f3ec4f-e172-408f-9de5-c2476d3b3034", "node_type": "1", "metadata": {"window": "As a result, operating profit was $1.1 billion for the quarter, an increase of 4% led by growth in US Pharmaceutical \nand improved prescription transaction volumes in the Prescription Technology Solutio ns segment.  When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical. ", "original_text": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42f9baca300bfc4d44fb4004f194036d0f4000057978b7228d155ccdc3d7440f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c9c3f27-fcdf-469b-9510-1ba20b63f70d", "node_type": "1", "metadata": {"window": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n"}, "hash": "b9197b24f2daef923ccf04241ecc366b1131a69d9011b84e88020f7a2fb590b8", "class_name": "RelatedNodeInfo"}}, "text": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n", "start_char_idx": 3034, "end_char_idx": 3155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c9c3f27-fcdf-469b-9510-1ba20b63f70d": {"__data__": {"id_": "7c9c3f27-fcdf-469b-9510-1ba20b63f70d", "embedding": null, "metadata": {"window": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a539cf1-12ee-4a83-9693-309d5cd4ad5c", "node_type": "1", "metadata": {"window": "When \nexcluding the impact related to the distribution of COVID -19-related products and services and gains and losses \nassociated with McKesson Ventures' equity investments, operating profit increased 13% year -over-year.  \n \n Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n", "original_text": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c81960792f293be79dab8ec00ed162ed5c4561a055792937c7d29b509d6f4be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a5f685e-083d-4bcc-b5ad-869205e48092", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Starting with US Pharmaceutical. "}, "hash": "101244822b059452ffd84f4a5b92d13181565ff36c7f6e2bcf1c72bb7da4ad32", "class_name": "RelatedNodeInfo"}}, "text": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n", "start_char_idx": 3155, "end_char_idx": 3247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a5f685e-083d-4bcc-b5ad-869205e48092": {"__data__": {"id_": "1a5f685e-083d-4bcc-b5ad-869205e48092", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Starting with US Pharmaceutical. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c9c3f27-fcdf-469b-9510-1ba20b63f70d", "node_type": "1", "metadata": {"window": "Interest expense was $45  million in the quarter, a decrease of 8% due a net reduction of debt year -over-year, and \nthe effective tax rate was 18.4% for the quarter.  \n \n Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "441988a79ef021ed4c4e7ec6db5a496d95a3e31b9674a94b7540e7705bfab5ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e4a36f-8cb7-482f-bfa0-01ff9a483b45", "node_type": "1", "metadata": {"window": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n"}, "hash": "9ffc66edec269d7c9c0cf4737c0d1e8cfc5645c5b281ebab7ca76ae31f62266c", "class_name": "RelatedNodeInfo"}}, "text": "Starting with US Pharmaceutical. ", "start_char_idx": 3247, "end_char_idx": 3280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e4a36f-8cb7-482f-bfa0-01ff9a483b45": {"__data__": {"id_": "50e4a36f-8cb7-482f-bfa0-01ff9a483b45", "embedding": null, "metadata": {"window": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a5f685e-083d-4bcc-b5ad-869205e48092", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, first quarter diluted weighted average shares outstanding were 145.9 \nmillion,  a decrease of 8% year -over-year resulting from share repurchases throughout fiscal 2022 and the first \nquarter of fiscal 2023.  Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Starting with US Pharmaceutical. ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c0c7a216890481f86637e2c145b7cdbe882b4066325f558abc76239849f3ac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73fa310e-a499-4926-af74-ad9456ea9f46", "node_type": "1", "metadata": {"window": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  "}, "hash": "bad79015f1961549e02c234427559443dc91f5b432baaf3cc2190e52a93d79cc", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n", "start_char_idx": 3280, "end_char_idx": 3524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73fa310e-a499-4926-af74-ad9456ea9f46": {"__data__": {"id_": "73fa310e-a499-4926-af74-ad9456ea9f46", "embedding": null, "metadata": {"window": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f730b85324d07cb9011796c39b00936abc4b969da58b55192b4036043cac6b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e4a36f-8cb7-482f-bfa0-01ff9a483b45", "node_type": "1", "metadata": {"window": "Overall, first quarter adjusted earnings per diluted share was $5.83, an increase of 5% \ncompared to the prior year.  \n \n Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "006db2d1834fbc082ce2f0e23524d9f436603d574937863524aa81762ce552f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a57d1ad-16b3-435d-a8e5-44d22bc493b0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "49aff7493b69df5ffe6fb414b53a27eeae1068b1f993bf38ef2c6d3b808cd914", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "start_char_idx": 3524, "end_char_idx": 3792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a57d1ad-16b3-435d-a8e5-44d22bc493b0": {"__data__": {"id_": "7a57d1ad-16b3-435d-a8e5-44d22bc493b0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73fa310e-a499-4926-af74-ad9456ea9f46", "node_type": "1", "metadata": {"window": "Now onto our  first quarter segment results, which can be found on slides 7 through 12.  \n \n Starting with US Pharmaceutical.  Revenues were $56.9 billion, an increase of 14% year -over-year resulting from \nincreased specialty product volumes led by retail national account cu stomers and market growth, which was \npartially offset by branded to generic conversions.  \n \n Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "original_text": "Operating profit increased 4% to $711 million led by growth in distribution of specialty products to providers and \nhealth systems, generic launches, and improved perf ormance of Ontada, which was partially offset by lower \nvolumes of COVID -19 vaccine distribution.  ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e33b08d89634b519c706a6c466bca7223b4b69bc66756671f633dcffa5af4d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b635ece-64a4-4ccc-be95-17e1ef3d557d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022. "}, "hash": "ffe197370d067f6a5833ce3fbee8d7336605aea2eb996afd527d669bc87d926f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b635ece-64a4-4ccc-be95-17e1ef3d557d": {"__data__": {"id_": "1b635ece-64a4-4ccc-be95-17e1ef3d557d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a57d1ad-16b3-435d-a8e5-44d22bc493b0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9471f28fc82109d169b971080f19dbc06c481ea960de8a8acbe323808008619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc1afb08-5ede-484b-be20-202066a03e9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n", "original_text": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%. "}, "hash": "a645021b51640353d2bebc22e85367f19ced058143f334d0e2245247bbdac66f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022. ", "start_char_idx": 16, "end_char_idx": 420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc1afb08-5ede-484b-be20-202066a03e9f": {"__data__": {"id_": "dc1afb08-5ede-484b-be20-202066a03e9f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n", "original_text": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b635ece-64a4-4ccc-be95-17e1ef3d557d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0095c5b65415ff204e80c07bc44d97072276166cfa629876d80ac22b65b97b60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f627ce10-2aef-42ba-8773-a4d994248e50", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. ", "original_text": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n"}, "hash": "dea46a92880e22403e8d8fd1f5438f754d7f7658e29cb983c1605928ad63cf25", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%. ", "start_char_idx": 420, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f627ce10-2aef-42ba-8773-a4d994248e50": {"__data__": {"id_": "f627ce10-2aef-42ba-8773-a4d994248e50", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. ", "original_text": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc1afb08-5ede-484b-be20-202066a03e9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n", "original_text": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98515f8f01b76781a5244a3cc6e1205e1667907957900a2a77d8d23c13d22099", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85dc9ee2-c492-430a-852a-d1d07364954e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n", "original_text": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n"}, "hash": "d068a0c59b61e2340c7e0ddf5957705d09e8f08b5a1c1f93bd6baaf217f40e2d", "class_name": "RelatedNodeInfo"}}, "text": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "start_char_idx": 548, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85dc9ee2-c492-430a-852a-d1d07364954e": {"__data__": {"id_": "85dc9ee2-c492-430a-852a-d1d07364954e", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n", "original_text": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f627ce10-2aef-42ba-8773-a4d994248e50", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. ", "original_text": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8135d4406d57742b89eca77630da856aed82f6e2bffe2e0b827c51ae4bf40ccb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bc9011e-2767-4063-b7d8-144b98bb2830", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. ", "original_text": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n"}, "hash": "c9bfb54b9097db651b7cfb0742a4d3bade9e3dd37db097e6cd5ffe3fe4c78091", "class_name": "RelatedNodeInfo"}}, "text": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n", "start_char_idx": 661, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bc9011e-2767-4063-b7d8-144b98bb2830": {"__data__": {"id_": "7bc9011e-2767-4063-b7d8-144b98bb2830", "embedding": null, "metadata": {"window": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. ", "original_text": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85dc9ee2-c492-430a-852a-d1d07364954e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n", "original_text": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99a380c4f0fa3828814ba2bbe5b957f8c08dea30b7d39a599a71a071888a9586", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eb1a97f-c35f-4628-a3ff-416e5d27d779", "node_type": "1", "metadata": {"window": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n", "original_text": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. "}, "hash": "84931e8a0a5cd980c1577b6996e50deff9e5284d37bf015ca850eb84ac4693c5", "class_name": "RelatedNodeInfo"}}, "text": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n", "start_char_idx": 946, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eb1a97f-c35f-4628-a3ff-416e5d27d779": {"__data__": {"id_": "0eb1a97f-c35f-4628-a3ff-416e5d27d779", "embedding": null, "metadata": {"window": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n", "original_text": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bc9011e-2767-4063-b7d8-144b98bb2830", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. ", "original_text": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "823cb997c5b45dec67e0a00838d3e5717fd710253fdca449e44623a8797d7a17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980d3633-9b27-42ef-bc6d-f99e2db6b61c", "node_type": "1", "metadata": {"window": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n", "original_text": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n"}, "hash": "fbd2ea72fa0afa5ac1b8c8cc172afe006a4f5f3ae89f0746b13408b9022e82f0", "class_name": "RelatedNodeInfo"}}, "text": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. ", "start_char_idx": 1057, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980d3633-9b27-42ef-bc6d-f99e2db6b61c": {"__data__": {"id_": "980d3633-9b27-42ef-bc6d-f99e2db6b61c", "embedding": null, "metadata": {"window": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n", "original_text": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eb1a97f-c35f-4628-a3ff-416e5d27d779", "node_type": "1", "metadata": {"window": "Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n", "original_text": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f418fa3cd3d9dab5209008923a278b4343ed25185266e7e381bb0a169590f4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b332e1a4-83a6-40d0-b5d2-1b7688189df3", "node_type": "1", "metadata": {"window": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business. ", "original_text": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. "}, "hash": "e2daa0be4e5c040c1d3fbdb141e5718255352320a5a69d2ea9d33cbf6297f039", "class_name": "RelatedNodeInfo"}}, "text": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n", "start_char_idx": 1184, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b332e1a4-83a6-40d0-b5d2-1b7688189df3": {"__data__": {"id_": "b332e1a4-83a6-40d0-b5d2-1b7688189df3", "embedding": null, "metadata": {"window": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business. ", "original_text": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980d3633-9b27-42ef-bc6d-f99e2db6b61c", "node_type": "1", "metadata": {"window": "Operating margins were modestly lower in the quarter, impacted by mix as the growth from health systems in \nmultispecialty providers were partially offset by robust retail national account customer growt h, which contributed \n7% to the overall 14% year -over-year top line growth.  \n \n Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n", "original_text": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb4e70ecfe6bebb8c407b56680a01e3ea8855aae94f9e4d3bc5619e8bd9aaa43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5adc672-7b0b-4972-8f9e-7c8305828ff9", "node_type": "1", "metadata": {"window": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n", "original_text": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n"}, "hash": "2f65fd3ea0634d24ff27e8742ebd990e7f9fe8507f492b482d76c2be29e41388", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. ", "start_char_idx": 1291, "end_char_idx": 1496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5adc672-7b0b-4972-8f9e-7c8305828ff9": {"__data__": {"id_": "e5adc672-7b0b-4972-8f9e-7c8305828ff9", "embedding": null, "metadata": {"window": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n", "original_text": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b332e1a4-83a6-40d0-b5d2-1b7688189df3", "node_type": "1", "metadata": {"window": "Next, as Brian noted earlier, our Prescription Technology Solutions segment delivered another strong quarter. \n Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business. ", "original_text": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f72bf401eba9764cc04b88728008177b12e52a3e9a98b47fc97b2a84148e89ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66485863-969c-47e2-8375-b8718ce44dc5", "node_type": "1", "metadata": {"window": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n"}, "hash": "c4a8bfdd25eadc721d8a9d8095839d3fcaaa05376624c70aa411792b63306f82", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n", "start_char_idx": 1496, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66485863-969c-47e2-8375-b8718ce44dc5": {"__data__": {"id_": "66485863-969c-47e2-8375-b8718ce44dc5", "embedding": null, "metadata": {"window": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5adc672-7b0b-4972-8f9e-7c8305828ff9", "node_type": "1", "metadata": {"window": "Response to our access, affordability, and adherence solutions continu e to be strong across biopharma, providers \nand payers.  The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n", "original_text": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4939129a05898288d8deb4064c88ce2d763f61eaeb746e6eae5e1a7759503271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5447f708-183d-4d94-91aa-99be4622ef48", "node_type": "1", "metadata": {"window": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n", "original_text": "Operating profit increased 4% to $268 million, driven by strength across the primary care business. "}, "hash": "113f884fc9e46f5a6ccfd279ac5f45b070f97cf043370d63628e4e1954dafc25", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n", "start_char_idx": 1672, "end_char_idx": 2035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5447f708-183d-4d94-91aa-99be4622ef48": {"__data__": {"id_": "5447f708-183d-4d94-91aa-99be4622ef48", "embedding": null, "metadata": {"window": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n", "original_text": "Operating profit increased 4% to $268 million, driven by strength across the primary care business. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66485863-969c-47e2-8375-b8718ce44dc5", "node_type": "1", "metadata": {"window": "The scale and expanded suite of offerings continue to deliver for all stakeholders including patients.  \n \n Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87d9f2bdc705e0899285ba5e8a863d5ffa3cd6c1b1d0599cb849c2dce91ac3a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "417c575b-c7a6-42e0-9e61-5e5a195aa80c", "node_type": "1", "metadata": {"window": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results. ", "original_text": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n"}, "hash": "fc956d8671f74782fad552a4f962ca66c7e3ecfa885a14eb799f721bd5b2137a", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 4% to $268 million, driven by strength across the primary care business. ", "start_char_idx": 2035, "end_char_idx": 2135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "417c575b-c7a6-42e0-9e61-5e5a195aa80c": {"__data__": {"id_": "417c575b-c7a6-42e0-9e61-5e5a195aa80c", "embedding": null, "metadata": {"window": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results. ", "original_text": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5447f708-183d-4d94-91aa-99be4622ef48", "node_type": "1", "metadata": {"window": "Revenues were $1.1 billion, an increase of 21% year -over-year, driven by volume growth from bioph arma \nservices, which includes third -party logistics services and increased technology service revenues.  Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n", "original_text": "Operating profit increased 4% to $268 million, driven by strength across the primary care business. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36d3cc83fd23fdf52b9e67e1a1ac548ced9593bc2fe2c67e724037d97bade289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eb3a48b-63c0-45e0-80ca-b1a547c70ca3", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion. ", "original_text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. "}, "hash": "fddc572e09ed8e3ddaaaa99591742144dfe36ddff6d6f3d01e1f4ee19cad29ed", "class_name": "RelatedNodeInfo"}}, "text": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n", "start_char_idx": 2135, "end_char_idx": 2294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eb3a48b-63c0-45e0-80ca-b1a547c70ca3": {"__data__": {"id_": "3eb3a48b-63c0-45e0-80ca-b1a547c70ca3", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion. ", "original_text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "417c575b-c7a6-42e0-9e61-5e5a195aa80c", "node_type": "1", "metadata": {"window": "Operating profit \nincreased 19% to $165 million, reflecting the continued favorable market acceptance to a growing set of access, \naffordability, and adhe rence solutions.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results. ", "original_text": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b1698e76abeac5da97ea585c084eb9ad866f10688d36e889c17095d7cbf18d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690b3f22-014b-4d1a-8174-ffd7185765bc", "node_type": "1", "metadata": {"window": "Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%. ", "original_text": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n"}, "hash": "3671cb16d478b733a75179d8893d5733555c0889e8100b6641ad1b293b206f59", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. ", "start_char_idx": 2294, "end_char_idx": 2578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690b3f22-014b-4d1a-8174-ffd7185765bc": {"__data__": {"id_": "690b3f22-014b-4d1a-8174-ffd7185765bc", "embedding": null, "metadata": {"window": "Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%. ", "original_text": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eb3a48b-63c0-45e0-80ca-b1a547c70ca3", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.6 billion, an increase of 3% year -over-year, as \ngrowth in the primary care business, partially offset anticipated lower demand and sales for COVID -19 tests, and \nlower contribution  from kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program.  \n \n Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion. ", "original_text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2f7fde27fd343d8c1a694ec854dbe52473cb9fccbf1faa5dcebdddb4933ee19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61f5eab5-5a05-4af7-bb3e-4f5b6f29870d", "node_type": "1", "metadata": {"window": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. ", "original_text": "Next, let me address our International results. "}, "hash": "76c1b77f4f83830d5f5f1b17bf71092209f02c3d6ac83d91c1b59379abbe1a9d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n", "start_char_idx": 2578, "end_char_idx": 2717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61f5eab5-5a05-4af7-bb3e-4f5b6f29870d": {"__data__": {"id_": "61f5eab5-5a05-4af7-bb3e-4f5b6f29870d", "embedding": null, "metadata": {"window": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. ", "original_text": "Next, let me address our International results. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690b3f22-014b-4d1a-8174-ffd7185765bc", "node_type": "1", "metadata": {"window": "Operating profit increased 4% to $268 million, driven by strength across the primary care business.  Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%. ", "original_text": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "791a01dd360ca5ad0de8151c7d8a248c120f2abbd11a86761055abe327968a66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1426518-3dea-4330-a19b-221685f7266b", "node_type": "1", "metadata": {"window": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n", "original_text": "Revenues were $6.5 billion. "}, "hash": "582d76c573d166ff1071dc9a45f21848cb5155823db52c7edd092919011e63a4", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our International results. ", "start_char_idx": 2717, "end_char_idx": 2765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1426518-3dea-4330-a19b-221685f7266b": {"__data__": {"id_": "c1426518-3dea-4330-a19b-221685f7266b", "embedding": null, "metadata": {"window": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n", "original_text": "Revenues were $6.5 billion. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61f5eab5-5a05-4af7-bb3e-4f5b6f29870d", "node_type": "1", "metadata": {"window": "Improved \nvolumes and greater incidence of respiratory illness and the flu contributed to higher testing and patient visits in \nthe primary care business.  \n \n The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. ", "original_text": "Next, let me address our International results. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dc9225395ef2779d847e9ffb1450ebaf12775c6deb5c5862c15ca2e9769e895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccca91bd-e7dc-43e4-93d8-4ba89dd55254", "node_type": "1", "metadata": {"window": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate. ", "original_text": "And operating profit was $138 million, \nwhich was a decrease of 19%. "}, "hash": "0f27d02f61ad6f758222ec6d94dd593b326fbf8dde3ae63811dcc70b16a312ec", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $6.5 billion. ", "start_char_idx": 2765, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccca91bd-e7dc-43e4-93d8-4ba89dd55254": {"__data__": {"id_": "ccca91bd-e7dc-43e4-93d8-4ba89dd55254", "embedding": null, "metadata": {"window": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate. ", "original_text": "And operating profit was $138 million, \nwhich was a decrease of 19%. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1426518-3dea-4330-a19b-221685f7266b", "node_type": "1", "metadata": {"window": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies pr ovided a total benefit of approximately $0.25 per share in the quarter compared \nto $0.35 per share in the first quarter of fiscal 2022.  Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n", "original_text": "Revenues were $6.5 billion. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5703b9dd9b1b19ca4e26581a2f1bd9a4024a2977919ac54bafca8ad56473a56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d53254db-f586-4b7d-8ef5-3631c4da16c4", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year. ", "original_text": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. "}, "hash": "cf0b196a934b1f937dbe5892ecdea516166eab4d8d21acc012560f111243f777", "class_name": "RelatedNodeInfo"}}, "text": "And operating profit was $138 million, \nwhich was a decrease of 19%. ", "start_char_idx": 2793, "end_char_idx": 2862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d53254db-f586-4b7d-8ef5-3631c4da16c4": {"__data__": {"id_": "d53254db-f586-4b7d-8ef5-3631c4da16c4", "embedding": null, "metadata": {"window": "Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year. ", "original_text": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccca91bd-e7dc-43e4-93d8-4ba89dd55254", "node_type": "1", "metadata": {"window": "Excluding the impact of these COVID related items, the \nMedical -Surgical Solutions segment delivered operating profit gro wth of 20%.  \n \n Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate. ", "original_text": "And operating profit was $138 million, \nwhich was a decrease of 19%. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d73864b8a2d6c9536bb9e478b6572441073072dc494201aad16c718cf2da9d0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fb9c586-798d-49de-b2c0-557974056f1c", "node_type": "1", "metadata": {"window": "Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. ", "original_text": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n"}, "hash": "4c1c7328cd560300bb1ed5002fe442d0c1d76d2c36e1e0a6db2a75baf5718b49", "class_name": "RelatedNodeInfo"}}, "text": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. ", "start_char_idx": 2862, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fb9c586-798d-49de-b2c0-557974056f1c": {"__data__": {"id_": "2fb9c586-798d-49de-b2c0-557974056f1c", "embedding": null, "metadata": {"window": "Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. ", "original_text": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d53254db-f586-4b7d-8ef5-3631c4da16c4", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year. ", "original_text": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcf8fe47074a69cc367e38219ad8e0cdd99eb71cd5f4cc944abde2f2ddba1593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49b8cc77-f0d6-4417-bda7-b4ec623cfedf", "node_type": "1", "metadata": {"window": "And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n", "original_text": "Moving onto corporate. "}, "hash": "2397982e557687f5deaf25462ec3885e2a7bd81344a62ef0a42d839b843e2d78", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n", "start_char_idx": 2994, "end_char_idx": 3108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49b8cc77-f0d6-4417-bda7-b4ec623cfedf": {"__data__": {"id_": "49b8cc77-f0d6-4417-bda7-b4ec623cfedf", "embedding": null, "metadata": {"window": "And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n", "original_text": "Moving onto corporate. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fb9c586-798d-49de-b2c0-557974056f1c", "node_type": "1", "metadata": {"window": "Revenues were $6.5 billion.  And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. ", "original_text": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf1ede83f83599ee3862f585d888a9430c0ccc4009b0dfb11ed0f36800a0ffde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f235ed21-b917-4ca0-a240-c385fd7d8c4d", "node_type": "1", "metadata": {"window": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n", "original_text": "Our corporate expenses were $145 million, a decrease of 6% year -over-year. "}, "hash": "7069630e3cf553390e1104f2568ca99643f84d2435ba68fa8523f90c0bb2038b", "class_name": "RelatedNodeInfo"}}, "text": "Moving onto corporate. ", "start_char_idx": 3108, "end_char_idx": 3131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f235ed21-b917-4ca0-a240-c385fd7d8c4d": {"__data__": {"id_": "f235ed21-b917-4ca0-a240-c385fd7d8c4d", "embedding": null, "metadata": {"window": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n", "original_text": "Our corporate expenses were $145 million, a decrease of 6% year -over-year. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49b8cc77-f0d6-4417-bda7-b4ec623cfedf", "node_type": "1", "metadata": {"window": "And operating profit was $138 million, \nwhich was a decrease of 19%.  On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n", "original_text": "Moving onto corporate. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83c3be2898e87aab47525e20020378b11552f8fda9ab54785a9ff2b0b29e6018", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4be4d90d-dc0c-4576-87f6-8208c3d8a83b", "node_type": "1", "metadata": {"window": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. "}, "hash": "964a38dc44e7283ef00f0842bce9d875d3d0dead46bed25d2302fb3115b20030", "class_name": "RelatedNodeInfo"}}, "text": "Our corporate expenses were $145 million, a decrease of 6% year -over-year. ", "start_char_idx": 3131, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4be4d90d-dc0c-4576-87f6-8208c3d8a83b": {"__data__": {"id_": "4be4d90d-dc0c-4576-87f6-8208c3d8a83b", "embedding": null, "metadata": {"window": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f235ed21-b917-4ca0-a240-c385fd7d8c4d", "node_type": "1", "metadata": {"window": "On an FX adjusted basis, revenues were $7.1 billion, a decrease of 23%, and \noperating profit was $1 52 million, a decrease of 11%.  Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n", "original_text": "Our corporate expenses were $145 million, a decrease of 6% year -over-year. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1194b5751abbb3f0345a7eb21ad13a9e3eb98759f80ef074728afd6870f768b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a0bc333-4464-4171-9203-c1cc04b9e2b3", "node_type": "1", "metadata": {"window": "Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "We incurred opioid -related litigation expenses of $19 million in the first quarter. \n"}, "hash": "9e6b034f43263068e46b7d210f4a4dcf80f8d99584c0d2a4db50fec62c452084", "class_name": "RelatedNodeInfo"}}, "text": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. ", "start_char_idx": 3207, "end_char_idx": 3362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a0bc333-4464-4171-9203-c1cc04b9e2b3": {"__data__": {"id_": "2a0bc333-4464-4171-9203-c1cc04b9e2b3", "embedding": null, "metadata": {"window": "Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "We incurred opioid -related litigation expenses of $19 million in the first quarter. \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4be4d90d-dc0c-4576-87f6-8208c3d8a83b", "node_type": "1", "metadata": {"window": "Our first quarter results reflect the impact from the \ndivestitures of McKesson's UK and Austrian businesses.  \n \n Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses. ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c93fd30b6fac4cdb2f8ba185a6f767f4cff6d1e603c50e5b117605ce6f05dcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c85e7fe-3225-490b-9473-1b12a55070d9", "node_type": "1", "metadata": {"window": "Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n"}, "hash": "76a361996c4a19a63eec067c61b3328b453da2b01df9437598b5d321df2ec31e", "class_name": "RelatedNodeInfo"}}, "text": "We incurred opioid -related litigation expenses of $19 million in the first quarter. \n", "start_char_idx": 3362, "end_char_idx": 3448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c85e7fe-3225-490b-9473-1b12a55070d9": {"__data__": {"id_": "4c85e7fe-3225-490b-9473-1b12a55070d9", "embedding": null, "metadata": {"window": "Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a0bc333-4464-4171-9203-c1cc04b9e2b3", "node_type": "1", "metadata": {"window": "Moving onto corporate.  Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "We incurred opioid -related litigation expenses of $19 million in the first quarter. \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cede09a8a07c235be0fbd8cd36c95c6ab6e299fc7dbca6f0c7ba6744ffd796ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14adc5c5-3bbf-43d3-b9a1-0b8095bf8bdc", "node_type": "1", "metadata": {"window": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n "}, "hash": "0a2b6861771bde847daf4160dfd3029f46e7f3cb3d605d460b47b4391e8244a6", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n", "start_char_idx": 3448, "end_char_idx": 3558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14adc5c5-3bbf-43d3-b9a1-0b8095bf8bdc": {"__data__": {"id_": "14adc5c5-3bbf-43d3-b9a1-0b8095bf8bdc", "embedding": null, "metadata": {"window": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a376ff29e4b92f733651165372cb184e2a9a6373310b6a6c7c47e50394d379d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c85e7fe-3225-490b-9473-1b12a55070d9", "node_type": "1", "metadata": {"window": "Our corporate expenses were $145 million, a decrease of 6% year -over-year.  In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd70a06a4e11c009b88bd6962899078ac754e2834c6233509c010dd4251fc395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8593620-175d-46c7-b052-d9bba51cda99", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13. ", "original_text": "McKesson Corp.  "}, "hash": "6e00030a7f41a5a70779d22acd3d3328156cc4c118d0feb603e081f96f78cf60", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "start_char_idx": 3558, "end_char_idx": 3780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8593620-175d-46c7-b052-d9bba51cda99": {"__data__": {"id_": "b8593620-175d-46c7-b052-d9bba51cda99", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14adc5c5-3bbf-43d3-b9a1-0b8095bf8bdc", "node_type": "1", "metadata": {"window": "In the \nquarter, w e recognized a tax receivable gain related to our previous change healthcare investment and lower \nopioid -related litigation expenses.  We incurred opioid -related litigation expenses of $19 million in the first quarter. \n We anticipate that the fiscal 2023 opi oid-related litigation expenses will be approximately $45 million.  \n \n During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "original_text": "During the quarter, we had net losses of $22 million related to equity investments within the McKesson Ventures' \nportfolio, which compares to net gains of approximately $7 million in the f irst quarter of fiscal 2022.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8de3404e2dc5650643b5a8e6a5aebd8833da83c1c1f2000136ff34c3a825925c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a01c12b1-5b24-445f-93e0-9b826509fe71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment. "}, "hash": "e95328d0eeafe2c11da4332a6f5381d595a2a662cafcf2236133fdd9ddae1bde", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a01c12b1-5b24-445f-93e0-9b826509fe71": {"__data__": {"id_": "a01c12b1-5b24-445f-93e0-9b826509fe71", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8593620-175d-46c7-b052-d9bba51cda99", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c892eabb740e2d8789ef5a4a79136c504ac9d38b38255eab44822f7c6c12c375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f3fb6f5-9371-4b43-bf66-53adacdc2141", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n", "original_text": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n"}, "hash": "551fc9b1710a8856ce7d7fcf0d288b92debc3020dbfa20c4a58e684ad172a941", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment. ", "start_char_idx": 16, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f3fb6f5-9371-4b43-bf66-53adacdc2141": {"__data__": {"id_": "6f3fb6f5-9371-4b43-bf66-53adacdc2141", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n", "original_text": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a01c12b1-5b24-445f-93e0-9b826509fe71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e96b8902316a679976284577253c85bb9a27b0dc3e41495bae7eb1ea105a6a48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00c2e69a-06f7-4b7e-8058-460d02ad1d69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. ", "original_text": "Let me turn to our cash position, which can be found on slide 13. "}, "hash": "8049a764c07f379dabceefa22439ba26dd6922cd8053079213ef6d0aa8474b7d", "class_name": "RelatedNodeInfo"}}, "text": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n", "start_char_idx": 461, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00c2e69a-06f7-4b7e-8058-460d02ad1d69": {"__data__": {"id_": "00c2e69a-06f7-4b7e-8058-460d02ad1d69", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. ", "original_text": "Let me turn to our cash position, which can be found on slide 13. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3fb6f5-9371-4b43-bf66-53adacdc2141", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n", "original_text": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b8dc8e3e4bea01aadc4d64b1df353305b39c64ab55264180e7e1519da88c245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "523b0679-382e-478f-ab8d-4f7e747debfe", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n", "original_text": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. "}, "hash": "87f1ccbce91975d0a324a35865d08b25b915b70d39cb7a6c8ff93b0900dd944c", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn to our cash position, which can be found on slide 13. ", "start_char_idx": 693, "end_char_idx": 759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "523b0679-382e-478f-ab8d-4f7e747debfe": {"__data__": {"id_": "523b0679-382e-478f-ab8d-4f7e747debfe", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n", "original_text": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00c2e69a-06f7-4b7e-8058-460d02ad1d69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. ", "original_text": "Let me turn to our cash position, which can be found on slide 13. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca1a5935cb1aadafae330ed3d5b29699497403eca54ea7e9ded0a4d7097e8360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4567667-42bf-4253-977d-a89361b32779", "node_type": "1", "metadata": {"window": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n", "original_text": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n"}, "hash": "03385045ff47eb1154a72fd993144793a6ca525aeaad19fb3be066d6686e51cc", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. ", "start_char_idx": 759, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4567667-42bf-4253-977d-a89361b32779": {"__data__": {"id_": "b4567667-42bf-4253-977d-a89361b32779", "embedding": null, "metadata": {"window": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n", "original_text": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "523b0679-382e-478f-ab8d-4f7e747debfe", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n", "original_text": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7b86eec8ed9196ecc2806268577639cecf4827070aaf29def6f7b5171d87918", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32e21420-d87e-42d6-971f-577b8bb50c09", "node_type": "1", "metadata": {"window": "Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. ", "original_text": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. "}, "hash": "4cd2535cad8f2373b200d0863c034718a1938fc5498628292ae334bf4a9084c3", "class_name": "RelatedNodeInfo"}}, "text": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n", "start_char_idx": 909, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32e21420-d87e-42d6-971f-577b8bb50c09": {"__data__": {"id_": "32e21420-d87e-42d6-971f-577b8bb50c09", "embedding": null, "metadata": {"window": "Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. ", "original_text": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4567667-42bf-4253-977d-a89361b32779", "node_type": "1", "metadata": {"window": "It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n", "original_text": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ce11e6379deb6ed327049b7e7573c20cc84f690391a0bb05093c35a02b40cd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "970f9052-0018-48af-9d56-f0bf1b685ecc", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. ", "original_text": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n"}, "hash": "121a94f6b3f891f2934df7d1b989c9935bd2901340a8cec441f54ea8451c13f0", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. ", "start_char_idx": 984, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "970f9052-0018-48af-9d56-f0bf1b685ecc": {"__data__": {"id_": "970f9052-0018-48af-9d56-f0bf1b685ecc", "embedding": null, "metadata": {"window": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. ", "original_text": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32e21420-d87e-42d6-971f-577b8bb50c09", "node_type": "1", "metadata": {"window": "Let me turn to our cash position, which can be found on slide 13.  As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. ", "original_text": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3d32db371b374f92f23d875ac19574a6a60289e33c98dd4572abb0bfc4292aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeffcac5-8152-4d5e-87c8-b1540ea5a7f6", "node_type": "1", "metadata": {"window": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n", "original_text": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n"}, "hash": "3b53c712375d89c94342d88507d38f1bb0e974fad7a71c83ee24fa1a9ea6faf0", "class_name": "RelatedNodeInfo"}}, "text": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n", "start_char_idx": 1206, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeffcac5-8152-4d5e-87c8-b1540ea5a7f6": {"__data__": {"id_": "eeffcac5-8152-4d5e-87c8-b1540ea5a7f6", "embedding": null, "metadata": {"window": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n", "original_text": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "970f9052-0018-48af-9d56-f0bf1b685ecc", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working capital \nmetrics, and resulting free cash flow can be impacted by timing and vary from quarter -to-quarter.  We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. ", "original_text": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c8aefbe2abb8aecd31afac7df274a5735d534aef3c9cffb7c5e63a43e42bce4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "146d4ba3-43d7-4e50-a6bc-2b7bcf518407", "node_type": "1", "metadata": {"window": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. ", "original_text": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. "}, "hash": "710ee68c4a75cdc2e554f1f431334dcb03fa0a6a7036f16ded0e7f196a5b3fd2", "class_name": "RelatedNodeInfo"}}, "text": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n", "start_char_idx": 1274, "end_char_idx": 1443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "146d4ba3-43d7-4e50-a6bc-2b7bcf518407": {"__data__": {"id_": "146d4ba3-43d7-4e50-a6bc-2b7bcf518407", "embedding": null, "metadata": {"window": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. ", "original_text": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeffcac5-8152-4d5e-87c8-b1540ea5a7f6", "node_type": "1", "metadata": {"window": "We ended the \nquarte r with $2.2 billion in cash and cash equivalents.  \n \n During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n", "original_text": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93d17dcf1beaa027c17a82feaebce588068ee70be1a7885feee80f70085830f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3c5fc2d-f79a-4927-8fe5-81c192b8f536", "node_type": "1", "metadata": {"window": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.  ", "original_text": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. "}, "hash": "975133cb61dd5fcc3482b9bc5f292015543dd7fefafe6e058340bfeef52a4ccf", "class_name": "RelatedNodeInfo"}}, "text": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. ", "start_char_idx": 1443, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3c5fc2d-f79a-4927-8fe5-81c192b8f536": {"__data__": {"id_": "a3c5fc2d-f79a-4927-8fe5-81c192b8f536", "embedding": null, "metadata": {"window": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.  ", "original_text": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "146d4ba3-43d7-4e50-a6bc-2b7bcf518407", "node_type": "1", "metadata": {"window": "During the quarter, we made $100 million of capital expenditures, which includes investments in technology, data, \nand analytics to support our growth priorities, including our oncology and biopharma servic es ecosystems.  For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. ", "original_text": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "150034b3b14f5bb6036940cdcc741fcc269e9e1f88080768e3db01599a039317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e48558a8-a525-479a-826f-7f72caf61724", "node_type": "1", "metadata": {"window": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A. ", "original_text": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n"}, "hash": "62e401ec047cf1c492141da21f543f1834bc70cc46cf7ee1f24e260dc20aeefe", "class_name": "RelatedNodeInfo"}}, "text": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. ", "start_char_idx": 1546, "end_char_idx": 1706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e48558a8-a525-479a-826f-7f72caf61724": {"__data__": {"id_": "e48558a8-a525-479a-826f-7f72caf61724", "embedding": null, "metadata": {"window": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A. ", "original_text": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3c5fc2d-f79a-4927-8fe5-81c192b8f536", "node_type": "1", "metadata": {"window": "For the \nquarter, we had negative free cash flow of $1 billion.  \n \n We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.  ", "original_text": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b003d13f6847ad8719e5f0db6a859ca17c6849f63a615e8be7fec5ef50e2743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd312b3d-55a7-4bab-9243-ea38382edcae", "node_type": "1", "metadata": {"window": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n", "original_text": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. "}, "hash": "4b0693a4e88f5b74defeb6ef8697c78cd146ec7de6b0ea7cf3260200c690069a", "class_name": "RelatedNodeInfo"}}, "text": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n", "start_char_idx": 1706, "end_char_idx": 1777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd312b3d-55a7-4bab-9243-ea38382edcae": {"__data__": {"id_": "cd312b3d-55a7-4bab-9243-ea38382edcae", "embedding": null, "metadata": {"window": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n", "original_text": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e48558a8-a525-479a-826f-7f72caf61724", "node_type": "1", "metadata": {"window": "We also returned $1.1 billion of cash to shareholders during the June quarter, which included $1 billion of share \nrepurchases and $71 million in dividend payments.  \n \n In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A. ", "original_text": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82c8da3cb9bdf1645149e9cde9079b23439cf91b6dfdbe21ca94b7723bf58838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fb1dbc8-286c-405e-ae01-533851687a57", "node_type": "1", "metadata": {"window": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. ", "original_text": "Our capital deployment principles remain firmly in place.  "}, "hash": "a7544e87ecc3ad568430a3766922cd3f581621126831251dd50a94f41df4ebe0", "class_name": "RelatedNodeInfo"}}, "text": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. ", "start_char_idx": 1777, "end_char_idx": 1918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fb1dbc8-286c-405e-ae01-533851687a57": {"__data__": {"id_": "3fb1dbc8-286c-405e-ae01-533851687a57", "embedding": null, "metadata": {"window": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. ", "original_text": "Our capital deployment principles remain firmly in place.  ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd312b3d-55a7-4bab-9243-ea38382edcae", "node_type": "1", "metadata": {"window": "In July, our  board of directors approved a 15% increase to our quarterly dividend to $0.54 per share.  And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n", "original_text": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bf027c63c3a5547a0566ff6e27ef2f1a8e7770aee9c820ed237bc268bb76ba6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9248b214-925e-4c61-9ff8-fbf5458be95c", "node_type": "1", "metadata": {"window": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n", "original_text": "We prioritize growth by \ninvesting internally and through M&A. "}, "hash": "039106f8675f15dbcceee6c655995075fb1143589c2db6f12f91a40794aafa54", "class_name": "RelatedNodeInfo"}}, "text": "Our capital deployment principles remain firmly in place.  ", "start_char_idx": 1918, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9248b214-925e-4c61-9ff8-fbf5458be95c": {"__data__": {"id_": "9248b214-925e-4c61-9ff8-fbf5458be95c", "embedding": null, "metadata": {"window": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n", "original_text": "We prioritize growth by \ninvesting internally and through M&A. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fb1dbc8-286c-405e-ae01-533851687a57", "node_type": "1", "metadata": {"window": "And the \nboard also approved a new $4 billion share repurchase authorization, which brings the total remaining share \nrepurchase authorization to $6.3 billion.  Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. ", "original_text": "Our capital deployment principles remain firmly in place.  ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d0a2f3fae241ba577b777b116a0ba25cae30b8b2b30e2c27a5b2a4b03b964d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb2b454d-0217-4d2c-9e3c-d46436320a85", "node_type": "1", "metadata": {"window": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view. ", "original_text": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n"}, "hash": "56a2565075998870d0de28fb81fba61b0c49592bbe83436221673b89e059795d", "class_name": "RelatedNodeInfo"}}, "text": "We prioritize growth by \ninvesting internally and through M&A. ", "start_char_idx": 1977, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb2b454d-0217-4d2c-9e3c-d46436320a85": {"__data__": {"id_": "eb2b454d-0217-4d2c-9e3c-d46436320a85", "embedding": null, "metadata": {"window": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view. ", "original_text": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9248b214-925e-4c61-9ff8-fbf5458be95c", "node_type": "1", "metadata": {"window": "Our fisc al 2023 guidance for share repurchases remains unchanged.  \n \n These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n", "original_text": "We prioritize growth by \ninvesting internally and through M&A. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c2c96a7584f346196da3acec3e539961e992608aaed985f03161918130d7dc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bcfbcb4-b014-41d5-b62f-87da7b78fe47", "node_type": "1", "metadata": {"window": "Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. ", "original_text": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. "}, "hash": "caddebc5d009c4bde61cc5c7a1ba5bb36b9f0bb05dfef3dbce2ef5a5ef442271", "class_name": "RelatedNodeInfo"}}, "text": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n", "start_char_idx": 2040, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bcfbcb4-b014-41d5-b62f-87da7b78fe47": {"__data__": {"id_": "3bcfbcb4-b014-41d5-b62f-87da7b78fe47", "embedding": null, "metadata": {"window": "Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. ", "original_text": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb2b454d-0217-4d2c-9e3c-d46436320a85", "node_type": "1", "metadata": {"window": "These actions demonstrate the confidence that the board of directors and management have in the execution \nagainst our strategic priorities.  Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view. ", "original_text": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be731c3d64042fb4426527e62f668e2defbd4032bbaa2455081d057acd7e0502", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "166eb00b-1774-40a9-99da-54ac0de7b175", "node_type": "1", "metadata": {"window": "We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n", "original_text": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n"}, "hash": "a01a81699f8b068a04de76429844e45fc0b17bd63fdbd399ce1bf43c26da7814", "class_name": "RelatedNodeInfo"}}, "text": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. ", "start_char_idx": 2199, "end_char_idx": 2325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "166eb00b-1774-40a9-99da-54ac0de7b175": {"__data__": {"id_": "166eb00b-1774-40a9-99da-54ac0de7b175", "embedding": null, "metadata": {"window": "We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n", "original_text": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bcfbcb4-b014-41d5-b62f-87da7b78fe47", "node_type": "1", "metadata": {"window": "Our capital deployment principles remain firmly in place.   We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. ", "original_text": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c3e96a6647bb7e8dda773fab4f38864e11f3c27635b9eae3ad43c51a4c4ead5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "804e60d5-d078-4cfc-8d77-66c10d68e695", "node_type": "1", "metadata": {"window": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. ", "original_text": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view. "}, "hash": "0d2d2c6ed4f775429c883d2edb01fd1f25431925eae2441ffe0cc0d55ceb08d4", "class_name": "RelatedNodeInfo"}}, "text": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n", "start_char_idx": 2325, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "804e60d5-d078-4cfc-8d77-66c10d68e695": {"__data__": {"id_": "804e60d5-d078-4cfc-8d77-66c10d68e695", "embedding": null, "metadata": {"window": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. ", "original_text": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "166eb00b-1774-40a9-99da-54ac0de7b175", "node_type": "1", "metadata": {"window": "We prioritize growth by \ninvesting internally and through M&A.  Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n", "original_text": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6355d0583a3931291987cedcdaf2890deb0812af27553e2e9a590201c9bd25f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b15a076-a877-4923-867e-63f1bd864feb", "node_type": "1", "metadata": {"window": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n", "original_text": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. "}, "hash": "d7ebd4254034134c0b57c547e5253da8d697ffee88dfd82e7f6e8cdec91a0e07", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view. ", "start_char_idx": 2504, "end_char_idx": 2581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b15a076-a877-4923-867e-63f1bd864feb": {"__data__": {"id_": "7b15a076-a877-4923-867e-63f1bd864feb", "embedding": null, "metadata": {"window": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n", "original_text": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "804e60d5-d078-4cfc-8d77-66c10d68e695", "node_type": "1", "metadata": {"window": "Our focus continues to center on the areas of oncology and biopharma \nservices, including the expansion of access, affordability, and adherence solutions.  \n \n Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. ", "original_text": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef18863b3786327c069857f47b51e298774722f2a578e8f566f70d382818879f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed323203-a3b6-4f1a-afff-3a7381e17bff", "node_type": "1", "metadata": {"window": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n", "original_text": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n"}, "hash": "2d376c1ea0e7ff559663707480cf61c333607f4194fe2dbde3ad07e34b9f4ddb", "class_name": "RelatedNodeInfo"}}, "text": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. ", "start_char_idx": 2581, "end_char_idx": 2691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed323203-a3b6-4f1a-afff-3a7381e17bff": {"__data__": {"id_": "ed323203-a3b6-4f1a-afff-3a7381e17bff", "embedding": null, "metadata": {"window": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n", "original_text": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b15a076-a877-4923-867e-63f1bd864feb", "node_type": "1", "metadata": {"window": "Next, we'll continue to return capital  to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n", "original_text": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c43fe927ea878a00d031a4b309d9691b5b7ab22bad7d514c4bfd6daab3c79018", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08fbcc77-8224-496d-baef-8aa3f7f12dfd", "node_type": "1", "metadata": {"window": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. ", "original_text": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. "}, "hash": "cf6a1babbb3359644d76e99d484e1dc3d6a905b01053453b77203e2c80476456", "class_name": "RelatedNodeInfo"}}, "text": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n", "start_char_idx": 2691, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08fbcc77-8224-496d-baef-8aa3f7f12dfd": {"__data__": {"id_": "08fbcc77-8224-496d-baef-8aa3f7f12dfd", "embedding": null, "metadata": {"window": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. ", "original_text": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed323203-a3b6-4f1a-afff-3a7381e17bff", "node_type": "1", "metadata": {"window": "And the third piece of the framework focuses on a strong balance sheet and financial position, which \nis underpinned by the maintenance of our investment grade credit rati ng. \n \n Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n", "original_text": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18cc4cb67d4cadaac6760adb886bf9c0d639eb3b7b5d3fd5888bb35ab90d5419", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc0ef75d-53ca-4c21-a065-8fe084813e6b", "node_type": "1", "metadata": {"window": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n", "original_text": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n"}, "hash": "ebf72b113dc2d38f07189d5a89415118671a7a21551dfa66e0582fb0e479215a", "class_name": "RelatedNodeInfo"}}, "text": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. ", "start_char_idx": 2807, "end_char_idx": 2951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc0ef75d-53ca-4c21-a065-8fe084813e6b": {"__data__": {"id_": "bc0ef75d-53ca-4c21-a065-8fe084813e6b", "embedding": null, "metadata": {"window": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n", "original_text": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08fbcc77-8224-496d-baef-8aa3f7f12dfd", "node_type": "1", "metadata": {"window": "Let me turn to our fiscal 2023 outlook, starting with the consolidated view.  I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. ", "original_text": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "302bb9e18919493faaaa6dd0ad150cbabb1310321c7e645628104791e8a8cd5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8e13406-93bd-4639-bb02-2bebbc45b681", "node_type": "1", "metadata": {"window": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n"}, "hash": "74e24d1dddc4e301ec0548af13323885c66a18e52c7f41a92fa2e2676e4eb3c2", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n", "start_char_idx": 2951, "end_char_idx": 3240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8e13406-93bd-4639-bb02-2bebbc45b681": {"__data__": {"id_": "f8e13406-93bd-4639-bb02-2bebbc45b681", "embedding": null, "metadata": {"window": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc0ef75d-53ca-4c21-a065-8fe084813e6b", "node_type": "1", "metadata": {"window": "I'll walk you through the key items, \nbeginning with additional details of fiscal 2023 consolidated guidance.  A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n", "original_text": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0044cbdc099f4f711c9e88b8b5b405f8d733340bbfe7f07e0d38bbed913d112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19892139-7960-4077-baf8-ceabcc8f48b9", "node_type": "1", "metadata": {"window": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. "}, "hash": "e145877d37f702bedb5a472e65664ff4b5d705a5633c4d95974e9e3da3d8475f", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n", "start_char_idx": 3240, "end_char_idx": 3446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19892139-7960-4077-baf8-ceabcc8f48b9": {"__data__": {"id_": "19892139-7960-4077-baf8-ceabcc8f48b9", "embedding": null, "metadata": {"window": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8e13406-93bd-4639-bb02-2bebbc45b681", "node_type": "1", "metadata": {"window": "A full list of these assumptions can be \nfound on slides 15 throug h 19 in our supplemental slide presentation.  \n \n On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc9ad10242f0984dec71691dee1b72e3aafc94d42cd2954455bd131bc1766a45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7613544-cea7-4715-b080-01f56703a754", "node_type": "1", "metadata": {"window": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n"}, "hash": "c415c582faf00fc06bba81392da7bf7cb4aa13972bc1416db4ee9d1059a1bf68", "class_name": "RelatedNodeInfo"}}, "text": "Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. ", "start_char_idx": 3446, "end_char_idx": 3602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7613544-cea7-4715-b080-01f56703a754": {"__data__": {"id_": "f7613544-cea7-4715-b080-01f56703a754", "embedding": null, "metadata": {"window": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19892139-7960-4077-baf8-ceabcc8f48b9", "node_type": "1", "metadata": {"window": "On a reported basis, our fiscal 2023 guidance assumes 3% to 7% revenue growth and flat to 6% operating profit \ndecline compared to fiscal 2022.  When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million. ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5ccc231089a192864aadad92c2601688e093876619e8a4810e01acb64dcfd6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31c1776c-c4f7-4d5a-9ae6-c484e5f941c2", "node_type": "1", "metadata": {"window": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of "}, "hash": "6cb5dc410934acbe7d35caba4b624b65ccca2d3a1e8a055603ade7245f46247c", "class_name": "RelatedNodeInfo"}}, "text": "Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n", "start_char_idx": 3602, "end_char_idx": 3699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31c1776c-c4f7-4d5a-9ae6-c484e5f941c2": {"__data__": {"id_": "31c1776c-c4f7-4d5a-9ae6-c484e5f941c2", "embedding": null, "metadata": {"window": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae4056506699987322e5870160fb8ffc81dcb0b23ca2ba1dcff44826a0407496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7613544-cea7-4715-b080-01f56703a754", "node_type": "1", "metadata": {"window": "When excluding the impacts related to the US government's centraliz ed COVID -\n19 vaccine and kitting distribution programs, COVID -19 tests, and net gains or losses associated with McKesson \nVentures' equity investments, we anticipate adjusted operating profit to increase 4% to 10%.  \n \n We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da63a32e4cdc55eaf4194d8e4a0c07c73452505cc871077df6d7b3548a2fa276", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9850b72b-0794-401c-89d0-bd810ed8df27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "original_text": "McKesson Corp.  "}, "hash": "aac562242cfc678488d2c7dc640fd23352b27017c9d1f00d7fb6356af7610cb8", "class_name": "RelatedNodeInfo"}}, "text": "Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "start_char_idx": 3699, "end_char_idx": 3928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9850b72b-0794-401c-89d0-bd810ed8df27": {"__data__": {"id_": "9850b72b-0794-401c-89d0-bd810ed8df27", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31c1776c-c4f7-4d5a-9ae6-c484e5f941c2", "node_type": "1", "metadata": {"window": "We also anticipate corporate expenses in t he range of $550 million to $620 million, which includes the impact of \nnet losses associated with McKesson Ventures' equity investments in the first quarter.  \n \n Given the current interest rate environment, we now anticipate interest expense to modestly incre ase and be in \nthe range of $205 million to $225 million.  Our anticipated full year effective tax rate of approximately 18% to 20% \nremains unchanged.  \n \n Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "original_text": "Based on our first quarter results, our continued solid operating performance in each segment, and the con tract \nextensions with the US government for COVID -19 vaccine distribution and the kitting, storage, and distribution of ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acae369719e3e00624bbbc2ea9878b2882d555f0ddeac0634706c4e060fd6c30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6fd67a6-b87c-4b62-b6fb-f44de75a50e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 . "}, "hash": "219171088a4bc6edfa82e881df0cf9fea3188443814cd31e5d8f1fec75f56b9c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6fd67a6-b87c-4b62-b6fb-f44de75a50e0": {"__data__": {"id_": "f6fd67a6-b87c-4b62-b6fb-f44de75a50e0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 . ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9850b72b-0794-401c-89d0-bd810ed8df27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90efc22220304815d610e6322087e6754afed28bd6d29a9b21c2dce9f087f95d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb124faa-ea1d-4ab2-ba40-bd52cbfa1aff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n", "original_text": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n"}, "hash": "8463dc2dd82838f2e19bf986f2e0848e4538de96c50af1947d25cdf64f3bd287", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 . ", "start_char_idx": 16, "end_char_idx": 321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb124faa-ea1d-4ab2-ba40-bd52cbfa1aff": {"__data__": {"id_": "cb124faa-ea1d-4ab2-ba40-bd52cbfa1aff", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n", "original_text": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6fd67a6-b87c-4b62-b6fb-f44de75a50e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 . ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9272eaee280a2712fc630453b5a36d18a7a08a7a1226db5cac8c4eca121efcdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c557e8e1-ec14-49dc-b4f5-b40c25a25f55", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook. ", "original_text": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. "}, "hash": "440111582dd07b4b34ea870cb1abcb59b92d98618ce892b50689fded185663b0", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n", "start_char_idx": 321, "end_char_idx": 482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c557e8e1-ec14-49dc-b4f5-b40c25a25f55": {"__data__": {"id_": "c557e8e1-ec14-49dc-b4f5-b40c25a25f55", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook. ", "original_text": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb124faa-ea1d-4ab2-ba40-bd52cbfa1aff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n", "original_text": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02996d47b7a3e2def3dab69d0f8dc8cf95db2294406808a94a4ab56bcb8e95bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70a1ebe0-7b7f-4b9e-8183-c7e2a37eb66d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. ", "original_text": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n"}, "hash": "9ae623090f55f573b010bb5b31764f31349797ac4aa0296b4e48e6328ae71cdb", "class_name": "RelatedNodeInfo"}}, "text": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "start_char_idx": 482, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70a1ebe0-7b7f-4b9e-8183-c7e2a37eb66d": {"__data__": {"id_": "70a1ebe0-7b7f-4b9e-8183-c7e2a37eb66d", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. ", "original_text": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c557e8e1-ec14-49dc-b4f5-b40c25a25f55", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook. ", "original_text": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54ee6dc4724ec64d4649b464191da576015f02f7a7a2fd11d28d85726bf5a2d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a12a8bf-26dd-4195-b4f5-bdeb70defb5f", "node_type": "1", "metadata": {"window": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n", "original_text": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n"}, "hash": "b9feb883c85332361218ab7ec176c99d8f4e0bd8e38066988fd5a38348d23045", "class_name": "RelatedNodeInfo"}}, "text": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n", "start_char_idx": 586, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a12a8bf-26dd-4195-b4f5-bdeb70defb5f": {"__data__": {"id_": "2a12a8bf-26dd-4195-b4f5-bdeb70defb5f", "embedding": null, "metadata": {"window": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n", "original_text": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70a1ebe0-7b7f-4b9e-8183-c7e2a37eb66d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. ", "original_text": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091c7d02586483eef974f5794593b162d87c8bab17504f5e81993bb9e1320a38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab579a46-c3bc-4ecc-a6ff-4b2ad76e4434", "node_type": "1", "metadata": {"window": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. ", "original_text": "Moving now to the segment outlook. "}, "hash": "afa38385c60d0b1527639d22a2415a4f30c21ad6d88180f0a48dc589c4145987", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n", "start_char_idx": 920, "end_char_idx": 1212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab579a46-c3bc-4ecc-a6ff-4b2ad76e4434": {"__data__": {"id_": "ab579a46-c3bc-4ecc-a6ff-4b2ad76e4434", "embedding": null, "metadata": {"window": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. ", "original_text": "Moving now to the segment outlook. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a12a8bf-26dd-4195-b4f5-bdeb70defb5f", "node_type": "1", "metadata": {"window": "Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n", "original_text": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "925c57b5825eb91c5ede80057e95a0665df458903e3aa035d11c343a8c8e4b6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e852c05-30b3-43d0-86fa-5be7100ada2a", "node_type": "1", "metadata": {"window": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n", "original_text": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. "}, "hash": "0bd82932c1d89fc0e267fe35805327a504f3026ad9c1e9bf91860e29bedb7dd8", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to the segment outlook. ", "start_char_idx": 1212, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e852c05-30b3-43d0-86fa-5be7100ada2a": {"__data__": {"id_": "0e852c05-30b3-43d0-86fa-5be7100ada2a", "embedding": null, "metadata": {"window": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n", "original_text": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab579a46-c3bc-4ecc-a6ff-4b2ad76e4434", "node_type": "1", "metadata": {"window": "Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems.  $0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. ", "original_text": "Moving now to the segment outlook. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d784af6cfec00f865f0220cdc3bf53fcda7b9252b9f363bbe3e723f23ae747fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "942b9948-d9af-4b7a-a3bf-4fc9f0a852bd", "node_type": "1", "metadata": {"window": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n", "original_text": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n"}, "hash": "d46a4e635330effa93a4ae5515b98307af2013263a9d81b520b8a58a1157ac75", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. ", "start_char_idx": 1247, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "942b9948-d9af-4b7a-a3bf-4fc9f0a852bd": {"__data__": {"id_": "942b9948-d9af-4b7a-a3bf-4fc9f0a852bd", "embedding": null, "metadata": {"window": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n", "original_text": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e852c05-30b3-43d0-86fa-5be7100ada2a", "node_type": "1", "metadata": {"window": "$0.35 to \n$0.45 related to US government's vaccine distribution in our US Pharmaceutical segment, $0.75 to $0.95 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies in our Medical -Surgical Solutions \nsegment, and $0.11 of net losses associated with McKesson Ventures' equity investments.  \n \n Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n", "original_text": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92d51d0b0ebbe31cb4ad18efbc4c46adc6cc9e1f8c035dbe2813c2af5137bdc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ae8b5c8-09c8-42ee-b627-a769fbd82da7", "node_type": "1", "metadata": {"window": "Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. ", "original_text": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. "}, "hash": "5380f7a2e95a555d97394f2da391a5a593349b36f693e1b028f9a265d5d7a940", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n", "start_char_idx": 1476, "end_char_idx": 1614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ae8b5c8-09c8-42ee-b627-a769fbd82da7": {"__data__": {"id_": "2ae8b5c8-09c8-42ee-b627-a769fbd82da7", "embedding": null, "metadata": {"window": "Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. ", "original_text": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "942b9948-d9af-4b7a-a3bf-4fc9f0a852bd", "node_type": "1", "metadata": {"window": "Excluding the impacts of these COVID -19-related items and net gains and losses from McKesson Ventures' \nequity investments from both fiscal 2023 guidance and fiscal 2022 results, ou r fiscal 2023 adjusted earnings \nguidance indicates approximately 10% to 15% growth over the prior year.  \n \n Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n", "original_text": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3996901408e1de0dc81a9e834e40188e03ca3328fe1554cba96b2c8ed024f264", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fd7a4e6-9c78-4024-8006-75d281692e33", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. ", "original_text": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n"}, "hash": "01584b3e892a00bda5a28d1cb4feb354cc912e7dfd32e9d076d9d8d90e09f59b", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. ", "start_char_idx": 1614, "end_char_idx": 1764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fd7a4e6-9c78-4024-8006-75d281692e33": {"__data__": {"id_": "4fd7a4e6-9c78-4024-8006-75d281692e33", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. ", "original_text": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ae8b5c8-09c8-42ee-b627-a769fbd82da7", "node_type": "1", "metadata": {"window": "Moving now to the segment outlook.  In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. ", "original_text": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6176cc98e58555aba87069436702cd1b8f9b890e587daaeb77eab85da782dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e199973e-1dbb-44ea-ac15-97ed694d8347", "node_type": "1", "metadata": {"window": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n", "original_text": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n"}, "hash": "7d04d902851448e9001a8061a5721d9c7116c88287d26efe773e86cee4c5de80", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n", "start_char_idx": 1764, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e199973e-1dbb-44ea-ac15-97ed694d8347": {"__data__": {"id_": "e199973e-1dbb-44ea-ac15-97ed694d8347", "embedding": null, "metadata": {"window": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n", "original_text": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fd7a4e6-9c78-4024-8006-75d281692e33", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, our outlook reflects the solid operating \nperformance in the first quarter, the efficiency and durability of our core distribution platform, and continued \ndevelopment of our oncology ecosystem.  We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. ", "original_text": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "913a1c1b953f12cffece4a97455fd496d7dcb91b4521145db73c00dfe85077ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ee7474a-9bd1-4514-aa67-cd3304211d29", "node_type": "1", "metadata": {"window": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. "}, "hash": "c01a10098ee2ef14eea61d66f98c0e1fc391d2881f4eb5e54b6f13718b4e0d9e", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n", "start_char_idx": 1954, "end_char_idx": 2157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ee7474a-9bd1-4514-aa67-cd3304211d29": {"__data__": {"id_": "9ee7474a-9bd1-4514-aa67-cd3304211d29", "embedding": null, "metadata": {"window": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e199973e-1dbb-44ea-ac15-97ed694d8347", "node_type": "1", "metadata": {"window": "We anticipate reported revenue to increase 11% to 14% and operating \nprofit to decline approximately 1% to 3% growth year -over-year.  \n \n Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n", "original_text": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8cf057451edc3fb718378f2dc72b9ade21881110763096ee5fbcbc37a4fea77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd55764a-041f-43ea-8f17-efcadc6b3c5a", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "original_text": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. "}, "hash": "b1d8d3ab5181b1adf3959b48382ff193edfa0244b35180441133ee3410d711e2", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. ", "start_char_idx": 2157, "end_char_idx": 2299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd55764a-041f-43ea-8f17-efcadc6b3c5a": {"__data__": {"id_": "cd55764a-041f-43ea-8f17-efcadc6b3c5a", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "original_text": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ee7474a-9bd1-4514-aa67-cd3304211d29", "node_type": "1", "metadata": {"window": "Our outlook includes approximately $0.35 to $0.45 related to COVID -19 vaccine distribution, a result of the \npreviously outlined contract extension.  When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da0612f96c699572223417ba20220c7e74f83bac56dfbfe65b4629f69f44e41c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d29805d5-d2f8-48aa-960d-279c69cccdc6", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n", "original_text": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n"}, "hash": "f167cc5ae5f010b85f7d800f2dfa570ca5a935a1d7df381ac445a08ad85f784c", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. ", "start_char_idx": 2299, "end_char_idx": 2550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d29805d5-d2f8-48aa-960d-279c69cccdc6": {"__data__": {"id_": "d29805d5-d2f8-48aa-960d-279c69cccdc6", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n", "original_text": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd55764a-041f-43ea-8f17-efcadc6b3c5a", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19 vaccine distribution for the US \ngovernment, we anticipate 4% to 6% operati ng profit growth, which is modestly above the long term growth target.  \n \n In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "original_text": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d4540a4fd5b741f27415d97d46146c9d96d0051548aa654ab109a9741ad9cf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc7e915d-9dda-47c3-97dd-a6d1325e2817", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. ", "original_text": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n"}, "hash": "4d795f14a8585540fc5e37f161cb0bfb71ad726ff284fb89000a0c4a10596691", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n", "start_char_idx": 2550, "end_char_idx": 2684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc7e915d-9dda-47c3-97dd-a6d1325e2817": {"__data__": {"id_": "cc7e915d-9dda-47c3-97dd-a6d1325e2817", "embedding": null, "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. ", "original_text": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d29805d5-d2f8-48aa-960d-279c69cccdc6", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we now anticipate revenue growth of 15% to 21% and \noperating profit growth of 16% to 22%, which reflects increased affordability solut ion volumes.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n", "original_text": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51fcb56e59314f9af1d79cbf266f488c78e0eb611c6887ca64434d897aebe517", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7035cf63-5521-42ed-8fc3-c6dc93393c05", "node_type": "1", "metadata": {"window": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n", "original_text": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. "}, "hash": "f9e0b8eb429895511d57893ed17bf6d5bc2b2ba3448f5c0ceee6df53b2acdb41", "class_name": "RelatedNodeInfo"}}, "text": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n", "start_char_idx": 2684, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7035cf63-5521-42ed-8fc3-c6dc93393c05": {"__data__": {"id_": "7035cf63-5521-42ed-8fc3-c6dc93393c05", "embedding": null, "metadata": {"window": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n", "original_text": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc7e915d-9dda-47c3-97dd-a6d1325e2817", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 3% to 7% and operating \nprofit to decrease 5% to 10%.  Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. ", "original_text": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "867edd34fdb9c6bd829dd5cb165ce62cb0107cb884b020761d1fc2b022d4ebae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2744b4a5-8d83-4d52-8259-97e16346baaa", "node_type": "1", "metadata": {"window": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. ", "original_text": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n"}, "hash": "2a63c88a2e02826fc46c9ba486052f6ff991da0b41b7cbcd0b68ef6aa0555b62", "class_name": "RelatedNodeInfo"}}, "text": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "start_char_idx": 3029, "end_char_idx": 3126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2744b4a5-8d83-4d52-8259-97e16346baaa": {"__data__": {"id_": "2744b4a5-8d83-4d52-8259-97e16346baaa", "embedding": null, "metadata": {"window": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. ", "original_text": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7035cf63-5521-42ed-8fc3-c6dc93393c05", "node_type": "1", "metadata": {"window": "Our outlook includes approximately $0.75 to $0.95 related to COVID -19 tests and \nthe kitting, storage, and distribution of ancillary supplies, for the US government, which incorporates the contract \nextension of the US government to January of 2023.  Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n", "original_text": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "947618acca21ae0173544a100087d154d2f232fa399902411f78002bf0cad964", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93170ee9-a5a9-45d3-b9d3-90c10467f574", "node_type": "1", "metadata": {"window": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. "}, "hash": "1c85750ed7b400fc7ab5b7ba14ff0880c78d8570cc7867d25feddb7d379c6846", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n", "start_char_idx": 3126, "end_char_idx": 3310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93170ee9-a5a9-45d3-b9d3-90c10467f574": {"__data__": {"id_": "93170ee9-a5a9-45d3-b9d3-90c10467f574", "embedding": null, "metadata": {"window": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2744b4a5-8d83-4d52-8259-97e16346baaa", "node_type": "1", "metadata": {"window": "Excluding the impact of these COVID -19-related items, we \nanticipate Medical -Surgical operating profit to incre ase 11% to 17%.  \n \n And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. ", "original_text": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0457bb0daa0300ab24a9f45068d12c5c200b7dc8f69de2ff7d9c9e9c4c33e141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0054d63-b886-4feb-b2bf-d88ecfb9fad8", "node_type": "1", "metadata": {"window": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n"}, "hash": "20cce6240d3f96d72a811fcac52a3f7c2d4cb6c645fd56a28271246906b0124e", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. ", "start_char_idx": 3310, "end_char_idx": 3409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0054d63-b886-4feb-b2bf-d88ecfb9fad8": {"__data__": {"id_": "a0054d63-b886-4feb-b2bf-d88ecfb9fad8", "embedding": null, "metadata": {"window": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93170ee9-a5a9-45d3-b9d3-90c10467f574", "node_type": "1", "metadata": {"window": "And finally, in the International segment, we continue to anticipate revenues to decline by 34% to 38% and \noperating profit to decline by 22% to 28%, and this year -over-year decrease includes a loss of operating profit \ncontribution from bu sinesses and transactions we've closed to -date and those we expect to close during fiscal \n2023.  \n \n Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbd95e3b5e03c4930248ee81fcd7f4f35b897475758b591da690677b02eae15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58e3e786-db30-44a1-a374-eb9d1ad38690", "node_type": "1", "metadata": {"window": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. "}, "hash": "109976b36493c52c389eaad7916c7c04a25bc1b665f6580b05b9dd6c35200e39", "class_name": "RelatedNodeInfo"}}, "text": "Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n", "start_char_idx": 3409, "end_char_idx": 3601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58e3e786-db30-44a1-a374-eb9d1ad38690": {"__data__": {"id_": "58e3e786-db30-44a1-a374-eb9d1ad38690", "embedding": null, "metadata": {"window": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0054d63-b886-4feb-b2bf-d88ecfb9fad8", "node_type": "1", "metadata": {"window": "Let me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6d2519a988e1bfd6b3639e987e14b8a508d031f343706c43ec94170f6d9585f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5005bc8-ca98-4127-9c77-d6c3e235a943", "node_type": "1", "metadata": {"window": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n "}, "hash": "2b7881d6b952eabb06e203f911c08ea2c86fa961dbc5996cda17eaf6a170b3c0", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. ", "start_char_idx": 3601, "end_char_idx": 3696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5005bc8-ca98-4127-9c77-d6c3e235a943": {"__data__": {"id_": "f5005bc8-ca98-4127-9c77-d6c3e235a943", "embedding": null, "metadata": {"window": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8bf0574c-99ab-424e-be71-b964b648c234", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7f0c10c2a236493bd59d90abf3120759f488d5a02dbce4a36db81160a387ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58e3e786-db30-44a1-a374-eb9d1ad38690", "node_type": "1", "metadata": {"window": "In fiscal 2023, \nwe continue to anticipate free cash flow of ap proximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  \n \n As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares. ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c92ba3e5a46774aeb7fdf483fe3bee6ebd7d20498d9e2e6c53ece9ae6e12020d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc408fa4-995a-48ea-9dc1-1edf55b8ab1b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "original_text": "McKesson Corp.  "}, "hash": "b1b2486167274a5c0faa575a3d93746c14d721354e12494ec8fd4f0eef898d4a", "class_name": "RelatedNodeInfo"}}, "text": "A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "start_char_idx": 3696, "end_char_idx": 3834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc408fa4-995a-48ea-9dc1-1edf55b8ab1b": {"__data__": {"id_": "dc408fa4-995a-48ea-9dc1-1edf55b8ab1b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5005bc8-ca98-4127-9c77-d6c3e235a943", "node_type": "1", "metadata": {"window": "As a reminder, our working capital metrics and resulting cash flows vary from quarter -to-quarter.  Each working \ncapital metric can be impacte d by timing, and in fiscal 2023 our cash flows including the progression of these \ncash flows may be impacted by European divestiture activity.  \n \n Our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of shares.  A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "original_text": "A significant por tion \nof the share buyback assumption is associated with mitigating year -over-year impact of European divestitures.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "daccc29cbdff78d13b0ec95a48408a24d136b7bc63c2d90bde9ac704cf8d9d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b6a146-042b-41e6-801c-7e792863f9a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n"}, "hash": "ca9b5e2a274a80f6ac8c8eb0f6b39fc80d4e9edf665c22cc0f0863d6951ed96a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b6a146-042b-41e6-801c-7e792863f9a2": {"__data__": {"id_": "09b6a146-042b-41e6-801c-7e792863f9a2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc408fa4-995a-48ea-9dc1-1edf55b8ab1b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "932c82d889786626c005f714b6f8875e19c389a93dbbae467f5bc30de1378a2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f06e1a8-38d3-4e57-a9d0-dd859cea4efe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n", "original_text": "To wrap up, we are pleased with our solid start to the fiscal year. "}, "hash": "d3e18f31be8d759261cdd195dff644155dd382c9949eb564161420167f697107", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n", "start_char_idx": 16, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f06e1a8-38d3-4e57-a9d0-dd859cea4efe": {"__data__": {"id_": "9f06e1a8-38d3-4e57-a9d0-dd859cea4efe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n", "original_text": "To wrap up, we are pleased with our solid start to the fiscal year. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b6a146-042b-41e6-801c-7e792863f9a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3d0cb8c2acab81a01fe04be09671e1df172c4a19c6159e48133ec5058f9e2b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7777f1de-81bf-4826-9e5f-44e3fadc84f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n", "original_text": "We continue to deliver on our growth strategy as \na diversified healthcare services company. "}, "hash": "4f9c61cc899c48eb41ec0765d13559d9e7d8b84af71290c4b46361feb7a058c7", "class_name": "RelatedNodeInfo"}}, "text": "To wrap up, we are pleased with our solid start to the fiscal year. ", "start_char_idx": 368, "end_char_idx": 436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7777f1de-81bf-4826-9e5f-44e3fadc84f0": {"__data__": {"id_": "7777f1de-81bf-4826-9e5f-44e3fadc84f0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n", "original_text": "We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f06e1a8-38d3-4e57-a9d0-dd859cea4efe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n", "original_text": "To wrap up, we are pleased with our solid start to the fiscal year. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cf90058dfd69be3690a986d2b7f0a4ca481ef3ec1309c2530b8a7ad0447ebea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e3ae12f-aead-488b-a9dd-7c758e9fb722", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n ", "original_text": "Our talented associates continue to deliver exception al performance. \n"}, "hash": "2c443c0df9b510b7f4b3149bb2059a7b953c124568c57153e02b04d8e6fd46eb", "class_name": "RelatedNodeInfo"}}, "text": "We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "start_char_idx": 436, "end_char_idx": 529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e3ae12f-aead-488b-a9dd-7c758e9fb722": {"__data__": {"id_": "1e3ae12f-aead-488b-a9dd-7c758e9fb722", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n ", "original_text": "Our talented associates continue to deliver exception al performance. \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7777f1de-81bf-4826-9e5f-44e3fadc84f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n", "original_text": "We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05ff1279374a8bfe7ecff8576543a5e9a0888e1c3147a93a53c4a7c089ff98bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee887a18-9f61-4f7d-96e4-eff26a04aaae", "node_type": "1", "metadata": {"window": "To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. ", "original_text": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n"}, "hash": "42c77ae4db1047c6a9dfebe87737be4a84d9fc9e5c24539a7bc68f1854cf6b79", "class_name": "RelatedNodeInfo"}}, "text": "Our talented associates continue to deliver exception al performance. \n", "start_char_idx": 529, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee887a18-9f61-4f7d-96e4-eff26a04aaae": {"__data__": {"id_": "ee887a18-9f61-4f7d-96e4-eff26a04aaae", "embedding": null, "metadata": {"window": "To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. ", "original_text": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e3ae12f-aead-488b-a9dd-7c758e9fb722", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n ", "original_text": "Our talented associates continue to deliver exception al performance. \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "524c1c75bb529aa0c4716ea3d7eb818b0272018ccf15900a4fc62681411ebf3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37d762d6-8108-4713-a191-9594bfd66277", "node_type": "1", "metadata": {"window": "We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n ", "original_text": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n"}, "hash": "dcfd052a34e62d0258024cdeaf21be820f29cf099546384d619194f509c94a4f", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n", "start_char_idx": 600, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37d762d6-8108-4713-a191-9594bfd66277": {"__data__": {"id_": "37d762d6-8108-4713-a191-9594bfd66277", "embedding": null, "metadata": {"window": "We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n ", "original_text": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee887a18-9f61-4f7d-96e4-eff26a04aaae", "node_type": "1", "metadata": {"window": "To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. ", "original_text": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39f43a9b8bd3a79149493e6a5e7c46336bce63572edda54f690f393e8da9a2c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "337e1084-22a3-4ee4-85dc-a80f60fd2cfe", "node_type": "1", "metadata": {"window": "Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "With that, let me turn it back to the operator for your questions.  \n "}, "hash": "04b2c55f0bb9b8088f01d1c806829c11a75716c927774fe83f0ba47e9ab97425", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n", "start_char_idx": 781, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "337e1084-22a3-4ee4-85dc-a80f60fd2cfe": {"__data__": {"id_": "337e1084-22a3-4ee4-85dc-a80f60fd2cfe", "embedding": null, "metadata": {"window": "Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "With that, let me turn it back to the operator for your questions.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37d762d6-8108-4713-a191-9594bfd66277", "node_type": "1", "metadata": {"window": "We continue to deliver on our growth strategy as \na diversified healthcare services company.  Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n ", "original_text": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be00245406d5bdb6bca2f4fb7a0a626dcd122f9b9ab9fa0eba8d121f65393317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83a6836a-35d2-4237-8bdd-8c25d3f529e7", "node_type": "1", "metadata": {"window": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. "}, "hash": "7534df3c32ae6ca5b5cd93a1ad705cb9fefd039492c5070f65cac9b84b3f38dd", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it back to the operator for your questions.  \n ", "start_char_idx": 1010, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83a6836a-35d2-4237-8bdd-8c25d3f529e7": {"__data__": {"id_": "83a6836a-35d2-4237-8bdd-8c25d3f529e7", "embedding": null, "metadata": {"window": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "337e1084-22a3-4ee4-85dc-a80f60fd2cfe", "node_type": "1", "metadata": {"window": "Our talented associates continue to deliver exception al performance. \n Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "With that, let me turn it back to the operator for your questions.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d8e032ffa3bd2782a2f2f59f46c140c4cb5650f178dca058b2bda23eb5e2a7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afb3ef58-2193-409d-b12e-eb01ce794458", "node_type": "1", "metadata": {"window": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color. ", "original_text": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n "}, "hash": "94743a8c3904b1886a393ca779fd522e811661ddf353928af04846a885111732", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. ", "start_char_idx": 1080, "end_char_idx": 1409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afb3ef58-2193-409d-b12e-eb01ce794458": {"__data__": {"id_": "afb3ef58-2193-409d-b12e-eb01ce794458", "embedding": null, "metadata": {"window": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color. ", "original_text": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83a6836a-35d2-4237-8bdd-8c25d3f529e7", "node_type": "1", "metadata": {"window": "Our first quarter financial performance reflects their dedication and our execution in a dynamic operating \nenvironment, and it also represents the resiliency of our portfolio.  \n \n Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5ce1a2cce10b6ea31345679ec3c2107a2eead48fcccf857883ba0f594254453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "498bccfa-a0c4-4dd1-b304-36200d51308e", "node_type": "1", "metadata": {"window": "With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "3c0383ab1a759253375dcaf04b47033ac29bc37f0385382ed10a5334256dc2a1", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n ", "start_char_idx": 1409, "end_char_idx": 1495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "498bccfa-a0c4-4dd1-b304-36200d51308e": {"__data__": {"id_": "498bccfa-a0c4-4dd1-b304-36200d51308e", "embedding": null, "metadata": {"window": "With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afb3ef58-2193-409d-b12e-eb01ce794458", "node_type": "1", "metadata": {"window": "Looking ahead, the combination of our solid first quarter finan cial performance, our growth strategy, and \ncontinued execution positions McKesson to deliver sustainable long term performance and shareholder value \ncreation.  \n \n With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color. ", "original_text": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab4767d9b4d5c69dcd422b6f744f755c3080f6afe1cbe67b78e456ebda7d39cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e35adc5-f39b-46cb-9d22-7a4fe04106bb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial. ", "original_text": "Thanks very much and good afternoon. "}, "hash": "22c4a60a99866472add67c148f67de5514f4f3b0bdad140cf05065856ff5f21d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 1495, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e35adc5-f39b-46cb-9d22-7a4fe04106bb": {"__data__": {"id_": "7e35adc5-f39b-46cb-9d22-7a4fe04106bb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial. ", "original_text": "Thanks very much and good afternoon. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "498bccfa-a0c4-4dd1-b304-36200d51308e", "node_type": "1", "metadata": {"window": "With that, let me turn it back to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3748d650fc4676149394f2c7b93b438db07c1a6bfb9db8190febd90bf9f5d5c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c062b31-292f-4ec1-811d-cd5831816429", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses. ", "original_text": "Thanks, Britt, for all of the color. "}, "hash": "d12c3c3f37f671809851d478854b2a215cc48d1c254f63b616b09c0472b5c68b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much and good afternoon. ", "start_char_idx": 1837, "end_char_idx": 1874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c062b31-292f-4ec1-811d-cd5831816429": {"__data__": {"id_": "0c062b31-292f-4ec1-811d-cd5831816429", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses. ", "original_text": "Thanks, Britt, for all of the color. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e35adc5-f39b-46cb-9d22-7a4fe04106bb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTIO N \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial. ", "original_text": "Thanks very much and good afternoon. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cde06271829d3da8dbd4abfe9eb5c69a692debee38a79ff2d97db548947859a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d7cbd65-0e68-4425-b4cc-186b6313d676", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages. ", "original_text": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n"}, "hash": "78b3e4c9284e14cbb0c521253ac6fa51ef768ddf26626dfcb7d0f646b4a26fa6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Britt, for all of the color. ", "start_char_idx": 1874, "end_char_idx": 1911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d7cbd65-0e68-4425-b4cc-186b6313d676": {"__data__": {"id_": "7d7cbd65-0e68-4425-b4cc-186b6313d676", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages. ", "original_text": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c062b31-292f-4ec1-811d-cd5831816429", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses. ", "original_text": "Thanks, Britt, for all of the color. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cc701cee4c14b09f1c96d8c18c3cffd30c6c8d313a45f5417038b18dbbe2097", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a27aec26-3409-4531-8434-b7db57f94d8e", "node_type": "1", "metadata": {"window": "Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works. ", "original_text": "One, the comment around macroeconomic trends being immaterial. "}, "hash": "9af330cc8bb85deb118d2adb011bee52a17d1ab2e95fc6b0d12ee251f646fc0a", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n", "start_char_idx": 1911, "end_char_idx": 1998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a27aec26-3409-4531-8434-b7db57f94d8e": {"__data__": {"id_": "a27aec26-3409-4531-8434-b7db57f94d8e", "embedding": null, "metadata": {"window": "Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works. ", "original_text": "One, the comment around macroeconomic trends being immaterial. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d7cbd65-0e68-4425-b4cc-186b6313d676", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages. ", "original_text": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c68979a3370ebdd35f5c252e530851c812e7a18fb5cc027ec4a303d22d9dd58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a2e21b7-9321-4ec4-97e4-b92c5104f322", "node_type": "1", "metadata": {"window": "Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through? ", "original_text": "I know last year you had some wage inflation \nor gave people bonuses. "}, "hash": "bfeecf69a2ce2fa4a4456b5137a998566875e54a08b8ed17ccf752b551c95a62", "class_name": "RelatedNodeInfo"}}, "text": "One, the comment around macroeconomic trends being immaterial. ", "start_char_idx": 1998, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a2e21b7-9321-4ec4-97e4-b92c5104f322": {"__data__": {"id_": "0a2e21b7-9321-4ec4-97e4-b92c5104f322", "embedding": null, "metadata": {"window": "Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through? ", "original_text": "I know last year you had some wage inflation \nor gave people bonuses. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a27aec26-3409-4531-8434-b7db57f94d8e", "node_type": "1", "metadata": {"window": "Thanks very much and good afternoon.  Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works. ", "original_text": "One, the comment around macroeconomic trends being immaterial. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b1606da5b9d8fc74b5ec36142bc17591c7428b3cb4da2d5749ca03b4ca55bf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcad8b29-0bac-4c0f-8be7-a5b38b15198f", "node_type": "1", "metadata": {"window": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n ", "original_text": "I'm curious as to what you're seeing right now around wages. "}, "hash": "5edfdb3c6e7024a283c1e39e42360744374eb9132217168e161cdc2706ce9091", "class_name": "RelatedNodeInfo"}}, "text": "I know last year you had some wage inflation \nor gave people bonuses. ", "start_char_idx": 2061, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcad8b29-0bac-4c0f-8be7-a5b38b15198f": {"__data__": {"id_": "fcad8b29-0bac-4c0f-8be7-a5b38b15198f", "embedding": null, "metadata": {"window": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n ", "original_text": "I'm curious as to what you're seeing right now around wages. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a2e21b7-9321-4ec4-97e4-b92c5104f322", "node_type": "1", "metadata": {"window": "Thanks, Britt, for all of the color.  I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through? ", "original_text": "I know last year you had some wage inflation \nor gave people bonuses. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eefbbd5b6d3e3f9d97e0a86efc86db5077731fec6968ff814b4bc7f4cc7adb79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00c31910-950f-4573-bfac-1620b959b963", "node_type": "1", "metadata": {"window": "One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then secondly, I want \nto make sure that I understand how fuel works. "}, "hash": "1656dfa5467e21140f2e09e65eacee73cf2e0ff0af4894b094bc7798e8c21b57", "class_name": "RelatedNodeInfo"}}, "text": "I'm curious as to what you're seeing right now around wages. ", "start_char_idx": 2131, "end_char_idx": 2192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00c31910-950f-4573-bfac-1620b959b963": {"__data__": {"id_": "00c31910-950f-4573-bfac-1620b959b963", "embedding": null, "metadata": {"window": "One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then secondly, I want \nto make sure that I understand how fuel works. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcad8b29-0bac-4c0f-8be7-a5b38b15198f", "node_type": "1", "metadata": {"window": "I just wanted to go \nback and make sure I just understand just a couple of things.  \n \n One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n ", "original_text": "I'm curious as to what you're seeing right now around wages. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "308f0be2e6cac32c50c451a677538588d4484799097d140f4591eda0956d4a3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b659ebc-fe60-4fb3-9c2e-f2a26482f027", "node_type": "1", "metadata": {"window": "I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. ", "original_text": "Is that just a pass -through? "}, "hash": "55d1da43e0d7cd340bb5688b28782972dbe3b2f760d6eb1b46c258b866c5ef46", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, I want \nto make sure that I understand how fuel works. ", "start_char_idx": 2192, "end_char_idx": 2266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b659ebc-fe60-4fb3-9c2e-f2a26482f027": {"__data__": {"id_": "3b659ebc-fe60-4fb3-9c2e-f2a26482f027", "embedding": null, "metadata": {"window": "I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. ", "original_text": "Is that just a pass -through? ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00c31910-950f-4573-bfac-1620b959b963", "node_type": "1", "metadata": {"window": "One, the comment around macroeconomic trends being immaterial.  I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then secondly, I want \nto make sure that I understand how fuel works. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00d16b76a265b8192e37cc7e2fedf2be4b13ede3d0960dfcdd5c2b6e1fc52552", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f3a0bef-cfc3-4349-8cd5-5586b86c5aa2", "node_type": "1", "metadata": {"window": "I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments. ", "original_text": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n "}, "hash": "efeb1800fb628157e2cb751aeed68cdece81557f68b236c382e43a83e025c2c6", "class_name": "RelatedNodeInfo"}}, "text": "Is that just a pass -through? ", "start_char_idx": 2266, "end_char_idx": 2296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f3a0bef-cfc3-4349-8cd5-5586b86c5aa2": {"__data__": {"id_": "6f3a0bef-cfc3-4349-8cd5-5586b86c5aa2", "embedding": null, "metadata": {"window": "I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments. ", "original_text": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b659ebc-fe60-4fb3-9c2e-f2a26482f027", "node_type": "1", "metadata": {"window": "I know last year you had some wage inflation \nor gave people bonuses.  I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. ", "original_text": "Is that just a pass -through? ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e851f3a17899c5cf2380a261ef58b803ba4781061fb14502b7e71059df0a0bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e940f77-4cdb-4e9d-af08-c42913b4c402", "node_type": "1", "metadata": {"window": "And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "94a51a381b9224480c75da35c3eb1072565d6ff3271531c7d888c02f4a99baa9", "class_name": "RelatedNodeInfo"}}, "text": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n ", "start_char_idx": 2296, "end_char_idx": 2464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e940f77-4cdb-4e9d-af08-c42913b4c402": {"__data__": {"id_": "9e940f77-4cdb-4e9d-af08-c42913b4c402", "embedding": null, "metadata": {"window": "And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3a0bef-cfc3-4349-8cd5-5586b86c5aa2", "node_type": "1", "metadata": {"window": "I'm curious as to what you're seeing right now around wages.  And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments. ", "original_text": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80eeffcdd6f5875fb4dabec854b8409f21f5a1c5bfba68467acd340008b42f43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d442ae9-aba3-40aa-8f86-ee746b18780f", "node_type": "1", "metadata": {"window": "Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch. ", "original_text": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. "}, "hash": "8bef15116241d5a4e841f87415680d2d836f73ba0a185639c1f40cfb611f0523", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2464, "end_char_idx": 2805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d442ae9-aba3-40aa-8f86-ee746b18780f": {"__data__": {"id_": "9d442ae9-aba3-40aa-8f86-ee746b18780f", "embedding": null, "metadata": {"window": "Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch. ", "original_text": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e940f77-4cdb-4e9d-af08-c42913b4c402", "node_type": "1", "metadata": {"window": "And then secondly, I want \nto make sure that I understand how fuel works.  Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7785d5c7511a2d852cff6c88153932bf4d42bc9a0a781d010434637e943ed77c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51ee0bb6-79e7-43b2-b10f-7d9d8198bc44", "node_type": "1", "metadata": {"window": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism. ", "original_text": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments. "}, "hash": "eb7ebc5a66fa5693419ef58ea6744514c7a1f75921c8b3dbbd72e980b521c801", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. ", "start_char_idx": 2805, "end_char_idx": 2992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51ee0bb6-79e7-43b2-b10f-7d9d8198bc44": {"__data__": {"id_": "51ee0bb6-79e7-43b2-b10f-7d9d8198bc44", "embedding": null, "metadata": {"window": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism. ", "original_text": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d442ae9-aba3-40aa-8f86-ee746b18780f", "node_type": "1", "metadata": {"window": "Is that just a pass -through?  So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch. ", "original_text": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "892162969f614e761b831840ed44c8da0a0fd46032ae1e641f5d8f9ce8333ee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a97add94-b04b-4f0b-82ca-e3a68212611a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it. ", "original_text": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n"}, "hash": "30da2127085926a42a8158b8a1fed3fb30aef855926eb2ecbe5d10c4d8a88f2f", "class_name": "RelatedNodeInfo"}}, "text": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments. ", "start_char_idx": 2992, "end_char_idx": 3064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a97add94-b04b-4f0b-82ca-e3a68212611a": {"__data__": {"id_": "a97add94-b04b-4f0b-82ca-e3a68212611a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it. ", "original_text": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51ee0bb6-79e7-43b2-b10f-7d9d8198bc44", "node_type": "1", "metadata": {"window": "So as we've seen rising oil prices and \nhigher gas prices, is that something that you can just pass along to your customer, and that's wh y it's immaterial \nto you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism. ", "original_text": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f29420b688ee7ba78de801cd93ac7ce3626ff6883ea7b8b82067440e6e006786", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36503a7a-bab1-4a4c-a8a0-e9489f5b2e91", "node_type": "1", "metadata": {"window": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n", "original_text": "It's something that we'll continue to watch. "}, "hash": "9f4061a10cc5c8fd7d50132744d5ff85d7cd4d64b958ea8f19bc75333ed0164a", "class_name": "RelatedNodeInfo"}}, "text": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n", "start_char_idx": 3064, "end_char_idx": 3221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36503a7a-bab1-4a4c-a8a0-e9489f5b2e91": {"__data__": {"id_": "36503a7a-bab1-4a4c-a8a0-e9489f5b2e91", "embedding": null, "metadata": {"window": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n", "original_text": "It's something that we'll continue to watch. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a97add94-b04b-4f0b-82ca-e3a68212611a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it. ", "original_text": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9b4b2ef208e16502c7a1a9c1b67c55341e2e87225d77bd100bd568c5e88ebf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "865bedc4-f651-4ec9-a5ac-4876e327ad38", "node_type": "1", "metadata": {"window": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer. ", "original_text": "People are an important part of our value delivery mechanism. "}, "hash": "def6e5d72d42397cc62b4c45a18b9ca842ab2d24954176c21e6cad89560d7a66", "class_name": "RelatedNodeInfo"}}, "text": "It's something that we'll continue to watch. ", "start_char_idx": 3221, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "865bedc4-f651-4ec9-a5ac-4876e327ad38": {"__data__": {"id_": "865bedc4-f651-4ec9-a5ac-4876e327ad38", "embedding": null, "metadata": {"window": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer. ", "original_text": "People are an important part of our value delivery mechanism. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36503a7a-bab1-4a4c-a8a0-e9489f5b2e91", "node_type": "1", "metadata": {"window": "A \nWell, so, Lisa, I'll start with the wage component, and you'll recall last year as we tracked the markets, both \nnationally and locally, we decided midyear to t ake some wage actions.  We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n", "original_text": "It's something that we'll continue to watch. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ecf1b803450f6dbd35d3cf410ffff2fd9508c16c491f186bbc2b4f4c909116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b10d6782-6bc7-40c0-a105-ef39e8848f98", "node_type": "1", "metadata": {"window": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. ", "original_text": "It's \nimportant that we stay on top of it. "}, "hash": "fcf8ab38ccc2d495852a6167e7293d6859ac38a0ddb02920e73694478ccebe95", "class_name": "RelatedNodeInfo"}}, "text": "People are an important part of our value delivery mechanism. ", "start_char_idx": 3266, "end_char_idx": 3328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b10d6782-6bc7-40c0-a105-ef39e8848f98": {"__data__": {"id_": "b10d6782-6bc7-40c0-a105-ef39e8848f98", "embedding": null, "metadata": {"window": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. ", "original_text": "It's \nimportant that we stay on top of it. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "865bedc4-f651-4ec9-a5ac-4876e327ad38", "node_type": "1", "metadata": {"window": "We mentioned that was probably $0.10 to \n$0.20 in each of the segments.  We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer. ", "original_text": "People are an important part of our value delivery mechanism. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16ff89ed046c135e9b236991a305b379964fda2458d724466a50b8010bc919ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7e13ccb-0ecb-4384-b1f8-f8088f1098b7", "node_type": "1", "metadata": {"window": "It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through. ", "original_text": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n"}, "hash": "6cf26a78c091bdd5efc251f70896ee81c8f05303d6f2080640f5c8cfb3712574", "class_name": "RelatedNodeInfo"}}, "text": "It's \nimportant that we stay on top of it. ", "start_char_idx": 3328, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7e13ccb-0ecb-4384-b1f8-f8088f1098b7": {"__data__": {"id_": "f7e13ccb-0ecb-4384-b1f8-f8088f1098b7", "embedding": null, "metadata": {"window": "It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through. ", "original_text": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b10d6782-6bc7-40c0-a105-ef39e8848f98", "node_type": "1", "metadata": {"window": "We brought a perspective into our fiscal 2023 guide, and at this point we still think \nthat our views on the labor markets and the guidance are in sync.  \n \n It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. ", "original_text": "It's \nimportant that we stay on top of it. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9529632e7619e1d0f426f63c6215d6b8ce5e37ac4b431fb131d74ad642cc4f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc5f88ec-1b59-48ce-b7f8-3ab8fcbb8fc7", "node_type": "1", "metadata": {"window": "People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price. ", "original_text": "As it relates to fuel specifically, it's probably a nuanced answer. "}, "hash": "baf64d6df8101ea23d7ae2bd6071bc01ad15bfaa0d8f7d13a21e5ee4331d72e9", "class_name": "RelatedNodeInfo"}}, "text": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n", "start_char_idx": 3371, "end_char_idx": 3575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc5f88ec-1b59-48ce-b7f8-3ab8fcbb8fc7": {"__data__": {"id_": "dc5f88ec-1b59-48ce-b7f8-3ab8fcbb8fc7", "embedding": null, "metadata": {"window": "People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price. ", "original_text": "As it relates to fuel specifically, it's probably a nuanced answer. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7e13ccb-0ecb-4384-b1f8-f8088f1098b7", "node_type": "1", "metadata": {"window": "It's something that we'll continue to watch.  People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through. ", "original_text": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a141fc04fb568ac5e79a4c279e61f59e9ae1a6868d4090a264b701284646cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72d2ac53-2929-48b5-8963-0263132097de", "node_type": "1", "metadata": {"window": "It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n ", "original_text": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. "}, "hash": "02cbc41e59f8fc91897eddc2462f35aeebfe159d742221947bc3a0bb8f3c9da3", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to fuel specifically, it's probably a nuanced answer. ", "start_char_idx": 3575, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72d2ac53-2929-48b5-8963-0263132097de": {"__data__": {"id_": "72d2ac53-2929-48b5-8963-0263132097de", "embedding": null, "metadata": {"window": "It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n ", "original_text": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc5f88ec-1b59-48ce-b7f8-3ab8fcbb8fc7", "node_type": "1", "metadata": {"window": "People are an important part of our value delivery mechanism.  It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price. ", "original_text": "As it relates to fuel specifically, it's probably a nuanced answer. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b9002df1d2e3bd3ff369d197f5bb6c70735518286405ffed57652ce3d40e59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99050864-04fa-490e-97c1-5ba332e92ea8", "node_type": "1", "metadata": {"window": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "In some inst ances we can contractually pass it through. "}, "hash": "7cea85ed50720900e56fda001ff04b525ee5bb62b91c485965e047caee4fe639", "class_name": "RelatedNodeInfo"}}, "text": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. ", "start_char_idx": 3643, "end_char_idx": 3733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99050864-04fa-490e-97c1-5ba332e92ea8": {"__data__": {"id_": "99050864-04fa-490e-97c1-5ba332e92ea8", "embedding": null, "metadata": {"window": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "In some inst ances we can contractually pass it through. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72d2ac53-2929-48b5-8963-0263132097de", "node_type": "1", "metadata": {"window": "It's \nimportant that we stay on top of it.  But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n ", "original_text": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e33594f9219bbcb97955a951f2ab4725a48a9a1d0af8df316a48107ebd6d7859", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cb2097f-2350-401c-97c1-39544deb0ad2", "node_type": "1", "metadata": {"window": "As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "In other instances we have \nthe ability to set price. "}, "hash": "5cb4804731c697487154882898b591e861eec8f7d14f881c30640545b4816807", "class_name": "RelatedNodeInfo"}}, "text": "In some inst ances we can contractually pass it through. ", "start_char_idx": 3733, "end_char_idx": 3790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cb2097f-2350-401c-97c1-39544deb0ad2": {"__data__": {"id_": "5cb2097f-2350-401c-97c1-39544deb0ad2", "embedding": null, "metadata": {"window": "As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "In other instances we have \nthe ability to set price. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99050864-04fa-490e-97c1-5ba332e92ea8", "node_type": "1", "metadata": {"window": "But as we look at key metrics like turnover and service out our doors, we're still \ncomfortable that our assumpti ons for FY 2023 are the initial outlook we provided you for FY 2023 will be relevant.  \n \n As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "In some inst ances we can contractually pass it through. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0118060b185492b5bc3f98f509db859a9bc5190dc89520c189dac61ad7844a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "532e37d8-65ab-467f-9edd-5994d2efbde2", "node_type": "1", "metadata": {"window": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n "}, "hash": "be7003e948b2cb1dafe60fd7617197f481f9d5e2b597f47fb9d58b8f6de1cd07", "class_name": "RelatedNodeInfo"}}, "text": "In other instances we have \nthe ability to set price. ", "start_char_idx": 3790, "end_char_idx": 3844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "532e37d8-65ab-467f-9edd-5994d2efbde2": {"__data__": {"id_": "532e37d8-65ab-467f-9edd-5994d2efbde2", "embedding": null, "metadata": {"window": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cb2097f-2350-401c-97c1-39544deb0ad2", "node_type": "1", "metadata": {"window": "As it relates to fuel specifically, it's probably a nuanced answer.  I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "In other instances we have \nthe ability to set price. ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ec23f4e8028ff1ce20a6627d17b40110611a1bf45cc911eb23573502106ca2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cec87931-ab96-477e-a156-69996a26d650", "node_type": "1", "metadata": {"window": "In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "669c7fb666aaff22f8b1b6cf5ad9df5d9b056f033f0aa3b571622f6c65e841ed", "class_name": "RelatedNodeInfo"}}, "text": "And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n ", "start_char_idx": 3844, "end_char_idx": 3982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cec87931-ab96-477e-a156-69996a26d650": {"__data__": {"id_": "cec87931-ab96-477e-a156-69996a26d650", "embedding": null, "metadata": {"window": "In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c57fb2ff9d687feea7d036fab82ff678c2a32107dfb3efb82abf1eb6d894e3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "532e37d8-65ab-467f-9edd-5994d2efbde2", "node_type": "1", "metadata": {"window": "I think Britt characterized it correctly that it's been \nimmaterial for this fiscal year.  In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba7a63ce5bded40849c8c72892ddc662ccc36330482a773d4a0afdd310fe6e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "874237ae-64c3-4f86-9ce3-cce31348227f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  "}, "hash": "b5d7bf204a53ddce9c1fb682aa5d6059038f74619b585ec55800e5ca0a5c090d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1080, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "874237ae-64c3-4f86-9ce3-cce31348227f": {"__data__": {"id_": "874237ae-64c3-4f86-9ce3-cce31348227f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cec87931-ab96-477e-a156-69996a26d650", "node_type": "1", "metadata": {"window": "In some inst ances we can contractually pass it through.  In other instances we have \nthe ability to set price.  And certainly, we take actions for efficiency within the operations to continually offset any \nexpenses like that, that we might have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dc263ebbdf86668a2aab662ad90b7647375f168f6b06abc6d931025230af884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2908f896-0327-453c-8a2b-b4a9a38161a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "1fec82aeb96507944e1d91a352fd7f67a52893775014f7141e47ee1ea726d20e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2908f896-0327-453c-8a2b-b4a9a38161a2": {"__data__": {"id_": "2908f896-0327-453c-8a2b-b4a9a38161a2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "874237ae-64c3-4f86-9ce3-cce31348227f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f13511f5da8c62b7a93bf501a77cd8c1bc555a436a3133e078a55ac542e9cda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89219999-aca7-4332-8f1d-d43a2821ed14", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n "}, "hash": "9cfa6a04fb43f987f862da83ab341c1d0eafa9fda28e8d5b251b67bb0da989af", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 16, "end_char_idx": 273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89219999-aca7-4332-8f1d-d43a2821ed14": {"__data__": {"id_": "89219999-aca7-4332-8f1d-d43a2821ed14", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2908f896-0327-453c-8a2b-b4a9a38161a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "933e8505b82a2deb6b2db280925c105e7d38844cad5834becdd6a845a9256ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "250e6ca2-200a-4e20-b10c-63e08b3f632f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "5182b9c18a9751c14b7689d9241bb904a8fdcd45a9435eeb85b70e2206379a26", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "start_char_idx": 273, "end_char_idx": 615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "250e6ca2-200a-4e20-b10c-63e08b3f632f": {"__data__": {"id_": "250e6ca2-200a-4e20-b10c-63e08b3f632f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89219999-aca7-4332-8f1d-d43a2821ed14", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "128211ca4984565ed3e4047810004c0fc79bd7554269f1a1d2a3d07fa7d6fb99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32be5c8a-da6b-4a6e-a7dd-d8129a091024", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n ", "original_text": "Q \nGood afternoon, and congratulations on a really nice quarter. "}, "hash": "77fd904e18a6c1bac22b8be6d0fab193e6491b3467f651c6e4e2232e6bdc8fcc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 615, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32be5c8a-da6b-4a6e-a7dd-d8129a091024": {"__data__": {"id_": "32be5c8a-da6b-4a6e-a7dd-d8129a091024", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n ", "original_text": "Q \nGood afternoon, and congratulations on a really nice quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "250e6ca2-200a-4e20-b10c-63e08b3f632f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1c49ef8a0d9a8a83ac84f8132fd50dc97deb6629be878ca2187421a415ab999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83042ad9-ddd8-4693-9338-77c5caf91e5a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. "}, "hash": "e472104c6de5ac4aea02f93eb4c81e3b36afd2010e68eb6e00a6ae1049a213e6", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon, and congratulations on a really nice quarter. ", "start_char_idx": 936, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83042ad9-ddd8-4693-9338-77c5caf91e5a": {"__data__": {"id_": "83042ad9-ddd8-4693-9338-77c5caf91e5a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32be5c8a-da6b-4a6e-a7dd-d8129a091024", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n ", "original_text": "Q \nGood afternoon, and congratulations on a really nice quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a80e63806cbbb2743a54181b690730bea70df6a551a2dc91fe67614e19a0c09c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad680dcb-5766-46ca-a5c1-b7dde3a9532f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question. ", "original_text": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? "}, "hash": "a406de92f963de33cf5c313546a061f9e9cbd7a56e152a41cb05fd95759da9c6", "class_name": "RelatedNodeInfo"}}, "text": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. ", "start_char_idx": 1001, "end_char_idx": 1127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad680dcb-5766-46ca-a5c1-b7dde3a9532f": {"__data__": {"id_": "ad680dcb-5766-46ca-a5c1-b7dde3a9532f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question. ", "original_text": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83042ad9-ddd8-4693-9338-77c5caf91e5a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5e5877a16886ca039039ab00a3c8415f122a31df5bc5c8992c620f1758a39bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e064b09c-1dd9-4e7b-9ab2-2279e8b83381", "node_type": "1", "metadata": {"window": "Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that. ", "original_text": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n "}, "hash": "c3394ca9cdcd34642b3b2c471e37c53177883f2e20a79d6111f16e3533e4df71", "class_name": "RelatedNodeInfo"}}, "text": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? ", "start_char_idx": 1127, "end_char_idx": 1277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e064b09c-1dd9-4e7b-9ab2-2279e8b83381": {"__data__": {"id_": "e064b09c-1dd9-4e7b-9ab2-2279e8b83381", "embedding": null, "metadata": {"window": "Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that. ", "original_text": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad680dcb-5766-46ca-a5c1-b7dde3a9532f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question. ", "original_text": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear? ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d75b0655352276903e31ce29bd8780b600495afd12feca1832416037985802ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50514a46-142a-4b44-b1b8-cdc814b9e50a", "node_type": "1", "metadata": {"window": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "4d6bfb8aa63317fbbef799f9a2f06323e6f2391066177dd3711992cba18ab7c6", "class_name": "RelatedNodeInfo"}}, "text": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n ", "start_char_idx": 1277, "end_char_idx": 1564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50514a46-142a-4b44-b1b8-cdc814b9e50a": {"__data__": {"id_": "50514a46-142a-4b44-b1b8-cdc814b9e50a", "embedding": null, "metadata": {"window": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e064b09c-1dd9-4e7b-9ab2-2279e8b83381", "node_type": "1", "metadata": {"window": "Q \nGood afternoon, and congratulations on a really nice quarter.  As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that. ", "original_text": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afb2458e83bd089f0a85978ffb31887ad2fc734cb484c4e1a6ae86464a36384e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8406f484-1ca4-445e-9dbc-402b3ba607bd", "node_type": "1", "metadata": {"window": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n", "original_text": "A \nHey, Mike, thanks for the question. "}, "hash": "8887bc0fe14b4af68fd2beff1678ab42e69a92f200e0385e613fdce801f31a7c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1564, "end_char_idx": 1921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8406f484-1ca4-445e-9dbc-402b3ba607bd": {"__data__": {"id_": "8406f484-1ca4-445e-9dbc-402b3ba607bd", "embedding": null, "metadata": {"window": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n", "original_text": "A \nHey, Mike, thanks for the question. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50514a46-142a-4b44-b1b8-cdc814b9e50a", "node_type": "1", "metadata": {"window": "As I think about the OpEx management in the \nquarter, it was something that clearly stood out relative to the outperformance.  Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a518e2493e6a512237957880e1305cc3e746bb734b16f94eac2a946ca047524", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4efb4c2b-8318-47ff-872d-55d01ea39f28", "node_type": "1", "metadata": {"window": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. ", "original_text": "Let me try to tackle that. "}, "hash": "4f9996b4623afb80ca4776fe874e53c3fd8df90935f3ee61202edb2175c88233", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, Mike, thanks for the question. ", "start_char_idx": 1921, "end_char_idx": 1960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4efb4c2b-8318-47ff-872d-55d01ea39f28": {"__data__": {"id_": "4efb4c2b-8318-47ff-872d-55d01ea39f28", "embedding": null, "metadata": {"window": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. ", "original_text": "Let me try to tackle that. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8406f484-1ca4-445e-9dbc-402b3ba607bd", "node_type": "1", "metadata": {"window": "Aside from some of those \ndynamics on wage investments, what are some of the pushes and pulls you're seeing in the OpEx line relative to \nlast y ear?  And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n", "original_text": "A \nHey, Mike, thanks for the question. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cd911e6bb77395e70161dc6f6951b78acda88109324643d67a8dbd2724487f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "238b2569-729e-4fc5-ae1a-ce04afaf2673", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. ", "original_text": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. "}, "hash": "95ce46704f34d2d714686e351250eca83ecb39336ca44d2b9ae0ecccc1b70faf", "class_name": "RelatedNodeInfo"}}, "text": "Let me try to tackle that. ", "start_char_idx": 1960, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "238b2569-729e-4fc5-ae1a-ce04afaf2673": {"__data__": {"id_": "238b2569-729e-4fc5-ae1a-ce04afaf2673", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. ", "original_text": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4efb4c2b-8318-47ff-872d-55d01ea39f28", "node_type": "1", "metadata": {"window": "And how should we think about the trajectory of OpEx at least in terms as a percent of revenue as what \n\u2013 in terms of what you can both manage as well as what will clearly benefit as you get more leverage from faster \ngrowth, some of these incremental r evenue upside pull -throughs?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. ", "original_text": "Let me try to tackle that. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a760fe4236da91be321110ec9b5e7dce180d46a3dced8223521a329700fb47fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24c3ab10-00b7-4eab-b139-1bbbbadd049e", "node_type": "1", "metadata": {"window": "A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n ", "original_text": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n"}, "hash": "2a9b484966a26c21a094b708259fa23924de9fe0bd592ac99cf7391a3608ff0f", "class_name": "RelatedNodeInfo"}}, "text": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. ", "start_char_idx": 1987, "end_char_idx": 2164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24c3ab10-00b7-4eab-b139-1bbbbadd049e": {"__data__": {"id_": "24c3ab10-00b7-4eab-b139-1bbbbadd049e", "embedding": null, "metadata": {"window": "A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n ", "original_text": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "238b2569-729e-4fc5-ae1a-ce04afaf2673", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. ", "original_text": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e847c2b4609803414b037773659ca25385ab472611326a0bd7b71a0ad707b66d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55dde3ff-aacf-4dc8-9069-369e76a9e056", "node_type": "1", "metadata": {"window": "Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n ", "original_text": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. "}, "hash": "a252446f141a81c000ba81782338438651f8f296b02a140e329eeb7a21ba6f0e", "class_name": "RelatedNodeInfo"}}, "text": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n", "start_char_idx": 2164, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55dde3ff-aacf-4dc8-9069-369e76a9e056": {"__data__": {"id_": "55dde3ff-aacf-4dc8-9069-369e76a9e056", "embedding": null, "metadata": {"window": "Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n ", "original_text": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24c3ab10-00b7-4eab-b139-1bbbbadd049e", "node_type": "1", "metadata": {"window": "A \nHey, Mike, thanks for the question.  Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n ", "original_text": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "715b83a44843dd61989e8d844affbe197f3949835add46a9e4b674cfb6fd52e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2a46f91-3662-4d01-8896-5fea931d9924", "node_type": "1", "metadata": {"window": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. "}, "hash": "c4e77372b02b90f576a65d08268c2a1d417e52c7c1e3af85a05a5c5bcd153c49", "class_name": "RelatedNodeInfo"}}, "text": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. ", "start_char_idx": 2445, "end_char_idx": 2597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2a46f91-3662-4d01-8896-5fea931d9924": {"__data__": {"id_": "b2a46f91-3662-4d01-8896-5fea931d9924", "embedding": null, "metadata": {"window": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55dde3ff-aacf-4dc8-9069-369e76a9e056", "node_type": "1", "metadata": {"window": "Let me try to tackle that.  I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n ", "original_text": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "790916cdd3e34015d30d4ed4ca3e45f246c0d71169c21f79f94921427ff15f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b17a52e6-67e4-47a5-b257-5a3d5cd3c492", "node_type": "1", "metadata": {"window": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n "}, "hash": "04444401fef648b47246deb7cc78be8002142799500a1831f86f900ff3cfbb71", "class_name": "RelatedNodeInfo"}}, "text": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. ", "start_char_idx": 2597, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b17a52e6-67e4-47a5-b257-5a3d5cd3c492": {"__data__": {"id_": "b17a52e6-67e4-47a5-b257-5a3d5cd3c492", "embedding": null, "metadata": {"window": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2a46f91-3662-4d01-8896-5fea931d9924", "node_type": "1", "metadata": {"window": "I think the biggest piece that we identify for our \nconsolidated operations wa s the divestitures in Europe, that drove a lot of the operating expense decline year -\nover-year.  And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40116053605c4585e24ec821102201d048b609212f7a7dddc00f829fbc9c9d1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "424422c0-ce30-4521-81eb-8dab3e5632b8", "node_type": "1", "metadata": {"window": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n "}, "hash": "9bff2cba26eb92e77a5c378a9a500d62d6aa88189fcb4fc9fb849f077c2d2c88", "class_name": "RelatedNodeInfo"}}, "text": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n ", "start_char_idx": 2780, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "424422c0-ce30-4521-81eb-8dab3e5632b8": {"__data__": {"id_": "424422c0-ce30-4521-81eb-8dab3e5632b8", "embedding": null, "metadata": {"window": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b17a52e6-67e4-47a5-b257-5a3d5cd3c492", "node_type": "1", "metadata": {"window": "And we also have continued to execute against a lot of our cost initiatives that we began three years \nago and a lot of the efficiency that we've driven into the  organization and continue to be focused on not only \nefficiencies, but driving automation in the company as well.  \n \n Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "840608b1a779a7711f8567e3f19ffd25798fa1130c22b87969521b186a675439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f73b5f4d-2e72-46f7-92ed-133fa5aee23f", "node_type": "1", "metadata": {"window": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "f562d9869cae49be547c29d95ac9425ecec6d57119edb5209e20a696b0b90c24", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 3067, "end_char_idx": 3431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f73b5f4d-2e72-46f7-92ed-133fa5aee23f": {"__data__": {"id_": "f73b5f4d-2e72-46f7-92ed-133fa5aee23f", "embedding": null, "metadata": {"window": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "424422c0-ce30-4521-81eb-8dab3e5632b8", "node_type": "1", "metadata": {"window": "Couple other things that I would point out, for sure, is in our corporate line we saw lower opioid litigation expenses \nas compared to the pri or year.  Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "258e3243d8d5bd455f4230c468aa567d3036846b67301e0cadb980e64a668ca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de00843a-66c2-4398-9f0b-aa49c7b1cb5d", "node_type": "1", "metadata": {"window": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone. ", "original_text": "Our next question comes from Steven Valiquette with Barclays.  \n "}, "hash": "61084a0bb86872c4cb0829610ac3ce19474d07c741925259a025c8f11acc1eae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 3431, "end_char_idx": 3727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de00843a-66c2-4398-9f0b-aa49c7b1cb5d": {"__data__": {"id_": "de00843a-66c2-4398-9f0b-aa49c7b1cb5d", "embedding": null, "metadata": {"window": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone. ", "original_text": "Our next question comes from Steven Valiquette with Barclays.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f73b5f4d-2e72-46f7-92ed-133fa5aee23f", "node_type": "1", "metadata": {"window": "Now, we called that out in our guidance at the beginning of the year, but on a year -\nover-year basis, it was lower in the first quarter, and that's going through our corporate line.  But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1be44a94af13b6a8d38cf024261f3f1c1b4fb2b6499e7ee5962eee6a76a55d7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09209a84-99b6-4de4-99f9-410c2a765054", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. "}, "hash": "d4cd1c1a61217eb2f1b73160c9d7d11544d657144d6155494a51585b6b01a3e5", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Steven Valiquette with Barclays.  \n ", "start_char_idx": 3727, "end_char_idx": 3792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09209a84-99b6-4de4-99f9-410c2a765054": {"__data__": {"id_": "09209a84-99b6-4de4-99f9-410c2a765054", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de00843a-66c2-4398-9f0b-aa49c7b1cb5d", "node_type": "1", "metadata": {"window": "But I think overall, it's \na lot of the efficiencies that we've dri ven in the organization, our cost programs that we've been after now for the \nlast three to four years, and the leverage that we're able to get as we continue to drive the corporation forward \nand gain productivity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone. ", "original_text": "Our next question comes from Steven Valiquette with Barclays.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57c478eda0924e3643ea1bffc2153b3476d67d847547b71068b57a7a0274fab2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39a35fde-471e-483c-aad1-2404c4b5181b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. ", "original_text": "Thanks. "}, "hash": "a9b76d2cc51d963c279167b63a16bc8e07fd17e777b8a4450084755b4297f67a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. ", "start_char_idx": 3792, "end_char_idx": 4128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39a35fde-471e-483c-aad1-2404c4b5181b": {"__data__": {"id_": "39a35fde-471e-483c-aad1-2404c4b5181b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. ", "original_text": "Thanks. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09209a84-99b6-4de4-99f9-410c2a765054", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Cont act, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f3539721be0353d918e9b5974fe6082e079ba99a4cbd432da9ac76cd9730203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f81bbbf2-e23f-47d4-9347-caa9c9ef659d", "node_type": "1", "metadata": {"window": "Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize. ", "original_text": "Good afternoon, everyone. "}, "hash": "095b9d603654481dbcd5fc2ab725ea1216283c9f91b32bfabf234e1c5115c9c7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 4128, "end_char_idx": 4136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f81bbbf2-e23f-47d4-9347-caa9c9ef659d": {"__data__": {"id_": "f81bbbf2-e23f-47d4-9347-caa9c9ef659d", "embedding": null, "metadata": {"window": "Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize. ", "original_text": "Good afternoon, everyone. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39a35fde-471e-483c-aad1-2404c4b5181b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. ", "original_text": "Thanks. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bbadc241c798be4d954af0d8d65acb81c6af5ae2b51546390e1807dda37b3f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed0ce3c0-0617-4235-bb38-66a57bb126a7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items. ", "original_text": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. "}, "hash": "8b6a49aba3c17ce4cc1e8ba75834ee3335a92646c6aa298669d2174c0d6cedab", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, everyone. ", "start_char_idx": 4136, "end_char_idx": 4162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed0ce3c0-0617-4235-bb38-66a57bb126a7": {"__data__": {"id_": "ed0ce3c0-0617-4235-bb38-66a57bb126a7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items. ", "original_text": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f81bbbf2-e23f-47d4-9347-caa9c9ef659d", "node_type": "1", "metadata": {"window": "Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize. ", "original_text": "Good afternoon, everyone. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ad321c41bbf1be2fd1ab9fadf0482687c81ee9e4675485cd38daf0acb723ec6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25903631-0a63-4213-90ea-4d072bae1002", "node_type": "1", "metadata": {"window": "Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? ", "original_text": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. "}, "hash": "297efedd3328b0a15a2eb19ea8dcf896fc4d7a4cf714acbeadaa8bfe489bd833", "class_name": "RelatedNodeInfo"}}, "text": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. ", "start_char_idx": 4162, "end_char_idx": 4313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25903631-0a63-4213-90ea-4d072bae1002": {"__data__": {"id_": "25903631-0a63-4213-90ea-4d072bae1002", "embedding": null, "metadata": {"window": "Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? ", "original_text": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed0ce3c0-0617-4235-bb38-66a57bb126a7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nYeah.  Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items. ", "original_text": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d15b96e8456cfdd36fb1209b880519f14906a810f43df99c416bcccd1aa4354f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b9d3203-bb73-4411-9c02-9742d7c7a02d", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n ", "original_text": "I think on slide 19 \u2013 actually slide 15, I apologize. "}, "hash": "9d131026560f1b5799f91f5069935bbed07453872a688effe1f4f060494c33d9", "class_name": "RelatedNodeInfo"}}, "text": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. ", "start_char_idx": 4313, "end_char_idx": 4388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b9d3203-bb73-4411-9c02-9742d7c7a02d": {"__data__": {"id_": "2b9d3203-bb73-4411-9c02-9742d7c7a02d", "embedding": null, "metadata": {"window": "Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n ", "original_text": "I think on slide 19 \u2013 actually slide 15, I apologize. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25903631-0a63-4213-90ea-4d072bae1002", "node_type": "1", "metadata": {"window": "Thanks.  Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? ", "original_text": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "461170fe7e16c29cb9e474d6528f14e499f3b3782cdc4744543bc9b1b0b7e71f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b1a0d5-136c-4a8a-95fd-a05e67a9bee1", "node_type": "1", "metadata": {"window": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Yo u show the \n10% to 15% growth, excluding those items. "}, "hash": "cc807028293b74314b3e81737579505605668badcbfc8232ad4f1c670b79e7de", "class_name": "RelatedNodeInfo"}}, "text": "I think on slide 19 \u2013 actually slide 15, I apologize. ", "start_char_idx": 4388, "end_char_idx": 4442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b1a0d5-136c-4a8a-95fd-a05e67a9bee1": {"__data__": {"id_": "18b1a0d5-136c-4a8a-95fd-a05e67a9bee1", "embedding": null, "metadata": {"window": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Yo u show the \n10% to 15% growth, excluding those items. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b9d3203-bb73-4411-9c02-9742d7c7a02d", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n ", "original_text": "I think on slide 19 \u2013 actually slide 15, I apologize. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e76d99643c026c00f9f5991fadb72d3805b84d61f18fa7b5fd9fb7f4203c7e38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef7447d0-5423-4d6b-b33d-abe6ca1c83a2", "node_type": "1", "metadata": {"window": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? "}, "hash": "2f5cb0130e8e0f017aaa956555c0ca10e8383eb5fec6417b19b9608d4a572c26", "class_name": "RelatedNodeInfo"}}, "text": "Yo u show the \n10% to 15% growth, excluding those items. ", "start_char_idx": 4442, "end_char_idx": 4499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef7447d0-5423-4d6b-b33d-abe6ca1c83a2": {"__data__": {"id_": "ef7447d0-5423-4d6b-b33d-abe6ca1c83a2", "embedding": null, "metadata": {"window": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b1a0d5-136c-4a8a-95fd-a05e67a9bee1", "node_type": "1", "metadata": {"window": "So if we go back to the Analyst Day back in December, you guys \ntalked about 12% to 14% EPS growth, excluding COVID and some of the European dilution.  I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Yo u show the \n10% to 15% growth, excluding those items. ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f28d679f6d4c514295fff2ac9469894225a8056513c840525b5c629cc713adf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58574996-bef0-444b-aefd-cbee74381dab", "node_type": "1", "metadata": {"window": "I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thanks.  \n "}, "hash": "8ef435565a739ac382d9fec84a13153964cf3fd4f26e6b66bff96742c78548be", "class_name": "RelatedNodeInfo"}}, "text": "I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? ", "start_char_idx": 4499, "end_char_idx": 4646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58574996-bef0-444b-aefd-cbee74381dab": {"__data__": {"id_": "58574996-bef0-444b-aefd-cbee74381dab", "embedding": null, "metadata": {"window": "I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef7447d0-5423-4d6b-b33d-abe6ca1c83a2", "node_type": "1", "metadata": {"window": "I'm trying to quantify \nhow that's tracking in fiscal 2023 ex those items.  I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously? ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "149389007c104858f95a1c2ae6643141a2f5418f6e83c0b61aca23026bd55843", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d00eaa23-b6c5-4293-b4c6-53f133254204", "node_type": "1", "metadata": {"window": "Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "38ced6f2b299e0e6759787c81253b17786267ffa9ed6516e1a9dc37d4fb40b5f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 4646, "end_char_idx": 4657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d00eaa23-b6c5-4293-b4c6-53f133254204": {"__data__": {"id_": "d00eaa23-b6c5-4293-b4c6-53f133254204", "embedding": null, "metadata": {"window": "Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91497534-9f73-495e-8234-8857f0469491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23021d358077aa844575a491eed67efb0b73087556bc4558b1cb6daf2a8751", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58574996-bef0-444b-aefd-cbee74381dab", "node_type": "1", "metadata": {"window": "I think on slide 19 \u2013 actually slide 15, I apologize.  Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "066148710a2dd844da215d66b788652ba81d22053b24cc6ea34b98777fb83dbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f12ec521-5665-4e3b-b506-16844f65d8ea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "original_text": "McKesson Corp.  "}, "hash": "0bcd24d0e434db960da6d71ed4ad71e9a80d7feb56bd4b1ecaec05aad9e8aea5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 273, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f12ec521-5665-4e3b-b506-16844f65d8ea": {"__data__": {"id_": "f12ec521-5665-4e3b-b506-16844f65d8ea", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d00eaa23-b6c5-4293-b4c6-53f133254204", "node_type": "1", "metadata": {"window": "Yo u show the \n10% to 15% growth, excluding those items.  I'm wondering, is that the closest poxy for how this fiscal year is \ntracking relative to that 12% to 14% metric that you talked about previously?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15918bd35e5848696b792b24dacccc8f0a430edd3b262d9f5011f5078c7cf760", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a208041-4887-42a4-973f-c69a8ed78ed5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  "}, "hash": "bff1101ff1e74f2617069b4d3a61e169997bb8b4a1532a8f65cc9047f192af84", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a208041-4887-42a4-973f-c69a8ed78ed5": {"__data__": {"id_": "1a208041-4887-42a4-973f-c69a8ed78ed5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f12ec521-5665-4e3b-b506-16844f65d8ea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "725ec4f3f0a49d6f588a2fcf5aaacf688f01bb82d3e82ac0ad0c2f5fe2074bb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27cffdc3-e870-437e-87e9-caa620db432e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n", "original_text": "A \nHey, Steven, thanks for the question. "}, "hash": "5debde1b19f3a99a3574abe7c5815efc15ea1fc869ae0040f08e49fbddac2ec2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27cffdc3-e870-437e-87e9-caa620db432e": {"__data__": {"id_": "27cffdc3-e870-437e-87e9-caa620db432e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n", "original_text": "A \nHey, Steven, thanks for the question. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a208041-4887-42a4-973f-c69a8ed78ed5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72e1800ad1b944a8b8c4db2f4875cd8b92fc7dbe0fb4c8b8b405251aa0514124", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36c02981-8e3c-4e93-86ed-b913d811c0d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n", "original_text": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. "}, "hash": "0969ffce74d7138e4bdbca917dee1d333e4596898e556e070a94ed2c39d249ca", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, Steven, thanks for the question. ", "start_char_idx": 267, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36c02981-8e3c-4e93-86ed-b913d811c0d1": {"__data__": {"id_": "36c02981-8e3c-4e93-86ed-b913d811c0d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n", "original_text": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27cffdc3-e870-437e-87e9-caa620db432e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n", "original_text": "A \nHey, Steven, thanks for the question. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "886b2c4620258fd36b0730ba4e16d4a3b0f4732ce10ea853d4edb9387b720258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8a28949-f56f-4ace-ac6a-a0b9e8c0afa7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. ", "original_text": "Obviously, we have COVID test kits and vaccines an d so \nforth. "}, "hash": "c05d2ba8cfc06edf00508da477db9a143edf32b254d32c93de98efb82465f4ad", "class_name": "RelatedNodeInfo"}}, "text": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "start_char_idx": 308, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8a28949-f56f-4ace-ac6a-a0b9e8c0afa7": {"__data__": {"id_": "c8a28949-f56f-4ace-ac6a-a0b9e8c0afa7", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. ", "original_text": "Obviously, we have COVID test kits and vaccines an d so \nforth. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36c02981-8e3c-4e93-86ed-b913d811c0d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n", "original_text": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99bd776455f43e0f4cc589a034999848789719e2f1260b5fa89ed3fe3de75be9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bb3a59c-2f17-4c67-b5db-cf3ec273da8b", "node_type": "1", "metadata": {"window": "A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. ", "original_text": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n"}, "hash": "b9914f0e443a27787c5e4e78cf6dc839c077257e3d76cd22b04b8163a989ef24", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, we have COVID test kits and vaccines an d so \nforth. ", "start_char_idx": 439, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bb3a59c-2f17-4c67-b5db-cf3ec273da8b": {"__data__": {"id_": "4bb3a59c-2f17-4c67-b5db-cf3ec273da8b", "embedding": null, "metadata": {"window": "A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. ", "original_text": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8a28949-f56f-4ace-ac6a-a0b9e8c0afa7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. ", "original_text": "Obviously, we have COVID test kits and vaccines an d so \nforth. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b5652440a918629bebdc0f8a18b23ffca9bdd7591c2c2cfb97d359ef8edb7ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4715729c-111e-4945-bd8a-3e244b5eec98", "node_type": "1", "metadata": {"window": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n ", "original_text": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n"}, "hash": "5294809cf2540bb37b448d458fbff44fe3bcf4ff24bc6f942464fc2ac6753716", "class_name": "RelatedNodeInfo"}}, "text": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n", "start_char_idx": 503, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4715729c-111e-4945-bd8a-3e244b5eec98": {"__data__": {"id_": "4715729c-111e-4945-bd8a-3e244b5eec98", "embedding": null, "metadata": {"window": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n ", "original_text": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bb3a59c-2f17-4c67-b5db-cf3ec273da8b", "node_type": "1", "metadata": {"window": "A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. ", "original_text": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "def1028d54633f8730ca9222e5367c05cd106259d189071abf01853d242976e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c62002f-108f-4cf7-910b-953210f6e2e4", "node_type": "1", "metadata": {"window": "Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. "}, "hash": "fda561bc63d4764ae1b991b011446ecb1d1c6f103b491829391fb5120e6e6027", "class_name": "RelatedNodeInfo"}}, "text": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n", "start_char_idx": 866, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c62002f-108f-4cf7-910b-953210f6e2e4": {"__data__": {"id_": "7c62002f-108f-4cf7-910b-953210f6e2e4", "embedding": null, "metadata": {"window": "Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4715729c-111e-4945-bd8a-3e244b5eec98", "node_type": "1", "metadata": {"window": "So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here.  Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n ", "original_text": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2d81783d9a3ce9804fdf48beb07b2fcb65a2014beb5cfd5f8c33c07aaa7bba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aee6925-f296-4237-991d-8c530599cb64", "node_type": "1", "metadata": {"window": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. "}, "hash": "f4c415a6ff969481fcbd813fec220d7554d4641b5603353952d50dca1bdb9250", "class_name": "RelatedNodeInfo"}}, "text": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. ", "start_char_idx": 1134, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aee6925-f296-4237-991d-8c530599cb64": {"__data__": {"id_": "7aee6925-f296-4237-991d-8c530599cb64", "embedding": null, "metadata": {"window": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c62002f-108f-4cf7-910b-953210f6e2e4", "node_type": "1", "metadata": {"window": "Obviously, we have COVID test kits and vaccines an d so \nforth.  The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3131c1c5d9709dd928d3371c2e3687c24ea77bbb900c70659ab53232e4e025e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dc2fc9-e16f-4522-ac6e-8711f48db93a", "node_type": "1", "metadata": {"window": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n "}, "hash": "a486d8838c76415a223c4906ceacce0276b94a30e6775b6b9af2e5f1dfc2ed66", "class_name": "RelatedNodeInfo"}}, "text": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. ", "start_char_idx": 1383, "end_char_idx": 1511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dc2fc9-e16f-4522-ac6e-8711f48db93a": {"__data__": {"id_": "a3dc2fc9-e16f-4522-ac6e-8711f48db93a", "embedding": null, "metadata": {"window": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aee6925-f296-4237-991d-8c530599cb64", "node_type": "1", "metadata": {"window": "The guidance that we gave you is more on a long term basis and again excluding some of the programs \nthat we have in place and obviously excluding McKesson Ventures, when you look at each of our segments, as I \ntalked about them here today, our s egments have actually performed slightly ahead of the long term growth rates \nthat we provided at Investor Day.  \n \n One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc2ea815109574f0ad6faca0af62d618091ec6469c2b327441d5393992c1ba69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e59e2adb-f0ae-47d0-b634-587d5c622fff", "node_type": "1", "metadata": {"window": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "09eaf57531e6b34e091ea8f1ea28763b590acb6667b8fa1f082e9e4664b390ff", "class_name": "RelatedNodeInfo"}}, "text": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n ", "start_char_idx": 1511, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e59e2adb-f0ae-47d0-b634-587d5c622fff": {"__data__": {"id_": "e59e2adb-f0ae-47d0-b634-587d5c622fff", "embedding": null, "metadata": {"window": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dc2fc9-e16f-4522-ac6e-8711f48db93a", "node_type": "1", "metadata": {"window": "One of the things that we're obviously working through here is the divestitures of Europe and the cadence of \nthose divestitures, and obviously w hat we've talked about from the beginning here is we're going to try to offset \nthat dilution with share repurchases.  \n \n But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56641565dc64535c1111b67fdd08734baa73b953a31dd6509ec286bcf69492be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54f07a9b-bd27-48c4-9913-88a63e527d39", "node_type": "1", "metadata": {"window": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n "}, "hash": "421f68970cc321f67415d4b03e5cda9793808f750fa90b243af1f592c2a03d63", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 1635, "end_char_idx": 1998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54f07a9b-bd27-48c4-9913-88a63e527d39": {"__data__": {"id_": "54f07a9b-bd27-48c4-9913-88a63e527d39", "embedding": null, "metadata": {"window": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e59e2adb-f0ae-47d0-b634-587d5c622fff", "node_type": "1", "metadata": {"window": "But if you look at our operating profit growth, excluding the programs that we have with the US government and \nCOVID test kits and you loo k at the segments, that is really in line with the long term growth rates that we \nprovided at Investor Day.  And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50d92d849754184e30726ed60b2bcbc2ea2ed7dd57ba4245b001407e36328eb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cb72f2b-0a05-42e2-94bf-b18f92e29a1e", "node_type": "1", "metadata": {"window": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "2d998ac0a9575e0f334a3dc4b3ec771484b10737528175d30ee303af42f675f6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "start_char_idx": 1998, "end_char_idx": 2339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cb72f2b-0a05-42e2-94bf-b18f92e29a1e": {"__data__": {"id_": "8cb72f2b-0a05-42e2-94bf-b18f92e29a1e", "embedding": null, "metadata": {"window": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54f07a9b-bd27-48c4-9913-88a63e527d39", "node_type": "1", "metadata": {"window": "And on a consolidated basis, the 10% to 15% that we've talked about here today again \nalso aligns with that long term guidance.  We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2785111b3d83e848dc20967160eeb1f16859f0de719cfd2396a5a85a45630eaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75129aca-16eb-4ddd-81a9-9db3f309153f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n ", "original_text": "Question relative to the contract extension with the government. "}, "hash": "83a13e7b290cde30f6759c354048c54114f5b52159df29b461fac26e6876176b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 2339, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75129aca-16eb-4ddd-81a9-9db3f309153f": {"__data__": {"id_": "75129aca-16eb-4ddd-81a9-9db3f309153f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n ", "original_text": "Question relative to the contract extension with the government. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cb72f2b-0a05-42e2-94bf-b18f92e29a1e", "node_type": "1", "metadata": {"window": "We feel very good tha t we're on pace and that we're tracking against \nwhat we told you at our Investor Day in December.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3926c7fc76442ceef2fbe1504091a0a5c8e0c89de38a7f18507425f2332d71f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "047a2b80-2744-4f07-b274-7f91862e3450", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax? "}, "hash": "7d624356eba1b649bb709736f7b75e2aad63628ed44e4f4ebe43e87528baae00", "class_name": "RelatedNodeInfo"}}, "text": "Question relative to the contract extension with the government. ", "start_char_idx": 2671, "end_char_idx": 2736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "047a2b80-2744-4f07-b274-7f91862e3450": {"__data__": {"id_": "047a2b80-2744-4f07-b274-7f91862e3450", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax? ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75129aca-16eb-4ddd-81a9-9db3f309153f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n ", "original_text": "Question relative to the contract extension with the government. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5785e9434ec245fdcc2ee19dfdcd4bfcc01b8b1df47670d54b0579d1c9dba370", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e35bad2a-58d1-438c-9668-4ef2e71612fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. ", "original_text": "Would you potentially support Novavax or Pfiz er? "}, "hash": "731cd627f82454206f014400d389649191d78026a08db8502c0127b87f15ce7c", "class_name": "RelatedNodeInfo"}}, "text": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax? ", "start_char_idx": 2736, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e35bad2a-58d1-438c-9668-4ef2e71612fe": {"__data__": {"id_": "e35bad2a-58d1-438c-9668-4ef2e71612fe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. ", "original_text": "Would you potentially support Novavax or Pfiz er? ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "047a2b80-2744-4f07-b274-7f91862e3450", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax? ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79dee85c3404b00143f2c526986e270b9cfaf90a46dc81d43a64751a49b60880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee718048-2442-4506-a218-40325ec0af73", "node_type": "1", "metadata": {"window": "Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. ", "original_text": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n "}, "hash": "81593653e9c99c26370c583f9c3e72c61747e2a767b58a74e7b9ebc722d78b22", "class_name": "RelatedNodeInfo"}}, "text": "Would you potentially support Novavax or Pfiz er? ", "start_char_idx": 2826, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee718048-2442-4506-a218-40325ec0af73": {"__data__": {"id_": "ee718048-2442-4506-a218-40325ec0af73", "embedding": null, "metadata": {"window": "Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. ", "original_text": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e35bad2a-58d1-438c-9668-4ef2e71612fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. ", "original_text": "Would you potentially support Novavax or Pfiz er? ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b85536f6abe099931410c8552a398790481bc125800b885c9d29911d8fe6464", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d22337-2e04-4326-9018-b9d3091f87a6", "node_type": "1", "metadata": {"window": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "bfdc9ef81311383d87ca2eaa48d52ea8c959c8429709869edc8e23f7ebe28ab4", "class_name": "RelatedNodeInfo"}}, "text": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n ", "start_char_idx": 2876, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d22337-2e04-4326-9018-b9d3091f87a6": {"__data__": {"id_": "c7d22337-2e04-4326-9018-b9d3091f87a6", "embedding": null, "metadata": {"window": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee718048-2442-4506-a218-40325ec0af73", "node_type": "1", "metadata": {"window": "Question relative to the contract extension with the government.  And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. ", "original_text": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9b9bbee9d5ed74cb4e6528dd2658ab863decf66d28dc37832d9135169e5f664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3883e3bb-ced0-4e5a-83e0-5c89fd48dd09", "node_type": "1", "metadata": {"window": "Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. ", "original_text": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. "}, "hash": "8537a7d65464c9e902e8741d3c384c8eda008c554c896ceb7d60518955acb754", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3003, "end_char_idx": 3344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3883e3bb-ced0-4e5a-83e0-5c89fd48dd09": {"__data__": {"id_": "3883e3bb-ced0-4e5a-83e0-5c89fd48dd09", "embedding": null, "metadata": {"window": "Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. ", "original_text": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d22337-2e04-4326-9018-b9d3091f87a6", "node_type": "1", "metadata": {"window": "And first, are there any changes in \nthe scope of operations for vax and kitting and vax?  Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1515bcae2146c7d9601cd4690bd838dd8d37dd5b0bb708f2063ebff9ffe4d91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c15df65-7aad-4c24-abe9-7f56468041f5", "node_type": "1", "metadata": {"window": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n ", "original_text": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. "}, "hash": "34f86a603d6a5a8beddc0f191f3cd24dddeb8b6e77211c4120ab03b21d760598", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. ", "start_char_idx": 3344, "end_char_idx": 3496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c15df65-7aad-4c24-abe9-7f56468041f5": {"__data__": {"id_": "2c15df65-7aad-4c24-abe9-7f56468041f5", "embedding": null, "metadata": {"window": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n ", "original_text": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3883e3bb-ced0-4e5a-83e0-5c89fd48dd09", "node_type": "1", "metadata": {"window": "Would you potentially support Novavax or Pfiz er?  And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. ", "original_text": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa4770937e2c7bd5bff63bf91fce34c34ca2e341d500be5378216d355e5bf058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8e3c233-9d8f-42ae-a506-b5d72c4e3d1b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "A nd our facilities are \ncapable and ready to support that.  \n \n"}, "hash": "a34a9e6d3d6fd97e5d3092b85c917f727ad8f7a9ed65669f0275888f9437c226", "class_name": "RelatedNodeInfo"}}, "text": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. ", "start_char_idx": 3496, "end_char_idx": 3658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8e3c233-9d8f-42ae-a506-b5d72c4e3d1b": {"__data__": {"id_": "f8e3c233-9d8f-42ae-a506-b5d72c4e3d1b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "A nd our facilities are \ncapable and ready to support that.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c15df65-7aad-4c24-abe9-7f56468041f5", "node_type": "1", "metadata": {"window": "And I'd be \ninterested in your perspective on normalization of distribution of both vaccines and COVID therapies over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n ", "original_text": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d609abbf13d610ab1d0e6d3b3c28db9538253f8942e04b01be73a18f923f0a8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f986e258-fbce-4d60-9e47-c10765ba513f", "node_type": "1", "metadata": {"window": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. "}, "hash": "d2386dfc571793ce03bf34ac6634060bddb07be30764e550e2cd12c0b9b626aa", "class_name": "RelatedNodeInfo"}}, "text": "A nd our facilities are \ncapable and ready to support that.  \n \n", "start_char_idx": 3658, "end_char_idx": 3722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f986e258-fbce-4d60-9e47-c10765ba513f": {"__data__": {"id_": "f986e258-fbce-4d60-9e47-c10765ba513f", "embedding": null, "metadata": {"window": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8e3c233-9d8f-42ae-a506-b5d72c4e3d1b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "A nd our facilities are \ncapable and ready to support that.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6c4874a2a8aeaaad8cadf48fc5a6d3846fc0cb2b74bd1a8cb1fe88532ef4153", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32b7315a-a679-49a6-a8e0-141cf8fc5081", "node_type": "1", "metadata": {"window": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n "}, "hash": "6cae20d04c80ac453b315e9d49d5bb516df676deaad0a75514443967f9301ed4", "class_name": "RelatedNodeInfo"}}, "text": "And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. ", "start_char_idx": 3722, "end_char_idx": 3914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32b7315a-a679-49a6-a8e0-141cf8fc5081": {"__data__": {"id_": "32b7315a-a679-49a6-a8e0-141cf8fc5081", "embedding": null, "metadata": {"window": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f986e258-fbce-4d60-9e47-c10765ba513f", "node_type": "1", "metadata": {"window": "A \nSo in terms of the scope of the agreement, really the scope of either agreement has not really changed in terms \nof the services that we'll provide.  We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive. ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11738488b9447d7323b70c0ac92e6c544a3dad0a58117beded7e4962d8015c87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad041167-1cce-42ed-9f04-21bf9559b536", "node_type": "1", "metadata": {"window": "A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  "}, "hash": "b36c305d0de3054e8e90d7d3fe4e37ccee5c9fcf281d736609af4e105a5f09da", "class_name": "RelatedNodeInfo"}}, "text": "And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n ", "start_char_idx": 3914, "end_char_idx": 3986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad041167-1cce-42ed-9f04-21bf9559b536": {"__data__": {"id_": "ad041167-1cce-42ed-9f04-21bf9559b536", "embedding": null, "metadata": {"window": "A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c30deb0e79f89dfa6f59440dad55aa36a56f9fbed74b252e7ec6c21bea208052", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32b7315a-a679-49a6-a8e0-141cf8fc5081", "node_type": "1", "metadata": {"window": "We are not going to expand to do Pfizer, but we are committed to do all of the \nother US government approved including Novavax, as directed by the US government.  A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fb5151c089f3e9e77bfff74ab68ad0773109435b33196db6c65b9a9d61f624a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55ed0b93-f0fe-4b14-90e1-302ff8319b66", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "original_text": "McKesson Corp.  "}, "hash": "44b4c2503554ec6d899ea2d3c2708893b38265116512256bd7bf004bddfacabb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "start_char_idx": 3986, "end_char_idx": 4468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55ed0b93-f0fe-4b14-90e1-302ff8319b66": {"__data__": {"id_": "55ed0b93-f0fe-4b14-90e1-302ff8319b66", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad041167-1cce-42ed-9f04-21bf9559b536", "node_type": "1", "metadata": {"window": "A nd our facilities are \ncapable and ready to support that.  \n \n And I would just mimic similarly for the kitting side, although it's probably a little more storage than kitting vis -\u00e0-vis \nthe early phases of the program, when kitting was quite intensive.  And what  was the \u2013 I'm sorry, Eric, what was \nyour second question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nJust your thought on the normalization of distribution into all distributors, both for vax and COVID therapies, are \nyou seeing some of that for your channels?  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4afa001b593cca2b7373adc90f25581d6a4ddb70f3fcc506ab409cf3162dd9df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "982d19ee-ea81-49a9-a0e5-ac03a5aa7ec9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "2467a5c78bce8cb1a3962a6888738678924a855d5c11a3099f496f4870a9e475", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "982d19ee-ea81-49a9-a0e5-ac03a5aa7ec9": {"__data__": {"id_": "982d19ee-ea81-49a9-a0e5-ac03a5aa7ec9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55ed0b93-f0fe-4b14-90e1-302ff8319b66", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "790f9646e53f8fa1e40c1664bd862c0c5787656ebf928c1a18e057d3e91ee825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adfabef2-fc79-4884-a5d8-12e7903cb5ef", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. ", "original_text": "A \nYeah. "}, "hash": "8aad8cad994b9d4235890710381fe8ca741ca489461f51fec5817ed71e79febd", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adfabef2-fc79-4884-a5d8-12e7903cb5ef": {"__data__": {"id_": "adfabef2-fc79-4884-a5d8-12e7903cb5ef", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "982d19ee-ea81-49a9-a0e5-ac03a5aa7ec9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe0b46a863e31b80c8f3f6bcdc115fd6abdcb51319e7bf0b05d505a4b0ad1e6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6eb30b5e-e3c5-40f6-aaf0-b81ac347f729", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n ", "original_text": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. "}, "hash": "6ac4f699ca3c4b969bac053867a093b9e5a68164e183389b07a91d2b7df7ecb1", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 250, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6eb30b5e-e3c5-40f6-aaf0-b81ac347f729": {"__data__": {"id_": "6eb30b5e-e3c5-40f6-aaf0-b81ac347f729", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n ", "original_text": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adfabef2-fc79-4884-a5d8-12e7903cb5ef", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c5f041195d78e9f1197660714d9b65925128857f8a8c14be05797ae36cb861b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a383c03f-bbd9-4f0f-9b22-dd999a5f7969", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n"}, "hash": "c1e118ff809854252df47361f4c3989abc6112d838de8c4c2d5012739308ef29", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "start_char_idx": 259, "end_char_idx": 396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a383c03f-bbd9-4f0f-9b22-dd999a5f7969": {"__data__": {"id_": "a383c03f-bbd9-4f0f-9b22-dd999a5f7969", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6eb30b5e-e3c5-40f6-aaf0-b81ac347f729", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n ", "original_text": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "094b1ff98d981bd804b9271fd5a99324f04c2ef1a63afe52afcab7f2668c99e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b64e020e-cb3e-4909-92e6-23484bb2e49f", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. "}, "hash": "2594c9ca4991c11b5a70697484b773d69a447e43bfff87483b88381976c138c1", "class_name": "RelatedNodeInfo"}}, "text": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n", "start_char_idx": 396, "end_char_idx": 616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b64e020e-cb3e-4909-92e6-23484bb2e49f": {"__data__": {"id_": "b64e020e-cb3e-4909-92e6-23484bb2e49f", "embedding": null, "metadata": {"window": "A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a383c03f-bbd9-4f0f-9b22-dd999a5f7969", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c2bb1dc7fa9d142b0b953396c686db5f2382c0935b68d728be4cec0c9cf3a00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e893593f-f495-4efa-883c-9a91ceec9f07", "node_type": "1", "metadata": {"window": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n "}, "hash": "f13549866520c52c1e7bd26eedd85a5019da550ada311f71f923eea1ae873ec9", "class_name": "RelatedNodeInfo"}}, "text": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. ", "start_char_idx": 616, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e893593f-f495-4efa-883c-9a91ceec9f07": {"__data__": {"id_": "e893593f-f495-4efa-883c-9a91ceec9f07", "embedding": null, "metadata": {"window": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b64e020e-cb3e-4909-92e6-23484bb2e49f", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3c841b4a203dc9bd2cf8fc5fa747600fcedaf42ae3cb1e883b320d7abe9c137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ceea00b-e3ff-4379-9ab9-25f965bcb4e5", "node_type": "1", "metadata": {"window": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "994e97f55735e6cc5f09ef8fa038f62efb77d3f4953998f9d33dc35344422eb1", "class_name": "RelatedNodeInfo"}}, "text": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n ", "start_char_idx": 758, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ceea00b-e3ff-4379-9ab9-25f965bcb4e5": {"__data__": {"id_": "9ceea00b-e3ff-4379-9ab9-25f965bcb4e5", "embedding": null, "metadata": {"window": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e893593f-f495-4efa-883c-9a91ceec9f07", "node_type": "1", "metadata": {"window": "I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model.  To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27dd8836978beb1f19531dd256782b704776080b6ba6356aa3d98c70f920de11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c3fb57a-1172-4311-b228-ce68fc8e71c7", "node_type": "1", "metadata": {"window": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "3a969d63442e9970a86768358157fb64699f7626a2c1b45fb5eb12d878d1b14d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 951, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c3fb57a-1172-4311-b228-ce68fc8e71c7": {"__data__": {"id_": "6c3fb57a-1172-4311-b228-ce68fc8e71c7", "embedding": null, "metadata": {"window": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ceea00b-e3ff-4379-9ab9-25f965bcb4e5", "node_type": "1", "metadata": {"window": "To be perfectly candid, two -and-a-half years ago, it would have been hard to \nimagine we'd still be in this scenario as a nation, just thinking of public health and the prevalence of the disease \nthat we still see.  \n \n As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1289dfdb01a7928d4267cd137fc373273f7be028415bacda71d1fe84862630a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfea3d2f-134d-42f0-83c9-973485af88a7", "node_type": "1", "metadata": {"window": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "cd41275a9bd1e10e7461a570518a802dc9a36613b109073b0dbb1d6f9573b795", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 1314, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfea3d2f-134d-42f0-83c9-973485af88a7": {"__data__": {"id_": "cfea3d2f-134d-42f0-83c9-973485af88a7", "embedding": null, "metadata": {"window": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c3fb57a-1172-4311-b228-ce68fc8e71c7", "node_type": "1", "metadata": {"window": "As we've said all along, we're committed to bring our assets and capabilities  to help support the public health \nresponse in any way we can.  We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dff8663eb77e382569324beabc65d21a61c18eea37ce2befa50da287cb03cea4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09c35a12-1648-48b1-807c-e1a518dc0846", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines. ", "original_text": "LLC  Q \nYeah. "}, "hash": "f3a1af9fe2773b5e6d636f3f01c3ef38b2d114b4ceb2a831715ac21f2b35de08", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1653, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09c35a12-1648-48b1-807c-e1a518dc0846": {"__data__": {"id_": "09c35a12-1648-48b1-807c-e1a518dc0846", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines. ", "original_text": "LLC  Q \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfea3d2f-134d-42f0-83c9-973485af88a7", "node_type": "1", "metadata": {"window": "We're, I guess, happy, we have the facility and can continue to support the \ngovernment program, but like most of us probably will not be sad, when there's no longer a need for any of this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a436f9acacfe19b71f74284c28238479168d245c868dca6779582f701887232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3232c6bb-3720-49c0-a7a1-84f16e517da8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? ", "original_text": "Hi. "}, "hash": "dbc0dfe672201153b582cfb9f5aa75ad00e15f9a590c5c680ab6547cdc66a1da", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 1977, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3232c6bb-3720-49c0-a7a1-84f16e517da8": {"__data__": {"id_": "3232c6bb-3720-49c0-a7a1-84f16e517da8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? ", "original_text": "Hi. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09c35a12-1648-48b1-807c-e1a518dc0846", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines. ", "original_text": "LLC  Q \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dfdf0de3962d2cb0e58d39695bdeb92322b06606f025b0dfa879706d9603328", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c227e76-536f-42cc-a7d4-6aca10ecbc14", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n", "original_text": "Good afternoon, and congrats on a great quarter. "}, "hash": "642af36355a7b5865127101181b15d725bb083949de1e80d6e379b419d673aaf", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 1991, "end_char_idx": 1995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c227e76-536f-42cc-a7d4-6aca10ecbc14": {"__data__": {"id_": "4c227e76-536f-42cc-a7d4-6aca10ecbc14", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n", "original_text": "Good afternoon, and congrats on a great quarter. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3232c6bb-3720-49c0-a7a1-84f16e517da8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? ", "original_text": "Hi. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beeac070e6f03a1273867b8b114db2c65384753e5add3384a174d024f0b13887", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fc7cadc-653f-4598-b139-5c17a13d5917", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. ", "original_text": "So [indiscernible] (40:05) question on the COVID \nvaccines. "}, "hash": "d3db143abfbabaab5c5863c1aa2edd3659740fde28a6f316deb85bc0b60193a6", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and congrats on a great quarter. ", "start_char_idx": 1995, "end_char_idx": 2044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fc7cadc-653f-4598-b139-5c17a13d5917": {"__data__": {"id_": "7fc7cadc-653f-4598-b139-5c17a13d5917", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. ", "original_text": "So [indiscernible] (40:05) question on the COVID \nvaccines. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c227e76-536f-42cc-a7d4-6aca10ecbc14", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n", "original_text": "Good afternoon, and congrats on a great quarter. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e746c3b39028370e9931efc26cc6f7c8ff7cf11fee3ce9971bb0eba1751ad706", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f79930d-2662-4d50-b442-fd91f77a66e1", "node_type": "1", "metadata": {"window": "Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it? ", "original_text": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? "}, "hash": "ea6650da4a89d2384bbd14aac590382bc5a4b1a3110e0e58cabb6eb512d8520a", "class_name": "RelatedNodeInfo"}}, "text": "So [indiscernible] (40:05) question on the COVID \nvaccines. ", "start_char_idx": 2044, "end_char_idx": 2104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f79930d-2662-4d50-b442-fd91f77a66e1": {"__data__": {"id_": "0f79930d-2662-4d50-b442-fd91f77a66e1", "embedding": null, "metadata": {"window": "Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it? ", "original_text": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fc7cadc-653f-4598-b139-5c17a13d5917", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. ", "original_text": "So [indiscernible] (40:05) question on the COVID \nvaccines. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "685b1fc6253e06bcac3a27961a8fd1cfb30b13eb01b632d17a54116ad5c3a3ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "253620cf-25d7-474b-957b-43be6be68fea", "node_type": "1", "metadata": {"window": "Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n", "original_text": "So that's \nquestion number one.  \n \n"}, "hash": "1c9dcdef24951a4f7e0cb20ae99aeb6589d58668fa48d66dafc124e437775ee4", "class_name": "RelatedNodeInfo"}}, "text": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? ", "start_char_idx": 2104, "end_char_idx": 2305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "253620cf-25d7-474b-957b-43be6be68fea": {"__data__": {"id_": "253620cf-25d7-474b-957b-43be6be68fea", "embedding": null, "metadata": {"window": "Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n", "original_text": "So that's \nquestion number one.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f79930d-2662-4d50-b442-fd91f77a66e1", "node_type": "1", "metadata": {"window": "Hi.  Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it? ", "original_text": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward? ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfb7ab24436e25fb837d66d3b2d4998f814b9aa6eebb5d46cd82197aa2b3d081", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24968584-4068-42ea-9706-6ca75812f6d8", "node_type": "1", "metadata": {"window": "So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n ", "original_text": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. "}, "hash": "0a2eb68e2454fb82689467ce8395a30878946cd9201b9567fb294968fe946b11", "class_name": "RelatedNodeInfo"}}, "text": "So that's \nquestion number one.  \n \n", "start_char_idx": 2305, "end_char_idx": 2341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24968584-4068-42ea-9706-6ca75812f6d8": {"__data__": {"id_": "24968584-4068-42ea-9706-6ca75812f6d8", "embedding": null, "metadata": {"window": "So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n ", "original_text": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "253620cf-25d7-474b-957b-43be6be68fea", "node_type": "1", "metadata": {"window": "Good afternoon, and congrats on a great quarter.  So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n", "original_text": "So that's \nquestion number one.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78619d12dfef75022639dc1ae86997e8fcf8aa9edd2b968ad1dc10a310705d9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05f0fe20-a836-4242-b138-59a06e44ed75", "node_type": "1", "metadata": {"window": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So just can you maybe help us frame it? "}, "hash": "6b9007e5b452dc6ff34ada2ebbdafb3ec6cc734598938389503a5696d1fc9f1b", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. ", "start_char_idx": 2341, "end_char_idx": 2489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05f0fe20-a836-4242-b138-59a06e44ed75": {"__data__": {"id_": "05f0fe20-a836-4242-b138-59a06e44ed75", "embedding": null, "metadata": {"window": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So just can you maybe help us frame it? ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24968584-4068-42ea-9706-6ca75812f6d8", "node_type": "1", "metadata": {"window": "So [indiscernible] (40:05) question on the COVID \nvaccines.  If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n ", "original_text": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ee777a5a7f8472413040dd94a2057dc45001ea54b82376f1f73b029fb0a356", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9879f195-fc95-4647-b260-a239429de9a5", "node_type": "1", "metadata": {"window": "So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n ", "original_text": "How should we think about it? \n"}, "hash": "1421f390c521ca22ce7f84ab07db7b07d5e93077ba6521fe520afb16f296c656", "class_name": "RelatedNodeInfo"}}, "text": "So just can you maybe help us frame it? ", "start_char_idx": 2489, "end_char_idx": 2529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9879f195-fc95-4647-b260-a239429de9a5": {"__data__": {"id_": "9879f195-fc95-4647-b260-a239429de9a5", "embedding": null, "metadata": {"window": "So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n ", "original_text": "How should we think about it? \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05f0fe20-a836-4242-b138-59a06e44ed75", "node_type": "1", "metadata": {"window": "If we think about the step -up in guidance for vaccines and kitting, how much of that [indiscernible] \n(40:16) already captured in the $0.54 beat in the quarter versus your expectation going  forward?  So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So just can you maybe help us frame it? ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "924099276d91963b22b58ae81c1ddf8a7d9bbbb3c16d9a93c9964556abb93190", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f238d41-7a2a-40ec-8a4e-659903a1dd1f", "node_type": "1", "metadata": {"window": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n "}, "hash": "cc320c92c5213cc8abb9030b7b846f0972393eb0c14ad19a30c948b2cd0b3edb", "class_name": "RelatedNodeInfo"}}, "text": "How should we think about it? \n", "start_char_idx": 2529, "end_char_idx": 2560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f238d41-7a2a-40ec-8a4e-659903a1dd1f": {"__data__": {"id_": "1f238d41-7a2a-40ec-8a4e-659903a1dd1f", "embedding": null, "metadata": {"window": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9879f195-fc95-4647-b260-a239429de9a5", "node_type": "1", "metadata": {"window": "So that's \nquestion number one.  \n \n And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n ", "original_text": "How should we think about it? \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9caccffad399feea98c7475d22f56522ba83d12d3f21c3c29b206a26d581878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b998fc6-4320-421e-ad60-96f62a0d5131", "node_type": "1", "metadata": {"window": "So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "9792572310a49267f44345d482f405e55e2e04731c1e54d784db385e2d92ed2e", "class_name": "RelatedNodeInfo"}}, "text": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n ", "start_char_idx": 2560, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b998fc6-4320-421e-ad60-96f62a0d5131": {"__data__": {"id_": "3b998fc6-4320-421e-ad60-96f62a0d5131", "embedding": null, "metadata": {"window": "So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f238d41-7a2a-40ec-8a4e-659903a1dd1f", "node_type": "1", "metadata": {"window": "And then secondly, to follow up somewhat on Eric's question, I think Moderna said today that they expect a \ncommercial market in 2023 for vaccines.  So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0342657390d466514b2897aa87f63e9dd9c11b0b43eeed2a0777cdb44c32d0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cca11ec7-9295-4c94-afa1-c08d2685e3d8", "node_type": "1", "metadata": {"window": "How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky. ", "original_text": "A \nYou want to take the guidance question, and I'll take the second part?  \n "}, "hash": "1303d9f15fe0c59b8e5c04e28c50705a7b0e1313501c7982bb31c432baa9a584", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2666, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cca11ec7-9295-4c94-afa1-c08d2685e3d8": {"__data__": {"id_": "cca11ec7-9295-4c94-afa1-c08d2685e3d8", "embedding": null, "metadata": {"window": "How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky. ", "original_text": "A \nYou want to take the guidance question, and I'll take the second part?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b998fc6-4320-421e-ad60-96f62a0d5131", "node_type": "1", "metadata": {"window": "So just can you maybe help us frame it?  How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4acdc86d4600150203bb30efa080cbe8de3ceb72170c8aa31b7ff25647961a88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fb3d9ba-5d6b-4ad6-8e00-ded695865538", "node_type": "1", "metadata": {"window": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "21ac7efa0eb9598e5983d052a0f61aa6351363a675d5e8b8dc42cd3252203b68", "class_name": "RelatedNodeInfo"}}, "text": "A \nYou want to take the guidance question, and I'll take the second part?  \n ", "start_char_idx": 3007, "end_char_idx": 3084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fb3d9ba-5d6b-4ad6-8e00-ded695865538": {"__data__": {"id_": "1fb3d9ba-5d6b-4ad6-8e00-ded695865538", "embedding": null, "metadata": {"window": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cca11ec7-9295-4c94-afa1-c08d2685e3d8", "node_type": "1", "metadata": {"window": "How should we think about it? \n Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky. ", "original_text": "A \nYou want to take the guidance question, and I'll take the second part?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a254e10a828b2b602a0b4558eae2ea80dbadd289245786827597af4a20482e14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e64df7cc-039f-41ef-ad26-11ddd943ed96", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n", "original_text": "A \nYeah. "}, "hash": "77e39d9284dfc1c6db9a31d08892ccc5c8b6acc95e0d339a40f861a2963d445f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3084, "end_char_idx": 3442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e64df7cc-039f-41ef-ad26-11ddd943ed96": {"__data__": {"id_": "e64df7cc-039f-41ef-ad26-11ddd943ed96", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fb3d9ba-5d6b-4ad6-8e00-ded695865538", "node_type": "1", "metadata": {"window": "Would this be on top of the contract that you have with the US government or would that be in lieu of?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94975d9060c4b2ebcdeaf7577ca4666982fad758f42153e1ccbf318162d47d75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d705a731-282a-4c64-90bd-3cd8a9b02d0e", "node_type": "1", "metadata": {"window": "A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022. ", "original_text": "Thanks for the question, Ricky. "}, "hash": "f3f441ffeb53cb902003f8ad392817c089582d34da0ec8615becb40419d89d2b", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 250, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d705a731-282a-4c64-90bd-3cd8a9b02d0e": {"__data__": {"id_": "d705a731-282a-4c64-90bd-3cd8a9b02d0e", "embedding": null, "metadata": {"window": "A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022. ", "original_text": "Thanks for the question, Ricky. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e64df7cc-039f-41ef-ad26-11ddd943ed96", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b2b54ea03d8e7b52304dd89b5954e2d8e37176a5c6ef8d771b0cc7e69537c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfcbade4-0043-4233-89e8-479d16a2e4c4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. ", "original_text": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. "}, "hash": "bce7ba5e635da3f3858f21856c36995874b0e820a779ab8c2864c8d67faf0b6f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Ricky. ", "start_char_idx": 3451, "end_char_idx": 3483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfcbade4-0043-4233-89e8-479d16a2e4c4": {"__data__": {"id_": "cfcbade4-0043-4233-89e8-479d16a2e4c4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. ", "original_text": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d705a731-282a-4c64-90bd-3cd8a9b02d0e", "node_type": "1", "metadata": {"window": "A \nYou want to take the guidance question, and I'll take the second part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022. ", "original_text": "Thanks for the question, Ricky. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8444d62ef294d7a811471c2fff7a9a6897aa2afe8c7540fd50b5b68e71cfe433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81ab3ced-249e-4df5-97fe-3756134a7bdc", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year. ", "original_text": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n"}, "hash": "41575b4cc6c5a02b482ed638682f5dec695d72e30c0d9cb9ee5bff7421c7ca4c", "class_name": "RelatedNodeInfo"}}, "text": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. ", "start_char_idx": 3483, "end_char_idx": 3609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81ab3ced-249e-4df5-97fe-3756134a7bdc": {"__data__": {"id_": "81ab3ced-249e-4df5-97fe-3756134a7bdc", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year. ", "original_text": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfcbade4-0043-4233-89e8-479d16a2e4c4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt  Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. ", "original_text": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4f57b06e880e1d4177e8b7c913c91addcbe4589b0f223a577158f9836dfc532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "452efd88-f1b9-489c-ba51-2ea08021180f", "node_type": "1", "metadata": {"window": "Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n", "original_text": "COVID test kits, as we told you in our guidance, would be lower than FY 2022. "}, "hash": "edc5bb532e8bcc679070e436fb1bca0c65d1eea65b15a428f5fde7d3870a8f4c", "class_name": "RelatedNodeInfo"}}, "text": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n", "start_char_idx": 3609, "end_char_idx": 3759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "452efd88-f1b9-489c-ba51-2ea08021180f": {"__data__": {"id_": "452efd88-f1b9-489c-ba51-2ea08021180f", "embedding": null, "metadata": {"window": "Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n", "original_text": "COVID test kits, as we told you in our guidance, would be lower than FY 2022. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81ab3ced-249e-4df5-97fe-3756134a7bdc", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year. ", "original_text": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eec469ff1a1aa9b06bc772a6959cfcbf48802b8d6386f44c2a7312c818f7016d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05b8dd6b-5122-4ee1-a652-2e07e4421d1a", "node_type": "1", "metadata": {"window": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. ", "original_text": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. "}, "hash": "ab5d25c8f0b7197545a8c8c53b6085080e2fea37fe0a3935e579d2e974f733e5", "class_name": "RelatedNodeInfo"}}, "text": "COVID test kits, as we told you in our guidance, would be lower than FY 2022. ", "start_char_idx": 3759, "end_char_idx": 3837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05b8dd6b-5122-4ee1-a652-2e07e4421d1a": {"__data__": {"id_": "05b8dd6b-5122-4ee1-a652-2e07e4421d1a", "embedding": null, "metadata": {"window": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. ", "original_text": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "452efd88-f1b9-489c-ba51-2ea08021180f", "node_type": "1", "metadata": {"window": "Thanks for the question, Ricky.  So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n", "original_text": "COVID test kits, as we told you in our guidance, would be lower than FY 2022. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65f6eb5746c074c183f35dc3bf4aa05a398ff8d8a97318391fd254c367759962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29c4a902-1cd5-4da5-9170-b31f483af96f", "node_type": "1", "metadata": {"window": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "We continue to expect that test kits will be \nsignificantly lower than last year. "}, "hash": "2aac67f268fc4a4a7795be7af3f5bd8f0ef3e27acd137fb823d89aedc7d71c75", "class_name": "RelatedNodeInfo"}}, "text": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. ", "start_char_idx": 3837, "end_char_idx": 3937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29c4a902-1cd5-4da5-9170-b31f483af96f": {"__data__": {"id_": "29c4a902-1cd5-4da5-9170-b31f483af96f", "embedding": null, "metadata": {"window": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "We continue to expect that test kits will be \nsignificantly lower than last year. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05b8dd6b-5122-4ee1-a652-2e07e4421d1a", "node_type": "1", "metadata": {"window": "So again, I think if you look at our slide presentation, we've tried to call out \nhere what the big changes are in our guide.  Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. ", "original_text": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8aa48830aec7a89bd352d938874cad1875f832a765aa8d0d2bcd87f1d3c96be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "541d8724-6576-4652-8d03-a87f3b93d257", "node_type": "1", "metadata": {"window": "COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "They are a little bit ahead of our expectations.  \n \n"}, "hash": "c99dde68601bd7a274dd5685bf1353b74542e2604d21a6c58f77b9065751ad55", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect that test kits will be \nsignificantly lower than last year. ", "start_char_idx": 3937, "end_char_idx": 4019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "541d8724-6576-4652-8d03-a87f3b93d257": {"__data__": {"id_": "541d8724-6576-4652-8d03-a87f3b93d257", "embedding": null, "metadata": {"window": "COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "They are a little bit ahead of our expectations.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29c4a902-1cd5-4da5-9170-b31f483af96f", "node_type": "1", "metadata": {"window": "Certainly a p ortion of our first quarter was a result of the increase in \nboth vaccine distribution and the kitting storage and COVID test kits.  \n \n COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "We continue to expect that test kits will be \nsignificantly lower than last year. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e95c1eb79fd0e6d6baf587ead1e26b70e6d8696ea439da07ea31ea698ba4133", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ea841ba-11ef-4e60-a8f7-1459f2c74e2f", "node_type": "1", "metadata": {"window": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. "}, "hash": "5dfd9eb08cccdca81d160cfecc33363fd62abff54b38e578e77ed0b9b96311fd", "class_name": "RelatedNodeInfo"}}, "text": "They are a little bit ahead of our expectations.  \n \n", "start_char_idx": 4019, "end_char_idx": 4072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ea841ba-11ef-4e60-a8f7-1459f2c74e2f": {"__data__": {"id_": "0ea841ba-11ef-4e60-a8f7-1459f2c74e2f", "embedding": null, "metadata": {"window": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "541d8724-6576-4652-8d03-a87f3b93d257", "node_type": "1", "metadata": {"window": "COVID test kits, as we told you in our guidance, would be lower than FY 2022.  That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "They are a little bit ahead of our expectations.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f87c20ce55b57f440bce6acdc37b6412446daa45de8b917f1e91564da09f4f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76d4c230-924f-4057-9b76-a675c050ea4f", "node_type": "1", "metadata": {"window": "We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  "}, "hash": "235cffe6be947c22f9dae6f93bb4650226addac87ca1a23048e6cb0f0d775647", "class_name": "RelatedNodeInfo"}}, "text": "So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. ", "start_char_idx": 4072, "end_char_idx": 4226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76d4c230-924f-4057-9b76-a675c050ea4f": {"__data__": {"id_": "76d4c230-924f-4057-9b76-a675c050ea4f", "embedding": null, "metadata": {"window": "We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0756e478-fc2c-4319-af5b-383d053c9f26", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57b44238965dfb376497ac92dc893eb84af049ed01585bf7bd5825f9dba83909", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ea841ba-11ef-4e60-a8f7-1459f2c74e2f", "node_type": "1", "metadata": {"window": "That has certainly been the case, \nalthough it was slightly ahead of our own internal expectations.  We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong. ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c5b0d94ea669416ffa95caa81481d0fd878c1c67baba3146baea151f7357e49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db068485-9980-4cae-b9d1-3849d6291af3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "c64ce9bd325350e12c364b06b0b2b359674ec289238292db9b0849dbc53648ac", "class_name": "RelatedNodeInfo"}}, "text": "You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "start_char_idx": 4226, "end_char_idx": 4480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db068485-9980-4cae-b9d1-3849d6291af3": {"__data__": {"id_": "db068485-9980-4cae-b9d1-3849d6291af3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76d4c230-924f-4057-9b76-a675c050ea4f", "node_type": "1", "metadata": {"window": "We continue to expect that test kits will be \nsignificantly lower than last year.  They are a little bit ahead of our expectations.  \n \n So in our first quarter, some of the COVID -related items and programs did drive some of the upside, but certainly \nour operating performance was strong.  You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "original_text": "You can see that from the slide that talks about our guidance increase, \nthat there is a significant portion of the increase that's related to those COVID programs, but there' s also a very \nstrong component that's related to our operating performance.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ee7d7c7aadcfc8cca64909d83d75e393541a6b4c33e10d2ea3cd954797370dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d5ff84e-6ed7-45f6-a979-312da79a2730", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "c9d3572661587ff4bba090d6e59c2d66f7602db71554505db4da27ac002a2ce7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d5ff84e-6ed7-45f6-a979-312da79a2730": {"__data__": {"id_": "3d5ff84e-6ed7-45f6-a979-312da79a2730", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db068485-9980-4cae-b9d1-3849d6291af3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03025039966723703037e4762335f251c0ece3cac2efc7f39e006523629c4455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3a30358-6dd0-4ebb-ab93-e215cea18152", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu. ", "original_text": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts. "}, "hash": "145340e51a2b1f33a7c740cc5d290b4ec8ca6ece2c61308837b3c82d939503bf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3a30358-6dd0-4ebb-ab93-e215cea18152": {"__data__": {"id_": "b3a30358-6dd0-4ebb-ab93-e215cea18152", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu. ", "original_text": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d5ff84e-6ed7-45f6-a979-312da79a2730", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e70bc6adda8b5a196e9cc8931feb29a88f842bc9c25b600a6c69e7effa0b019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49fc7e99-248f-4fbf-b0bb-3eeaeca54635", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program. ", "original_text": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n"}, "hash": "a2293e20702c510762d4d4f036c07dc316174cfe58868006340fe3731fbf2ec3", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts. ", "start_char_idx": 250, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49fc7e99-248f-4fbf-b0bb-3eeaeca54635": {"__data__": {"id_": "49fc7e99-248f-4fbf-b0bb-3eeaeca54635", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program. ", "original_text": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3a30358-6dd0-4ebb-ab93-e215cea18152", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu. ", "original_text": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "072ed1e1a966329e8df273b5942e93584eeffb59336cac18331956dec4700d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e91f949-33a0-47e9-88aa-930923cb992c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n ", "original_text": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. "}, "hash": "c013cf66e899bb7ab0d8f10035d31e8ffc50733c3fce872750c2b1ae3f16ae1f", "class_name": "RelatedNodeInfo"}}, "text": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "start_char_idx": 387, "end_char_idx": 622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e91f949-33a0-47e9-88aa-930923cb992c": {"__data__": {"id_": "6e91f949-33a0-47e9-88aa-930923cb992c", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n ", "original_text": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49fc7e99-248f-4fbf-b0bb-3eeaeca54635", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program. ", "original_text": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92d1db65941f118707c2ccc1ec7bfb33d28c9302724c3dbb152cfdf2b8449893", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21a34a14-841a-4901-b5ff-22fcd7f48c7c", "node_type": "1", "metadata": {"window": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We're the leading distributor of the \nseasonal flu. "}, "hash": "304d280a807ddc495526ddf28912358ea0951cd7f94779e7d9c9f4cad3ed192f", "class_name": "RelatedNodeInfo"}}, "text": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. ", "start_char_idx": 622, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21a34a14-841a-4901-b5ff-22fcd7f48c7c": {"__data__": {"id_": "21a34a14-841a-4901-b5ff-22fcd7f48c7c", "embedding": null, "metadata": {"window": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We're the leading distributor of the \nseasonal flu. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e91f949-33a0-47e9-88aa-930923cb992c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n ", "original_text": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0ec4387852151b742763ce5faa8894c77d18f429fef5a8e8b13cf87e600bb1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5eb3be2-53ca-4cd9-84d9-8f8561916056", "node_type": "1", "metadata": {"window": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n ", "original_text": "We support the Vaccines for Children program. "}, "hash": "7e0a9ead8bbfddd08b3c129abdfc0a91449700f05020a83a1405a6bb361e2158", "class_name": "RelatedNodeInfo"}}, "text": "We're the leading distributor of the \nseasonal flu. ", "start_char_idx": 806, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5eb3be2-53ca-4cd9-84d9-8f8561916056": {"__data__": {"id_": "d5eb3be2-53ca-4cd9-84d9-8f8561916056", "embedding": null, "metadata": {"window": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n ", "original_text": "We support the Vaccines for Children program. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21a34a14-841a-4901-b5ff-22fcd7f48c7c", "node_type": "1", "metadata": {"window": "A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We're the leading distributor of the \nseasonal flu. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2db642bd3f52a08592a2087607b8f73cb869a6bbff9047bdbfbd5625857e88e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "958d3dd2-0bdc-4c84-8a61-ee685b03ac37", "node_type": "1", "metadata": {"window": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. ", "original_text": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n "}, "hash": "1e054e5b21c1d4b0e0d74c9ff34bc7bcc067397a0cc58dc3853c0eed8862b3a7", "class_name": "RelatedNodeInfo"}}, "text": "We support the Vaccines for Children program. ", "start_char_idx": 858, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "958d3dd2-0bdc-4c84-8a61-ee685b03ac37": {"__data__": {"id_": "958d3dd2-0bdc-4c84-8a61-ee685b03ac37", "embedding": null, "metadata": {"window": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. ", "original_text": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5eb3be2-53ca-4cd9-84d9-8f8561916056", "node_type": "1", "metadata": {"window": "We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n ", "original_text": "We support the Vaccines for Children program. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dd50599d0a95d4ec3d74f0e4df390383517422f7892e7a6de9a1ac0061ac273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "025da32a-d485-498a-b11b-1b4c1fe13d36", "node_type": "1", "metadata": {"window": "We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "0225c509c4552de0d3cf50fbabb33202d9c89cffea7caab9b2dc83697aef5016", "class_name": "RelatedNodeInfo"}}, "text": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n ", "start_char_idx": 904, "end_char_idx": 1085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "025da32a-d485-498a-b11b-1b4c1fe13d36": {"__data__": {"id_": "025da32a-d485-498a-b11b-1b4c1fe13d36", "embedding": null, "metadata": {"window": "We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "958d3dd2-0bdc-4c84-8a61-ee685b03ac37", "node_type": "1", "metadata": {"window": "Shoul d another model emerge and a distributor wants to use commercial markets, obviously McKesson continues \nto have incredible vaccine capabilities in the commercial market as well.  We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. ", "original_text": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55e75e4a2fad41e75ff5c8ad5c81859195d45585ac76179d880d14fb3c334a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0383caf-7345-4df7-9889-380e8fef3df6", "node_type": "1", "metadata": {"window": "We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n "}, "hash": "b6a96610b6716ba2cb6020df7bda301eb2cf7b90f31da8cd90621143e37b17c8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 1085, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0383caf-7345-4df7-9889-380e8fef3df6": {"__data__": {"id_": "b0383caf-7345-4df7-9889-380e8fef3df6", "embedding": null, "metadata": {"window": "We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "025da32a-d485-498a-b11b-1b4c1fe13d36", "node_type": "1", "metadata": {"window": "We're the leading distributor of the \nseasonal flu.  We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85e9cef10074d9301af631b74a812e88091105faad389863b1bdebaa46f0321f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0a95acf-24c1-4c94-b3d5-a7040067d1e4", "node_type": "1", "metadata": {"window": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. "}, "hash": "bcbf07cd69af0a73b6a17e25dabe7d54d6484856f1bd6c4e0acfe89e541a6132", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n ", "start_char_idx": 1448, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0a95acf-24c1-4c94-b3d5-a7040067d1e4": {"__data__": {"id_": "b0a95acf-24c1-4c94-b3d5-a7040067d1e4", "embedding": null, "metadata": {"window": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0383caf-7345-4df7-9889-380e8fef3df6", "node_type": "1", "metadata": {"window": "We support the Vaccines for Children program.  We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85af71fc280a515b779de497788afd357f723112eb771118c5761516b76cce81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "575342f9-635d-4be5-aa23-14b87d38d3d4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing? ", "original_text": "Thanks for taking my questions. "}, "hash": "c370a113310554c0c6d21f382fe405e26433ad85f6accf2ec53c57d2dca1e7a1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. ", "start_char_idx": 1769, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "575342f9-635d-4be5-aa23-14b87d38d3d4": {"__data__": {"id_": "575342f9-635d-4be5-aa23-14b87d38d3d4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing? ", "original_text": "Thanks for taking my questions. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0a95acf-24c1-4c94-b3d5-a7040067d1e4", "node_type": "1", "metadata": {"window": "We've got great relationships with community \nproviders all over the country, and we would obviously be anxious, ready, and willing to support those commercial \nefforts as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a84c4717f3fd0a0f4f22dc2b068b3b7f78f186de3fb989b02c03ac1a4beb45ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d64dfb9-373e-48df-9bef-3d4b33b73a9a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. ", "original_text": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. "}, "hash": "c26902d1e6f915764161230666a84d50fc06f2621abafe3c0ba12bce85461c9b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my questions. ", "start_char_idx": 2101, "end_char_idx": 2133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d64dfb9-373e-48df-9bef-3d4b33b73a9a": {"__data__": {"id_": "4d64dfb9-373e-48df-9bef-3d4b33b73a9a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. ", "original_text": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "575342f9-635d-4be5-aa23-14b87d38d3d4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing? ", "original_text": "Thanks for taking my questions. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3612607d5756c473b3abea045268da8b79ea565f21f8f2674c7f5ec943e20f27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72130b12-70ab-4032-bcd3-fa22e249083e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets? ", "original_text": "You're raising numbers. "}, "hash": "f55a8ce38d0ceefbd9a8715a9e8d205f5a1e9c04062ba78cf2bb80c3bf0788ca", "class_name": "RelatedNodeInfo"}}, "text": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. ", "start_char_idx": 2133, "end_char_idx": 2367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72130b12-70ab-4032-bcd3-fa22e249083e": {"__data__": {"id_": "72130b12-70ab-4032-bcd3-fa22e249083e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets? ", "original_text": "You're raising numbers. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d64dfb9-373e-48df-9bef-3d4b33b73a9a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. ", "original_text": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3943add484e67cf95c29d2e87b587fad7df4254132fa7b84ade9dc93a13c649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "798314a9-d05b-4ba5-9ea0-9d9757afa945", "node_type": "1", "metadata": {"window": "Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share? ", "original_text": "Is this a macro thing? "}, "hash": "7068c5572942d5e4c84475667988218bea487ed76494dd16789eec4a598b26ed", "class_name": "RelatedNodeInfo"}}, "text": "You're raising numbers. ", "start_char_idx": 2367, "end_char_idx": 2391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "798314a9-d05b-4ba5-9ea0-9d9757afa945": {"__data__": {"id_": "798314a9-d05b-4ba5-9ea0-9d9757afa945", "embedding": null, "metadata": {"window": "Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share? ", "original_text": "Is this a macro thing? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72130b12-70ab-4032-bcd3-fa22e249083e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThank you.  Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets? ", "original_text": "You're raising numbers. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fcad656585c54607abc367b0c96ae0a48dc7ffff669bfc1e63a845c0dd29454", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14396577-8bc9-4fbe-b0ba-c6cc0b577bec", "node_type": "1", "metadata": {"window": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic? ", "original_text": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. "}, "hash": "41f66d9c9608281adce5eaa04e504973f9e9869fda0a2681cf0a51fec6238bc1", "class_name": "RelatedNodeInfo"}}, "text": "Is this a macro thing? ", "start_char_idx": 2391, "end_char_idx": 2414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14396577-8bc9-4fbe-b0ba-c6cc0b577bec": {"__data__": {"id_": "14396577-8bc9-4fbe-b0ba-c6cc0b577bec", "embedding": null, "metadata": {"window": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic? ", "original_text": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "798314a9-d05b-4ba5-9ea0-9d9757afa945", "node_type": "1", "metadata": {"window": "Thanks for taking my questions.  If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share? ", "original_text": "Is this a macro thing? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e525e990773a164a5d81f76290848021ee9402f53fde9ba8efd53617a57a4e37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb99d49b-52dd-491c-a508-87bfbfa0f931", "node_type": "1", "metadata": {"window": "You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? ", "original_text": "Are you just in the right markets? "}, "hash": "91f7aea88707ba38d8296e12f1563af21e4271071af7d73760d7622b7e4c5094", "class_name": "RelatedNodeInfo"}}, "text": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. ", "start_char_idx": 2414, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb99d49b-52dd-491c-a508-87bfbfa0f931": {"__data__": {"id_": "eb99d49b-52dd-491c-a508-87bfbfa0f931", "embedding": null, "metadata": {"window": "You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? ", "original_text": "Are you just in the right markets? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14396577-8bc9-4fbe-b0ba-c6cc0b577bec", "node_type": "1", "metadata": {"window": "If I'm looking at the growth \u2013 just looking at revenue growth in the \nPharmaceutical segment and the Med -Surg segment, trying to back out the benefit of COVID, just the guidance \nrange, you apparently are growing faster than market.  You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic? ", "original_text": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba51ccbe79916fdcfab533078ace734edeca0b6bcaa11acc963a783de2baac3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d885caaf-dac7-4ce4-ba30-7c7612c68f1a", "node_type": "1", "metadata": {"window": "Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n ", "original_text": "Are \nyou taking share? "}, "hash": "1da596467b2e067b8815b0919b327a2fc859cfc2ab6d1e9d0e982255b6a5f6d3", "class_name": "RelatedNodeInfo"}}, "text": "Are you just in the right markets? ", "start_char_idx": 2504, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d885caaf-dac7-4ce4-ba30-7c7612c68f1a": {"__data__": {"id_": "d885caaf-dac7-4ce4-ba30-7c7612c68f1a", "embedding": null, "metadata": {"window": "Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n ", "original_text": "Are \nyou taking share? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb99d49b-52dd-491c-a508-87bfbfa0f931", "node_type": "1", "metadata": {"window": "You're raising numbers.  Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? ", "original_text": "Are you just in the right markets? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96734fbd662ad34b1123d3799d077e0fcd107082b58c564893154ff5dc92207c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8da5ad0a-a796-4fca-913c-5544a97fb028", "node_type": "1", "metadata": {"window": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you maybe talk about whether it's a competitive dynamic? "}, "hash": "010bdd0b960dc5545a95411bf36e82f84f281e67a052913c9f3c3cad67893751", "class_name": "RelatedNodeInfo"}}, "text": "Are \nyou taking share? ", "start_char_idx": 2539, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8da5ad0a-a796-4fca-913c-5544a97fb028": {"__data__": {"id_": "8da5ad0a-a796-4fca-913c-5544a97fb028", "embedding": null, "metadata": {"window": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you maybe talk about whether it's a competitive dynamic? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d885caaf-dac7-4ce4-ba30-7c7612c68f1a", "node_type": "1", "metadata": {"window": "Is this a macro thing?  Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n ", "original_text": "Are \nyou taking share? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb242a105f1f97de70417fc36f737f8784a67ae43ad521801056e55db49bf621", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6fe85b0-4f15-41e7-9e4d-21f2e2fc3e0e", "node_type": "1", "metadata": {"window": "Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? "}, "hash": "d2f44a302e40eebc40874e365bfc27ad3c238a39bad6dc1ac6237be0722000ac", "class_name": "RelatedNodeInfo"}}, "text": "Can you maybe talk about whether it's a competitive dynamic? ", "start_char_idx": 2562, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6fe85b0-4f15-41e7-9e4d-21f2e2fc3e0e": {"__data__": {"id_": "a6fe85b0-4f15-41e7-9e4d-21f2e2fc3e0e", "embedding": null, "metadata": {"window": "Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8da5ad0a-a796-4fca-913c-5544a97fb028", "node_type": "1", "metadata": {"window": "Because \nyou're not seeing utilization necessarily at the levels that y ou're growing at.  Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you maybe talk about whether it's a competitive dynamic? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6daaf44572feaf9dd5b400234e148f885e640c872acc381fb37b5a32759538a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d0601a6-5274-4f5c-9be0-2caeeea67129", "node_type": "1", "metadata": {"window": "Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "What's driving your faster -than-market growth in those \ntwo segments?  \n "}, "hash": "ef3f600dffb4d292918a46d9a5cf0af4200b2e3637c1632555e40028d5c27d22", "class_name": "RelatedNodeInfo"}}, "text": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? ", "start_char_idx": 2623, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d0601a6-5274-4f5c-9be0-2caeeea67129": {"__data__": {"id_": "8d0601a6-5274-4f5c-9be0-2caeeea67129", "embedding": null, "metadata": {"window": "Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "What's driving your faster -than-market growth in those \ntwo segments?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6fe85b0-4f15-41e7-9e4d-21f2e2fc3e0e", "node_type": "1", "metadata": {"window": "Are you just in the right markets?  Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side? ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cace8149d1acc2a0e3b72072e6be20659d69c53185ba89db34156abb316ff4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b61c3a2-978a-477e-8536-43005467df83", "node_type": "1", "metadata": {"window": "Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "f824c683eb5adebec108a049fc6b6085892a826473c670f47e2516f2de6150b7", "class_name": "RelatedNodeInfo"}}, "text": "What's driving your faster -than-market growth in those \ntwo segments?  \n ", "start_char_idx": 2718, "end_char_idx": 2792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b61c3a2-978a-477e-8536-43005467df83": {"__data__": {"id_": "5b61c3a2-978a-477e-8536-43005467df83", "embedding": null, "metadata": {"window": "Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d0601a6-5274-4f5c-9be0-2caeeea67129", "node_type": "1", "metadata": {"window": "Are \nyou taking share?  Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "What's driving your faster -than-market growth in those \ntwo segments?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37fb90a34370ae5d559bed23c6262385dfc800968ce9ff8696712bb3fa1b2f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b1d4ada-a13e-48fc-bcb6-2e8149624779", "node_type": "1", "metadata": {"window": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year. ", "original_text": "A \nYeah. "}, "hash": "b77b84bb1709713c641b4688948fafbc3896aea7ec94a93f2e20cd630305f63f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2792, "end_char_idx": 3149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b1d4ada-a13e-48fc-bcb6-2e8149624779": {"__data__": {"id_": "0b1d4ada-a13e-48fc-bcb6-2e8149624779", "embedding": null, "metadata": {"window": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b61c3a2-978a-477e-8536-43005467df83", "node_type": "1", "metadata": {"window": "Can you maybe talk about whether it's a competitive dynamic?  Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2190378862851690c3caa509b5f59572fc5c8a1eb34f5b8c695961ad0343e05f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae117dd3-8e67-4d11-8af6-3577b3394ffc", "node_type": "1", "metadata": {"window": "What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. ", "original_text": "Thanks for the question. "}, "hash": "cf679473ec6ccbd6bbf04e8aca7fa64d68d2ff6624b717e15900a969706b75f3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3149, "end_char_idx": 3158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae117dd3-8e67-4d11-8af6-3577b3394ffc": {"__data__": {"id_": "ae117dd3-8e67-4d11-8af6-3577b3394ffc", "embedding": null, "metadata": {"window": "What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b1d4ada-a13e-48fc-bcb6-2e8149624779", "node_type": "1", "metadata": {"window": "Is it just that you're in ASCs, \nand all the utilization's moving there in the Med -Surg side?  What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c5a4800fc03e5ad187b3a6aea52970e81aa2b2b41a73a6fdd0dc318ae49dd25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3795d9cc-4468-4dd5-83c9-b28b30584f1c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n", "original_text": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n"}, "hash": "fb6c36fb0c0b571eaea775dc87108e9b25454cdb5d773c9849f88013bacd5ad4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 3158, "end_char_idx": 3183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3795d9cc-4468-4dd5-83c9-b28b30584f1c": {"__data__": {"id_": "3795d9cc-4468-4dd5-83c9-b28b30584f1c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n", "original_text": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae117dd3-8e67-4d11-8af6-3577b3394ffc", "node_type": "1", "metadata": {"window": "What's driving your faster -than-market growth in those \ntwo segments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e02ecbdf38e257f394cdad52b653a1dc5e76176fab05ad4a7aec40adada1ae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f584a46c-6dd2-4a2d-90f7-4627657ae5ab", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. ", "original_text": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year. "}, "hash": "1a6f432caa38ecec7f9f7d14ef99ec56ccd3a1c63b0eca33d96a1ce435b2f817", "class_name": "RelatedNodeInfo"}}, "text": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n", "start_char_idx": 3183, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f584a46c-6dd2-4a2d-90f7-4627657ae5ab": {"__data__": {"id_": "f584a46c-6dd2-4a2d-90f7-4627657ae5ab", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. ", "original_text": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3795d9cc-4468-4dd5-83c9-b28b30584f1c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n", "original_text": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13e81000c5e81c8449ad1ec54642469bd869fd7923acc5f2b3da71d4dcdf31b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74dab664-dbef-4c04-a317-37a48919990c", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. ", "original_text": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. "}, "hash": "d0d1f133966217bd20092a9a200158eea6fa8a80115e0b6ba2c0bb28b17f8cf9", "class_name": "RelatedNodeInfo"}}, "text": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year. ", "start_char_idx": 3279, "end_char_idx": 3366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74dab664-dbef-4c04-a317-37a48919990c": {"__data__": {"id_": "74dab664-dbef-4c04-a317-37a48919990c", "embedding": null, "metadata": {"window": "Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. ", "original_text": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f584a46c-6dd2-4a2d-90f7-4627657ae5ab", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. ", "original_text": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eba81e1d4ae3709e00f0f3dec9f954577017d23623d8ae1052eb884478427de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b834d9-bb9b-4886-9d17-017d414c9575", "node_type": "1", "metadata": {"window": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters. ", "original_text": "So that is significan t from what we've seen over the last few years.  \n \n"}, "hash": "9f262d00e23e5cd8b174187ac30a1a672c148d8cb4a310a2f7a9e27d329f9205", "class_name": "RelatedNodeInfo"}}, "text": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. ", "start_char_idx": 3366, "end_char_idx": 3521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b834d9-bb9b-4886-9d17-017d414c9575": {"__data__": {"id_": "68b834d9-bb9b-4886-9d17-017d414c9575", "embedding": null, "metadata": {"window": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters. ", "original_text": "So that is significan t from what we've seen over the last few years.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74dab664-dbef-4c04-a317-37a48919990c", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. ", "original_text": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae6760e9131bcea40167718c728f7a22b15fd11085136d9f4c8c26fc732e111", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24d89fd9-1976-428f-9f05-96f7f1baf912", "node_type": "1", "metadata": {"window": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n", "original_text": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. "}, "hash": "3ef45fef74db9aee283c5e2c05c38963dc8fa4c2e80974c41759dc70bb9c1936", "class_name": "RelatedNodeInfo"}}, "text": "So that is significan t from what we've seen over the last few years.  \n \n", "start_char_idx": 3521, "end_char_idx": 3595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24d89fd9-1976-428f-9f05-96f7f1baf912": {"__data__": {"id_": "24d89fd9-1976-428f-9f05-96f7f1baf912", "embedding": null, "metadata": {"window": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n", "original_text": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b834d9-bb9b-4886-9d17-017d414c9575", "node_type": "1", "metadata": {"window": "Let me parse that out because I think there are some differences between the two \nsegments.  \n \n In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters. ", "original_text": "So that is significan t from what we've seen over the last few years.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "191f200413d45e702346cea87af787c2d47de11c862e1636d0a5de2c9b84c763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c40338f-315c-4122-b347-22b9ae435bcf", "node_type": "1", "metadata": {"window": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. ", "original_text": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. "}, "hash": "5bbfce0fc042d021a552b9886adc4bd19ebe631a260cf477cce27f75d50ab7ed", "class_name": "RelatedNodeInfo"}}, "text": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. ", "start_char_idx": 3595, "end_char_idx": 3743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c40338f-315c-4122-b347-22b9ae435bcf": {"__data__": {"id_": "0c40338f-315c-4122-b347-22b9ae435bcf", "embedding": null, "metadata": {"window": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. ", "original_text": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24d89fd9-1976-428f-9f05-96f7f1baf912", "node_type": "1", "metadata": {"window": "In the Pharmaceutical segment, we did talk about improved utilization year -over-year.  I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n", "original_text": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "151bc7b330353ae081d4ae8e00f35a25fabff3601100d8687d71ac020a7936cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a6483b5-4569-463a-b368-3429b70a4038", "node_type": "1", "metadata": {"window": "So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues. ", "original_text": "We've talked about that now for the previous four or five quarters. "}, "hash": "8640e046708f967f80b86fad789a08b5dcee8a6b75c2dbcfce3b220f817c0f8f", "class_name": "RelatedNodeInfo"}}, "text": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. ", "start_char_idx": 3743, "end_char_idx": 3850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a6483b5-4569-463a-b368-3429b70a4038": {"__data__": {"id_": "1a6483b5-4569-463a-b368-3429b70a4038", "embedding": null, "metadata": {"window": "So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues. ", "original_text": "We've talked about that now for the previous four or five quarters. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c40338f-315c-4122-b347-22b9ae435bcf", "node_type": "1", "metadata": {"window": "I think if you look at IQVIA \nnumbers, you'll see that first quarter versus last year there's approximately 7% growth in prescription transaction \nvolume.  So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. ", "original_text": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa36ce414e853f617e0fc1e9f52f8b801af716be9e8d4ad356d7004b20b5351b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c11f9324-2f11-4b9e-88da-3be7bd270c42", "node_type": "1", "metadata": {"window": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season. ", "original_text": "We have seen \nfaster growth in those retail national account customers.  \n \n"}, "hash": "50a705c59bac65bc331390d1b19be556d33fa99baa90ee474d6a1c1ccade050e", "class_name": "RelatedNodeInfo"}}, "text": "We've talked about that now for the previous four or five quarters. ", "start_char_idx": 3850, "end_char_idx": 3918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c11f9324-2f11-4b9e-88da-3be7bd270c42": {"__data__": {"id_": "c11f9324-2f11-4b9e-88da-3be7bd270c42", "embedding": null, "metadata": {"window": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season. ", "original_text": "We have seen \nfaster growth in those retail national account customers.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a6483b5-4569-463a-b368-3429b70a4038", "node_type": "1", "metadata": {"window": "So that is significan t from what we've seen over the last few years.  \n \n I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues. ", "original_text": "We've talked about that now for the previous four or five quarters. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37ccaeaf47ba3a22e6503bf0b73b5b18d0aa9ac256dc2706f2730767fe59c3e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb949474-6db1-46dc-8906-b9127d2abfd2", "node_type": "1", "metadata": {"window": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. "}, "hash": "c59c539544a8cf7c40bdf5fe025bb022b001be3b43f25acc5c8015a270bd6410", "class_name": "RelatedNodeInfo"}}, "text": "We have seen \nfaster growth in those retail national account customers.  \n \n", "start_char_idx": 3918, "end_char_idx": 3994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb949474-6db1-46dc-8906-b9127d2abfd2": {"__data__": {"id_": "eb949474-6db1-46dc-8906-b9127d2abfd2", "embedding": null, "metadata": {"window": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c11f9324-2f11-4b9e-88da-3be7bd270c42", "node_type": "1", "metadata": {"window": "I also talked about in my remarks that within our US Pharmaceutical segment, we are seeing faster growth in our \nretail national account customers.  So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season. ", "original_text": "We have seen \nfaster growth in those retail national account customers.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ffe99a00bec94b4248c1b4af869eb9992ce2b94d6adb02c977db3ecb3ca6369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efa6d016-9707-45bc-b266-e52d835a0bf5", "node_type": "1", "metadata": {"window": "We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "That continues. "}, "hash": "e37d23bdf2bbbaad6a3641527ea0004a196566914f6aea5cca97cae9f7b9b0b1", "class_name": "RelatedNodeInfo"}}, "text": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. ", "start_char_idx": 3994, "end_char_idx": 4185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efa6d016-9707-45bc-b266-e52d835a0bf5": {"__data__": {"id_": "efa6d016-9707-45bc-b266-e52d835a0bf5", "embedding": null, "metadata": {"window": "We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "That continues. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb949474-6db1-46dc-8906-b9127d2abfd2", "node_type": "1", "metadata": {"window": "So our largest accounts are growing faster than the market, and that's not \nsomething new to this quarter.  We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56c11671def11a8add5b41b806f5f95543533b6bd854088e158e853e2721bf8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "365eb388-026f-456b-9751-0d3252f12268", "node_type": "1", "metadata": {"window": "We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "What we did see \nin the first quarter is really what I would call an extended flu season. "}, "hash": "c51e7126c541f6ef9a0f93e94afbbb276d8c62efc8ee41a76d00d97858d44d1e", "class_name": "RelatedNodeInfo"}}, "text": "That continues. ", "start_char_idx": 4185, "end_char_idx": 4201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "365eb388-026f-456b-9751-0d3252f12268": {"__data__": {"id_": "365eb388-026f-456b-9751-0d3252f12268", "embedding": null, "metadata": {"window": "We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "What we did see \nin the first quarter is really what I would call an extended flu season. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efa6d016-9707-45bc-b266-e52d835a0bf5", "node_type": "1", "metadata": {"window": "We've talked about that now for the previous four or five quarters.  We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "That continues. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e48a33d39c79b554f7dde2cbcbbf3fbd12db4a78de3a9a43a3ae59b98ca23813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "072001cd-493b-4ae5-a2be-9bd8d26a2efa", "node_type": "1", "metadata": {"window": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "So we talked about higher level  of illness and "}, "hash": "d0ee875fd6f9779b6bb93c1eb2e1a4f1491ba0be335743a7046d2f74db720af0", "class_name": "RelatedNodeInfo"}}, "text": "What we did see \nin the first quarter is really what I would call an extended flu season. ", "start_char_idx": 4201, "end_char_idx": 4291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "072001cd-493b-4ae5-a2be-9bd8d26a2efa": {"__data__": {"id_": "072001cd-493b-4ae5-a2be-9bd8d26a2efa", "embedding": null, "metadata": {"window": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "So we talked about higher level  of illness and ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea74283-efb4-4b1c-af58-756548490b1d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48620c6c6b9dc9d976a714817bd2c38c5c7692189a862372a79baf2966315e2d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "365eb388-026f-456b-9751-0d3252f12268", "node_type": "1", "metadata": {"window": "We have seen \nfaster growth in those retail national account customers.  \n \n In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "What we did see \nin the first quarter is really what I would call an extended flu season. ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "478fb7a42b46c6ae675300242fe259e8ac42b1a11ee5ab06e7c96816705b769c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7745062-43d7-4bbe-bcf9-05d1016992e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "McKesson Corp.  "}, "hash": "241958279425b4473306389df68159aa7ebbf1d9eaa8ebfc645f36abd9c7cd27", "class_name": "RelatedNodeInfo"}}, "text": "So we talked about higher level  of illness and ", "start_char_idx": 4291, "end_char_idx": 4339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7745062-43d7-4bbe-bcf9-05d1016992e2": {"__data__": {"id_": "d7745062-43d7-4bbe-bcf9-05d1016992e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "072001cd-493b-4ae5-a2be-9bd8d26a2efa", "node_type": "1", "metadata": {"window": "In our Medical business, we have a very strong primary care business, and we've talked about the strength that \nwe've had across all of the channels and the breadth of products and services.  That continues.  What we did see \nin the first quarter is really what I would call an extended flu season.  So we talked about higher level  of illness and ", "original_text": "So we talked about higher level  of illness and ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72b8c6c3084d79bf002b89bc8bce7e78d099988e8d693acbc66d1226824b5bf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2364da4-bb29-47bd-9fb2-e6808f107d3c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter. "}, "hash": "43676b29d721a8e24a07ef60c3efcff78fe20d7428bb5f60c47f422d7e2d6942", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2364da4-bb29-47bd-9fb2-e6808f107d3c": {"__data__": {"id_": "c2364da4-bb29-47bd-9fb2-e6808f107d3c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7745062-43d7-4bbe-bcf9-05d1016992e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab8dcf9825a19ed71a53f8b704c85c45ee0d39048b60e304747b963f5bce1531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db0e6b0-9018-4b73-b7fb-ccf0b5298117", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n "}, "hash": "7a347d33545dfb5177ede38c0dbc7795624f0fe84a66d5a111d0fb33c723df2d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter. ", "start_char_idx": 16, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db0e6b0-9018-4b73-b7fb-ccf0b5298117": {"__data__": {"id_": "7db0e6b0-9018-4b73-b7fb-ccf0b5298117", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2364da4-bb29-47bd-9fb2-e6808f107d3c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "098c928c3b71919159df65a29c1aa44c3b77f75509cac14bb9653c0a75a32dbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aad361b-c4ab-47c2-8728-422f1edd33eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "c03e062b2df868a68e437b8c9d376b833bafb2076f4677dde6c3fba1553ff489", "class_name": "RelatedNodeInfo"}}, "text": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n ", "start_char_idx": 207, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aad361b-c4ab-47c2-8728-422f1edd33eb": {"__data__": {"id_": "6aad361b-c4ab-47c2-8728-422f1edd33eb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db0e6b0-9018-4b73-b7fb-ccf0b5298117", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "500e71a12d006f7840a085bd1834cf374d0377ea7811d94a48bac887255ecb9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "199dac59-8dfd-4495-b6db-c3ce80f0aaa5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n "}, "hash": "4830acb44ebaeccacc9296055ec5accb5fe31918e9644371333323be253d6c41", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 362, "end_char_idx": 725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "199dac59-8dfd-4495-b6db-c3ce80f0aaa5": {"__data__": {"id_": "199dac59-8dfd-4495-b6db-c3ce80f0aaa5", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aad361b-c4ab-47c2-8728-422f1edd33eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3123e428064341ecdaf326ee975fa5d9d40acf68ecb4d6e4c7553684e72e899d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1447ddd6-0338-4cec-8ea0-a75d69f6c2c6", "node_type": "1", "metadata": {"window": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "a727106b367809cfad6619c2295a2601229dfb183f13f0590ef94fc38474b2e1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n ", "start_char_idx": 725, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1447ddd6-0338-4cec-8ea0-a75d69f6c2c6": {"__data__": {"id_": "1447ddd6-0338-4cec-8ea0-a75d69f6c2c6", "embedding": null, "metadata": {"window": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "199dac59-8dfd-4495-b6db-c3ce80f0aaa5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "792811682c0fe9815756f62510e428dc2c5fd3dbee6078c53c6e7d0842ddfa4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "111684b4-c497-42d6-80b5-5fd15e7dba3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Q \nThanks. "}, "hash": "28c54869087981aa967d8f27677848a0e323910d1169163bfc31617846c520f4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 1047, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "111684b4-c497-42d6-80b5-5fd15e7dba3c": {"__data__": {"id_": "111684b4-c497-42d6-80b5-5fd15e7dba3c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1447ddd6-0338-4cec-8ea0-a75d69f6c2c6", "node_type": "1", "metadata": {"window": "That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61a158cf7652dea49dee5c62cb0538bf9d8b41a5aad0440f07e8864c22e0d49a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f4aaa66-fe09-4df9-831d-00993e460428", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric. ", "original_text": "Can you hear me? "}, "hash": "c569b6aaaa758c311ef2e2fb6f17c94b0530fa44c1fcb64eaf50f0bb06b242e4", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks. ", "start_char_idx": 1379, "end_char_idx": 1390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f4aaa66-fe09-4df9-831d-00993e460428": {"__data__": {"id_": "8f4aaa66-fe09-4df9-831d-00993e460428", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric. ", "original_text": "Can you hear me? ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "111684b4-c497-42d6-80b5-5fd15e7dba3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6201ab914ce5f5fb2308fe4399ea652b0b8545a1b7a28bed544cd278fc250540", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e6231ed-d8da-4cc5-bf24-1029339827b9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you. ", "original_text": "Hello?  \n "}, "hash": "0531219c8194487d4b4d1e258cfac497f2e290f8de557ce1fe1dcbaed0e536e3", "class_name": "RelatedNodeInfo"}}, "text": "Can you hear me? ", "start_char_idx": 1390, "end_char_idx": 1407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e6231ed-d8da-4cc5-bf24-1029339827b9": {"__data__": {"id_": "2e6231ed-d8da-4cc5-bf24-1029339827b9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you. ", "original_text": "Hello?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f4aaa66-fe09-4df9-831d-00993e460428", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next is Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric. ", "original_text": "Can you hear me? ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "806a9b056dd7f8eac8bff70efd1bb356511def86a545c42e4c3ea990eefe6283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6560cb30-2760-4880-8615-c411cdef42cb", "node_type": "1", "metadata": {"window": "Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "7b30bc8b11f8c857fbb151026ceb044cc6e6df07ed9813a9e206aadcabd7ea11", "class_name": "RelatedNodeInfo"}}, "text": "Hello?  \n ", "start_char_idx": 1407, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6560cb30-2760-4880-8615-c411cdef42cb": {"__data__": {"id_": "6560cb30-2760-4880-8615-c411cdef42cb", "embedding": null, "metadata": {"window": "Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e6231ed-d8da-4cc5-bf24-1029339827b9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you. ", "original_text": "Hello?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c0f1f0949ca3114b2263bfb015e2c86f3e839c60f911cc1e8c17bb578e37f5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bed7e969-1f4b-4927-97df-4d2d8fcd13c3", "node_type": "1", "metadata": {"window": "Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nYes, Eric. "}, "hash": "ee574d52b1274cb8b8681664d3c3de2dddfb1fc288447b67014d405ff1769cd3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1417, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bed7e969-1f4b-4927-97df-4d2d8fcd13c3": {"__data__": {"id_": "bed7e969-1f4b-4927-97df-4d2d8fcd13c3", "embedding": null, "metadata": {"window": "Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nYes, Eric. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6560cb30-2760-4880-8615-c411cdef42cb", "node_type": "1", "metadata": {"window": "Q \nThanks.  Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29fdd3c2a099c62ace6b86a6ae215c6aea249244a7310aaec384e23871ab7751", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11cb590a-4709-4722-ad58-99f58d32ea9f", "node_type": "1", "metadata": {"window": "Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah. ", "original_text": "We can hear you. "}, "hash": "49cfc8847cdea58864ba5a2f60494d4d68e21a8fea6c75c63834f8b14924c8b0", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes, Eric. ", "start_char_idx": 2061, "end_char_idx": 2075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11cb590a-4709-4722-ad58-99f58d32ea9f": {"__data__": {"id_": "11cb590a-4709-4722-ad58-99f58d32ea9f", "embedding": null, "metadata": {"window": "Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah. ", "original_text": "We can hear you. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bed7e969-1f4b-4927-97df-4d2d8fcd13c3", "node_type": "1", "metadata": {"window": "Can you hear me?  Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nYes, Eric. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0bbd929500d36c8db724f7b1b6745908541b899ff988cc28a55143990052948", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9351c92-e520-46ac-9102-08a459e58a24", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry. ", "original_text": "Go ahead.  \n "}, "hash": "7dba50b865091c84a213979e3549f49444553fa4a92521d6d7497f61dd7425c6", "class_name": "RelatedNodeInfo"}}, "text": "We can hear you. ", "start_char_idx": 2075, "end_char_idx": 2092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9351c92-e520-46ac-9102-08a459e58a24": {"__data__": {"id_": "b9351c92-e520-46ac-9102-08a459e58a24", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry. ", "original_text": "Go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11cb590a-4709-4722-ad58-99f58d32ea9f", "node_type": "1", "metadata": {"window": "Hello?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah. ", "original_text": "We can hear you. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62dc57ae6688860c94e3bad03bb80c8f748b79c4b22f94c48200662424339630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cff05a4d-2212-4243-a6f2-7db9871d65e6", "node_type": "1", "metadata": {"window": "A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "7a0d732b2c22656c92c4e87524c9c72197a5bf3e486ea50e7d9260ce0e7094d2", "class_name": "RelatedNodeInfo"}}, "text": "Go ahead.  \n ", "start_char_idx": 2092, "end_char_idx": 2105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cff05a4d-2212-4243-a6f2-7db9871d65e6": {"__data__": {"id_": "cff05a4d-2212-4243-a6f2-7db9871d65e6", "embedding": null, "metadata": {"window": "A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9351c92-e520-46ac-9102-08a459e58a24", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, we can...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry. ", "original_text": "Go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9ec1d1bda837657b0660be0e844b35c60d228a89dd2a885cc81f058c59e053d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6b1ef8d-0def-4929-8459-e9d8e6a2e194", "node_type": "1", "metadata": {"window": "We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. ", "original_text": "Q \nYeah. "}, "hash": "8684a5b474325c0982142d2662fdd73f979da717ac5100778de9ddad8fd53b44", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 1047, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6b1ef8d-0def-4929-8459-e9d8e6a2e194": {"__data__": {"id_": "c6b1ef8d-0def-4929-8459-e9d8e6a2e194", "embedding": null, "metadata": {"window": "We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. ", "original_text": "Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cff05a4d-2212-4243-a6f2-7db9871d65e6", "node_type": "1", "metadata": {"window": "A \nYes, Eric.  We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2ba1c765120967dcd17c191f3fcb67d4fcee9d1aebf0b310cc85c6016605890", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "396cdcfe-f7ff-4645-8ca5-fe61c805b83e", "node_type": "1", "metadata": {"window": "Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets. ", "original_text": "Sorry. "}, "hash": "f388efd7555837505d5426df11fa127c278afcc8af07bbd0f73e77511143416b", "class_name": "RelatedNodeInfo"}}, "text": "Q \nYeah. ", "start_char_idx": 2437, "end_char_idx": 2446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "396cdcfe-f7ff-4645-8ca5-fe61c805b83e": {"__data__": {"id_": "396cdcfe-f7ff-4645-8ca5-fe61c805b83e", "embedding": null, "metadata": {"window": "Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets. ", "original_text": "Sorry. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6b1ef8d-0def-4929-8459-e9d8e6a2e194", "node_type": "1", "metadata": {"window": "We can hear you.  Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. ", "original_text": "Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e9500b73cdc87f5cd7dcb839ba4507372ddf366d70ca5069082413f1e717a29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564165c3-9478-485c-8cb3-5fcfa6a73b0c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. ", "original_text": "Thank you. "}, "hash": "c6b929a5cebd8c91ca331519658a40e75a694e3b09240f628c2bc95e3dbe1628", "class_name": "RelatedNodeInfo"}}, "text": "Sorry. ", "start_char_idx": 2446, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564165c3-9478-485c-8cb3-5fcfa6a73b0c": {"__data__": {"id_": "564165c3-9478-485c-8cb3-5fcfa6a73b0c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. ", "original_text": "Thank you. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "396cdcfe-f7ff-4645-8ca5-fe61c805b83e", "node_type": "1", "metadata": {"window": "Go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets. ", "original_text": "Sorry. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "424e96bdf523bf4961f9bbe8a5a1f60463ac6aff4c8563a9a194b582b892f9b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb5eaba2-d061-4574-a521-a3a34f422f67", "node_type": "1", "metadata": {"window": "Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well. ", "original_text": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. "}, "hash": "7ddaedc5ac6d5217c4dcbead3382fcac9fe76a1a70795b8a6b63706f497b20dd", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 2453, "end_char_idx": 2464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb5eaba2-d061-4574-a521-a3a34f422f67": {"__data__": {"id_": "bb5eaba2-d061-4574-a521-a3a34f422f67", "embedding": null, "metadata": {"window": "Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well. ", "original_text": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564165c3-9478-485c-8cb3-5fcfa6a73b0c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. ", "original_text": "Thank you. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0313c0a5e8be26e744f7a236a4ba5c23ca87d72fa0548a67adbdd86fbaf02879", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a8249ab-aa78-491a-a4ce-6821ba3ee5c7", "node_type": "1", "metadata": {"window": "Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. ", "original_text": "Those two were offsets. "}, "hash": "29bebc9447169b3ae94caefdef6995594c0ad694837ff9de347341e2a43443fe", "class_name": "RelatedNodeInfo"}}, "text": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. ", "start_char_idx": 2464, "end_char_idx": 2672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a8249ab-aa78-491a-a4ce-6821ba3ee5c7": {"__data__": {"id_": "8a8249ab-aa78-491a-a4ce-6821ba3ee5c7", "embedding": null, "metadata": {"window": "Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. ", "original_text": "Those two were offsets. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb5eaba2-d061-4574-a521-a3a34f422f67", "node_type": "1", "metadata": {"window": "Q \nYeah.  Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well. ", "original_text": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04ebf0f25591db7d439e866a37eb39f3ad957bc76716b9059376d9ba7b42be90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7321422d-2d6e-4ea7-9518-a587a199931f", "node_type": "1", "metadata": {"window": "Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n ", "original_text": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. "}, "hash": "8c6476ede7ea010c7a697eeca47b2741c60337eb15c78a9b220cdd27e8ec0c65", "class_name": "RelatedNodeInfo"}}, "text": "Those two were offsets. ", "start_char_idx": 2672, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7321422d-2d6e-4ea7-9518-a587a199931f": {"__data__": {"id_": "7321422d-2d6e-4ea7-9518-a587a199931f", "embedding": null, "metadata": {"window": "Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n ", "original_text": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a8249ab-aa78-491a-a4ce-6821ba3ee5c7", "node_type": "1", "metadata": {"window": "Sorry.  Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. ", "original_text": "Those two were offsets. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "892b28cc0231601d276c7f24f2db485bf28c71e51b7e01aba1c3c08ea5c214a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e850790-a896-47ee-bfaa-6922d908cbdb", "node_type": "1", "metadata": {"window": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "They offset, and all is well. "}, "hash": "d2ba99747198e6e62f69cc095cb1316f9016c1cc62ee454e23e754e1ba4f0b9d", "class_name": "RelatedNodeInfo"}}, "text": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. ", "start_char_idx": 2696, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e850790-a896-47ee-bfaa-6922d908cbdb": {"__data__": {"id_": "2e850790-a896-47ee-bfaa-6922d908cbdb", "embedding": null, "metadata": {"window": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "They offset, and all is well. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7321422d-2d6e-4ea7-9518-a587a199931f", "node_type": "1", "metadata": {"window": "Thank you.  Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n ", "original_text": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed8a915b95b82b1c765c98f1291ed4d59357fe85177d19698d029cd1ae7281b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df38b331-6406-4701-9ebf-b3057d673bff", "node_type": "1", "metadata": {"window": "Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric. ", "original_text": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. "}, "hash": "60051f0831f8298941a8e00bb45d5363982da07db5cef4b5f64a2acb8e90bc8b", "class_name": "RelatedNodeInfo"}}, "text": "They offset, and all is well. ", "start_char_idx": 2854, "end_char_idx": 2884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df38b331-6406-4701-9ebf-b3057d673bff": {"__data__": {"id_": "df38b331-6406-4701-9ebf-b3057d673bff", "embedding": null, "metadata": {"window": "Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric. ", "original_text": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e850790-a896-47ee-bfaa-6922d908cbdb", "node_type": "1", "metadata": {"window": "Following on to an earlier question about the OpEx, SG&A control, the incredible upside \nin that number, I guess my follow -on or twist would be versus Street gross margin was I think also materially \nlower.  Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "They offset, and all is well. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "511d097ba35e49b52058599e5061b02af8bf954684636889713e3ee6faae0895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ede6c87f-fd9f-46cc-b911-d9ee750c20e5", "node_type": "1", "metadata": {"window": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n", "original_text": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n "}, "hash": "61dd6d0714b3dc695d1d259631111ec81c939efcdb5bf3ec6f1bd75018adefca", "class_name": "RelatedNodeInfo"}}, "text": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. ", "start_char_idx": 2884, "end_char_idx": 3116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ede6c87f-fd9f-46cc-b911-d9ee750c20e5": {"__data__": {"id_": "ede6c87f-fd9f-46cc-b911-d9ee750c20e5", "embedding": null, "metadata": {"window": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n", "original_text": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df38b331-6406-4701-9ebf-b3057d673bff", "node_type": "1", "metadata": {"window": "Those two were offsets.  We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric. ", "original_text": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a520cc0c7c38c0d7c0b1ebc50805d69fe689fddc490c774e60f29b0f7f591e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1dea752-a732-4864-8e70-300f3b3b041a", "node_type": "1", "metadata": {"window": "They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "7a12ccdf30f8801ac6bca0280e8a67524addf85da4b180d23ea9227b5ed2ab31", "class_name": "RelatedNodeInfo"}}, "text": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n ", "start_char_idx": 3116, "end_char_idx": 3220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1dea752-a732-4864-8e70-300f3b3b041a": {"__data__": {"id_": "f1dea752-a732-4864-8e70-300f3b3b041a", "embedding": null, "metadata": {"window": "They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ede6c87f-fd9f-46cc-b911-d9ee750c20e5", "node_type": "1", "metadata": {"window": "We see this substantial variance in the P&L each and every quarter I think where \nthe Street's just way too high on one number and way too low on the o ther.  They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n", "original_text": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3157d4ad43e73a261225b212fdf458c5708420e5747a7c8b6007631e8ab9582d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fdd39e7-0b82-42c8-b526-a35b1123c9d6", "node_type": "1", "metadata": {"window": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022. ", "original_text": "A \nWell, thanks for the question, Eric. "}, "hash": "985cc74b143d5b846082f0d0d941f5585d8cedddbd861c8b2b1e8d811ef53c86", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1720, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fdd39e7-0b82-42c8-b526-a35b1123c9d6": {"__data__": {"id_": "7fdd39e7-0b82-42c8-b526-a35b1123c9d6", "embedding": null, "metadata": {"window": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022. ", "original_text": "A \nWell, thanks for the question, Eric. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1dea752-a732-4864-8e70-300f3b3b041a", "node_type": "1", "metadata": {"window": "They offset, and all is well.  But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd6cdfedbdfdecac00865be6010b94613b6b56e1f803e5ca8d8eb6dd678f9ddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f66588c1-3207-456b-9a05-2fe111ba688c", "node_type": "1", "metadata": {"window": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. ", "original_text": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n"}, "hash": "1e70fe968bafb48766f682742e66c675db2b391993699d47e95b95935e5a4446", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, thanks for the question, Eric. ", "start_char_idx": 3561, "end_char_idx": 3601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f66588c1-3207-456b-9a05-2fe111ba688c": {"__data__": {"id_": "f66588c1-3207-456b-9a05-2fe111ba688c", "embedding": null, "metadata": {"window": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. ", "original_text": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fdd39e7-0b82-42c8-b526-a35b1123c9d6", "node_type": "1", "metadata": {"window": "But I was \nhoping to get maybe a little more color on what in your mind, if you could think about where the Street was, why \nwould gross margin be perhaps lower than consensus expectations, to a lesser extent than OpEx was  upside.  But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022. ", "original_text": "A \nWell, thanks for the question, Eric. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31fd909d25220fad7da6a84cefb14f7b5961d8a80526ace982a4905871dc0126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daee8b5b-7390-4f4e-9374-47bee6515772", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. ", "original_text": "The cadence of our European divestiture activity could be a big part of that. "}, "hash": "c85f3e7f5a3ce7da35494cad696bc56cbd852a1e2cd6afe1706ba955749cc8fc", "class_name": "RelatedNodeInfo"}}, "text": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n", "start_char_idx": 3601, "end_char_idx": 3819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daee8b5b-7390-4f4e-9374-47bee6515772": {"__data__": {"id_": "daee8b5b-7390-4f4e-9374-47bee6515772", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. ", "original_text": "The cadence of our European divestiture activity could be a big part of that. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f66588c1-3207-456b-9a05-2fe111ba688c", "node_type": "1", "metadata": {"window": "But \nwhat would be the major gross margin factors or things we should be considering moving forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. ", "original_text": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7fa70a49db933b1ffe32a038ca7be99a1cd8c28489b8f48b24a13bf61974969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcaedbc5-4cf7-4052-95a7-c3331455ac78", "node_type": "1", "metadata": {"window": "A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n", "original_text": "We closed our UK retail and \nwholesale operations in April of 2022. "}, "hash": "16d55e3a637f8fb2364680b7251c4b8a03aecf8d6b9805be30440e46c407efb6", "class_name": "RelatedNodeInfo"}}, "text": "The cadence of our European divestiture activity could be a big part of that. ", "start_char_idx": 3819, "end_char_idx": 3897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcaedbc5-4cf7-4052-95a7-c3331455ac78": {"__data__": {"id_": "fcaedbc5-4cf7-4052-95a7-c3331455ac78", "embedding": null, "metadata": {"window": "A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n", "original_text": "We closed our UK retail and \nwholesale operations in April of 2022. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daee8b5b-7390-4f4e-9374-47bee6515772", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. ", "original_text": "The cadence of our European divestiture activity could be a big part of that. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfc41ae5ee5d150e9a0d80ff9f1550f8384dc96eb37e6d53d0b644da530f3114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe1eb9e-0fcb-46f2-8adb-8c934a59e47c", "node_type": "1", "metadata": {"window": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment. ", "original_text": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. "}, "hash": "f87adea742d2bec377ebbc1670fb326700ab700d462c15ff3d86bdfbb23171c8", "class_name": "RelatedNodeInfo"}}, "text": "We closed our UK retail and \nwholesale operations in April of 2022. ", "start_char_idx": 3897, "end_char_idx": 3965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe1eb9e-0fcb-46f2-8adb-8c934a59e47c": {"__data__": {"id_": "6fe1eb9e-0fcb-46f2-8adb-8c934a59e47c", "embedding": null, "metadata": {"window": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment. ", "original_text": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcaedbc5-4cf7-4052-95a7-c3331455ac78", "node_type": "1", "metadata": {"window": "A \nWell, thanks for the question, Eric.  I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n", "original_text": "We closed our UK retail and \nwholesale operations in April of 2022. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22bdde1483ee4207c18197248e0439a772125b31477b981f9942ed0d4920e237", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a967c22f-0802-4331-811b-3fc317305b32", "node_type": "1", "metadata": {"window": "The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. ", "original_text": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. "}, "hash": "b3e5ec8d4334a768e530a8267257e94ff1d27e4f50ab2abb2e26089bcacf612c", "class_name": "RelatedNodeInfo"}}, "text": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. ", "start_char_idx": 3965, "end_char_idx": 4124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a967c22f-0802-4331-811b-3fc317305b32": {"__data__": {"id_": "a967c22f-0802-4331-811b-3fc317305b32", "embedding": null, "metadata": {"window": "The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. ", "original_text": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe1eb9e-0fcb-46f2-8adb-8c934a59e47c", "node_type": "1", "metadata": {"window": "I don't really want to try to project what's in the Street models, but I will call out \na couple things that I did talk about in my remarks that I think could be a part of the disconnect at least for the \nquarter.  \n \n The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment. ", "original_text": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8cb257b9fa964d41e317335848dc096049a2a3e83c5d99149a8003d8e84cdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "860abcc1-2130-4c84-9087-b9246700b15a", "node_type": "1", "metadata": {"window": "We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. ", "original_text": "And that was in my initial remarks.  \n \n"}, "hash": "95aa87c2202808cbbeb20aa4526a0c9b64b13c90504d0d05110b52e0f9653e8a", "class_name": "RelatedNodeInfo"}}, "text": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. ", "start_char_idx": 4124, "end_char_idx": 4225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "860abcc1-2130-4c84-9087-b9246700b15a": {"__data__": {"id_": "860abcc1-2130-4c84-9087-b9246700b15a", "embedding": null, "metadata": {"window": "We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. ", "original_text": "And that was in my initial remarks.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a967c22f-0802-4331-811b-3fc317305b32", "node_type": "1", "metadata": {"window": "The cadence of our European divestiture activity could be a big part of that.  We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. ", "original_text": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff6afc9ab36a92404a671ca0693695238adf050630ffa32a1762445802c2ffb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14b521f0-a224-45ad-bedd-b75a490a8495", "node_type": "1", "metadata": {"window": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. ", "original_text": "The other thing that I would just go back to a prior comment. "}, "hash": "aa3c820fb27d5333db9ef7a665ba50b0fc04bbf681de9c289e36b13d0e6e8d5b", "class_name": "RelatedNodeInfo"}}, "text": "And that was in my initial remarks.  \n \n", "start_char_idx": 4225, "end_char_idx": 4265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14b521f0-a224-45ad-bedd-b75a490a8495": {"__data__": {"id_": "14b521f0-a224-45ad-bedd-b75a490a8495", "embedding": null, "metadata": {"window": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. ", "original_text": "The other thing that I would just go back to a prior comment. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "860abcc1-2130-4c84-9087-b9246700b15a", "node_type": "1", "metadata": {"window": "We closed our UK retail and \nwholesale operations in April of 2022.  And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. ", "original_text": "And that was in my initial remarks.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7457226e7c30fdf7b1acb8d809c53dce245aa013adec220c9503a77de2b2f4ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "387d87c5-b879-478e-a637-bb6d724a6ad5", "node_type": "1", "metadata": {"window": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n ", "original_text": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. "}, "hash": "22ffb53e3a01d28baa08ba29d6cf7d1cc9812aebe3b4f0489471bf6b4302dffd", "class_name": "RelatedNodeInfo"}}, "text": "The other thing that I would just go back to a prior comment. ", "start_char_idx": 4265, "end_char_idx": 4327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "387d87c5-b879-478e-a637-bb6d724a6ad5": {"__data__": {"id_": "387d87c5-b879-478e-a637-bb6d724a6ad5", "embedding": null, "metadata": {"window": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n ", "original_text": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14b521f0-a224-45ad-bedd-b75a490a8495", "node_type": "1", "metadata": {"window": "And so when you look at the UK business and the Austrian businesses \nbeing divested, that drove a significant delta in gross profit and in operating expenses.  In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. ", "original_text": "The other thing that I would just go back to a prior comment. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88d605dba28779cedf4a2fc8655982aea9d2b52f57df60bcbe5eb5cf70187f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5881f5e2-2e34-476c-9cf3-6bc59fc35d68", "node_type": "1", "metadata": {"window": "And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. "}, "hash": "4da8f9fe8dd01dd1facdefba86b1b3b63efadcb45bc4a52f57463fec3e362f1f", "class_name": "RelatedNodeInfo"}}, "text": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. ", "start_char_idx": 4327, "end_char_idx": 4435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5881f5e2-2e34-476c-9cf3-6bc59fc35d68": {"__data__": {"id_": "5881f5e2-2e34-476c-9cf3-6bc59fc35d68", "embedding": null, "metadata": {"window": "And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "387d87c5-b879-478e-a637-bb6d724a6ad5", "node_type": "1", "metadata": {"window": "In gross profit, if you \nexclude th e European divestitures, our gross profit actually increased 9%.  And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n ", "original_text": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfe4c08e18b667d93ca8aa55a77a2da7aa5dbd909bac78aeb06748bb2754f76e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8bec91b-9513-430c-9d8f-35ce3f4d8c4f", "node_type": "1", "metadata": {"window": "The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. "}, "hash": "889bfa5f1fae1665e44c447d91ba61f34caf02b79313b815b5d6481ba531248e", "class_name": "RelatedNodeInfo"}}, "text": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. ", "start_char_idx": 4435, "end_char_idx": 4585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8bec91b-9513-430c-9d8f-35ce3f4d8c4f": {"__data__": {"id_": "d8bec91b-9513-430c-9d8f-35ce3f4d8c4f", "embedding": null, "metadata": {"window": "The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5881f5e2-2e34-476c-9cf3-6bc59fc35d68", "node_type": "1", "metadata": {"window": "And that was in my initial remarks.  \n \n The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "978a80db237e0ccf77f12cecb5dcbbd63f3be0135c6cff5e165209c7957a10d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fcfbe1c-94be-4028-bd6c-3182f2447003", "node_type": "1", "metadata": {"window": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n "}, "hash": "87fee31826461b7414fb51af57965f249235b0536ff7c84114f95c9252b807f2", "class_name": "RelatedNodeInfo"}}, "text": "So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. ", "start_char_idx": 4585, "end_char_idx": 4712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fcfbe1c-94be-4028-bd6c-3182f2447003": {"__data__": {"id_": "3fcfbe1c-94be-4028-bd6c-3182f2447003", "embedding": null, "metadata": {"window": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8bec91b-9513-430c-9d8f-35ce3f4d8c4f", "node_type": "1", "metadata": {"window": "The other thing that I would just go back to a prior comment.  In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact. ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1621e1212c72db8b4b12368a79a0efba46bb33de1423efce7dc9d17884591827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8bdf535-169a-40ae-90bc-dcf3fd30b7c3", "node_type": "1", "metadata": {"window": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "e239894fe5e0b98b6c069b77b75efb31159a4436f525843add078d3787221c4a", "class_name": "RelatedNodeInfo"}}, "text": "But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n ", "start_char_idx": 4712, "end_char_idx": 4827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8bdf535-169a-40ae-90bc-dcf3fd30b7c3": {"__data__": {"id_": "f8bdf535-169a-40ae-90bc-dcf3fd30b7c3", "embedding": null, "metadata": {"window": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b74e13059a7cbc227e64cf3faf0869c318f05ad3017d61a7e02ed62369c62d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fcfbe1c-94be-4028-bd6c-3182f2447003", "node_type": "1", "metadata": {"window": "In our US Pharmaceutical segment, we are seeing \nfaster growth from our retail national accou nt customers.  And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04f853fb54ca813201bca68deb37d877561019c86ab012474a4d9148fd4d48be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2f80b5-8506-436f-aa99-6d0980bee0ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "original_text": "McKesson Corp.  "}, "hash": "b762cbfeec92be3bd31a983ab8aabb71b8a15e91afb06a5dfa86334dc1aad145", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 362, "end_char_idx": 633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2f80b5-8506-436f-aa99-6d0980bee0ad": {"__data__": {"id_": "bd2f80b5-8506-436f-aa99-6d0980bee0ad", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8bdf535-169a-40ae-90bc-dcf3fd30b7c3", "node_type": "1", "metadata": {"window": "And those customers, as we've talked about in prior \nquarters, have lower margins for us than the rest of our book, as you would expect that to have.  So again, our \nretail national account customers growing a little bit faster than the rest of the book, that has a mix impact.  But I \nthink the big delta in this quarter is really the timing and the cadence of these European divestitures.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdbbf4f2ddccdbc369387adca5948424dc6b3ab5e8e186ad4057ad1de5b8f792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f3425e5-1503-43b0-9bb7-cf90a13cb0c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. "}, "hash": "6b25372f1c4ea5a645a2e7fe74cc15c6a7832bc64e39dbc8050cd84270500073", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f3425e5-1503-43b0-9bb7-cf90a13cb0c0": {"__data__": {"id_": "9f3425e5-1503-43b0-9bb7-cf90a13cb0c0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2f80b5-8506-436f-aa99-6d0980bee0ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f38758bf084692fe53424180e1099a53f74955871cbc8c5bf05c2f0b518676a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9febf9b0-10cc-4bda-942b-cbe7f1fccff7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "Next question, please.  \n "}, "hash": "d581fcd28353b9e2e6741d2362ccc42c22e456c03b7ba4593791e3f78b0c916b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "start_char_idx": 16, "end_char_idx": 252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9febf9b0-10cc-4bda-942b-cbe7f1fccff7": {"__data__": {"id_": "9febf9b0-10cc-4bda-942b-cbe7f1fccff7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "Next question, please.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f3425e5-1503-43b0-9bb7-cf90a13cb0c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cad13b900e05e71d7c406a8ba7bdbf8dc688d437483d7bf96f0871b006156f79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e75d737c-eb85-4a67-b088-6dac5a057775", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n "}, "hash": "6e6abce1bf0a71420105a782e434c5e2f0632728ca3d5fe058c0cfb2e60815aa", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n ", "start_char_idx": 252, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e75d737c-eb85-4a67-b088-6dac5a057775": {"__data__": {"id_": "e75d737c-eb85-4a67-b088-6dac5a057775", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9febf9b0-10cc-4bda-942b-cbe7f1fccff7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "Next question, please.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd1f59f37d98b69ac9c53453d9ea2d1f060466e3055ee6638e5e5a1ade287863", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f6596c0-3509-47a2-904a-106f888325a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "6ce7491183bc05f0abfa38f0768080b2f27bc2e6c228ab587acb811875dcb3a5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "start_char_idx": 278, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f6596c0-3509-47a2-904a-106f888325a6": {"__data__": {"id_": "4f6596c0-3509-47a2-904a-106f888325a6", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e75d737c-eb85-4a67-b088-6dac5a057775", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8de00db33c930a255ae898f126f5129aeeb358b436cfd9675d157e01b244f759", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0e76304-23bd-41e4-a2cd-29730b0dae13", "node_type": "1", "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments. ", "original_text": "LLC  Q \nYeah. "}, "hash": "320da8d5753307546aaa78ffa1aa82be6ee84271a5d76415643cf87ae8fe288a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 605, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0e76304-23bd-41e4-a2cd-29730b0dae13": {"__data__": {"id_": "b0e76304-23bd-41e4-a2cd-29730b0dae13", "embedding": null, "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments. ", "original_text": "LLC  Q \nYeah. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f6596c0-3509-47a2-904a-106f888325a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8257900e8bb33917bc8effce37a578879263e1c18540bd228461a6e36cb938da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb70b871-2c25-4f3f-a920-227c43c4d404", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. ", "original_text": "Thanks for taking the question. "}, "hash": "1d5e9605167042712c904952b291b4ab4d786b4c412168faf0b46dbf9665702b", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 914, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb70b871-2c25-4f3f-a920-227c43c4d404": {"__data__": {"id_": "eb70b871-2c25-4f3f-a920-227c43c4d404", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. ", "original_text": "Thanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0e76304-23bd-41e4-a2cd-29730b0dae13", "node_type": "1", "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments. ", "original_text": "LLC  Q \nYeah. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dace9b110107c69de78229428ae707b20f447b1fbbfa237779bc41e4bbd862e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60a551fb-28c3-4819-88d6-bf36073c715b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there? ", "original_text": "Wanted to ask about the Prescription Technology Solutions. "}, "hash": "d468d26b580a86ff71c757a987e319be9ae568303ab38cf95d7468c7953b1c66", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 928, "end_char_idx": 960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60a551fb-28c3-4819-88d6-bf36073c715b": {"__data__": {"id_": "60a551fb-28c3-4819-88d6-bf36073c715b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there? ", "original_text": "Wanted to ask about the Prescription Technology Solutions. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb70b871-2c25-4f3f-a920-227c43c4d404", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. ", "original_text": "Thanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cf3df51127aee7a1df25700361753ee4a32206b695fa51ca45f50f0caec4863", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9648df9-7289-4b1e-94a8-014f567ed508", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though. ", "original_text": "I recall the \ncomments about demand is strong, and you continue to make investments. "}, "hash": "7032e59c5a595fe136192167cb9cf30db39463a4f8420953a76d44a2b04f7a9c", "class_name": "RelatedNodeInfo"}}, "text": "Wanted to ask about the Prescription Technology Solutions. ", "start_char_idx": 960, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9648df9-7289-4b1e-94a8-014f567ed508": {"__data__": {"id_": "d9648df9-7289-4b1e-94a8-014f567ed508", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though. ", "original_text": "I recall the \ncomments about demand is strong, and you continue to make investments. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60a551fb-28c3-4819-88d6-bf36073c715b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there? ", "original_text": "Wanted to ask about the Prescription Technology Solutions. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75e1b8694d2d5995a93e19497f93332e02a1e3c069423943e1add70958d12ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff23e906-603e-4704-810e-7bf40f95b091", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n ", "original_text": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. "}, "hash": "724701f548734d64fb8a6c37d8f57cccb1903a9801e1d7f6f7cd2ef9278b296d", "class_name": "RelatedNodeInfo"}}, "text": "I recall the \ncomments about demand is strong, and you continue to make investments. ", "start_char_idx": 1019, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff23e906-603e-4704-810e-7bf40f95b091": {"__data__": {"id_": "ff23e906-603e-4704-810e-7bf40f95b091", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n ", "original_text": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9648df9-7289-4b1e-94a8-014f567ed508", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though. ", "original_text": "I recall the \ncomments about demand is strong, and you continue to make investments. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e235559be54bdf1093f6c9395719db3caec43361fa74b3d99a50845d32fcbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31208c53-ad50-48c8-8750-2091cd789c2c", "node_type": "1", "metadata": {"window": "Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I might have missed it, but can you just mention \nwhat's happening there? "}, "hash": "5ab0182529b3badc20236fd868028c2ef4fc16730a900aee86e5edff183dfd16", "class_name": "RelatedNodeInfo"}}, "text": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. ", "start_char_idx": 1104, "end_char_idx": 1208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31208c53-ad50-48c8-8750-2091cd789c2c": {"__data__": {"id_": "31208c53-ad50-48c8-8750-2091cd789c2c", "embedding": null, "metadata": {"window": "Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I might have missed it, but can you just mention \nwhat's happening there? ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff23e906-603e-4704-810e-7bf40f95b091", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n ", "original_text": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5610cb1ca497094dff1913dbc858faadf52e1835ef4feff458c113a9eda8a07b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95747fac-5bf5-44e1-947a-6bd677a3325e", "node_type": "1", "metadata": {"window": "I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that. ", "original_text": "Obviously, it looks like the op income guidance is up though. "}, "hash": "d118f17d4a21dfbec3339d9bc8973b4c2a8aaa26b2ebbb288d385c8253a324da", "class_name": "RelatedNodeInfo"}}, "text": "I might have missed it, but can you just mention \nwhat's happening there? ", "start_char_idx": 1208, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95747fac-5bf5-44e1-947a-6bd677a3325e": {"__data__": {"id_": "95747fac-5bf5-44e1-947a-6bd677a3325e", "embedding": null, "metadata": {"window": "I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that. ", "original_text": "Obviously, it looks like the op income guidance is up though. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31208c53-ad50-48c8-8750-2091cd789c2c", "node_type": "1", "metadata": {"window": "Wanted to ask about the Prescription Technology Solutions.  I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I might have missed it, but can you just mention \nwhat's happening there? ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbd7162303eea01722e7a976313d72deb1f0bf89b2b6856abb796ee18856bd29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e00ec034-b256-47b4-8ae3-08bec3d0b376", "node_type": "1", "metadata": {"window": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment. ", "original_text": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n "}, "hash": "a989177d8f5243d6aa7a54680dc2aba82045731102d261cc3ed9c3f8c67ba671", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, it looks like the op income guidance is up though. ", "start_char_idx": 1282, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e00ec034-b256-47b4-8ae3-08bec3d0b376": {"__data__": {"id_": "e00ec034-b256-47b4-8ae3-08bec3d0b376", "embedding": null, "metadata": {"window": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment. ", "original_text": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95747fac-5bf5-44e1-947a-6bd677a3325e", "node_type": "1", "metadata": {"window": "I recall the \ncomments about demand is strong, and you continue to make investments.  And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that. ", "original_text": "Obviously, it looks like the op income guidance is up though. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3edea9ce94e98112564421b2d4da174de43cff7c57d9bdad51177a11b6995c05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5443a84-fb97-4ceb-95ee-35cd1ac5ea8c", "node_type": "1", "metadata": {"window": "I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "562d7af49b23a2687c75d07c3ec7899e84a9b228dc46001c0fe867a0cba7ef35", "class_name": "RelatedNodeInfo"}}, "text": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n ", "start_char_idx": 1344, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5443a84-fb97-4ceb-95ee-35cd1ac5ea8c": {"__data__": {"id_": "d5443a84-fb97-4ceb-95ee-35cd1ac5ea8c", "embedding": null, "metadata": {"window": "I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e00ec034-b256-47b4-8ae3-08bec3d0b376", "node_type": "1", "metadata": {"window": "And I guess looking at the guidance \nthough, looks like the revenue growth though is a little bit down.  I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment. ", "original_text": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "374cbd8cc826d113fc9ceb2ebcdf7cf96fe8c08f255a6c4ff7fc0401ac380f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c55a7763-4a39-4d0d-a869-ba239b2dc89b", "node_type": "1", "metadata": {"window": "Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong. ", "original_text": "A \nYeah, I'm happy to do that. "}, "hash": "d56b35364fc99e894b0e148e9bd4fa26f72f7fa2026a8ece5b58d7bb76ad1367", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1406, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c55a7763-4a39-4d0d-a869-ba239b2dc89b": {"__data__": {"id_": "c55a7763-4a39-4d0d-a869-ba239b2dc89b", "embedding": null, "metadata": {"window": "Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong. ", "original_text": "A \nYeah, I'm happy to do that. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5443a84-fb97-4ceb-95ee-35cd1ac5ea8c", "node_type": "1", "metadata": {"window": "I might have missed it, but can you just mention \nwhat's happening there?  Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4ddebb9a7834d25e7ed5545ea33c1ac592dbd7eb242babc42c9d5f49f134573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c928566-1139-4ef3-b738-74df3b0e0601", "node_type": "1", "metadata": {"window": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. ", "original_text": "We're very pleased with the performance in the segment. "}, "hash": "798f2d24b3aa10a96b4228dfd3336c00d440a13526ae8bebaf94f3bdc02dcdff", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, I'm happy to do that. ", "start_char_idx": 1763, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c928566-1139-4ef3-b738-74df3b0e0601": {"__data__": {"id_": "3c928566-1139-4ef3-b738-74df3b0e0601", "embedding": null, "metadata": {"window": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. ", "original_text": "We're very pleased with the performance in the segment. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c55a7763-4a39-4d0d-a869-ba239b2dc89b", "node_type": "1", "metadata": {"window": "Obviously, it looks like the op income guidance is up though.  Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong. ", "original_text": "A \nYeah, I'm happy to do that. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "638f9ac0349d2ef9abcd59778d92b81953b3806c2ba0511707ff63e34f4669ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f9d9284-e03c-43f9-93ce-f7a5814c80bf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n", "original_text": "Brian talked about some of \nour s olutions. "}, "hash": "b22f226a290d4219ecf80fe2a5afcf484514a0537defb61140a37fa9ab101a48", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased with the performance in the segment. ", "start_char_idx": 1794, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f9d9284-e03c-43f9-93ce-f7a5814c80bf": {"__data__": {"id_": "2f9d9284-e03c-43f9-93ce-f7a5814c80bf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n", "original_text": "Brian talked about some of \nour s olutions. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c928566-1139-4ef3-b738-74df3b0e0601", "node_type": "1", "metadata": {"window": "Just \u2013 if you could just \nmaybe clarify that a little bit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. ", "original_text": "We're very pleased with the performance in the segment. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99d9a92550ce40403c841a8d5b3c10f1cd3fcb78c8f85c8e958af0413cd60959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6f1b965-a615-418a-b9fa-ec6f509da753", "node_type": "1", "metadata": {"window": "A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. ", "original_text": "Our affordability solutions growth has been quite strong. "}, "hash": "56aade2588a5120fd3204cae619da23b008b17f960aadcf875b789d95150a1cc", "class_name": "RelatedNodeInfo"}}, "text": "Brian talked about some of \nour s olutions. ", "start_char_idx": 1850, "end_char_idx": 1894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6f1b965-a615-418a-b9fa-ec6f509da753": {"__data__": {"id_": "b6f1b965-a615-418a-b9fa-ec6f509da753", "embedding": null, "metadata": {"window": "A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. ", "original_text": "Our affordability solutions growth has been quite strong. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f9d9284-e03c-43f9-93ce-f7a5814c80bf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n", "original_text": "Brian talked about some of \nour s olutions. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d079d65ca779e7a97619164b4f7ba39530ed576c0a4f46fd753626b0114d5e7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81de230e-67a6-4a7a-bef2-6bdb62a01019", "node_type": "1", "metadata": {"window": "We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n ", "original_text": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. "}, "hash": "5e9f4f439ddba22e3ac7b199dab8fd36528fb794ab4a2e008cf9a7bf10138e44", "class_name": "RelatedNodeInfo"}}, "text": "Our affordability solutions growth has been quite strong. ", "start_char_idx": 1894, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81de230e-67a6-4a7a-bef2-6bdb62a01019": {"__data__": {"id_": "81de230e-67a6-4a7a-bef2-6bdb62a01019", "embedding": null, "metadata": {"window": "We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n ", "original_text": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6f1b965-a615-418a-b9fa-ec6f509da753", "node_type": "1", "metadata": {"window": "A \nYeah, I'm happy to do that.  We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. ", "original_text": "Our affordability solutions growth has been quite strong. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "757a8330d03b78698f3de0d6d3d3f3c4f95bbb90acf0df0b01c4db91425ddc9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f6515e9-ff0a-4c74-ab5f-52618b45d4ba", "node_type": "1", "metadata": {"window": "Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n"}, "hash": "c0fca1cfe44276aca7f79ace6439ebdf587c7ccf3b9518f01703f82ad6526c5e", "class_name": "RelatedNodeInfo"}}, "text": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. ", "start_char_idx": 1952, "end_char_idx": 2064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f6515e9-ff0a-4c74-ab5f-52618b45d4ba": {"__data__": {"id_": "3f6515e9-ff0a-4c74-ab5f-52618b45d4ba", "embedding": null, "metadata": {"window": "Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81de230e-67a6-4a7a-bef2-6bdb62a01019", "node_type": "1", "metadata": {"window": "We're very pleased with the performance in the segment.  Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n ", "original_text": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fc014d4a8f5e38bd76e8b61989e8c151f5935eaa93cd35f3bdb8e441c936675", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a461b597-b15c-446b-b237-491e89d9ef0e", "node_type": "1", "metadata": {"window": "Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. ", "original_text": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. "}, "hash": "75dd386bb53e806317d5930510fe9439b3df83aa13a0ae0f9f6c190956f174ea", "class_name": "RelatedNodeInfo"}}, "text": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n", "start_char_idx": 2064, "end_char_idx": 2209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a461b597-b15c-446b-b237-491e89d9ef0e": {"__data__": {"id_": "a461b597-b15c-446b-b237-491e89d9ef0e", "embedding": null, "metadata": {"window": "Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. ", "original_text": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f6515e9-ff0a-4c74-ab5f-52618b45d4ba", "node_type": "1", "metadata": {"window": "Brian talked about some of \nour s olutions.  Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fca1aeb04295e5ec7eba5134072ab0c5e32a797bb75c16e867c5bd146c895f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8b6b8da-4b0f-4a6b-a7c6-73b6ef1b030f", "node_type": "1", "metadata": {"window": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n ", "original_text": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n "}, "hash": "05028b23b94d41fce94ad770f24283ed735d30f524e6886d2b86c746b0413c89", "class_name": "RelatedNodeInfo"}}, "text": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. ", "start_char_idx": 2209, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8b6b8da-4b0f-4a6b-a7c6-73b6ef1b030f": {"__data__": {"id_": "b8b6b8da-4b0f-4a6b-a7c6-73b6ef1b030f", "embedding": null, "metadata": {"window": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n ", "original_text": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a461b597-b15c-446b-b237-491e89d9ef0e", "node_type": "1", "metadata": {"window": "Our affordability solutions growth has been quite strong.  When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. ", "original_text": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d645fba616a43903fdd63d951bf562140ae3513b354df69075509f70eb3a8a11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24a0928a-e58f-469c-b6db-f0940086196c", "node_type": "1", "metadata": {"window": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "19e48f971f49276e90e7dcdceccfc88badf9eeebdc9251e7624564e92f276aab", "class_name": "RelatedNodeInfo"}}, "text": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n ", "start_char_idx": 2342, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24a0928a-e58f-469c-b6db-f0940086196c": {"__data__": {"id_": "24a0928a-e58f-469c-b6db-f0940086196c", "embedding": null, "metadata": {"window": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8b6b8da-4b0f-4a6b-a7c6-73b6ef1b030f", "node_type": "1", "metadata": {"window": "When you look at the revenue and the \nmargin guidance versus our first quarter, that is purely a result of mix.  And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n ", "original_text": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3d2cc9a7474778c3627628fe29cbeaa44b4c31e5716be861e0f6b5217ff22db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3acd5945-1f17-4b8b-9378-28701c9540f6", "node_type": "1", "metadata": {"window": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n ", "original_text": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. "}, "hash": "1752e8b7cd9178889d3e08f308692a6cc0642275fc876535847c41b6b89c634c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2460, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3acd5945-1f17-4b8b-9378-28701c9540f6": {"__data__": {"id_": "3acd5945-1f17-4b8b-9378-28701c9540f6", "embedding": null, "metadata": {"window": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n ", "original_text": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24a0928a-e58f-469c-b6db-f0940086196c", "node_type": "1", "metadata": {"window": "And so we would expect that our mix would \nbe better as the year goes on and t hat has a slight impact on the top line for certain products.  \n \n So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7634231dc334a0c4d6da939b83adfed4f7a3a0acf79efc6cff65ba8ae3050da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "776ee46f-569e-4ca5-8094-400f8cd40e49", "node_type": "1", "metadata": {"window": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n "}, "hash": "92b1849170c58aec0a86e4a833ecd11590e6e35f75dedb86b0042f6363150b05", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. ", "start_char_idx": 2801, "end_char_idx": 2963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "776ee46f-569e-4ca5-8094-400f8cd40e49": {"__data__": {"id_": "776ee46f-569e-4ca5-8094-400f8cd40e49", "embedding": null, "metadata": {"window": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3acd5945-1f17-4b8b-9378-28701c9540f6", "node_type": "1", "metadata": {"window": "So that is a function of mix, but overall we're very pleased to be able to raise the guidance of profitability within \nthat segment.  And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n ", "original_text": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f98f7b3d122b5e55a6f6aaaf890959ee49563689f91cf13e2b95b6f96b8cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9af32a6-223a-4e7f-8a52-83dd516da29a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. "}, "hash": "cfcd3579d8aa0586eaebfb88a45c8ea899fc1d2e8b9252d22681e992a44a35d3", "class_name": "RelatedNodeInfo"}}, "text": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n ", "start_char_idx": 2963, "end_char_idx": 3053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9af32a6-223a-4e7f-8a52-83dd516da29a": {"__data__": {"id_": "f9af32a6-223a-4e7f-8a52-83dd516da29a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "776ee46f-569e-4ca5-8094-400f8cd40e49", "node_type": "1", "metadata": {"window": "And that kind of fits with what we've been focused on, which is these higher growth, higher margin \nopportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3aa5cfd24ea2f5ff98684b3a8ecbc17bfbf3fcc2ebcd51eb5af5525e8a5d9d1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "087fe0ac-52cd-44a7-9cf3-c0b26e635d28", "node_type": "1", "metadata": {"window": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. ", "original_text": "We have time for one more question, please.  \n "}, "hash": "07e22e46530bd40b3b25b0465296193df8088012964208f7f78aac50d1c64be1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "start_char_idx": 3053, "end_char_idx": 3396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "087fe0ac-52cd-44a7-9cf3-c0b26e635d28": {"__data__": {"id_": "087fe0ac-52cd-44a7-9cf3-c0b26e635d28", "embedding": null, "metadata": {"window": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. ", "original_text": "We have time for one more question, please.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9af32a6-223a-4e7f-8a52-83dd516da29a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96304f8c304c97ed061ad0398589cecbc18ae9f62ed0bb058439bfabd9542e1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6ed249a-f2fd-4820-8340-17665559fdba", "node_type": "1", "metadata": {"window": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "92143d6cd2740ccf8251d75b51da014ef2d3b076e95894cf297947d11958b337", "class_name": "RelatedNodeInfo"}}, "text": "We have time for one more question, please.  \n ", "start_char_idx": 3396, "end_char_idx": 3443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6ed249a-f2fd-4820-8340-17665559fdba": {"__data__": {"id_": "c6ed249a-f2fd-4820-8340-17665559fdba", "embedding": null, "metadata": {"window": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "087fe0ac-52cd-44a7-9cf3-c0b26e635d28", "node_type": "1", "metadata": {"window": "A \nYeah, I think the key is \u2013 the margin profile of the products and the services themselves is very stable, if not \nimproving, but the mix is a pure mix effect.  And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. ", "original_text": "We have time for one more question, please.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "149ae6370e30144bcd7c4995af595509d1632efaa5e070bb8e59fd0e47d5c21b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50844bd4-c826-478a-bdd2-4ec1aa34b25c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n ", "original_text": "And th at question will come from Brian Tanquilut with Jefferies.  \n "}, "hash": "c33d95b44c1b1d536d0dc105aed98c9b21f1f1f478a53665c2811c32362c0a8d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 3443, "end_char_idx": 3739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50844bd4-c826-478a-bdd2-4ec1aa34b25c": {"__data__": {"id_": "50844bd4-c826-478a-bdd2-4ec1aa34b25c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n ", "original_text": "And th at question will come from Brian Tanquilut with Jefferies.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6ed249a-f2fd-4820-8340-17665559fdba", "node_type": "1", "metadata": {"window": "And 3PL tends to be a high revenue, relatively low margin component \nof this business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89fd1c462a4a7d662aa28454d348be1eb32701c8b6a0ce721930e5c580d46509", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f29c23-bf45-49c8-bfbb-fcc910b90dee", "node_type": "1", "metadata": {"window": "We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. "}, "hash": "c73b4225927f112e19e2cc66145fea25184e6b0991b2255d4c3f1df97c8af3bd", "class_name": "RelatedNodeInfo"}}, "text": "And th at question will come from Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 3739, "end_char_idx": 3808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f29c23-bf45-49c8-bfbb-fcc910b90dee": {"__data__": {"id_": "09f29c23-bf45-49c8-bfbb-fcc910b90dee", "embedding": null, "metadata": {"window": "We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50844bd4-c826-478a-bdd2-4ec1aa34b25c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n ", "original_text": "And th at question will come from Brian Tanquilut with Jefferies.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "427fb63dca14f5c0708d1840c8fd9a19ee6c680c987b6d6c72451b4815de12af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e5f6d8-ce82-4d19-a22a-0bc850d4e396", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And congrats on the quarter. "}, "hash": "a2856730f151db205b0f5acb9d527f7465c9dbba57e0fc7d0a38d881acacd524", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. ", "start_char_idx": 3808, "end_char_idx": 4152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e5f6d8-ce82-4d19-a22a-0bc850d4e396": {"__data__": {"id_": "a4e5f6d8-ce82-4d19-a22a-0bc850d4e396", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And congrats on the quarter. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f29c23-bf45-49c8-bfbb-fcc910b90dee", "node_type": "1", "metadata": {"window": "We have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c0ed69dea9ed7ff2b92e36512218844687b8aaff821ebc411ea12a99e41919d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "998c2a0f-f7d6-4b4b-8320-fe3fb09d8729", "node_type": "1", "metadata": {"window": "And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n "}, "hash": "8f894d0fad07becc91ef7fcb23504c8365eac3c210fca102c22aadae1283d895", "class_name": "RelatedNodeInfo"}}, "text": "And congrats on the quarter. ", "start_char_idx": 4152, "end_char_idx": 4181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "998c2a0f-f7d6-4b4b-8320-fe3fb09d8729": {"__data__": {"id_": "998c2a0f-f7d6-4b4b-8320-fe3fb09d8729", "embedding": null, "metadata": {"window": "And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e5f6d8-ce82-4d19-a22a-0bc850d4e396", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And congrats on the quarter. ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1eb62a1e05cd3c41d0a93435f34a3ff866241b4f20202670421b0ee7c2b58fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68ca4f84-708c-4b94-be87-04fbc2133e65", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "778a414d1a6e95d47474a02fc1cf4b6a154b40ee25ef5f27a6910974ff6c9a2a", "class_name": "RelatedNodeInfo"}}, "text": "Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n ", "start_char_idx": 4181, "end_char_idx": 4538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68ca4f84-708c-4b94-be87-04fbc2133e65": {"__data__": {"id_": "68ca4f84-708c-4b94-be87-04fbc2133e65", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89fa598544bf07b996826f0cf1aa050046df2cf9a1025b3f287359b5a201d69", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "998c2a0f-f7d6-4b4b-8320-fe3fb09d8729", "node_type": "1", "metadata": {"window": "And th at question will come from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e77d20a9638be00f6dca9372ea6fc7a477c59942016c9527e05add9cd48f3ba5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d07af774-624c-4fd1-9814-23c8e2885d61", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "McKesson Corp.  "}, "hash": "fe99eefcd23321b056a24ae0340782095e404135eb8bd34c8322b7b2b5789050", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 278, "end_char_idx": 549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d07af774-624c-4fd1-9814-23c8e2885d61": {"__data__": {"id_": "d07af774-624c-4fd1-9814-23c8e2885d61", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68ca4f84-708c-4b94-be87-04fbc2133e65", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon, guys.  And congrats on the quarter.  Brian, just since you touched on the Sarah Cannon \npartnership, just curious if you can maybe walk  us through how you're thinking about how that's going to drive \ngrowth and how strategically it fits going forward and maybe the opportunities to expand that relationship with \nSarah Cannon, given they're one of the largest cancer groups in the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12fff607eb0e5c970d92b481baa3444f6c0a8f697c3d0e9fdd903a12c82a169c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0a67f7f-3301-4d06-b5a5-fbd6b91fb76a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "ab63e7f63e7f5ba8100f61c52194fa348ca2dc1ae5ad5d8de615093077fc0ba3", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0a67f7f-3301-4d06-b5a5-fbd6b91fb76a": {"__data__": {"id_": "d0a67f7f-3301-4d06-b5a5-fbd6b91fb76a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d07af774-624c-4fd1-9814-23c8e2885d61", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b42dccd2be2a5693e4b020bcd7b3348945a0b2d5b8fbe72e938e16b08be06a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55f735b3-f8e0-43f3-a48c-6251319179b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition. ", "original_text": "A \nYeah. "}, "hash": "1a8bc50e812b3ee4ff8ef276d059dcad470747df14229a29d6a31be9ad525ec9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55f735b3-f8e0-43f3-a48c-6251319179b5": {"__data__": {"id_": "55f735b3-f8e0-43f3-a48c-6251319179b5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a67f7f-3301-4d06-b5a5-fbd6b91fb76a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec2815875a824931f4753d4ff9292776f64e43820be5a2fca7940902fa8073d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "221479d8-3d82-4fc9-b3dd-2ecc026d9e9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. ", "original_text": "Sure. "}, "hash": "9a0b02d0f4681a8ef75d9ee4f87f1d555ed3c78e5f4ef96197c08bd71dcf82d3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 250, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "221479d8-3d82-4fc9-b3dd-2ecc026d9e9e": {"__data__": {"id_": "221479d8-3d82-4fc9-b3dd-2ecc026d9e9e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. ", "original_text": "Sure. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55f735b3-f8e0-43f3-a48c-6251319179b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f5a141a0d4fe1468f2a565f4d2533c2c32a64bc4e633cc1f0179fefa24c3d62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "672851b2-1ef4-464c-97fd-febf61a3a3b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n", "original_text": "We're really excited about this. "}, "hash": "443e3a3327c1393795ef593e6337ed3c256c491b1d5dcdf0e7faf848761a6c7d", "class_name": "RelatedNodeInfo"}}, "text": "Sure. ", "start_char_idx": 259, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "672851b2-1ef4-464c-97fd-febf61a3a3b8": {"__data__": {"id_": "672851b2-1ef4-464c-97fd-febf61a3a3b8", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n", "original_text": "We're really excited about this. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "221479d8-3d82-4fc9-b3dd-2ecc026d9e9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. ", "original_text": "Sure. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c27dcc94f64c827978289a24ff7a6bd5f283651dc5483cc07f8f6f99ed9fece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2816714-a8d1-49fb-b6bc-ad04b833266d", "node_type": "1", "metadata": {"window": "A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. ", "original_text": "There were two parts to the acquisition. "}, "hash": "99bf1d17470a3a730e3d96bd6e13f331823d13964a044e0f80a0cce14765d5bb", "class_name": "RelatedNodeInfo"}}, "text": "We're really excited about this. ", "start_char_idx": 265, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2816714-a8d1-49fb-b6bc-ad04b833266d": {"__data__": {"id_": "d2816714-a8d1-49fb-b6bc-ad04b833266d", "embedding": null, "metadata": {"window": "A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. ", "original_text": "There were two parts to the acquisition. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "672851b2-1ef4-464c-97fd-febf61a3a3b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n", "original_text": "We're really excited about this. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68e2176b9f9b46474f6b85ec6664856f7bd1cdf4f18d41f09986d8ab733281a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8e653d0-98b0-4b23-a5b1-a9b1c160268e", "node_type": "1", "metadata": {"window": "Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. ", "original_text": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. "}, "hash": "cbc3bf612022d620daf21dcab9f5ff25f5746b38febb27c09a0e1858b5a44082", "class_name": "RelatedNodeInfo"}}, "text": "There were two parts to the acquisition. ", "start_char_idx": 298, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8e653d0-98b0-4b23-a5b1-a9b1c160268e": {"__data__": {"id_": "e8e653d0-98b0-4b23-a5b1-a9b1c160268e", "embedding": null, "metadata": {"window": "Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. ", "original_text": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2816714-a8d1-49fb-b6bc-ad04b833266d", "node_type": "1", "metadata": {"window": "A \nYeah.  Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. ", "original_text": "There were two parts to the acquisition. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93955d9c4b25df77cbda61eb09ce6d89392ff47d2b67f89c6f6246ac0ff7902f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83d5ccc0-1c04-48bb-b965-ae202b79b888", "node_type": "1", "metadata": {"window": "We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n", "original_text": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n"}, "hash": "a1f299e640f90d0d445789ac1e2b42d07d6b9970813bba708e710be9a5c1d6a1", "class_name": "RelatedNodeInfo"}}, "text": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. ", "start_char_idx": 339, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83d5ccc0-1c04-48bb-b965-ae202b79b888": {"__data__": {"id_": "83d5ccc0-1c04-48bb-b965-ae202b79b888", "embedding": null, "metadata": {"window": "We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n", "original_text": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8e653d0-98b0-4b23-a5b1-a9b1c160268e", "node_type": "1", "metadata": {"window": "Sure.  We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. ", "original_text": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8ddcb64a29fd367c218ad1875fefbbb1ad11603ddecbb71e648988a7a678019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1fe66d9-9751-48e2-84a1-5c55207b2e17", "node_type": "1", "metadata": {"window": "There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace. ", "original_text": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. "}, "hash": "e387a1dab357982b3b167ac88989369b112c8bb93b3e5897c1dce6e7acd7e09e", "class_name": "RelatedNodeInfo"}}, "text": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n", "start_char_idx": 467, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1fe66d9-9751-48e2-84a1-5c55207b2e17": {"__data__": {"id_": "a1fe66d9-9751-48e2-84a1-5c55207b2e17", "embedding": null, "metadata": {"window": "There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace. ", "original_text": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83d5ccc0-1c04-48bb-b965-ae202b79b888", "node_type": "1", "metadata": {"window": "We're really excited about this.  There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n", "original_text": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "860635c43d37262296104ab26750bef97bd567a6d65088adbbad1b31c1ee2a47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a6bd073-8834-432a-ad3c-71f24edaf0e5", "node_type": "1", "metadata": {"window": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n", "original_text": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. "}, "hash": "4b2fe4971e635799d3f43106a8a9f5f18c2c6183565750885b78c2cd78a1632c", "class_name": "RelatedNodeInfo"}}, "text": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. ", "start_char_idx": 587, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a6bd073-8834-432a-ad3c-71f24edaf0e5": {"__data__": {"id_": "1a6bd073-8834-432a-ad3c-71f24edaf0e5", "embedding": null, "metadata": {"window": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n", "original_text": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1fe66d9-9751-48e2-84a1-5c55207b2e17", "node_type": "1", "metadata": {"window": "There were two parts to the acquisition.  The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace. ", "original_text": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d215917b2973085d464265b6d425338b6198395aab4ea7ec97208121dbf32a98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "478dfa71-6906-4a7b-aff5-56a8c7efd476", "node_type": "1", "metadata": {"window": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this. ", "original_text": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n"}, "hash": "89e97045b54bdb56c083e6e412b7b7afe7b00f58080f7ea7bf19c613aef65e71", "class_name": "RelatedNodeInfo"}}, "text": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. ", "start_char_idx": 789, "end_char_idx": 930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "478dfa71-6906-4a7b-aff5-56a8c7efd476": {"__data__": {"id_": "478dfa71-6906-4a7b-aff5-56a8c7efd476", "embedding": null, "metadata": {"window": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this. ", "original_text": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a6bd073-8834-432a-ad3c-71f24edaf0e5", "node_type": "1", "metadata": {"window": "The first is the JV partnership \nwith HCA, which brings Sarah Cannon and you saw organizations togethe r in the first instance.  I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n", "original_text": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "874aa61aa1c19400108458b3489cee535fa3609c318d02a3199ec2aaa65dc778", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2275b3c3-ce90-40fa-bc20-07655cb2710d", "node_type": "1", "metadata": {"window": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n ", "original_text": "And the second component of that was the acquisition of an asset called Genospace. "}, "hash": "f831c0ec268ce2d5178e56935fb1bbc9160a34b5d0cd7089b013b560acc52edf", "class_name": "RelatedNodeInfo"}}, "text": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n", "start_char_idx": 930, "end_char_idx": 1023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2275b3c3-ce90-40fa-bc20-07655cb2710d": {"__data__": {"id_": "2275b3c3-ce90-40fa-bc20-07655cb2710d", "embedding": null, "metadata": {"window": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n ", "original_text": "And the second component of that was the acquisition of an asset called Genospace. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "478dfa71-6906-4a7b-aff5-56a8c7efd476", "node_type": "1", "metadata": {"window": "I'd say they're \nboth really very community provider -facing organizations, both involved in the clinical research.  \n \n We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this. ", "original_text": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27049ad8edf8a61992782560e090772211f0f8386fe484ce3f46f0328d5c6ce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f964c73-514b-420e-a97d-a65e0a9e135a", "node_type": "1", "metadata": {"window": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n"}, "hash": "13b6ee17299e7849b82e991b45627b25b37fd5dedf9a13b3e0667a089485c78c", "class_name": "RelatedNodeInfo"}}, "text": "And the second component of that was the acquisition of an asset called Genospace. ", "start_char_idx": 1023, "end_char_idx": 1106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f964c73-514b-420e-a97d-a65e0a9e135a": {"__data__": {"id_": "0f964c73-514b-420e-a97d-a65e0a9e135a", "embedding": null, "metadata": {"window": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2275b3c3-ce90-40fa-bc20-07655cb2710d", "node_type": "1", "metadata": {"window": "We think that community oncology and bringing the community practices more prominently into clinical trials and \nthe development of new medications is going to be important for overall health outcomes.  So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n ", "original_text": "And the second component of that was the acquisition of an asset called Genospace. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6dd3dfb8dded931413d4e090851c5bf8fc67641dc461670a8b3288ae3153390", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52ae7650-4553-430d-a4bf-ff869250ad5a", "node_type": "1", "metadata": {"window": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "So we're really excited about this. "}, "hash": "207485e98c536322371156717ead1503eefd62e180bc9e3f4e7a5b43f7f3ddbe", "class_name": "RelatedNodeInfo"}}, "text": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n", "start_char_idx": 1106, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52ae7650-4553-430d-a4bf-ff869250ad5a": {"__data__": {"id_": "52ae7650-4553-430d-a4bf-ff869250ad5a", "embedding": null, "metadata": {"window": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "So we're really excited about this. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f964c73-514b-420e-a97d-a65e0a9e135a", "node_type": "1", "metadata": {"window": "So we see tremendous \ncomplementarity across the brands, across the teams, and really across the areas we've each historically \ninvested in.  So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54930a6e59e343eb61efcd443f7c0aa31a3a9bc19fd1f4de43322a4dc8abc167", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "568954f7-f269-41a0-a084-fdaf5d1e6dcf", "node_type": "1", "metadata": {"window": "And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it. ", "original_text": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n "}, "hash": "6ed0d196d6a64cc26fbf32ae8321eb163661943bd8f91c434bcfa155c7910506", "class_name": "RelatedNodeInfo"}}, "text": "So we're really excited about this. ", "start_char_idx": 1412, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "568954f7-f269-41a0-a084-fdaf5d1e6dcf": {"__data__": {"id_": "568954f7-f269-41a0-a084-fdaf5d1e6dcf", "embedding": null, "metadata": {"window": "And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it. ", "original_text": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52ae7650-4553-430d-a4bf-ff869250ad5a", "node_type": "1", "metadata": {"window": "So we're really excited, and we' re excited to be partnered with HCA in this initiative.  \n \n And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "So we're really excited about this. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6a901c6f04e2d9b444789344349ef3a47ea5db5b06e2c280bb33966e8efc412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "109b9966-6f40-404d-a8f6-e43e2a2483bf", "node_type": "1", "metadata": {"window": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "ad791a31bd90302efcceee7e3e803e625a9ade5728f176188fc7ca830a8277ac", "class_name": "RelatedNodeInfo"}}, "text": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n ", "start_char_idx": 1448, "end_char_idx": 1669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "109b9966-6f40-404d-a8f6-e43e2a2483bf": {"__data__": {"id_": "109b9966-6f40-404d-a8f6-e43e2a2483bf", "embedding": null, "metadata": {"window": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "568954f7-f269-41a0-a084-fdaf5d1e6dcf", "node_type": "1", "metadata": {"window": "And the second component of that was the acquisition of an asset called Genospace.  Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it. ", "original_text": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0006b150373bb1139de3881c9bd063f8750fb0b6069021d65f262510dec4e725", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca82a319-7acb-4259-9ebb-3c3d2c34f51b", "node_type": "1", "metadata": {"window": "So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions. ", "original_text": "Okay. "}, "hash": "66049d68f27b2fa622bf20fd58e5ec4e57bd5a9b6f24b2cc540c7c98e138d2c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1669, "end_char_idx": 2011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca82a319-7acb-4259-9ebb-3c3d2c34f51b": {"__data__": {"id_": "ca82a319-7acb-4259-9ebb-3c3d2c34f51b", "embedding": null, "metadata": {"window": "So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions. ", "original_text": "Okay. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "109b9966-6f40-404d-a8f6-e43e2a2483bf", "node_type": "1", "metadata": {"window": "Really think about that as a \ncomplementary data and analytics complement to our other capabilities like Ontada, but this is going to help us do \ntrial matching and recruiting, support clinical decision, support, and really just become another component of this \noncology ecosystem that we talk about.  \n \n So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c1a1fc092ed63355dbe50e776f1bb01b38db491e856967cc3e90c6448eb9a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1f45da3-dbf9-468e-80ab-4bd466e26c00", "node_type": "1", "metadata": {"window": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n", "original_text": "Rachel, that was it. "}, "hash": "3547cb65728c3284b8092f5c55230b38b0eb9f720909fa9b758e5c04c509010e", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 2011, "end_char_idx": 2017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1f45da3-dbf9-468e-80ab-4bd466e26c00": {"__data__": {"id_": "f1f45da3-dbf9-468e-80ab-4bd466e26c00", "embedding": null, "metadata": {"window": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n", "original_text": "Rachel, that was it. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca82a319-7acb-4259-9ebb-3c3d2c34f51b", "node_type": "1", "metadata": {"window": "So we're really excited about this.  We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions. ", "original_text": "Okay. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93cafd746c948143cb22cfba2e8a675c22d984c957bd18ac11b1d0fa4530c84c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "171dca37-abd8-44a0-97a3-1000be3bb074", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter. ", "original_text": "Well, look, let me again say thank you to everybody for taking time to join our call. \n"}, "hash": "7f252ed0bf8b2252a1b9b49718b29c24fdeee08fba15dd1e109a852b192e9932", "class_name": "RelatedNodeInfo"}}, "text": "Rachel, that was it. ", "start_char_idx": 2017, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "171dca37-abd8-44a0-97a3-1000be3bb074": {"__data__": {"id_": "171dca37-abd8-44a0-97a3-1000be3bb074", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter. ", "original_text": "Well, look, let me again say thank you to everybody for taking time to join our call. \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1f45da3-dbf9-468e-80ab-4bd466e26c00", "node_type": "1", "metadata": {"window": "We're obviously still in the phase o f waiting for a regulatory approvals and \npending close, but we're really excited about this and as another important step in building out our community -\nbased oncology ecosystem.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n", "original_text": "Rachel, that was it. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb92c2e3143cbce87bb7003f2290a8c69faad0af57eab91e93b4b165a49f6ba5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f150d0a-8140-4927-8138-e03bf163172e", "node_type": "1", "metadata": {"window": "Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. ", "original_text": "Really appreciate the thoughtful questions. "}, "hash": "ab94e74ab0ae9e2a7b78f534bd33d6f0a928c9a1a05d3b1b63d65032c364248d", "class_name": "RelatedNodeInfo"}}, "text": "Well, look, let me again say thank you to everybody for taking time to join our call. \n", "start_char_idx": 2038, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f150d0a-8140-4927-8138-e03bf163172e": {"__data__": {"id_": "1f150d0a-8140-4927-8138-e03bf163172e", "embedding": null, "metadata": {"window": "Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. ", "original_text": "Really appreciate the thoughtful questions. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "171dca37-abd8-44a0-97a3-1000be3bb074", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter. ", "original_text": "Well, look, let me again say thank you to everybody for taking time to join our call. \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4c24e0ce1362ff790a8eff106e76d3f497d613b7af8bef289867e3eb5a701e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6d4c0be-5393-40b6-a272-2d15ff1e2bd0", "node_type": "1", "metadata": {"window": "Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident. ", "original_text": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n"}, "hash": "fb1e903cb57b50636bf75461270ab64712e9c270fdcd02503198666979645211", "class_name": "RelatedNodeInfo"}}, "text": "Really appreciate the thoughtful questions. ", "start_char_idx": 2125, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6d4c0be-5393-40b6-a272-2d15ff1e2bd0": {"__data__": {"id_": "a6d4c0be-5393-40b6-a272-2d15ff1e2bd0", "embedding": null, "metadata": {"window": "Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident. ", "original_text": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f150d0a-8140-4927-8138-e03bf163172e", "node_type": "1", "metadata": {"window": "Okay.  Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. ", "original_text": "Really appreciate the thoughtful questions. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f49675515fee2190b878dba34d64331767f2ec13990048a45414ca826bcf62f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73bc9066-0a72-4441-864e-c440f05a803e", "node_type": "1", "metadata": {"window": "Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n", "original_text": "I'd just wrap by reiterating, we ha d a really solid first quarter. "}, "hash": "621015c6ab5283311c3a2cf80973dfc7e25c752fea5e03542a86d6fdf311c2a2", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n", "start_char_idx": 2169, "end_char_idx": 2242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73bc9066-0a72-4441-864e-c440f05a803e": {"__data__": {"id_": "73bc9066-0a72-4441-864e-c440f05a803e", "embedding": null, "metadata": {"window": "Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n", "original_text": "I'd just wrap by reiterating, we ha d a really solid first quarter. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6d4c0be-5393-40b6-a272-2d15ff1e2bd0", "node_type": "1", "metadata": {"window": "Rachel, that was it.  Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident. ", "original_text": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58eef482330e5496751444d25f30de19db15b2c2a1a40a2eb702435ef6ee3416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b174f473-1213-45c0-b2ac-27ce5823cc7b", "node_type": "1", "metadata": {"window": "Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. ", "original_text": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. "}, "hash": "3c549717232013874f04646f4d945c6e8780306fb666fd5f962ff4a9af2c1e8e", "class_name": "RelatedNodeInfo"}}, "text": "I'd just wrap by reiterating, we ha d a really solid first quarter. ", "start_char_idx": 2242, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b174f473-1213-45c0-b2ac-27ce5823cc7b": {"__data__": {"id_": "b174f473-1213-45c0-b2ac-27ce5823cc7b", "embedding": null, "metadata": {"window": "Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. ", "original_text": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73bc9066-0a72-4441-864e-c440f05a803e", "node_type": "1", "metadata": {"window": "Well, look, let me again say thank you to everybody for taking time to join our call. \n Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n", "original_text": "I'd just wrap by reiterating, we ha d a really solid first quarter. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f6db03e90bdcc54a21f530b3212f6cbc9c7932e196aca3aed3bce0bbd6ad58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ac23be5-0691-47d9-b088-097430717704", "node_type": "1", "metadata": {"window": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. ", "original_text": "I remain confident. "}, "hash": "a4154c810734f104ee38ace996cbbdc7d81fd0ab0008bca7a3f8bbd3ee4379af", "class_name": "RelatedNodeInfo"}}, "text": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. ", "start_char_idx": 2310, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ac23be5-0691-47d9-b088-097430717704": {"__data__": {"id_": "1ac23be5-0691-47d9-b088-097430717704", "embedding": null, "metadata": {"window": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. ", "original_text": "I remain confident. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b174f473-1213-45c0-b2ac-27ce5823cc7b", "node_type": "1", "metadata": {"window": "Really appreciate the thoughtful questions.  I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. ", "original_text": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d39d6031fe8134a38b3d5673e9f15144ea7236237902e94a6386419b34d8388c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baac0b91-843a-4994-a520-25f504c91cf0", "node_type": "1", "metadata": {"window": "I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again. ", "original_text": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n"}, "hash": "7aefb75b6687d4459f1adeac0893620fa0eea6437f86a78a7f0d9102b8178a57", "class_name": "RelatedNodeInfo"}}, "text": "I remain confident. ", "start_char_idx": 2429, "end_char_idx": 2449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baac0b91-843a-4994-a520-25f504c91cf0": {"__data__": {"id_": "baac0b91-843a-4994-a520-25f504c91cf0", "embedding": null, "metadata": {"window": "I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again. ", "original_text": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac23be5-0691-47d9-b088-097430717704", "node_type": "1", "metadata": {"window": "I want to thank [ph] Justin (52:04) for helping facilitate the call.  \n \n I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. ", "original_text": "I remain confident. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ca748098636a94e587cfee99324b6003b3aad3f9ca4b3e64aa105834269a895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54bd953c-3b4f-428a-9397-01cda48e94b1", "node_type": "1", "metadata": {"window": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n ", "original_text": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. "}, "hash": "b8c848ed8dd6acf4bcaa5ae86f2d0f74b94dae3df779bfc7a4b9a41fcc695ed6", "class_name": "RelatedNodeInfo"}}, "text": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n", "start_char_idx": 2449, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54bd953c-3b4f-428a-9397-01cda48e94b1": {"__data__": {"id_": "54bd953c-3b4f-428a-9397-01cda48e94b1", "embedding": null, "metadata": {"window": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n ", "original_text": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baac0b91-843a-4994-a520-25f504c91cf0", "node_type": "1", "metadata": {"window": "I'd just wrap by reiterating, we ha d a really solid first quarter.  Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again. ", "original_text": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d79431bc2a025a50a55a3ca4be1213d88b778be036578f4f4183fc96ead8d6a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "befa35d5-b0ca-4885-80ae-de55c7d0e32e", "node_type": "1", "metadata": {"window": "I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. "}, "hash": "9647ef5934f2caccad74f6b7d14e724ab5f2112c71a443a4e95c128bd5bfeabf", "class_name": "RelatedNodeInfo"}}, "text": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. ", "start_char_idx": 2635, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "befa35d5-b0ca-4885-80ae-de55c7d0e32e": {"__data__": {"id_": "befa35d5-b0ca-4885-80ae-de55c7d0e32e", "embedding": null, "metadata": {"window": "I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54bd953c-3b4f-428a-9397-01cda48e94b1", "node_type": "1", "metadata": {"window": "Total company revenue and adjusted earnings per \ndiluted share were ahead of our expectations that we laid out in May.  I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n ", "original_text": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7429b6bc868693b729a018475f835d7688eb26c5212c0d716e3b593c1f640d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01ff1200-a053-4f82-ba34-f0026995028f", "node_type": "1", "metadata": {"window": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "Thanks again. "}, "hash": "5d89849f29f3be16b2c0be7e73b7187a38a55db38b9a03f0ca4fd1dfbc7c62ec", "class_name": "RelatedNodeInfo"}}, "text": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. ", "start_char_idx": 2774, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01ff1200-a053-4f82-ba34-f0026995028f": {"__data__": {"id_": "01ff1200-a053-4f82-ba34-f0026995028f", "embedding": null, "metadata": {"window": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "Thanks again. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "befa35d5-b0ca-4885-80ae-de55c7d0e32e", "node_type": "1", "metadata": {"window": "I remain confident.  I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4dc4e90235a2728d5d73c54a58eea3b26e5e83d721985475a75c5ea93891c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b941731c-1af4-4a5c-a3c7-eb4184993ff8", "node_type": "1", "metadata": {"window": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "I hope you all have a terrific evening.  \n "}, "hash": "703cdde892a8be19d260cef480a8dc8629c5b2885fef9228cc6b8aa54e5cf01d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks again. ", "start_char_idx": 2997, "end_char_idx": 3011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b941731c-1af4-4a5c-a3c7-eb4184993ff8": {"__data__": {"id_": "b941731c-1af4-4a5c-a3c7-eb4184993ff8", "embedding": null, "metadata": {"window": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "I hope you all have a terrific evening.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01ff1200-a053-4f82-ba34-f0026995028f", "node_type": "1", "metadata": {"window": "I know Britt shares my \nconfidence in our resilient business model and our ability to d eliver sustainable growth and generate attractive \nshareholder returns in FQ 2023 and beyond.  \n \n I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "Thanks again. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d4d2e239b8239447b114f83509d4ef5640157edec32cf2fe7fdda35d31c672e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2749ece6-977c-43db-9c95-1e5e2aff33e2", "node_type": "1", "metadata": {"window": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "01d465758c2bfa0bc42258e1cbbb654671133218242516148e37f882c9561005", "class_name": "RelatedNodeInfo"}}, "text": "I hope you all have a terrific evening.  \n ", "start_char_idx": 3011, "end_char_idx": 3054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2749ece6-977c-43db-9c95-1e5e2aff33e2": {"__data__": {"id_": "2749ece6-977c-43db-9c95-1e5e2aff33e2", "embedding": null, "metadata": {"window": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b941731c-1af4-4a5c-a3c7-eb4184993ff8", "node_type": "1", "metadata": {"window": "I want to end again by thanking Team McKesson for their unwavering focus and commitment to our vision, to our \nstrategy and to each other.  The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "I hope you all have a terrific evening.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca7b3762a895d6378b1509a5688639960f7d02a62c94cc62b1de1cac2da0e9c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5da79e79-36d5-44d7-9f05-ac256a1bd5bb", "node_type": "1", "metadata": {"window": "Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n "}, "hash": "21e1dc8051aaacc0ebbac411f5a9d08deca070919d130189d21d40faad35a289", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 3054, "end_char_idx": 3386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5da79e79-36d5-44d7-9f05-ac256a1bd5bb": {"__data__": {"id_": "5da79e79-36d5-44d7-9f05-ac256a1bd5bb", "embedding": null, "metadata": {"window": "Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbce563dd0356e7d5483d1b0051f1feb6ade4708d5af9f5a61f04ee4f45617f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2749ece6-977c-43db-9c95-1e5e2aff33e2", "node_type": "1", "metadata": {"window": "The support of a strong and dedicated team is the powerful driving force that helps \nMcKesson transform itself into a diversified healthcare services company and make a meaningful difference for all \nthe patients we serve.  Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd6524fe6a622ff021129a6f9cbd9cf02f9877175284a1a3023c708cf31344f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d430f65-b1d6-4684-a33e-d8c8282a3389", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  "}, "hash": "d13ae7904f2f25d1f7f02ba882927c80da110739d4367907998f426608e8f8b5", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day.  \n \n \n \n \n \n ", "start_char_idx": 3386, "end_char_idx": 3444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d430f65-b1d6-4684-a33e-d8c8282a3389": {"__data__": {"id_": "8d430f65-b1d6-4684-a33e-d8c8282a3389", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5da79e79-36d5-44d7-9f05-ac256a1bd5bb", "node_type": "1", "metadata": {"window": "Thanks again.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "525c3e5f0926a74e1166cca32f0def55984d289bcc6c6dbfed78b67b1793a331", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e86fe58a-1d5c-46db-b4a5-df6ceb10bedf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "1969e69bdf9a4d83be8d0c79d716ab9c757d9fbc3929da0b66c2ef7fb4d41acf", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e86fe58a-1d5c-46db-b4a5-df6ceb10bedf": {"__data__": {"id_": "e86fe58a-1d5c-46db-b4a5-df6ceb10bedf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d430f65-b1d6-4684-a33e-d8c8282a3389", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "868df53ee3260cc65cbf1bd66e9faae828be014ef83a8e05defd32bff0cb6584", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098e8225-81bd-4d13-8cf6-e6e41319659c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "0ddebfe8d8999ba7c3ef254daeaf8ae9b88127400e0eb9c3b2f6a4f20a52b7f6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098e8225-81bd-4d13-8cf6-e6e41319659c": {"__data__": {"id_": "098e8225-81bd-4d13-8cf6-e6e41319659c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e86fe58a-1d5c-46db-b4a5-df6ceb10bedf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e642ac319775e04ebea583853a8658e5364259b8323db36d8a87f17a95d49e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f289b4f9-6fc4-460a-8231-dc5eb450a973", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "e950cd7000423485f86ea411ad955158df5a604200fcaeb5cf18e9aa4e9fb24e", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 400, "end_char_idx": 522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f289b4f9-6fc4-460a-8231-dc5eb450a973": {"__data__": {"id_": "f289b4f9-6fc4-460a-8231-dc5eb450a973", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098e8225-81bd-4d13-8cf6-e6e41319659c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7225bcbc27e3618a23d34938cd83cc7a74ea84e99741b11666e252550f8cbd50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32beb916-24ba-4b50-86f4-6cd08bbfad93", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. ", "original_text": "It should not be construed as advic e designed to meet the particular investment needs of any investor. "}, "hash": "6eabb0ab66402f022adbe0d0b4a8bfbab0fa2b69a227d842060d4f270e8adce2", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 522, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32beb916-24ba-4b50-86f4-6cd08bbfad93": {"__data__": {"id_": "32beb916-24ba-4b50-86f4-6cd08bbfad93", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. ", "original_text": "It should not be construed as advic e designed to meet the particular investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f289b4f9-6fc4-460a-8231-dc5eb450a973", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f1bacb11db59b4411167f3508767b740c60b941948885ab445c4a9914c49455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "680ee8a4-7c2a-464e-a4f7-1afc99e822e7", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. "}, "hash": "ba7494370c574e479f3eea3d184e1c0782507655c9d25eb235083b4326d101ef", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advic e designed to meet the particular investment needs of any investor. ", "start_char_idx": 815, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "680ee8a4-7c2a-464e-a4f7-1afc99e822e7": {"__data__": {"id_": "680ee8a4-7c2a-464e-a4f7-1afc99e822e7", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32beb916-24ba-4b50-86f4-6cd08bbfad93", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. ", "original_text": "It should not be construed as advic e designed to meet the particular investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba5ff7fb6507f0a37d10f6112649fcb8d6d844cbbf070c0a245e7be02f10da87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926ffa77-8d28-43c8-b4bd-ee8e1138fa1b", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "e2793ec8b186a262a802addee0b1ec3dd871340486cbe7909b76fe5fad1728ec", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 919, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926ffa77-8d28-43c8-b4bd-ee8e1138fa1b": {"__data__": {"id_": "926ffa77-8d28-43c8-b4bd-ee8e1138fa1b", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "680ee8a4-7c2a-464e-a4f7-1afc99e822e7", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf4fe5cee32bc59b59d6f1a5512a0091c7d0008d5b6860e6f6b1a3a5d928646b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c1c48a9-31cd-4651-8b3e-1801abed0bb6", "node_type": "1", "metadata": {"window": "It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. "}, "hash": "5ae5a69f7c4fa1b0cbb4ffc16c56844be715fb2c101e4227c5550d629904bc3e", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1178, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c1c48a9-31cd-4651-8b3e-1801abed0bb6": {"__data__": {"id_": "1c1c48a9-31cd-4651-8b3e-1801abed0bb6", "embedding": null, "metadata": {"window": "It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926ffa77-8d28-43c8-b4bd-ee8e1138fa1b", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bcbb305ce1ad49ed9654e26b9f1c65626627cb8982386b66a850f600eadfc3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bff86f8-8b8c-4095-b1ec-ec542ab75298", "node_type": "1", "metadata": {"window": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "0d1108e68250198a24f652b3ea193d1880b18c3a443432e9ad20845eff1fafd3", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. ", "start_char_idx": 1262, "end_char_idx": 1391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bff86f8-8b8c-4095-b1ec-ec542ab75298": {"__data__": {"id_": "3bff86f8-8b8c-4095-b1ec-ec542ab75298", "embedding": null, "metadata": {"window": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c1c48a9-31cd-4651-8b3e-1801abed0bb6", "node_type": "1", "metadata": {"window": "It should not be construed as advic e designed to meet the particular investment needs of any investor.  This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9056a8bee46238f75c1e6d0baf4127b083dc8cf2d5a475acd2452e6173ea97a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9c5f4fb-69d0-48f7-9fc6-b3c532ae8276", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "5968be8054685bf6224f31e83c8c1a463ddce991e0398c1fab55fa2f37311922", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 1391, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9c5f4fb-69d0-48f7-9fc6-b3c532ae8276": {"__data__": {"id_": "e9c5f4fb-69d0-48f7-9fc6-b3c532ae8276", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bff86f8-8b8c-4095-b1ec-ec542ab75298", "node_type": "1", "metadata": {"window": "This report is published solely for information purposes,  and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security  in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac60d1c0f082ae3c4b970e85c798b8582f5b777425bd08e32ef3970ea854b73a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea15c294-c572-47c3-9470-2d9e0ec7bbb6", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "8a04908d3d0811f11f146230030f937d7f30cea3d2a67e4fc41453130ffdb4c4", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1554, "end_char_idx": 1988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea15c294-c572-47c3-9470-2d9e0ec7bbb6": {"__data__": {"id_": "ea15c294-c572-47c3-9470-2d9e0ec7bbb6", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9c5f4fb-69d0-48f7-9fc6-b3c532ae8276", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e71649f9d88017434665cf976320519133d0a0548434d7b9fb0880077c3e706", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20f3c70f-36ae-4b9b-986a-c4845235b0e5", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "51e9df51adabc2c86814b82479a02d6569b6d78385e96fc31b584d5958514146", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 1988, "end_char_idx": 2667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20f3c70f-36ae-4b9b-986a-c4845235b0e5": {"__data__": {"id_": "20f3c70f-36ae-4b9b-986a-c4845235b0e5", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea15c294-c572-47c3-9470-2d9e0ec7bbb6", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of Fact Set \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8f51a44e019d7452f006e22f21ba075c59076aea808b9feeaac7b913183901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf6672a9-267d-4204-82fe-8ca4666954ef", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective compa nies. "}, "hash": "8f9d56b01b65527cf1bd4d8161b831c6566698bca43a500609bfad98142756a3", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2667, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf6672a9-267d-4204-82fe-8ca4666954ef": {"__data__": {"id_": "cf6672a9-267d-4204-82fe-8ca4666954ef", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective compa nies. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20f3c70f-36ae-4b9b-986a-c4845235b0e5", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbf405fc2b7bd67fbcbbbfd4950584cfe81b9ab523d37dddeac837a070aec9a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc57bfb7-50db-4070-871e-06afee1ebb56", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "148753f4fb1597d8fbf7bfe494ec8c938854e4748506f3f779d94c17a5e1cd58", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective compa nies. ", "start_char_idx": 2856, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc57bfb7-50db-4070-871e-06afee1ebb56": {"__data__": {"id_": "fc57bfb7-50db-4070-871e-06afee1ebb56", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "473fdb53-3cb8-4ae1-94b3-659842909edd", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "597f456257a4cde03dc1998ad80c24ee36fa891de4c8b1befe81e9a6cacea634", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf6672a9-267d-4204-82fe-8ca4666954ef", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIA TES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR  MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective compa nies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective compa nies. ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f4f9e981aadfda58531c37d6c21a22a9b31d71781715050cf0d240fa28f195b", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2935, "end_char_idx": 2957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"9d4fc53e-3c13-46e0-9782-a90f84a5c1ce": {"doc_hash": "ae3630d726d51e2db068ab7e7c61008a29b4bd4fd05b3da4038ea33d8f31c132", "ref_doc_id": "699dc1f6-bb15-4f76-9596-032d9c39cc28"}, "77136ac7-589c-443f-96f9-408ba599318b": {"doc_hash": "03109078aa3cba534280368282026cd94784b39cbc9e137c1f6d9e6fefb9bcb5", "ref_doc_id": "699dc1f6-bb15-4f76-9596-032d9c39cc28"}, "cf1f2fd1-4861-44b9-bbef-b7590a1e9984": {"doc_hash": "052feb0c4fb96a647d0c427d7065f4abea57610744e27025eafe8da66cecd367", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "cbd3740d-040a-4bda-b9f5-045f9755491a": {"doc_hash": "9370f6eb4fb44c5ed1f1a667fffe2e338c1f376314142070853358e22978af67", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "9485fb9e-8ec8-420d-a88d-6c7cd1a5bf9f": {"doc_hash": "105c5a314b2f5a4dc07d52e2d517e259c56caef6c354cd7850c5b88069cbc8e7", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "9147c473-bbdd-4656-a290-0f8f9cf6897f": {"doc_hash": "466a2d701bb9765907e6e5e28c439316eac3ab4a2129c2c0380c9cb9a6a3f2b2", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "5e348e8c-4782-4360-bb9f-6feba1216947": {"doc_hash": "8af8f6014c6c8bd9f3ce6a3cff2d0ff78dcb78276fde04529f4fc0c782ef25ef", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "93dd1fe7-5ee6-4d9a-b7db-e73e08a3ca2f": {"doc_hash": "18214eee6d06483af7477d922bca31d4466ea552392cc10b4465e68502fe8ca3", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "7ee80233-7a3d-48d1-863b-77289928fcb7": {"doc_hash": "316d9272b8b9932def2f03d57c43694ce4b25878b0ca65ca74c5a4e3e8290381", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "68b4430a-09df-4785-91bb-1ca7d2d97133": {"doc_hash": "f316d5e86943036b0a049bc9778b306e2aa713e37fa66ea41333eb7aa671249c", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "ab165856-0427-4286-bcaf-b129280bcf6b": {"doc_hash": "08cba5b5a82955401b3bdba81860941242d5100823723ffcec7a8fe2b686c485", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "c7fc95fc-df68-40ad-9960-8d30256d96b8": {"doc_hash": "e6ae263c2a1d80f6ff75c04b728605c00666362df59d616eb0ad8c8c020d4bea", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "80fcf69b-e66b-48b3-8a84-0324ff9c947a": {"doc_hash": "d73a7c097c777cd7446459f5ea66e30999b9f7e71592b631e2e4abbe7a98e17d", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "fed2e32d-a66c-4510-ac2c-91fabe5509f8": {"doc_hash": "280b8a43ff6165e76afc5bb6e7339e261ada084e0d8bda28c4ac88871c626a52", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "3f611f65-a3e7-475b-b1da-27785f85f965": {"doc_hash": "cea1fbf992d2a684b9ad330b2936bf2d0e34cb6005c7f5d2867a9fb585da7285", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "bdb043cc-acae-4bf3-ae61-1002785768f5": {"doc_hash": "d0761c078c733f69dfa2fe9f91e0c9784d71f0833beb3e6fab0a8e812f338499", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "e1ef161e-f04e-4b59-888a-b3fc1322f02a": {"doc_hash": "e4dcd3b2b337f20bf1effa0572061f7cfd596512b4b4511283ded2da2b8a276d", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "399256c1-cb60-4c23-88fa-0463a6b8a707": {"doc_hash": "2da60aa7a07f6e3f4512a92488e8bff95f471afd1f0f3ff4a353a51a65eb7f9b", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "6bf3fdae-5d3f-4b82-851b-a16f389407c4": {"doc_hash": "d8a08c006b68c90b33718e4cf7353d6df3bebce41c77741f70bcd1455d867b13", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "bbc009a4-7521-48c7-ab5b-49c26eca61bf": {"doc_hash": "ef992ceaa50f0f5a4a8211b47483af186e23c00c2cd3bf60d2f177cc731d27ba", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "8931bbfb-2721-4e70-b72d-d5e35c3692e0": {"doc_hash": "eee8ff1aef3969693b2cecfa2bec893d572aa7676e6097c1a6ff47fc16dcc5f7", "ref_doc_id": "befcd309-db1e-435f-b504-7c23466eec88"}, "11f55e55-b28a-410b-90b7-0227853b6d3f": {"doc_hash": "e1ded761053bcbf169c1871d10623fb1ac618ee95e7d73f36bb94e0f65dfb911", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "19114e22-1a19-4c3d-be4f-f5e2a0bbf8c6": {"doc_hash": "ca0d99845c1fb2331561b627457b357aff4191c240b3a74ae7acbdb34eec794e", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "bc403d46-426f-445a-a7f9-098ef6674364": {"doc_hash": "a96eabd297cd89ecd7ff6e57f625fa996b15a8388bf3f62e902388e872b424ea", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "e67d6c5a-170c-4c1d-9c1b-d2f241e054b4": {"doc_hash": "c9e0bbbcc9388b3b7a1723f7a8931ee3904d0a951d9899861cca9ed7ad260fa8", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "837c9bf5-2e5e-4cc6-9852-6875b53b87fb": {"doc_hash": "c9016b03c8b08bf9c7803eee88cec66612864787e5e5db36b22c3ec5e1fb57cd", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "44af2634-1c56-4852-99bd-2d777e66cb1a": {"doc_hash": "30a8092a7d1c417490a997da803dc457ace4a85bd646f80da130fca1103d919b", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "185d9c6c-0e72-42dd-a86e-3f82994d4992": {"doc_hash": "70d82cd2998dd63c439afd9ac6598daead5c9853a15662db21efa02c68715557", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "68514a8d-6d59-4538-a280-0785e612e1e9": {"doc_hash": "496b43b0a29ef033bac65d0936e0df273beafee046bdc3efa7eff1efdd06aaa7", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "3db40648-6700-4b59-8e9d-c8ae7703b506": {"doc_hash": "26047f89d1519cd48f7cb65b93e6e99f42c03bfe7c2989963e23dff8a1ad603a", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "80f25cc6-56cf-48af-aa49-59448247f9b1": {"doc_hash": "654e7b7b0be9e6228db114a1fa5d688d1ed682cb7140de7f64078fafd660a5ff", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "fb61f033-a0d2-4a75-9af4-43d583124139": {"doc_hash": "15f53612ef930f17714afaa73b4aeab42fec1c8b4b14cdccfc546feaf301e8ac", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "a75a7b6c-4c88-4e17-8267-c4eff571078b": {"doc_hash": "c32e6a2e17683a99b7a27ce5742fd29d45db7384eb6839df3b2efc486664ba22", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "e5b6ecec-f02e-4111-8dee-43791015d65b": {"doc_hash": "7f55a5b5849b9b24f41e5656a7d34bb1982e4de2280763e998e8391667c81b01", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "d547a3b3-37ed-430e-a3ed-0652f7de5987": {"doc_hash": "454a6e97f7eec6b4e076ec8275a8fa0bb0d7fe273d1edbd696ccd10316930cf3", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "6123132d-dd7e-4933-b9ee-912cc0d1a9c0": {"doc_hash": "4ce2d361e04c485e4298df919bfc3b1b2a138e1278728b8fe11d470131c86e7a", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "7ba592a0-2f9d-459c-b59b-424118ac9456": {"doc_hash": "6ab2e9e719088951c973e041825417e55ee5d07b1cd9af46f1135913ea3963c8", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "1a5523cb-3158-4c3b-ae53-09e230663013": {"doc_hash": "b331b5c1349f5bdff01c1ec7248658c808935a9e591584f2d5dc3d54f15d2380", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "65f35672-2e6f-42c0-b433-69df81107a10": {"doc_hash": "e46f4db421e57e3606bb333ef85b85ca3062855d9de45cb07a59f65645238086", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "533b090b-7cc2-44ac-b4a6-6127c9c19858": {"doc_hash": "a6699ad8fd52e5d7c61ddbb142534e3282441dd0be2cfcebc5fe21a1b111729e", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "63ac8c72-5510-4295-81c2-2bd1344ed2f2": {"doc_hash": "a3294c1e4db0c9c99a1d9112edbde3c03b212aaa1bea21f2859f9402c7579467", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "8a84099e-db3b-4dc1-92c7-46aec4b80118": {"doc_hash": "78513922d96aaa23957fac361ebf5c29d010ca61287a649d948f20ab4f1f87da", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "d9dc5178-5548-46a3-8da3-153882d73f23": {"doc_hash": "5b627ac433aa483bf7bcc75cb115d805d7bb89c72f8d3b94e77197f27aa7162a", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "68a624e7-2e93-479e-a194-bf74799a2af4": {"doc_hash": "0d4c83b72c1aab1580fb7266d3b95ac299a18b0525930a2a7d359d85659c9c4c", "ref_doc_id": "06bd177f-568f-45f6-a36c-6651eb0ec69e"}, "023b6cb2-bfa5-4bf1-8f79-a9761ec0682f": {"doc_hash": "31fd19207d084493cbbdfb8a597843f1bc632a86f46fa0a45793184128932e66", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "d0e62999-b7fe-42ff-a87f-c4e75aeba6b8": {"doc_hash": "e6124691341bc0142e14b8b28208e1622a9c0a42a5154f29d753183ac3e36140", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "36e2ef85-0b32-49c3-a5f3-3220904da5df": {"doc_hash": "d9fe3ebc64d69970c77e433f243c85a582c59de71e9ce525e11a1cdefa9c5300", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "c366bf7a-fb37-47e9-a3e5-1f5f86df74bf": {"doc_hash": "b9ade177b70167f51a972fa10eb1354c3d76b65abb5d5c04915c155c5264bac3", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "75895686-a0bc-4dbf-bdce-20e23786592f": {"doc_hash": "1e1a88bf8cc290de81504e47303eb7633f1aa226ae06cc6837a013370f147bbc", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "9c6022db-b147-4a01-9339-2f0313b7e4f5": {"doc_hash": "5dc7813806853e453b036c23331d822323040ad9b348117c89c0093e473ce404", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "efa1d6f0-2da9-43be-97b5-2f88390806bd": {"doc_hash": "bf4d92be2ce56f66f3825187c2a1391fcfef945fb6f74adc99eb013f266c3c87", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "8965e000-ea66-4421-a02b-d5162cbd34f3": {"doc_hash": "3279b187d72451f92d2fd575b97a9cad19d6fe3f04cebaa33685d5a1160f9f6f", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "306ae602-2cfc-41bb-980b-16609204522c": {"doc_hash": "2774b0ee25c48e54ee22394d7778316516b2e69d8adea29bb33a7435ef044e9b", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "fd337223-95ad-48d6-9ef7-42ec1b9d0ba7": {"doc_hash": "dfaa6c7e5fc9893a402b8e080bb286eb1210a3502cc48a069a44b3e1b3325923", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "ad4eda19-6634-43e2-bae7-e775bbf01cad": {"doc_hash": "f5359496d3d3694741bb2a084533d170808f8ec73fcd9c5dc81435c230e1cbc2", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "c79061c9-477d-4427-bab9-6c91d84173df": {"doc_hash": "2a698d8258474cc476c3c68b2ed4bd5a11e006eef7643959d85faefbff942ccb", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "eb33b505-d82b-4c55-990c-7d153cb9f477": {"doc_hash": "89864f360b82d9ee5b1368755e4bb9ccf3dd3a169b51c3b3da8e64013a31ab1f", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "670c85c1-1615-497c-869f-81dc26bffa1a": {"doc_hash": "a264dede33884f3d1cbb134bf4425e22826eaa9e8540382b6ddc0793d492a10d", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "a85679b1-cccf-42c8-8a8f-b0bbc095260f": {"doc_hash": "597eb3e04d96e72fc1f9c5db00644ab726e9bae6c85ea88711b7793bef5a64d5", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "019d0934-aa0a-4015-be8b-db21b9a28d8f": {"doc_hash": "3501bc8bb018e1572df6c55c369e07b43bfd16335f0da5ab9fc6150cf3bc091a", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "f2167ffd-37ad-423f-a863-6f87c8b80486": {"doc_hash": "79b28743a5d197a0f86fa59f1313d1d4db05e4c1e500c44967f091ce210f1069", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "d67204fa-54cf-4452-8124-301c0327151e": {"doc_hash": "e768593a0fb6933ab4b058d13cb6e873720bdbe869bf03768d4e7684996dcf03", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "98467f6b-e6a1-45c6-ad80-42ec5cf474c1": {"doc_hash": "3b2d1e5ac3f004d262b338dbf931a282d62190fa02561993ecf4f4d6a2df3544", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "b6f6d21f-12ea-40d7-9a22-3b182b08a4f5": {"doc_hash": "f19be960efb42b42b4955f90c3a884ab0c718443223c7486e271ff60fddde5fb", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "78a6bb53-5c9c-40ac-ad5b-94a6a019ac8c": {"doc_hash": "150904a9860aa59bd13296ef84b5f52a16ba9595890c2f939de2f1c56ce1143b", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "73182dc2-7644-42a0-9654-d3f1cbc43100": {"doc_hash": "2d2c227ff353e329a38cad9bf06ea4034bb77ca3ab611055c3c3f34b7ef26ae0", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "cba4d94a-df3a-41b8-b33c-e108217cae72": {"doc_hash": "6917c7f7080df8244c8592f5509f73c3f6fe98c245c27e8646745022e23f6aed", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "cc232171-0890-4b7d-8134-d3ee6e05b419": {"doc_hash": "b6199b713a4a70be24c34b373e410f8f9c8751c9a41f864e9a335d76a07d9638", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "a62a0587-b65a-4ad4-9abd-f1042605b8ec": {"doc_hash": "2dab07e15c795eda9420b6ca05cb90f68ee43d16ee9a36667c37dfada11f060d", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "174b2df9-e099-4211-ace4-ba57daa0e9f5": {"doc_hash": "aeb03609c29b8adf43c046f1fd830f64c61cf40b86f2da906d337cf0dd755db8", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "5eb6739c-bf4a-4707-b49e-50870f38bc5f": {"doc_hash": "6ccf2fdd46280360761ac7dbac87dc20573f39feb6d418b60d6f765818abf78b", "ref_doc_id": "16503e65-3ea3-4ec1-b853-6b98b4a65332"}, "828bcf49-3c8f-4eb8-99b6-3b811d87ec7e": {"doc_hash": "bdfbedc505c7550ae962efb376092cd5d9dc14376353e147d9ecbbeef2cb91fa", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "9683624b-4fec-4f16-88e0-da107bce3540": {"doc_hash": "10555fb3a5416334182cf6d935fb5d6daab705fbbaba6a12e5c6b89a23de451e", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "5fb117ce-5126-480c-9022-a36eb13d954e": {"doc_hash": "faed3c1abae9a129ac0aef5eb908870ee19883d2be4be046ed2b3b13ac1891c4", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "09d53872-5256-47f5-b048-c7ef6bf74d70": {"doc_hash": "03ec083da695cd1601781f966fcefeba5a59df0ec1cf16bf6d4cee8811637e87", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "9eaba3b9-009d-4cce-b7b1-12eccdcdb052": {"doc_hash": "7580cf4ba5baeb6c1fc10e37a3c521513aa72f0a42082f8da9513f9089d4e8bd", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "fe4af4a8-24db-456b-81d8-61fdd1fdae34": {"doc_hash": "8243d6104c4f9456746b41b6d36f12232d614ccfbf08e1068ae26f5a12438032", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "05e95049-ed59-486f-a7e6-44cea189deab": {"doc_hash": "149231fb633988a7ad44eecde9bf6db7455a87a8d60ed67d05b555d274326743", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "622434c9-071e-4ff9-aa2b-da3b4230aea7": {"doc_hash": "8c732c76136156eba1dda106d28c06b8983b5789efd4c0fb678dcf3d4fe989f0", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "47e0b962-1ff1-4969-a911-4db2cba6f4be": {"doc_hash": "1c878e45d7339dad66581ef38cfb162745abec1f04e3800f0f4822e6dc052303", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "297848d1-8949-4952-808c-65a70d8ed085": {"doc_hash": "5822620e6b99b7fb1587d481cd637c90e4af3e1c7f544672f3a9c8dd2dd46c75", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "0dbe34db-b60a-42d5-bf46-a053eb10be66": {"doc_hash": "8cdc7d56c6d1088c4b39959a7f7526f7298b979edce74fea01d89343ac5094e1", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "d4dfa8ed-5f14-411e-b586-46e2b512f948": {"doc_hash": "e64defd4ccc396ca0c9811a2ddea26d004ab8c759021cf6c515247650c04e3b9", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "a77c429a-ba69-4a81-994c-8ccb146bbfa5": {"doc_hash": "9575ea19d65dd5eafc9a0bead829a054eb729ee9369998fc494148adc3400ec1", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "e8685035-4f3f-41ac-a5a1-43418f5aa75e": {"doc_hash": "033f4a5ef6804240a0391ba811e33c73dc7e1ff24057c95c2c5d7954c80fd83f", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "fcc51e60-cc80-4d48-b946-a790aa65938a": {"doc_hash": "ed06b90967cf17f61c60792d03ac602f09ab6746f1bc74e6e85ddc02174a2885", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "ab097267-e0b3-4830-8467-6405848d9600": {"doc_hash": "d7668503f3c6dd7760f6dff6e9e5fba3b1c7d74380d1ed05f1bbddf9708c77ea", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "d8b07528-d3a7-4fe1-b182-404cf9a42398": {"doc_hash": "a86f9b7172ffa06c513d56288382614d943fca4fdd6ef284f229084539311d12", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "836a9f1d-fe94-4d59-8585-5e5b86007088": {"doc_hash": "a7761efd6dc77a06859b446c066a340f85dac406092b56f3eaa91935555d70d2", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "117fc85c-f11a-4c3f-9519-3e20486cbfd0": {"doc_hash": "94d6c7595a3d9b3791b4557b4b41cee6f94ba4756c8d380e4135bdb875c15d64", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "278d2b06-10e4-4389-b25e-348cfbbb28d1": {"doc_hash": "420c8c31888063bec46c0cb636a5c4a361259199f417a27483313af05e66a31b", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "dcb91b59-3e23-4a17-b475-c8f52ad7a3ab": {"doc_hash": "87b2f683007ba899db141f9d9789b7c166c8f6ed43f2d04e1e6452b86ed0f76c", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "f5025615-6ff1-4be4-b5be-68c0c57a9975": {"doc_hash": "c4d08f244d1858d5343a16945070ce7aa73e15be7940481fd35035e1c7de8d73", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "790d32c0-a7c5-4250-bb1f-c80f44129cff": {"doc_hash": "a259d593efa8204babbbdd566b6876e071f942df5968d13502fa226d5349470b", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "7fad3459-1921-4838-8d6c-02b1d09bde6c": {"doc_hash": "0324b5af4d8e90dd0b03e5da405359b3ab833d4b0a0d3c331b12f96e71bb74fe", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "38d98624-dd10-4f13-b0da-b0080978e474": {"doc_hash": "4518e1f575da921b21c795c125600cc4478c92c1b49599f5cc2b24143e2258ac", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "cd59befa-21b0-4735-8786-09c9cd8b29cb": {"doc_hash": "3c8626e41eca88fca11aa8b176890d1b6a4c751530c6fb4070baac8a7a0572c0", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "c7d47f5d-ba6e-4777-9a5a-a4c88896eb95": {"doc_hash": "26f78003157e0898c5fe69d0ca8e3091697452047e5cf21f1d04d506693423df", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "c3b452bc-227b-4dea-b57c-5bb7b75045ea": {"doc_hash": "4221ee389c158f2893670b40e9170516ef522c1b3c0a5b380392edab683a57ac", "ref_doc_id": "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa"}, "9f2aa3e8-3e65-4e17-9207-e3bc2c298fc8": {"doc_hash": "e2d89c709501e61ca6757fba2f13a4868b9c44e310ad736ab514ca30feffa76f", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "e734cdfa-1023-4e61-8af1-13e8d1c442be": {"doc_hash": "90d404b0ccebdfce389d8a846d2e05fc40278ceac470a9efc2afb209397937f9", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "b8247678-97a0-4131-ac6b-3e54d9b0f0f2": {"doc_hash": "bcec5579978cb10797e109af494bff02486a8dc88096233a58df0388d99b6915", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "e2b8040e-9f23-4302-acc3-dae612791244": {"doc_hash": "2eedf80adb71dc1cf73a0449ab148d1f7bc6132de3d42292e4eb9409a3558ed1", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "46e48568-a4b0-43f2-9ba3-0773c11c520f": {"doc_hash": "c592a3fefc512e9efe84f37a9160befaba3aae5391609ed362469bc221ccd8ae", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "b034b5e0-870f-4ac9-b6f5-7ce038427953": {"doc_hash": "c9205ffa5462b3dd69880cd4765831aec236b0302d7e7f2b531106140095ee18", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "59c9c593-2b1a-4576-b8b2-972b04762429": {"doc_hash": "c8d98801341bed3e4a266dbfddfe1dd75dcffadffeff41448ceeab37e40fdf58", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "235b920b-2d50-48dc-a44f-be7d700bb772": {"doc_hash": "d928335c4bc8b5e951e0182da340b42ab7475c75be2fa4ed159cc13a53bfcfb0", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "699c2272-1739-4cfd-bbdb-fcaa7b650556": {"doc_hash": "29a39977fcf525d3baf5f77f8e933bea8950db169cb027ce2bc7974712dc63c5", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "5986007f-b30c-4e11-880d-1d7ac8581cb2": {"doc_hash": "9c88995a97e276204b7d9677a19c2104e274a9a378ad2e2860554d7bce751748", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "4b4deed6-de40-4e1d-a4bd-1e55e7b162b0": {"doc_hash": "6afb08c7e1c3eee237c2eed2b0ca221311a1b8de243b8a676d9cc379b372a63b", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "1f7e3cc9-4ccd-468e-997b-b6176907d07b": {"doc_hash": "6bd4963f573f5f5a62cf02475a9bd738b57cc9c092a0211f59f9b5b69e641d09", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "bccbeeb9-17fb-4022-ae6f-98b74369c773": {"doc_hash": "6ccd160f69ef3401cad8720a6234869abe1c9cd0c12f7ccaca89260bf7298e35", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "6d1d55f3-dfee-414e-884e-f2299638372f": {"doc_hash": "08f825f97144d761ff0f7cf4c82d72e8c5762ad3c1f9f9c9ae94f7c94ac1dc91", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "26265ea8-e69b-4e6d-9383-4611c27120fa": {"doc_hash": "6dd6f62d991ad6399e81916c3ebf769ec6e92655dc487e7e5a7d7835f825b6f6", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "c10f8c20-f4d4-474e-a917-ecb9eeff97e9": {"doc_hash": "80c2604fda68acdef5dc030c6e9d8799fce25b37fa05e809ec93cfeaa2889763", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "ebe7f705-527b-421b-8d3f-0caf05317b60": {"doc_hash": "4280c78520ed89bb19471d3bb92bd50afd49ee4ea5cb7ba19c0b116b9e21aa91", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "612fc3a8-afb1-4675-a25c-c66a0c8c1510": {"doc_hash": "05f9d39e5dad85da359b4e8c5bd0aedce6bb9e0333a80741f2c370589086064e", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "79ca684a-7c3d-4f50-bed5-a61dc90ff398": {"doc_hash": "ec62640838a6f812d3da3d2f542b450f6a7a1d424f967f7a2567adf0c3e44c40", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "65b7502b-036d-46f7-a832-84ad3be1086a": {"doc_hash": "e5655ccc352800c46032083f993750407310da2dc3a2ccc5dc72b657a40bf682", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "59ff8e31-a4f7-48b1-912b-5198e4f3e73e": {"doc_hash": "d4e3fe6f35d52a3e63cd6fcbee21153d0a94481d1d9f17ae4ea72162a334885f", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "277644bc-5d78-4391-979b-90f89aa3c32c": {"doc_hash": "f258b0ede6e48022f18d1330d9f2566d2e9d23b39c2c513f258684bb56fe42b7", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "f09b6d7b-16cb-4fb9-9034-7b861fb31d25": {"doc_hash": "de9520a38d948767e2fb1b1e5392f8e1c19d288dbfa46f9f33283290f8b24d9a", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "ff858c9f-ecb4-4584-86ab-0525c7273aff": {"doc_hash": "4fb293243b48420ed7133d1577762c312e902ca3434390dd3a5135fe27f28b64", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "d04067ce-1aff-4a6a-9726-1019a9b4a05c": {"doc_hash": "8a5177e693750b44aad2e3be769e573cc5195dc513c880e43370642000c1d67c", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "1256cb6e-bb0e-44da-86d5-5a2a3186f545": {"doc_hash": "bdfc13b3aa4ed95aa6975552f0301ed20f52ff2e8fbe4086ad5c82e55ec1a8a2", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "e6de39b9-d334-42d4-9164-72259947c89e": {"doc_hash": "416a1e01e1003bf3e8c0e90ff8188e8b9f18cf18f5eac81798e9ea106af4df8f", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "fc1c4220-7f1e-4715-8e64-ee7d7918840e": {"doc_hash": "a03d240283d20dc737a6bc80e9fc12c7c7ac867c0a03ecb349ee4a0cd1e15a5b", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "1a0ce581-819b-43a9-a2a2-0c4cd91e4710": {"doc_hash": "a58f40e8956fd43b20ce116c4ed3f4100c8744969a182f5d5e2576bb0965cfed", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "19ac5f6d-f606-418b-a870-68adf754ea4d": {"doc_hash": "7e086def8e27446fe295eabc185a0ab06f5f58bca8c1e85f1c4a07232b17b2d8", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "7a3ebcac-9b94-42cd-a516-221d8f33eb81": {"doc_hash": "1110a1e03eb3cfe1e382697c54a5268502c38a44707211e02bd7f3c64f1f7e5c", "ref_doc_id": "b2e413e6-6b77-4793-bed9-63c6fcdb07dd"}, "1899a560-4162-4a44-98f7-cb46072067f5": {"doc_hash": "575d8a984a2157e1e29d62aa6f40ba391236f72b67d3719c1d23e32cd1fdd2f0", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "2cb24a6d-3b71-4b91-b4d2-bc6e13d914a6": {"doc_hash": "ca58f5fae9e0a55d37d60399f9814822df4b50a23ee943d556de728bca64c595", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "9892b113-5b2d-407a-a55a-c1b8d8151464": {"doc_hash": "bea597f3a6eef3fe483feeac0dda01d17e1d025ca357578c12bdce72c832c442", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "82156ea0-0724-4dd8-8422-e993de036909": {"doc_hash": "85b85d00ad03b15c63b87040138e4697223f46fd0758ed4ee874c4e94b42a31e", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "acc14f00-422f-4934-ae8a-6ed026c6f38f": {"doc_hash": "0dcc4f73d62a21ac1e0ecc67819e5a4cf135fcd3993b86a12415eaf66bb15911", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "a1d3e2e4-9adc-4b2e-a844-1c0f72d06ee5": {"doc_hash": "d0d5cf9fb5474b3296e696ff3384aeee7c42381809ffb14389e9d2cb05860704", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "f742c09d-4812-435a-8e9b-acccbdfa3c15": {"doc_hash": "cd4677cd4ca55e09bc39244832c4dd4c24593d35568f1932db012a0e6b54bcae", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "e6eebea9-638e-409d-886d-68725f159695": {"doc_hash": "cf908706e4e545bb2d4393cb298c78f70195ac6ce84604083bae98bdc358a3cb", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "75d5c319-ce35-4fee-9c2e-ae1e32ede272": {"doc_hash": "27a5ace098d37f65067badca353a13701c29afa6c0a0200cba541c4f6fefcebc", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "f10a455d-7792-486f-b65b-0b4f8d5bd831": {"doc_hash": "5c12c5f8473ca34b4d769745f3c3e5298af73af48afa0d90431a82a6a1db76d4", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "c627d022-4964-4c72-a9b4-a37048394f38": {"doc_hash": "d346efa7b49f0c0be7b03aaad98e9f7617535f75342795e9965504ce30ab4f32", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "da845238-27c1-456e-89d6-e3dec2cf38e9": {"doc_hash": "f57b0a40575cfe6f69d05f173d462f82abb937a6cd0710f0ca99c91294fc7038", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "7acd228b-f625-43f5-9521-f954c691a534": {"doc_hash": "1c7d69de740775c893545b43a39bf594e12719ff03de08c2605e41b98dc44c60", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "b6756821-2c34-449b-a6f2-6ccb5cdb43bf": {"doc_hash": "25dc325bfb4042c137c48eaa7defc963ca2a6181b8423108d0029f90b97091e3", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "6bf47647-ee3d-4d88-80f6-0aaec72b1991": {"doc_hash": "300a9805394b423560cdc638470018b8697384444483ec5ab1290097c3071b7c", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "70a9bf8e-6e3a-4d96-859e-b0c224a8400d": {"doc_hash": "1ee18f8957b0b23228554123c100820b3e406b4cf4c101f4dc2620e7757045c8", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "3b2a8a11-1844-4e40-99ae-d630baa9c981": {"doc_hash": "3210fd89aedd5231de00fb7abc779c0ad5ef19890408bd4bb8ba90a1cc9703d5", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "e393ee25-ac0b-48cd-9aa4-add91df17604": {"doc_hash": "8ddbb85af0bee8e8134a3071fc6aea15612a493e9fc48cc7a56e58daf5c72b46", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "524a8b8d-2afa-41bf-98c3-9581ad5e4800": {"doc_hash": "f256e771a95edbcf2da1b04e09bd1ff38327a99d20b781a48890faaf00a16f96", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "37fa92ce-943a-45ef-8c6c-a89d901819ab": {"doc_hash": "960f99484270e83ecb8669933489f083435d5b4a9989714bc822096feab537d3", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "8778d622-64dc-420a-8558-db6b9df538fe": {"doc_hash": "99653493fd43d273ae8096c1434679fca401c97a8031b7610d85edae73e35057", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "dfc10eb1-252f-436a-baa5-6026d39e4b2a": {"doc_hash": "1511e50c982b8a15998f8e831aea5c9825277bf8149bbdac25ebb6d727f5e2b5", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "937b3715-4164-44d6-83a0-542ffb9a3f05": {"doc_hash": "e12f54dbd09d8130f167b2218eede3f66763c512a0940b9222480e2fafc0cc3d", "ref_doc_id": "acdd98c6-6563-4a6e-b066-86f581f11c88"}, "9f2b410a-b583-4eb1-ada4-38f690166acd": {"doc_hash": "a2257d1c9d7edf5e9f9c6cc9eaf9167f83c665b39105a9590aa9d78c97f02d98", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "b2a12234-ff10-4715-9e93-e682a8019f96": {"doc_hash": "ba1442227492d3b545a98824949c4fc5acdb403d5dae89687a7a78fe242259cf", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "a8a35de9-ecf4-4e4a-960d-cb8a24669ca6": {"doc_hash": "1afa3dcb20994065193d2e1954d91cc7334ad2e04a4708451e03a13940e698ad", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "efce78af-7fbe-4f52-b86d-5326fff03f29": {"doc_hash": "95f5188205170531b289bcd311feacf771ed9dbaf252acf6b4131dd8c6b3fb4d", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "845d4e4f-72cb-4b19-813b-e0b6df9cb377": {"doc_hash": "8a101b436cfb1b2ac48903b2736b39156ff2ad20af3aa53abaacb1e830f34cf6", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "0d7a094f-1ef7-4fb1-86cf-29dfb09fad97": {"doc_hash": "068948aeb0724d5137928dfd78673544eb15ef320e4a93f1fdd68e7836ef6426", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "435d3427-9414-49d2-a646-a4ca1853d51d": {"doc_hash": "b2243cac61c068647a6654553b06090bfc41c6f7600692fbf92c6a32f8a5ad2c", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "197fca61-c016-4809-b584-5b63291c9e86": {"doc_hash": "ae17ee096788816a7e39daeae7fbbc1234051b43afd272d5c8d2344b29eb409b", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "57ab07d1-cad1-4552-bde7-729c07500c6c": {"doc_hash": "7536242e3c85cf92e402bf583c4421f84c46485509ca7deb1b07aedc9cc36a1b", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "216de203-dc90-402c-9045-57c1be875ffb": {"doc_hash": "f634f495be36228e551dc6e21f239d35e96ac61e0a7381dc3a2b9455b6c50919", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "f0950528-60c1-4172-a17c-fae3513f111b": {"doc_hash": "0e8cea0e7bd6bc41b83a799585179786b5ebe61035db4512a1a6d9809eb27f94", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "dfe07f87-6403-45fb-9ae0-080a27672c62": {"doc_hash": "8c8d9f05c0ccb0acf0b30340e5d133c4e1603808cd799dae930b84419068169e", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "2055d0d8-be83-41ff-a4de-1b0f0aa5e6fb": {"doc_hash": "18a974389b1ff1f00d94dbdee534ac310fa397716212ad6ea954f639bffa4469", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "4d19dcd6-46e5-4217-af45-ef122418c549": {"doc_hash": "2c5067d9222748502a0212e8d18ae1813dd99d52e8c6304a8e8fe4e4139a9793", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "a77dc1f1-6b0f-4562-8837-bd27d8814d45": {"doc_hash": "30d6e6b787bbe778e1ccb5e692c92c72678824051bd1b1c08b7812fab95fe8c3", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "0f563057-2ded-48e7-8892-0339e4355ef3": {"doc_hash": "aa315a172e189a02c505f988df2389c43fb78151c6b657aeb3395f64bcc67f73", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "34dbd582-5ad7-4716-8417-7ed83bbf7acb": {"doc_hash": "d5e23ab125874091c4d99929862bb2aec3a67c42140612de71961e3a3a76d52b", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "7a8b53c3-3d2f-40b6-99fa-b25c0be218b8": {"doc_hash": "4d8b911d772d1b7696769b1b5b39d43c32b03bf82a431fae4f32999b300d6406", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "b5f3ec4f-e172-408f-9de5-c2476d3b3034": {"doc_hash": "42f9baca300bfc4d44fb4004f194036d0f4000057978b7228d155ccdc3d7440f", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "8a539cf1-12ee-4a83-9693-309d5cd4ad5c": {"doc_hash": "5c81960792f293be79dab8ec00ed162ed5c4561a055792937c7d29b509d6f4be", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "7c9c3f27-fcdf-469b-9510-1ba20b63f70d": {"doc_hash": "441988a79ef021ed4c4e7ec6db5a496d95a3e31b9674a94b7540e7705bfab5ba", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "1a5f685e-083d-4bcc-b5ad-869205e48092": {"doc_hash": "9c0c7a216890481f86637e2c145b7cdbe882b4066325f558abc76239849f3ac3", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "50e4a36f-8cb7-482f-bfa0-01ff9a483b45": {"doc_hash": "006db2d1834fbc082ce2f0e23524d9f436603d574937863524aa81762ce552f7", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "73fa310e-a499-4926-af74-ad9456ea9f46": {"doc_hash": "e33b08d89634b519c706a6c466bca7223b4b69bc66756671f633dcffa5af4d43", "ref_doc_id": "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4"}, "7a57d1ad-16b3-435d-a8e5-44d22bc493b0": {"doc_hash": "d9471f28fc82109d169b971080f19dbc06c481ea960de8a8acbe323808008619", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "1b635ece-64a4-4ccc-be95-17e1ef3d557d": {"doc_hash": "0095c5b65415ff204e80c07bc44d97072276166cfa629876d80ac22b65b97b60", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "dc1afb08-5ede-484b-be20-202066a03e9f": {"doc_hash": "98515f8f01b76781a5244a3cc6e1205e1667907957900a2a77d8d23c13d22099", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "f627ce10-2aef-42ba-8773-a4d994248e50": {"doc_hash": "8135d4406d57742b89eca77630da856aed82f6e2bffe2e0b827c51ae4bf40ccb", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "85dc9ee2-c492-430a-852a-d1d07364954e": {"doc_hash": "99a380c4f0fa3828814ba2bbe5b957f8c08dea30b7d39a599a71a071888a9586", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "7bc9011e-2767-4063-b7d8-144b98bb2830": {"doc_hash": "823cb997c5b45dec67e0a00838d3e5717fd710253fdca449e44623a8797d7a17", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "0eb1a97f-c35f-4628-a3ff-416e5d27d779": {"doc_hash": "6f418fa3cd3d9dab5209008923a278b4343ed25185266e7e381bb0a169590f4b", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "980d3633-9b27-42ef-bc6d-f99e2db6b61c": {"doc_hash": "cb4e70ecfe6bebb8c407b56680a01e3ea8855aae94f9e4d3bc5619e8bd9aaa43", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "b332e1a4-83a6-40d0-b5d2-1b7688189df3": {"doc_hash": "f72bf401eba9764cc04b88728008177b12e52a3e9a98b47fc97b2a84148e89ed", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "e5adc672-7b0b-4972-8f9e-7c8305828ff9": {"doc_hash": "4939129a05898288d8deb4064c88ce2d763f61eaeb746e6eae5e1a7759503271", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "66485863-969c-47e2-8375-b8718ce44dc5": {"doc_hash": "87d9f2bdc705e0899285ba5e8a863d5ffa3cd6c1b1d0599cb849c2dce91ac3a9", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "5447f708-183d-4d94-91aa-99be4622ef48": {"doc_hash": "36d3cc83fd23fdf52b9e67e1a1ac548ced9593bc2fe2c67e724037d97bade289", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "417c575b-c7a6-42e0-9e61-5e5a195aa80c": {"doc_hash": "8b1698e76abeac5da97ea585c084eb9ad866f10688d36e889c17095d7cbf18d5", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "3eb3a48b-63c0-45e0-80ca-b1a547c70ca3": {"doc_hash": "d2f7fde27fd343d8c1a694ec854dbe52473cb9fccbf1faa5dcebdddb4933ee19", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "690b3f22-014b-4d1a-8174-ffd7185765bc": {"doc_hash": "791a01dd360ca5ad0de8151c7d8a248c120f2abbd11a86761055abe327968a66", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "61f5eab5-5a05-4af7-bb3e-4f5b6f29870d": {"doc_hash": "9dc9225395ef2779d847e9ffb1450ebaf12775c6deb5c5862c15ca2e9769e895", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "c1426518-3dea-4330-a19b-221685f7266b": {"doc_hash": "d5703b9dd9b1b19ca4e26581a2f1bd9a4024a2977919ac54bafca8ad56473a56", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "ccca91bd-e7dc-43e4-93d8-4ba89dd55254": {"doc_hash": "d73864b8a2d6c9536bb9e478b6572441073072dc494201aad16c718cf2da9d0a", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "d53254db-f586-4b7d-8ef5-3631c4da16c4": {"doc_hash": "fcf8fe47074a69cc367e38219ad8e0cdd99eb71cd5f4cc944abde2f2ddba1593", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "2fb9c586-798d-49de-b2c0-557974056f1c": {"doc_hash": "bf1ede83f83599ee3862f585d888a9430c0ccc4009b0dfb11ed0f36800a0ffde", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "49b8cc77-f0d6-4417-bda7-b4ec623cfedf": {"doc_hash": "83c3be2898e87aab47525e20020378b11552f8fda9ab54785a9ff2b0b29e6018", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "f235ed21-b917-4ca0-a240-c385fd7d8c4d": {"doc_hash": "1194b5751abbb3f0345a7eb21ad13a9e3eb98759f80ef074728afd6870f768b6", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "4be4d90d-dc0c-4576-87f6-8208c3d8a83b": {"doc_hash": "1c93fd30b6fac4cdb2f8ba185a6f767f4cff6d1e603c50e5b117605ce6f05dcd", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "2a0bc333-4464-4171-9203-c1cc04b9e2b3": {"doc_hash": "cede09a8a07c235be0fbd8cd36c95c6ab6e299fc7dbca6f0c7ba6744ffd796ed", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "4c85e7fe-3225-490b-9473-1b12a55070d9": {"doc_hash": "fd70a06a4e11c009b88bd6962899078ac754e2834c6233509c010dd4251fc395", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "14adc5c5-3bbf-43d3-b9a1-0b8095bf8bdc": {"doc_hash": "8de3404e2dc5650643b5a8e6a5aebd8833da83c1c1f2000136ff34c3a825925c", "ref_doc_id": "4172e64c-6c9d-43e6-a300-086d5a0a0209"}, "b8593620-175d-46c7-b052-d9bba51cda99": {"doc_hash": "c892eabb740e2d8789ef5a4a79136c504ac9d38b38255eab44822f7c6c12c375", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "a01c12b1-5b24-445f-93e0-9b826509fe71": {"doc_hash": "e96b8902316a679976284577253c85bb9a27b0dc3e41495bae7eb1ea105a6a48", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "6f3fb6f5-9371-4b43-bf66-53adacdc2141": {"doc_hash": "4b8dc8e3e4bea01aadc4d64b1df353305b39c64ab55264180e7e1519da88c245", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "00c2e69a-06f7-4b7e-8058-460d02ad1d69": {"doc_hash": "ca1a5935cb1aadafae330ed3d5b29699497403eca54ea7e9ded0a4d7097e8360", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "523b0679-382e-478f-ab8d-4f7e747debfe": {"doc_hash": "d7b86eec8ed9196ecc2806268577639cecf4827070aaf29def6f7b5171d87918", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "b4567667-42bf-4253-977d-a89361b32779": {"doc_hash": "5ce11e6379deb6ed327049b7e7573c20cc84f690391a0bb05093c35a02b40cd7", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "32e21420-d87e-42d6-971f-577b8bb50c09": {"doc_hash": "e3d32db371b374f92f23d875ac19574a6a60289e33c98dd4572abb0bfc4292aa", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "970f9052-0018-48af-9d56-f0bf1b685ecc": {"doc_hash": "2c8aefbe2abb8aecd31afac7df274a5735d534aef3c9cffb7c5e63a43e42bce4", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "eeffcac5-8152-4d5e-87c8-b1540ea5a7f6": {"doc_hash": "93d17dcf1beaa027c17a82feaebce588068ee70be1a7885feee80f70085830f2", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "146d4ba3-43d7-4e50-a6bc-2b7bcf518407": {"doc_hash": "150034b3b14f5bb6036940cdcc741fcc269e9e1f88080768e3db01599a039317", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "a3c5fc2d-f79a-4927-8fe5-81c192b8f536": {"doc_hash": "7b003d13f6847ad8719e5f0db6a859ca17c6849f63a615e8be7fec5ef50e2743", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "e48558a8-a525-479a-826f-7f72caf61724": {"doc_hash": "82c8da3cb9bdf1645149e9cde9079b23439cf91b6dfdbe21ca94b7723bf58838", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "cd312b3d-55a7-4bab-9243-ea38382edcae": {"doc_hash": "1bf027c63c3a5547a0566ff6e27ef2f1a8e7770aee9c820ed237bc268bb76ba6", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "3fb1dbc8-286c-405e-ae01-533851687a57": {"doc_hash": "4d0a2f3fae241ba577b777b116a0ba25cae30b8b2b30e2c27a5b2a4b03b964d5", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "9248b214-925e-4c61-9ff8-fbf5458be95c": {"doc_hash": "0c2c96a7584f346196da3acec3e539961e992608aaed985f03161918130d7dc2", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "eb2b454d-0217-4d2c-9e3c-d46436320a85": {"doc_hash": "be731c3d64042fb4426527e62f668e2defbd4032bbaa2455081d057acd7e0502", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "3bcfbcb4-b014-41d5-b62f-87da7b78fe47": {"doc_hash": "6c3e96a6647bb7e8dda773fab4f38864e11f3c27635b9eae3ad43c51a4c4ead5", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "166eb00b-1774-40a9-99da-54ac0de7b175": {"doc_hash": "f6355d0583a3931291987cedcdaf2890deb0812af27553e2e9a590201c9bd25f", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "804e60d5-d078-4cfc-8d77-66c10d68e695": {"doc_hash": "ef18863b3786327c069857f47b51e298774722f2a578e8f566f70d382818879f", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "7b15a076-a877-4923-867e-63f1bd864feb": {"doc_hash": "c43fe927ea878a00d031a4b309d9691b5b7ab22bad7d514c4bfd6daab3c79018", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "ed323203-a3b6-4f1a-afff-3a7381e17bff": {"doc_hash": "18cc4cb67d4cadaac6760adb886bf9c0d639eb3b7b5d3fd5888bb35ab90d5419", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "08fbcc77-8224-496d-baef-8aa3f7f12dfd": {"doc_hash": "302bb9e18919493faaaa6dd0ad150cbabb1310321c7e645628104791e8a8cd5c", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "bc0ef75d-53ca-4c21-a065-8fe084813e6b": {"doc_hash": "e0044cbdc099f4f711c9e88b8b5b405f8d733340bbfe7f07e0d38bbed913d112", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "f8e13406-93bd-4639-bb02-2bebbc45b681": {"doc_hash": "fc9ad10242f0984dec71691dee1b72e3aafc94d42cd2954455bd131bc1766a45", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "19892139-7960-4077-baf8-ceabcc8f48b9": {"doc_hash": "f5ccc231089a192864aadad92c2601688e093876619e8a4810e01acb64dcfd6e", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "f7613544-cea7-4715-b080-01f56703a754": {"doc_hash": "da63a32e4cdc55eaf4194d8e4a0c07c73452505cc871077df6d7b3548a2fa276", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "31c1776c-c4f7-4d5a-9ae6-c484e5f941c2": {"doc_hash": "acae369719e3e00624bbbc2ea9878b2882d555f0ddeac0634706c4e060fd6c30", "ref_doc_id": "b2cef74e-6340-49bb-bb57-2c460dfee5d1"}, "9850b72b-0794-401c-89d0-bd810ed8df27": {"doc_hash": "90efc22220304815d610e6322087e6754afed28bd6d29a9b21c2dce9f087f95d", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "f6fd67a6-b87c-4b62-b6fb-f44de75a50e0": {"doc_hash": "9272eaee280a2712fc630453b5a36d18a7a08a7a1226db5cac8c4eca121efcdb", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "cb124faa-ea1d-4ab2-ba40-bd52cbfa1aff": {"doc_hash": "02996d47b7a3e2def3dab69d0f8dc8cf95db2294406808a94a4ab56bcb8e95bd", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "c557e8e1-ec14-49dc-b4f5-b40c25a25f55": {"doc_hash": "54ee6dc4724ec64d4649b464191da576015f02f7a7a2fd11d28d85726bf5a2d5", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "70a1ebe0-7b7f-4b9e-8183-c7e2a37eb66d": {"doc_hash": "091c7d02586483eef974f5794593b162d87c8bab17504f5e81993bb9e1320a38", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "2a12a8bf-26dd-4195-b4f5-bdeb70defb5f": {"doc_hash": "925c57b5825eb91c5ede80057e95a0665df458903e3aa035d11c343a8c8e4b6c", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "ab579a46-c3bc-4ecc-a6ff-4b2ad76e4434": {"doc_hash": "d784af6cfec00f865f0220cdc3bf53fcda7b9252b9f363bbe3e723f23ae747fc", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "0e852c05-30b3-43d0-86fa-5be7100ada2a": {"doc_hash": "92d51d0b0ebbe31cb4ad18efbc4c46adc6cc9e1f8c035dbe2813c2af5137bdc5", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "942b9948-d9af-4b7a-a3bf-4fc9f0a852bd": {"doc_hash": "3996901408e1de0dc81a9e834e40188e03ca3328fe1554cba96b2c8ed024f264", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "2ae8b5c8-09c8-42ee-b627-a769fbd82da7": {"doc_hash": "f6176cc98e58555aba87069436702cd1b8f9b890e587daaeb77eab85da782dcc", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "4fd7a4e6-9c78-4024-8006-75d281692e33": {"doc_hash": "913a1c1b953f12cffece4a97455fd496d7dcb91b4521145db73c00dfe85077ae", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "e199973e-1dbb-44ea-ac15-97ed694d8347": {"doc_hash": "d8cf057451edc3fb718378f2dc72b9ade21881110763096ee5fbcbc37a4fea77", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "9ee7474a-9bd1-4514-aa67-cd3304211d29": {"doc_hash": "da0612f96c699572223417ba20220c7e74f83bac56dfbfe65b4629f69f44e41c", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "cd55764a-041f-43ea-8f17-efcadc6b3c5a": {"doc_hash": "3d4540a4fd5b741f27415d97d46146c9d96d0051548aa654ab109a9741ad9cf5", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "d29805d5-d2f8-48aa-960d-279c69cccdc6": {"doc_hash": "51fcb56e59314f9af1d79cbf266f488c78e0eb611c6887ca64434d897aebe517", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "cc7e915d-9dda-47c3-97dd-a6d1325e2817": {"doc_hash": "867edd34fdb9c6bd829dd5cb165ce62cb0107cb884b020761d1fc2b022d4ebae", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "7035cf63-5521-42ed-8fc3-c6dc93393c05": {"doc_hash": "947618acca21ae0173544a100087d154d2f232fa399902411f78002bf0cad964", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "2744b4a5-8d83-4d52-8259-97e16346baaa": {"doc_hash": "0457bb0daa0300ab24a9f45068d12c5c200b7dc8f69de2ff7d9c9e9c4c33e141", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "93170ee9-a5a9-45d3-b9d3-90c10467f574": {"doc_hash": "8dbd95e3b5e03c4930248ee81fcd7f4f35b897475758b591da690677b02eae15", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "a0054d63-b886-4feb-b2bf-d88ecfb9fad8": {"doc_hash": "b6d2519a988e1bfd6b3639e987e14b8a508d031f343706c43ec94170f6d9585f", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "58e3e786-db30-44a1-a374-eb9d1ad38690": {"doc_hash": "c92ba3e5a46774aeb7fdf483fe3bee6ebd7d20498d9e2e6c53ece9ae6e12020d", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "f5005bc8-ca98-4127-9c77-d6c3e235a943": {"doc_hash": "daccc29cbdff78d13b0ec95a48408a24d136b7bc63c2d90bde9ac704cf8d9d5a", "ref_doc_id": "8bf0574c-99ab-424e-be71-b964b648c234"}, "dc408fa4-995a-48ea-9dc1-1edf55b8ab1b": {"doc_hash": "932c82d889786626c005f714b6f8875e19c389a93dbbae467f5bc30de1378a2d", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "09b6a146-042b-41e6-801c-7e792863f9a2": {"doc_hash": "a3d0cb8c2acab81a01fe04be09671e1df172c4a19c6159e48133ec5058f9e2b8", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "9f06e1a8-38d3-4e57-a9d0-dd859cea4efe": {"doc_hash": "7cf90058dfd69be3690a986d2b7f0a4ca481ef3ec1309c2530b8a7ad0447ebea", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "7777f1de-81bf-4826-9e5f-44e3fadc84f0": {"doc_hash": "05ff1279374a8bfe7ecff8576543a5e9a0888e1c3147a93a53c4a7c089ff98bb", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "1e3ae12f-aead-488b-a9dd-7c758e9fb722": {"doc_hash": "524c1c75bb529aa0c4716ea3d7eb818b0272018ccf15900a4fc62681411ebf3f", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "ee887a18-9f61-4f7d-96e4-eff26a04aaae": {"doc_hash": "39f43a9b8bd3a79149493e6a5e7c46336bce63572edda54f690f393e8da9a2c9", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "37d762d6-8108-4713-a191-9594bfd66277": {"doc_hash": "be00245406d5bdb6bca2f4fb7a0a626dcd122f9b9ab9fa0eba8d121f65393317", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "337e1084-22a3-4ee4-85dc-a80f60fd2cfe": {"doc_hash": "8d8e032ffa3bd2782a2f2f59f46c140c4cb5650f178dca058b2bda23eb5e2a7f", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "83a6836a-35d2-4237-8bdd-8c25d3f529e7": {"doc_hash": "f5ce1a2cce10b6ea31345679ec3c2107a2eead48fcccf857883ba0f594254453", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "afb3ef58-2193-409d-b12e-eb01ce794458": {"doc_hash": "ab4767d9b4d5c69dcd422b6f744f755c3080f6afe1cbe67b78e456ebda7d39cc", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "498bccfa-a0c4-4dd1-b304-36200d51308e": {"doc_hash": "3748d650fc4676149394f2c7b93b438db07c1a6bfb9db8190febd90bf9f5d5c9", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "7e35adc5-f39b-46cb-9d22-7a4fe04106bb": {"doc_hash": "cde06271829d3da8dbd4abfe9eb5c69a692debee38a79ff2d97db548947859a0", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "0c062b31-292f-4ec1-811d-cd5831816429": {"doc_hash": "0cc701cee4c14b09f1c96d8c18c3cffd30c6c8d313a45f5417038b18dbbe2097", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "7d7cbd65-0e68-4425-b4cc-186b6313d676": {"doc_hash": "6c68979a3370ebdd35f5c252e530851c812e7a18fb5cc027ec4a303d22d9dd58", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "a27aec26-3409-4531-8434-b7db57f94d8e": {"doc_hash": "9b1606da5b9d8fc74b5ec36142bc17591c7428b3cb4da2d5749ca03b4ca55bf3", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "0a2e21b7-9321-4ec4-97e4-b92c5104f322": {"doc_hash": "eefbbd5b6d3e3f9d97e0a86efc86db5077731fec6968ff814b4bc7f4cc7adb79", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "fcad8b29-0bac-4c0f-8be7-a5b38b15198f": {"doc_hash": "308f0be2e6cac32c50c451a677538588d4484799097d140f4591eda0956d4a3b", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "00c31910-950f-4573-bfac-1620b959b963": {"doc_hash": "00d16b76a265b8192e37cc7e2fedf2be4b13ede3d0960dfcdd5c2b6e1fc52552", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "3b659ebc-fe60-4fb3-9c2e-f2a26482f027": {"doc_hash": "2e851f3a17899c5cf2380a261ef58b803ba4781061fb14502b7e71059df0a0bf", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "6f3a0bef-cfc3-4349-8cd5-5586b86c5aa2": {"doc_hash": "80eeffcdd6f5875fb4dabec854b8409f21f5a1c5bfba68467acd340008b42f43", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "9e940f77-4cdb-4e9d-af08-c42913b4c402": {"doc_hash": "7785d5c7511a2d852cff6c88153932bf4d42bc9a0a781d010434637e943ed77c", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "9d442ae9-aba3-40aa-8f86-ee746b18780f": {"doc_hash": "892162969f614e761b831840ed44c8da0a0fd46032ae1e641f5d8f9ce8333ee6", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "51ee0bb6-79e7-43b2-b10f-7d9d8198bc44": {"doc_hash": "f29420b688ee7ba78de801cd93ac7ce3626ff6883ea7b8b82067440e6e006786", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "a97add94-b04b-4f0b-82ca-e3a68212611a": {"doc_hash": "c9b4b2ef208e16502c7a1a9c1b67c55341e2e87225d77bd100bd568c5e88ebf0", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "36503a7a-bab1-4a4c-a8a0-e9489f5b2e91": {"doc_hash": "77ecf1b803450f6dbd35d3cf410ffff2fd9508c16c491f186bbc2b4f4c909116", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "865bedc4-f651-4ec9-a5ac-4876e327ad38": {"doc_hash": "16ff89ed046c135e9b236991a305b379964fda2458d724466a50b8010bc919ce", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "b10d6782-6bc7-40c0-a105-ef39e8848f98": {"doc_hash": "9529632e7619e1d0f426f63c6215d6b8ce5e37ac4b431fb131d74ad642cc4f17", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "f7e13ccb-0ecb-4384-b1f8-f8088f1098b7": {"doc_hash": "3a141fc04fb568ac5e79a4c279e61f59e9ae1a6868d4090a264b701284646cb6", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "dc5f88ec-1b59-48ce-b7f8-3ab8fcbb8fc7": {"doc_hash": "04b9002df1d2e3bd3ff369d197f5bb6c70735518286405ffed57652ce3d40e59", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "72d2ac53-2929-48b5-8963-0263132097de": {"doc_hash": "e33594f9219bbcb97955a951f2ab4725a48a9a1d0af8df316a48107ebd6d7859", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "99050864-04fa-490e-97c1-5ba332e92ea8": {"doc_hash": "0118060b185492b5bc3f98f509db859a9bc5190dc89520c189dac61ad7844a3c", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "5cb2097f-2350-401c-97c1-39544deb0ad2": {"doc_hash": "4ec23f4e8028ff1ce20a6627d17b40110611a1bf45cc911eb23573502106ca2a", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "532e37d8-65ab-467f-9edd-5994d2efbde2": {"doc_hash": "ba7a63ce5bded40849c8c72892ddc662ccc36330482a773d4a0afdd310fe6e85", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "cec87931-ab96-477e-a156-69996a26d650": {"doc_hash": "6dc263ebbdf86668a2aab662ad90b7647375f168f6b06abc6d931025230af884", "ref_doc_id": "4518dd85-3f7a-4adc-82f3-27f0920d1a72"}, "874237ae-64c3-4f86-9ce3-cce31348227f": {"doc_hash": "1f13511f5da8c62b7a93bf501a77cd8c1bc555a436a3133e078a55ac542e9cda", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "2908f896-0327-453c-8a2b-b4a9a38161a2": {"doc_hash": "933e8505b82a2deb6b2db280925c105e7d38844cad5834becdd6a845a9256ab6", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "89219999-aca7-4332-8f1d-d43a2821ed14": {"doc_hash": "128211ca4984565ed3e4047810004c0fc79bd7554269f1a1d2a3d07fa7d6fb99", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "250e6ca2-200a-4e20-b10c-63e08b3f632f": {"doc_hash": "f1c49ef8a0d9a8a83ac84f8132fd50dc97deb6629be878ca2187421a415ab999", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "32be5c8a-da6b-4a6e-a7dd-d8129a091024": {"doc_hash": "a80e63806cbbb2743a54181b690730bea70df6a551a2dc91fe67614e19a0c09c", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "83042ad9-ddd8-4693-9338-77c5caf91e5a": {"doc_hash": "e5e5877a16886ca039039ab00a3c8415f122a31df5bc5c8992c620f1758a39bd", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "ad680dcb-5766-46ca-a5c1-b7dde3a9532f": {"doc_hash": "d75b0655352276903e31ce29bd8780b600495afd12feca1832416037985802ad", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "e064b09c-1dd9-4e7b-9ab2-2279e8b83381": {"doc_hash": "afb2458e83bd089f0a85978ffb31887ad2fc734cb484c4e1a6ae86464a36384e", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "50514a46-142a-4b44-b1b8-cdc814b9e50a": {"doc_hash": "1a518e2493e6a512237957880e1305cc3e746bb734b16f94eac2a946ca047524", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "8406f484-1ca4-445e-9dbc-402b3ba607bd": {"doc_hash": "7cd911e6bb77395e70161dc6f6951b78acda88109324643d67a8dbd2724487f8", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "4efb4c2b-8318-47ff-872d-55d01ea39f28": {"doc_hash": "a760fe4236da91be321110ec9b5e7dce180d46a3dced8223521a329700fb47fd", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "238b2569-729e-4fc5-ae1a-ce04afaf2673": {"doc_hash": "e847c2b4609803414b037773659ca25385ab472611326a0bd7b71a0ad707b66d", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "24c3ab10-00b7-4eab-b139-1bbbbadd049e": {"doc_hash": "715b83a44843dd61989e8d844affbe197f3949835add46a9e4b674cfb6fd52e5", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "55dde3ff-aacf-4dc8-9069-369e76a9e056": {"doc_hash": "790916cdd3e34015d30d4ed4ca3e45f246c0d71169c21f79f94921427ff15f63", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "b2a46f91-3662-4d01-8896-5fea931d9924": {"doc_hash": "40116053605c4585e24ec821102201d048b609212f7a7dddc00f829fbc9c9d1b", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "b17a52e6-67e4-47a5-b257-5a3d5cd3c492": {"doc_hash": "840608b1a779a7711f8567e3f19ffd25798fa1130c22b87969521b186a675439", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "424422c0-ce30-4521-81eb-8dab3e5632b8": {"doc_hash": "258e3243d8d5bd455f4230c468aa567d3036846b67301e0cadb980e64a668ca2", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "f73b5f4d-2e72-46f7-92ed-133fa5aee23f": {"doc_hash": "1be44a94af13b6a8d38cf024261f3f1c1b4fb2b6499e7ee5962eee6a76a55d7d", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "de00843a-66c2-4398-9f0b-aa49c7b1cb5d": {"doc_hash": "57c478eda0924e3643ea1bffc2153b3476d67d847547b71068b57a7a0274fab2", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "09209a84-99b6-4de4-99f9-410c2a765054": {"doc_hash": "3f3539721be0353d918e9b5974fe6082e079ba99a4cbd432da9ac76cd9730203", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "39a35fde-471e-483c-aad1-2404c4b5181b": {"doc_hash": "1bbadc241c798be4d954af0d8d65acb81c6af5ae2b51546390e1807dda37b3f2", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "f81bbbf2-e23f-47d4-9347-caa9c9ef659d": {"doc_hash": "9ad321c41bbf1be2fd1ab9fadf0482687c81ee9e4675485cd38daf0acb723ec6", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "ed0ce3c0-0617-4235-bb38-66a57bb126a7": {"doc_hash": "d15b96e8456cfdd36fb1209b880519f14906a810f43df99c416bcccd1aa4354f", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "25903631-0a63-4213-90ea-4d072bae1002": {"doc_hash": "461170fe7e16c29cb9e474d6528f14e499f3b3782cdc4744543bc9b1b0b7e71f", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "2b9d3203-bb73-4411-9c02-9742d7c7a02d": {"doc_hash": "e76d99643c026c00f9f5991fadb72d3805b84d61f18fa7b5fd9fb7f4203c7e38", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "18b1a0d5-136c-4a8a-95fd-a05e67a9bee1": {"doc_hash": "1f28d679f6d4c514295fff2ac9469894225a8056513c840525b5c629cc713adf", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "ef7447d0-5423-4d6b-b33d-abe6ca1c83a2": {"doc_hash": "149389007c104858f95a1c2ae6643141a2f5418f6e83c0b61aca23026bd55843", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "58574996-bef0-444b-aefd-cbee74381dab": {"doc_hash": "066148710a2dd844da215d66b788652ba81d22053b24cc6ea34b98777fb83dbc", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "d00eaa23-b6c5-4293-b4c6-53f133254204": {"doc_hash": "15918bd35e5848696b792b24dacccc8f0a430edd3b262d9f5011f5078c7cf760", "ref_doc_id": "91497534-9f73-495e-8234-8857f0469491"}, "f12ec521-5665-4e3b-b506-16844f65d8ea": {"doc_hash": "725ec4f3f0a49d6f588a2fcf5aaacf688f01bb82d3e82ac0ad0c2f5fe2074bb8", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "1a208041-4887-42a4-973f-c69a8ed78ed5": {"doc_hash": "72e1800ad1b944a8b8c4db2f4875cd8b92fc7dbe0fb4c8b8b405251aa0514124", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "27cffdc3-e870-437e-87e9-caa620db432e": {"doc_hash": "886b2c4620258fd36b0730ba4e16d4a3b0f4732ce10ea853d4edb9387b720258", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "36c02981-8e3c-4e93-86ed-b913d811c0d1": {"doc_hash": "99bd776455f43e0f4cc589a034999848789719e2f1260b5fa89ed3fe3de75be9", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "c8a28949-f56f-4ace-ac6a-a0b9e8c0afa7": {"doc_hash": "4b5652440a918629bebdc0f8a18b23ffca9bdd7591c2c2cfb97d359ef8edb7ad", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "4bb3a59c-2f17-4c67-b5db-cf3ec273da8b": {"doc_hash": "def1028d54633f8730ca9222e5367c05cd106259d189071abf01853d242976e1", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "4715729c-111e-4945-bd8a-3e244b5eec98": {"doc_hash": "d2d81783d9a3ce9804fdf48beb07b2fcb65a2014beb5cfd5f8c33c07aaa7bba4", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "7c62002f-108f-4cf7-910b-953210f6e2e4": {"doc_hash": "3131c1c5d9709dd928d3371c2e3687c24ea77bbb900c70659ab53232e4e025e6", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "7aee6925-f296-4237-991d-8c530599cb64": {"doc_hash": "dc2ea815109574f0ad6faca0af62d618091ec6469c2b327441d5393992c1ba69", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "a3dc2fc9-e16f-4522-ac6e-8711f48db93a": {"doc_hash": "56641565dc64535c1111b67fdd08734baa73b953a31dd6509ec286bcf69492be", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "e59e2adb-f0ae-47d0-b634-587d5c622fff": {"doc_hash": "50d92d849754184e30726ed60b2bcbc2ea2ed7dd57ba4245b001407e36328eb4", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "54f07a9b-bd27-48c4-9913-88a63e527d39": {"doc_hash": "2785111b3d83e848dc20967160eeb1f16859f0de719cfd2396a5a85a45630eaf", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "8cb72f2b-0a05-42e2-94bf-b18f92e29a1e": {"doc_hash": "3926c7fc76442ceef2fbe1504091a0a5c8e0c89de38a7f18507425f2332d71f5", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "75129aca-16eb-4ddd-81a9-9db3f309153f": {"doc_hash": "5785e9434ec245fdcc2ee19dfdcd4bfcc01b8b1df47670d54b0579d1c9dba370", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "047a2b80-2744-4f07-b274-7f91862e3450": {"doc_hash": "79dee85c3404b00143f2c526986e270b9cfaf90a46dc81d43a64751a49b60880", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "e35bad2a-58d1-438c-9668-4ef2e71612fe": {"doc_hash": "2b85536f6abe099931410c8552a398790481bc125800b885c9d29911d8fe6464", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "ee718048-2442-4506-a218-40325ec0af73": {"doc_hash": "c9b9bbee9d5ed74cb4e6528dd2658ab863decf66d28dc37832d9135169e5f664", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "c7d22337-2e04-4326-9018-b9d3091f87a6": {"doc_hash": "c1515bcae2146c7d9601cd4690bd838dd8d37dd5b0bb708f2063ebff9ffe4d91", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "3883e3bb-ced0-4e5a-83e0-5c89fd48dd09": {"doc_hash": "fa4770937e2c7bd5bff63bf91fce34c34ca2e341d500be5378216d355e5bf058", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "2c15df65-7aad-4c24-abe9-7f56468041f5": {"doc_hash": "d609abbf13d610ab1d0e6d3b3c28db9538253f8942e04b01be73a18f923f0a8e", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "f8e3c233-9d8f-42ae-a506-b5d72c4e3d1b": {"doc_hash": "e6c4874a2a8aeaaad8cadf48fc5a6d3846fc0cb2b74bd1a8cb1fe88532ef4153", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "f986e258-fbce-4d60-9e47-c10765ba513f": {"doc_hash": "11738488b9447d7323b70c0ac92e6c544a3dad0a58117beded7e4962d8015c87", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "32b7315a-a679-49a6-a8e0-141cf8fc5081": {"doc_hash": "2fb5151c089f3e9e77bfff74ab68ad0773109435b33196db6c65b9a9d61f624a", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "ad041167-1cce-42ed-9f04-21bf9559b536": {"doc_hash": "4afa001b593cca2b7373adc90f25581d6a4ddb70f3fcc506ab409cf3162dd9df", "ref_doc_id": "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9"}, "55ed0b93-f0fe-4b14-90e1-302ff8319b66": {"doc_hash": "790f9646e53f8fa1e40c1664bd862c0c5787656ebf928c1a18e057d3e91ee825", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "982d19ee-ea81-49a9-a0e5-ac03a5aa7ec9": {"doc_hash": "fe0b46a863e31b80c8f3f6bcdc115fd6abdcb51319e7bf0b05d505a4b0ad1e6f", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "adfabef2-fc79-4884-a5d8-12e7903cb5ef": {"doc_hash": "1c5f041195d78e9f1197660714d9b65925128857f8a8c14be05797ae36cb861b", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "6eb30b5e-e3c5-40f6-aaf0-b81ac347f729": {"doc_hash": "094b1ff98d981bd804b9271fd5a99324f04c2ef1a63afe52afcab7f2668c99e4", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "a383c03f-bbd9-4f0f-9b22-dd999a5f7969": {"doc_hash": "9c2bb1dc7fa9d142b0b953396c686db5f2382c0935b68d728be4cec0c9cf3a00", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "b64e020e-cb3e-4909-92e6-23484bb2e49f": {"doc_hash": "c3c841b4a203dc9bd2cf8fc5fa747600fcedaf42ae3cb1e883b320d7abe9c137", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "e893593f-f495-4efa-883c-9a91ceec9f07": {"doc_hash": "27dd8836978beb1f19531dd256782b704776080b6ba6356aa3d98c70f920de11", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "9ceea00b-e3ff-4379-9ab9-25f965bcb4e5": {"doc_hash": "e1289dfdb01a7928d4267cd137fc373273f7be028415bacda71d1fe84862630a", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "6c3fb57a-1172-4311-b228-ce68fc8e71c7": {"doc_hash": "dff8663eb77e382569324beabc65d21a61c18eea37ce2befa50da287cb03cea4", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "cfea3d2f-134d-42f0-83c9-973485af88a7": {"doc_hash": "8a436f9acacfe19b71f74284c28238479168d245c868dca6779582f701887232", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "09c35a12-1648-48b1-807c-e1a518dc0846": {"doc_hash": "5dfdf0de3962d2cb0e58d39695bdeb92322b06606f025b0dfa879706d9603328", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "3232c6bb-3720-49c0-a7a1-84f16e517da8": {"doc_hash": "beeac070e6f03a1273867b8b114db2c65384753e5add3384a174d024f0b13887", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "4c227e76-536f-42cc-a7d4-6aca10ecbc14": {"doc_hash": "e746c3b39028370e9931efc26cc6f7c8ff7cf11fee3ce9971bb0eba1751ad706", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "7fc7cadc-653f-4598-b139-5c17a13d5917": {"doc_hash": "685b1fc6253e06bcac3a27961a8fd1cfb30b13eb01b632d17a54116ad5c3a3ff", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "0f79930d-2662-4d50-b442-fd91f77a66e1": {"doc_hash": "dfb7ab24436e25fb837d66d3b2d4998f814b9aa6eebb5d46cd82197aa2b3d081", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "253620cf-25d7-474b-957b-43be6be68fea": {"doc_hash": "78619d12dfef75022639dc1ae86997e8fcf8aa9edd2b968ad1dc10a310705d9a", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "24968584-4068-42ea-9706-6ca75812f6d8": {"doc_hash": "46ee777a5a7f8472413040dd94a2057dc45001ea54b82376f1f73b029fb0a356", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "05f0fe20-a836-4242-b138-59a06e44ed75": {"doc_hash": "924099276d91963b22b58ae81c1ddf8a7d9bbbb3c16d9a93c9964556abb93190", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "9879f195-fc95-4647-b260-a239429de9a5": {"doc_hash": "d9caccffad399feea98c7475d22f56522ba83d12d3f21c3c29b206a26d581878", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "1f238d41-7a2a-40ec-8a4e-659903a1dd1f": {"doc_hash": "f0342657390d466514b2897aa87f63e9dd9c11b0b43eeed2a0777cdb44c32d0a", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "3b998fc6-4320-421e-ad60-96f62a0d5131": {"doc_hash": "4acdc86d4600150203bb30efa080cbe8de3ceb72170c8aa31b7ff25647961a88", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "cca11ec7-9295-4c94-afa1-c08d2685e3d8": {"doc_hash": "a254e10a828b2b602a0b4558eae2ea80dbadd289245786827597af4a20482e14", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "1fb3d9ba-5d6b-4ad6-8e00-ded695865538": {"doc_hash": "94975d9060c4b2ebcdeaf7577ca4666982fad758f42153e1ccbf318162d47d75", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "e64df7cc-039f-41ef-ad26-11ddd943ed96": {"doc_hash": "6b2b54ea03d8e7b52304dd89b5954e2d8e37176a5c6ef8d771b0cc7e69537c82", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "d705a731-282a-4c64-90bd-3cd8a9b02d0e": {"doc_hash": "8444d62ef294d7a811471c2fff7a9a6897aa2afe8c7540fd50b5b68e71cfe433", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "cfcbade4-0043-4233-89e8-479d16a2e4c4": {"doc_hash": "a4f57b06e880e1d4177e8b7c913c91addcbe4589b0f223a577158f9836dfc532", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "81ab3ced-249e-4df5-97fe-3756134a7bdc": {"doc_hash": "eec469ff1a1aa9b06bc772a6959cfcbf48802b8d6386f44c2a7312c818f7016d", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "452efd88-f1b9-489c-ba51-2ea08021180f": {"doc_hash": "65f6eb5746c074c183f35dc3bf4aa05a398ff8d8a97318391fd254c367759962", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "05b8dd6b-5122-4ee1-a652-2e07e4421d1a": {"doc_hash": "8aa48830aec7a89bd352d938874cad1875f832a765aa8d0d2bcd87f1d3c96be0", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "29c4a902-1cd5-4da5-9170-b31f483af96f": {"doc_hash": "9e95c1eb79fd0e6d6baf587ead1e26b70e6d8696ea439da07ea31ea698ba4133", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "541d8724-6576-4652-8d03-a87f3b93d257": {"doc_hash": "6f87c20ce55b57f440bce6acdc37b6412446daa45de8b917f1e91564da09f4f0", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "0ea841ba-11ef-4e60-a8f7-1459f2c74e2f": {"doc_hash": "0c5b0d94ea669416ffa95caa81481d0fd878c1c67baba3146baea151f7357e49", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "76d4c230-924f-4057-9b76-a675c050ea4f": {"doc_hash": "9ee7d7c7aadcfc8cca64909d83d75e393541a6b4c33e10d2ea3cd954797370dc", "ref_doc_id": "0756e478-fc2c-4319-af5b-383d053c9f26"}, "db068485-9980-4cae-b9d1-3849d6291af3": {"doc_hash": "03025039966723703037e4762335f251c0ece3cac2efc7f39e006523629c4455", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "3d5ff84e-6ed7-45f6-a979-312da79a2730": {"doc_hash": "9e70bc6adda8b5a196e9cc8931feb29a88f842bc9c25b600a6c69e7effa0b019", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "b3a30358-6dd0-4ebb-ab93-e215cea18152": {"doc_hash": "072ed1e1a966329e8df273b5942e93584eeffb59336cac18331956dec4700d26", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "49fc7e99-248f-4fbf-b0bb-3eeaeca54635": {"doc_hash": "92d1db65941f118707c2ccc1ec7bfb33d28c9302724c3dbb152cfdf2b8449893", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "6e91f949-33a0-47e9-88aa-930923cb992c": {"doc_hash": "c0ec4387852151b742763ce5faa8894c77d18f429fef5a8e8b13cf87e600bb1e", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "21a34a14-841a-4901-b5ff-22fcd7f48c7c": {"doc_hash": "2db642bd3f52a08592a2087607b8f73cb869a6bbff9047bdbfbd5625857e88e7", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "d5eb3be2-53ca-4cd9-84d9-8f8561916056": {"doc_hash": "5dd50599d0a95d4ec3d74f0e4df390383517422f7892e7a6de9a1ac0061ac273", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "958d3dd2-0bdc-4c84-8a61-ee685b03ac37": {"doc_hash": "55e75e4a2fad41e75ff5c8ad5c81859195d45585ac76179d880d14fb3c334a36", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "025da32a-d485-498a-b11b-1b4c1fe13d36": {"doc_hash": "85e9cef10074d9301af631b74a812e88091105faad389863b1bdebaa46f0321f", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "b0383caf-7345-4df7-9889-380e8fef3df6": {"doc_hash": "85af71fc280a515b779de497788afd357f723112eb771118c5761516b76cce81", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "b0a95acf-24c1-4c94-b3d5-a7040067d1e4": {"doc_hash": "a84c4717f3fd0a0f4f22dc2b068b3b7f78f186de3fb989b02c03ac1a4beb45ad", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "575342f9-635d-4be5-aa23-14b87d38d3d4": {"doc_hash": "3612607d5756c473b3abea045268da8b79ea565f21f8f2674c7f5ec943e20f27", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "4d64dfb9-373e-48df-9bef-3d4b33b73a9a": {"doc_hash": "d3943add484e67cf95c29d2e87b587fad7df4254132fa7b84ade9dc93a13c649", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "72130b12-70ab-4032-bcd3-fa22e249083e": {"doc_hash": "5fcad656585c54607abc367b0c96ae0a48dc7ffff669bfc1e63a845c0dd29454", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "798314a9-d05b-4ba5-9ea0-9d9757afa945": {"doc_hash": "e525e990773a164a5d81f76290848021ee9402f53fde9ba8efd53617a57a4e37", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "14396577-8bc9-4fbe-b0ba-c6cc0b577bec": {"doc_hash": "ba51ccbe79916fdcfab533078ace734edeca0b6bcaa11acc963a783de2baac3a", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "eb99d49b-52dd-491c-a508-87bfbfa0f931": {"doc_hash": "96734fbd662ad34b1123d3799d077e0fcd107082b58c564893154ff5dc92207c", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "d885caaf-dac7-4ce4-ba30-7c7612c68f1a": {"doc_hash": "eb242a105f1f97de70417fc36f737f8784a67ae43ad521801056e55db49bf621", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "8da5ad0a-a796-4fca-913c-5544a97fb028": {"doc_hash": "a6daaf44572feaf9dd5b400234e148f885e640c872acc381fb37b5a32759538a", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "a6fe85b0-4f15-41e7-9e4d-21f2e2fc3e0e": {"doc_hash": "3cace8149d1acc2a0e3b72072e6be20659d69c53185ba89db34156abb316ff4b", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "8d0601a6-5274-4f5c-9be0-2caeeea67129": {"doc_hash": "37fb90a34370ae5d559bed23c6262385dfc800968ce9ff8696712bb3fa1b2f17", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "5b61c3a2-978a-477e-8536-43005467df83": {"doc_hash": "2190378862851690c3caa509b5f59572fc5c8a1eb34f5b8c695961ad0343e05f", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "0b1d4ada-a13e-48fc-bcb6-2e8149624779": {"doc_hash": "5c5a4800fc03e5ad187b3a6aea52970e81aa2b2b41a73a6fdd0dc318ae49dd25", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "ae117dd3-8e67-4d11-8af6-3577b3394ffc": {"doc_hash": "5e02ecbdf38e257f394cdad52b653a1dc5e76176fab05ad4a7aec40adada1ae8", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "3795d9cc-4468-4dd5-83c9-b28b30584f1c": {"doc_hash": "b13e81000c5e81c8449ad1ec54642469bd869fd7923acc5f2b3da71d4dcdf31b", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "f584a46c-6dd2-4a2d-90f7-4627657ae5ab": {"doc_hash": "0eba81e1d4ae3709e00f0f3dec9f954577017d23623d8ae1052eb884478427de", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "74dab664-dbef-4c04-a317-37a48919990c": {"doc_hash": "7ae6760e9131bcea40167718c728f7a22b15fd11085136d9f4c8c26fc732e111", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "68b834d9-bb9b-4886-9d17-017d414c9575": {"doc_hash": "191f200413d45e702346cea87af787c2d47de11c862e1636d0a5de2c9b84c763", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "24d89fd9-1976-428f-9f05-96f7f1baf912": {"doc_hash": "151bc7b330353ae081d4ae8e00f35a25fabff3601100d8687d71ac020a7936cd", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "0c40338f-315c-4122-b347-22b9ae435bcf": {"doc_hash": "aa36ce414e853f617e0fc1e9f52f8b801af716be9e8d4ad356d7004b20b5351b", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "1a6483b5-4569-463a-b368-3429b70a4038": {"doc_hash": "37ccaeaf47ba3a22e6503bf0b73b5b18d0aa9ac256dc2706f2730767fe59c3e1", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "c11f9324-2f11-4b9e-88da-3be7bd270c42": {"doc_hash": "7ffe99a00bec94b4248c1b4af869eb9992ce2b94d6adb02c977db3ecb3ca6369", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "eb949474-6db1-46dc-8906-b9127d2abfd2": {"doc_hash": "56c11671def11a8add5b41b806f5f95543533b6bd854088e158e853e2721bf8a", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "efa6d016-9707-45bc-b266-e52d835a0bf5": {"doc_hash": "e48a33d39c79b554f7dde2cbcbbf3fbd12db4a78de3a9a43a3ae59b98ca23813", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "365eb388-026f-456b-9751-0d3252f12268": {"doc_hash": "478fb7a42b46c6ae675300242fe259e8ac42b1a11ee5ab06e7c96816705b769c", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "072001cd-493b-4ae5-a2be-9bd8d26a2efa": {"doc_hash": "72b8c6c3084d79bf002b89bc8bce7e78d099988e8d693acbc66d1226824b5bf1", "ref_doc_id": "3ea74283-efb4-4b1c-af58-756548490b1d"}, "d7745062-43d7-4bbe-bcf9-05d1016992e2": {"doc_hash": "ab8dcf9825a19ed71a53f8b704c85c45ee0d39048b60e304747b963f5bce1531", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "c2364da4-bb29-47bd-9fb2-e6808f107d3c": {"doc_hash": "098c928c3b71919159df65a29c1aa44c3b77f75509cac14bb9653c0a75a32dbc", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "7db0e6b0-9018-4b73-b7fb-ccf0b5298117": {"doc_hash": "500e71a12d006f7840a085bd1834cf374d0377ea7811d94a48bac887255ecb9e", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "6aad361b-c4ab-47c2-8728-422f1edd33eb": {"doc_hash": "3123e428064341ecdaf326ee975fa5d9d40acf68ecb4d6e4c7553684e72e899d", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "199dac59-8dfd-4495-b6db-c3ce80f0aaa5": {"doc_hash": "792811682c0fe9815756f62510e428dc2c5fd3dbee6078c53c6e7d0842ddfa4c", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "1447ddd6-0338-4cec-8ea0-a75d69f6c2c6": {"doc_hash": "61a158cf7652dea49dee5c62cb0538bf9d8b41a5aad0440f07e8864c22e0d49a", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "111684b4-c497-42d6-80b5-5fd15e7dba3c": {"doc_hash": "6201ab914ce5f5fb2308fe4399ea652b0b8545a1b7a28bed544cd278fc250540", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "8f4aaa66-fe09-4df9-831d-00993e460428": {"doc_hash": "806a9b056dd7f8eac8bff70efd1bb356511def86a545c42e4c3ea990eefe6283", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "2e6231ed-d8da-4cc5-bf24-1029339827b9": {"doc_hash": "7c0f1f0949ca3114b2263bfb015e2c86f3e839c60f911cc1e8c17bb578e37f5a", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "6560cb30-2760-4880-8615-c411cdef42cb": {"doc_hash": "29fdd3c2a099c62ace6b86a6ae215c6aea249244a7310aaec384e23871ab7751", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "bed7e969-1f4b-4927-97df-4d2d8fcd13c3": {"doc_hash": "f0bbd929500d36c8db724f7b1b6745908541b899ff988cc28a55143990052948", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "11cb590a-4709-4722-ad58-99f58d32ea9f": {"doc_hash": "62dc57ae6688860c94e3bad03bb80c8f748b79c4b22f94c48200662424339630", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "b9351c92-e520-46ac-9102-08a459e58a24": {"doc_hash": "e9ec1d1bda837657b0660be0e844b35c60d228a89dd2a885cc81f058c59e053d", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "cff05a4d-2212-4243-a6f2-7db9871d65e6": {"doc_hash": "a2ba1c765120967dcd17c191f3fcb67d4fcee9d1aebf0b310cc85c6016605890", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "c6b1ef8d-0def-4929-8459-e9d8e6a2e194": {"doc_hash": "2e9500b73cdc87f5cd7dcb839ba4507372ddf366d70ca5069082413f1e717a29", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "396cdcfe-f7ff-4645-8ca5-fe61c805b83e": {"doc_hash": "424e96bdf523bf4961f9bbe8a5a1f60463ac6aff4c8563a9a194b582b892f9b8", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "564165c3-9478-485c-8cb3-5fcfa6a73b0c": {"doc_hash": "0313c0a5e8be26e744f7a236a4ba5c23ca87d72fa0548a67adbdd86fbaf02879", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "bb5eaba2-d061-4574-a521-a3a34f422f67": {"doc_hash": "04ebf0f25591db7d439e866a37eb39f3ad957bc76716b9059376d9ba7b42be90", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "8a8249ab-aa78-491a-a4ce-6821ba3ee5c7": {"doc_hash": "892b28cc0231601d276c7f24f2db485bf28c71e51b7e01aba1c3c08ea5c214a8", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "7321422d-2d6e-4ea7-9518-a587a199931f": {"doc_hash": "ed8a915b95b82b1c765c98f1291ed4d59357fe85177d19698d029cd1ae7281b9", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "2e850790-a896-47ee-bfaa-6922d908cbdb": {"doc_hash": "511d097ba35e49b52058599e5061b02af8bf954684636889713e3ee6faae0895", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "df38b331-6406-4701-9ebf-b3057d673bff": {"doc_hash": "a520cc0c7c38c0d7c0b1ebc50805d69fe689fddc490c774e60f29b0f7f591e2b", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "ede6c87f-fd9f-46cc-b911-d9ee750c20e5": {"doc_hash": "3157d4ad43e73a261225b212fdf458c5708420e5747a7c8b6007631e8ab9582d", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "f1dea752-a732-4864-8e70-300f3b3b041a": {"doc_hash": "fd6cdfedbdfdecac00865be6010b94613b6b56e1f803e5ca8d8eb6dd678f9ddf", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "7fdd39e7-0b82-42c8-b526-a35b1123c9d6": {"doc_hash": "31fd909d25220fad7da6a84cefb14f7b5961d8a80526ace982a4905871dc0126", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "f66588c1-3207-456b-9a05-2fe111ba688c": {"doc_hash": "b7fa70a49db933b1ffe32a038ca7be99a1cd8c28489b8f48b24a13bf61974969", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "daee8b5b-7390-4f4e-9374-47bee6515772": {"doc_hash": "bfc41ae5ee5d150e9a0d80ff9f1550f8384dc96eb37e6d53d0b644da530f3114", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "fcaedbc5-4cf7-4052-95a7-c3331455ac78": {"doc_hash": "22bdde1483ee4207c18197248e0439a772125b31477b981f9942ed0d4920e237", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "6fe1eb9e-0fcb-46f2-8adb-8c934a59e47c": {"doc_hash": "3c8cb257b9fa964d41e317335848dc096049a2a3e83c5d99149a8003d8e84cdb", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "a967c22f-0802-4331-811b-3fc317305b32": {"doc_hash": "ff6afc9ab36a92404a671ca0693695238adf050630ffa32a1762445802c2ffb6", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "860abcc1-2130-4c84-9087-b9246700b15a": {"doc_hash": "7457226e7c30fdf7b1acb8d809c53dce245aa013adec220c9503a77de2b2f4ad", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "14b521f0-a224-45ad-bedd-b75a490a8495": {"doc_hash": "88d605dba28779cedf4a2fc8655982aea9d2b52f57df60bcbe5eb5cf70187f39", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "387d87c5-b879-478e-a637-bb6d724a6ad5": {"doc_hash": "dfe4c08e18b667d93ca8aa55a77a2da7aa5dbd909bac78aeb06748bb2754f76e", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "5881f5e2-2e34-476c-9cf3-6bc59fc35d68": {"doc_hash": "978a80db237e0ccf77f12cecb5dcbbd63f3be0135c6cff5e165209c7957a10d3", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "d8bec91b-9513-430c-9d8f-35ce3f4d8c4f": {"doc_hash": "1621e1212c72db8b4b12368a79a0efba46bb33de1423efce7dc9d17884591827", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "3fcfbe1c-94be-4028-bd6c-3182f2447003": {"doc_hash": "04f853fb54ca813201bca68deb37d877561019c86ab012474a4d9148fd4d48be", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "f8bdf535-169a-40ae-90bc-dcf3fd30b7c3": {"doc_hash": "bdbbf4f2ddccdbc369387adca5948424dc6b3ab5e8e186ad4057ad1de5b8f792", "ref_doc_id": "690e83c5-e702-4f38-b4b1-8ffa91f10184"}, "bd2f80b5-8506-436f-aa99-6d0980bee0ad": {"doc_hash": "4f38758bf084692fe53424180e1099a53f74955871cbc8c5bf05c2f0b518676a", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "9f3425e5-1503-43b0-9bb7-cf90a13cb0c0": {"doc_hash": "cad13b900e05e71d7c406a8ba7bdbf8dc688d437483d7bf96f0871b006156f79", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "9febf9b0-10cc-4bda-942b-cbe7f1fccff7": {"doc_hash": "bd1f59f37d98b69ac9c53453d9ea2d1f060466e3055ee6638e5e5a1ade287863", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "e75d737c-eb85-4a67-b088-6dac5a057775": {"doc_hash": "8de00db33c930a255ae898f126f5129aeeb358b436cfd9675d157e01b244f759", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "4f6596c0-3509-47a2-904a-106f888325a6": {"doc_hash": "8257900e8bb33917bc8effce37a578879263e1c18540bd228461a6e36cb938da", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "b0e76304-23bd-41e4-a2cd-29730b0dae13": {"doc_hash": "dace9b110107c69de78229428ae707b20f447b1fbbfa237779bc41e4bbd862e6", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "eb70b871-2c25-4f3f-a920-227c43c4d404": {"doc_hash": "9cf3df51127aee7a1df25700361753ee4a32206b695fa51ca45f50f0caec4863", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "60a551fb-28c3-4819-88d6-bf36073c715b": {"doc_hash": "75e1b8694d2d5995a93e19497f93332e02a1e3c069423943e1add70958d12ace", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "d9648df9-7289-4b1e-94a8-014f567ed508": {"doc_hash": "a4e235559be54bdf1093f6c9395719db3caec43361fa74b3d99a50845d32fcbc", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "ff23e906-603e-4704-810e-7bf40f95b091": {"doc_hash": "5610cb1ca497094dff1913dbc858faadf52e1835ef4feff458c113a9eda8a07b", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "31208c53-ad50-48c8-8750-2091cd789c2c": {"doc_hash": "dbd7162303eea01722e7a976313d72deb1f0bf89b2b6856abb796ee18856bd29", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "95747fac-5bf5-44e1-947a-6bd677a3325e": {"doc_hash": "3edea9ce94e98112564421b2d4da174de43cff7c57d9bdad51177a11b6995c05", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "e00ec034-b256-47b4-8ae3-08bec3d0b376": {"doc_hash": "374cbd8cc826d113fc9ceb2ebcdf7cf96fe8c08f255a6c4ff7fc0401ac380f09", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "d5443a84-fb97-4ceb-95ee-35cd1ac5ea8c": {"doc_hash": "b4ddebb9a7834d25e7ed5545ea33c1ac592dbd7eb242babc42c9d5f49f134573", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "c55a7763-4a39-4d0d-a869-ba239b2dc89b": {"doc_hash": "638f9ac0349d2ef9abcd59778d92b81953b3806c2ba0511707ff63e34f4669ab", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "3c928566-1139-4ef3-b738-74df3b0e0601": {"doc_hash": "99d9a92550ce40403c841a8d5b3c10f1cd3fcb78c8f85c8e958af0413cd60959", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "2f9d9284-e03c-43f9-93ce-f7a5814c80bf": {"doc_hash": "d079d65ca779e7a97619164b4f7ba39530ed576c0a4f46fd753626b0114d5e7e", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "b6f1b965-a615-418a-b9fa-ec6f509da753": {"doc_hash": "757a8330d03b78698f3de0d6d3d3f3c4f95bbb90acf0df0b01c4db91425ddc9e", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "81de230e-67a6-4a7a-bef2-6bdb62a01019": {"doc_hash": "3fc014d4a8f5e38bd76e8b61989e8c151f5935eaa93cd35f3bdb8e441c936675", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "3f6515e9-ff0a-4c74-ab5f-52618b45d4ba": {"doc_hash": "0fca1aeb04295e5ec7eba5134072ab0c5e32a797bb75c16e867c5bd146c895f8", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "a461b597-b15c-446b-b237-491e89d9ef0e": {"doc_hash": "d645fba616a43903fdd63d951bf562140ae3513b354df69075509f70eb3a8a11", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "b8b6b8da-4b0f-4a6b-a7c6-73b6ef1b030f": {"doc_hash": "e3d2cc9a7474778c3627628fe29cbeaa44b4c31e5716be861e0f6b5217ff22db", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "24a0928a-e58f-469c-b6db-f0940086196c": {"doc_hash": "f7634231dc334a0c4d6da939b83adfed4f7a3a0acf79efc6cff65ba8ae3050da", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "3acd5945-1f17-4b8b-9378-28701c9540f6": {"doc_hash": "97f98f7b3d122b5e55a6f6aaaf890959ee49563689f91cf13e2b95b6f96b8cb6", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "776ee46f-569e-4ca5-8094-400f8cd40e49": {"doc_hash": "3aa5cfd24ea2f5ff98684b3a8ecbc17bfbf3fcc2ebcd51eb5af5525e8a5d9d1c", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "f9af32a6-223a-4e7f-8a52-83dd516da29a": {"doc_hash": "96304f8c304c97ed061ad0398589cecbc18ae9f62ed0bb058439bfabd9542e1e", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "087fe0ac-52cd-44a7-9cf3-c0b26e635d28": {"doc_hash": "149ae6370e30144bcd7c4995af595509d1632efaa5e070bb8e59fd0e47d5c21b", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "c6ed249a-f2fd-4820-8340-17665559fdba": {"doc_hash": "89fd1c462a4a7d662aa28454d348be1eb32701c8b6a0ce721930e5c580d46509", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "50844bd4-c826-478a-bdd2-4ec1aa34b25c": {"doc_hash": "427fb63dca14f5c0708d1840c8fd9a19ee6c680c987b6d6c72451b4815de12af", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "09f29c23-bf45-49c8-bfbb-fcc910b90dee": {"doc_hash": "0c0ed69dea9ed7ff2b92e36512218844687b8aaff821ebc411ea12a99e41919d", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "a4e5f6d8-ce82-4d19-a22a-0bc850d4e396": {"doc_hash": "c1eb62a1e05cd3c41d0a93435f34a3ff866241b4f20202670421b0ee7c2b58fc", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "998c2a0f-f7d6-4b4b-8320-fe3fb09d8729": {"doc_hash": "e77d20a9638be00f6dca9372ea6fc7a477c59942016c9527e05add9cd48f3ba5", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "68ca4f84-708c-4b94-be87-04fbc2133e65": {"doc_hash": "12fff607eb0e5c970d92b481baa3444f6c0a8f697c3d0e9fdd903a12c82a169c", "ref_doc_id": "a1b4582b-0316-4241-bbf8-f08c2e2dc26a"}, "d07af774-624c-4fd1-9814-23c8e2885d61": {"doc_hash": "0b42dccd2be2a5693e4b020bcd7b3348945a0b2d5b8fbe72e938e16b08be06a7", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "d0a67f7f-3301-4d06-b5a5-fbd6b91fb76a": {"doc_hash": "ec2815875a824931f4753d4ff9292776f64e43820be5a2fca7940902fa8073d2", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "55f735b3-f8e0-43f3-a48c-6251319179b5": {"doc_hash": "8f5a141a0d4fe1468f2a565f4d2533c2c32a64bc4e633cc1f0179fefa24c3d62", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "221479d8-3d82-4fc9-b3dd-2ecc026d9e9e": {"doc_hash": "9c27dcc94f64c827978289a24ff7a6bd5f283651dc5483cc07f8f6f99ed9fece", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "672851b2-1ef4-464c-97fd-febf61a3a3b8": {"doc_hash": "68e2176b9f9b46474f6b85ec6664856f7bd1cdf4f18d41f09986d8ab733281a9", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "d2816714-a8d1-49fb-b6bc-ad04b833266d": {"doc_hash": "93955d9c4b25df77cbda61eb09ce6d89392ff47d2b67f89c6f6246ac0ff7902f", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "e8e653d0-98b0-4b23-a5b1-a9b1c160268e": {"doc_hash": "b8ddcb64a29fd367c218ad1875fefbbb1ad11603ddecbb71e648988a7a678019", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "83d5ccc0-1c04-48bb-b965-ae202b79b888": {"doc_hash": "860635c43d37262296104ab26750bef97bd567a6d65088adbbad1b31c1ee2a47", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "a1fe66d9-9751-48e2-84a1-5c55207b2e17": {"doc_hash": "d215917b2973085d464265b6d425338b6198395aab4ea7ec97208121dbf32a98", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "1a6bd073-8834-432a-ad3c-71f24edaf0e5": {"doc_hash": "874aa61aa1c19400108458b3489cee535fa3609c318d02a3199ec2aaa65dc778", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "478dfa71-6906-4a7b-aff5-56a8c7efd476": {"doc_hash": "27049ad8edf8a61992782560e090772211f0f8386fe484ce3f46f0328d5c6ce5", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "2275b3c3-ce90-40fa-bc20-07655cb2710d": {"doc_hash": "b6dd3dfb8dded931413d4e090851c5bf8fc67641dc461670a8b3288ae3153390", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "0f964c73-514b-420e-a97d-a65e0a9e135a": {"doc_hash": "54930a6e59e343eb61efcd443f7c0aa31a3a9bc19fd1f4de43322a4dc8abc167", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "52ae7650-4553-430d-a4bf-ff869250ad5a": {"doc_hash": "c6a901c6f04e2d9b444789344349ef3a47ea5db5b06e2c280bb33966e8efc412", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "568954f7-f269-41a0-a084-fdaf5d1e6dcf": {"doc_hash": "0006b150373bb1139de3881c9bd063f8750fb0b6069021d65f262510dec4e725", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "109b9966-6f40-404d-a8f6-e43e2a2483bf": {"doc_hash": "3c1a1fc092ed63355dbe50e776f1bb01b38db491e856967cc3e90c6448eb9a4f", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "ca82a319-7acb-4259-9ebb-3c3d2c34f51b": {"doc_hash": "93cafd746c948143cb22cfba2e8a675c22d984c957bd18ac11b1d0fa4530c84c", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "f1f45da3-dbf9-468e-80ab-4bd466e26c00": {"doc_hash": "bb92c2e3143cbce87bb7003f2290a8c69faad0af57eab91e93b4b165a49f6ba5", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "171dca37-abd8-44a0-97a3-1000be3bb074": {"doc_hash": "b4c24e0ce1362ff790a8eff106e76d3f497d613b7af8bef289867e3eb5a701e1", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "1f150d0a-8140-4927-8138-e03bf163172e": {"doc_hash": "f49675515fee2190b878dba34d64331767f2ec13990048a45414ca826bcf62f5", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "a6d4c0be-5393-40b6-a272-2d15ff1e2bd0": {"doc_hash": "58eef482330e5496751444d25f30de19db15b2c2a1a40a2eb702435ef6ee3416", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "73bc9066-0a72-4441-864e-c440f05a803e": {"doc_hash": "e3f6db03e90bdcc54a21f530b3212f6cbc9c7932e196aca3aed3bce0bbd6ad58", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "b174f473-1213-45c0-b2ac-27ce5823cc7b": {"doc_hash": "d39d6031fe8134a38b3d5673e9f15144ea7236237902e94a6386419b34d8388c", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "1ac23be5-0691-47d9-b088-097430717704": {"doc_hash": "5ca748098636a94e587cfee99324b6003b3aad3f9ca4b3e64aa105834269a895", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "baac0b91-843a-4994-a520-25f504c91cf0": {"doc_hash": "d79431bc2a025a50a55a3ca4be1213d88b778be036578f4f4183fc96ead8d6a2", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "54bd953c-3b4f-428a-9397-01cda48e94b1": {"doc_hash": "f7429b6bc868693b729a018475f835d7688eb26c5212c0d716e3b593c1f640d2", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "befa35d5-b0ca-4885-80ae-de55c7d0e32e": {"doc_hash": "c4dc4e90235a2728d5d73c54a58eea3b26e5e83d721985475a75c5ea93891c48", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "01ff1200-a053-4f82-ba34-f0026995028f": {"doc_hash": "3d4d2e239b8239447b114f83509d4ef5640157edec32cf2fe7fdda35d31c672e", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "b941731c-1af4-4a5c-a3c7-eb4184993ff8": {"doc_hash": "ca7b3762a895d6378b1509a5688639960f7d02a62c94cc62b1de1cac2da0e9c0", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "2749ece6-977c-43db-9c95-1e5e2aff33e2": {"doc_hash": "cd6524fe6a622ff021129a6f9cbd9cf02f9877175284a1a3023c708cf31344f9", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "5da79e79-36d5-44d7-9f05-ac256a1bd5bb": {"doc_hash": "525c3e5f0926a74e1166cca32f0def55984d289bcc6c6dbfed78b67b1793a331", "ref_doc_id": "68597756-0004-4e4a-ac4a-afcaac0dccf6"}, "8d430f65-b1d6-4684-a33e-d8c8282a3389": {"doc_hash": "868df53ee3260cc65cbf1bd66e9faae828be014ef83a8e05defd32bff0cb6584", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "e86fe58a-1d5c-46db-b4a5-df6ceb10bedf": {"doc_hash": "e642ac319775e04ebea583853a8658e5364259b8323db36d8a87f17a95d49e4d", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "098e8225-81bd-4d13-8cf6-e6e41319659c": {"doc_hash": "7225bcbc27e3618a23d34938cd83cc7a74ea84e99741b11666e252550f8cbd50", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "f289b4f9-6fc4-460a-8231-dc5eb450a973": {"doc_hash": "7f1bacb11db59b4411167f3508767b740c60b941948885ab445c4a9914c49455", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "32beb916-24ba-4b50-86f4-6cd08bbfad93": {"doc_hash": "ba5ff7fb6507f0a37d10f6112649fcb8d6d844cbbf070c0a245e7be02f10da87", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "680ee8a4-7c2a-464e-a4f7-1afc99e822e7": {"doc_hash": "cf4fe5cee32bc59b59d6f1a5512a0091c7d0008d5b6860e6f6b1a3a5d928646b", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "926ffa77-8d28-43c8-b4bd-ee8e1138fa1b": {"doc_hash": "8bcbb305ce1ad49ed9654e26b9f1c65626627cb8982386b66a850f600eadfc3f", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "1c1c48a9-31cd-4651-8b3e-1801abed0bb6": {"doc_hash": "c9056a8bee46238f75c1e6d0baf4127b083dc8cf2d5a475acd2452e6173ea97a", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "3bff86f8-8b8c-4095-b1ec-ec542ab75298": {"doc_hash": "ac60d1c0f082ae3c4b970e85c798b8582f5b777425bd08e32ef3970ea854b73a", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "e9c5f4fb-69d0-48f7-9fc6-b3c532ae8276": {"doc_hash": "6e71649f9d88017434665cf976320519133d0a0548434d7b9fb0880077c3e706", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "ea15c294-c572-47c3-9470-2d9e0ec7bbb6": {"doc_hash": "3c8f51a44e019d7452f006e22f21ba075c59076aea808b9feeaac7b913183901", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "20f3c70f-36ae-4b9b-986a-c4845235b0e5": {"doc_hash": "cbf405fc2b7bd67fbcbbbfd4950584cfe81b9ab523d37dddeac837a070aec9a4", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "cf6672a9-267d-4204-82fe-8ca4666954ef": {"doc_hash": "9f4f9e981aadfda58531c37d6c21a22a9b31d71781715050cf0d240fa28f195b", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}, "fc57bfb7-50db-4070-871e-06afee1ebb56": {"doc_hash": "42f9fff763cdb902f03fa0bc9fea2a88cb69eb29022188f8475c9f2bcdcc04e5", "ref_doc_id": "473fdb53-3cb8-4ae1-94b3-659842909edd"}}, "docstore/ref_doc_info": {"699dc1f6-bb15-4f76-9596-032d9c39cc28": {"node_ids": ["9d4fc53e-3c13-46e0-9782-a90f84a5c1ce", "77136ac7-589c-443f-96f9-408ba599318b"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.   (MCK ) \nQ1 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n03-Aug-2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "befcd309-db1e-435f-b504-7c23466eec88": {"node_ids": ["cf1f2fd1-4861-44b9-bbef-b7590a1e9984", "cbd3740d-040a-4bda-b9f5-045f9755491a", "9485fb9e-8ec8-420d-a88d-6c7cd1a5bf9f", "9147c473-bbdd-4656-a290-0f8f9cf6897f", "5e348e8c-4782-4360-bb9f-6feba1216947", "93dd1fe7-5ee6-4d9a-b7db-e73e08a3ca2f", "7ee80233-7a3d-48d1-863b-77289928fcb7", "68b4430a-09df-4785-91bb-1ca7d2d97133", "ab165856-0427-4286-bcaf-b129280bcf6b", "c7fc95fc-df68-40ad-9960-8d30256d96b8", "80fcf69b-e66b-48b3-8a84-0324ff9c947a", "fed2e32d-a66c-4510-ac2c-91fabe5509f8", "3f611f65-a3e7-475b-b1da-27785f85f965", "bdb043cc-acae-4bf3-ae61-1002785768f5", "e1ef161e-f04e-4b59-888a-b3fc1322f02a", "399256c1-cb60-4c23-88fa-0463a6b8a707", "6bf3fdae-5d3f-4b82-851b-a16f389407c4", "bbc009a4-7521-48c7-ab5b-49c26eca61bf", "8931bbfb-2721-4e70-b72d-d5e35c3692e0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "06bd177f-568f-45f6-a36c-6651eb0ec69e": {"node_ids": ["11f55e55-b28a-410b-90b7-0227853b6d3f", "19114e22-1a19-4c3d-be4f-f5e2a0bbf8c6", "bc403d46-426f-445a-a7f9-098ef6674364", "e67d6c5a-170c-4c1d-9c1b-d2f241e054b4", "837c9bf5-2e5e-4cc6-9852-6875b53b87fb", "44af2634-1c56-4852-99bd-2d777e66cb1a", "185d9c6c-0e72-42dd-a86e-3f82994d4992", "68514a8d-6d59-4538-a280-0785e612e1e9", "3db40648-6700-4b59-8e9d-c8ae7703b506", "80f25cc6-56cf-48af-aa49-59448247f9b1", "fb61f033-a0d2-4a75-9af4-43d583124139", "a75a7b6c-4c88-4e17-8267-c4eff571078b", "e5b6ecec-f02e-4111-8dee-43791015d65b", "d547a3b3-37ed-430e-a3ed-0652f7de5987", "6123132d-dd7e-4933-b9ee-912cc0d1a9c0", "7ba592a0-2f9d-459c-b59b-424118ac9456", "1a5523cb-3158-4c3b-ae53-09e230663013", "65f35672-2e6f-42c0-b433-69df81107a10", "533b090b-7cc2-44ac-b4a6-6127c9c19858", "63ac8c72-5510-4295-81c2-2bd1344ed2f2", "8a84099e-db3b-4dc1-92c7-46aec4b80118", "d9dc5178-5548-46a3-8da3-153882d73f23", "68a624e7-2e93-479e-a194-bf74799a2af4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "16503e65-3ea3-4ec1-b853-6b98b4a65332": {"node_ids": ["023b6cb2-bfa5-4bf1-8f79-a9761ec0682f", "d0e62999-b7fe-42ff-a87f-c4e75aeba6b8", "36e2ef85-0b32-49c3-a5f3-3220904da5df", "c366bf7a-fb37-47e9-a3e5-1f5f86df74bf", "75895686-a0bc-4dbf-bdce-20e23786592f", "9c6022db-b147-4a01-9339-2f0313b7e4f5", "efa1d6f0-2da9-43be-97b5-2f88390806bd", "8965e000-ea66-4421-a02b-d5162cbd34f3", "306ae602-2cfc-41bb-980b-16609204522c", "fd337223-95ad-48d6-9ef7-42ec1b9d0ba7", "ad4eda19-6634-43e2-bae7-e775bbf01cad", "c79061c9-477d-4427-bab9-6c91d84173df", "eb33b505-d82b-4c55-990c-7d153cb9f477", "670c85c1-1615-497c-869f-81dc26bffa1a", "a85679b1-cccf-42c8-8a8f-b0bbc095260f", "019d0934-aa0a-4015-be8b-db21b9a28d8f", "f2167ffd-37ad-423f-a863-6f87c8b80486", "d67204fa-54cf-4452-8124-301c0327151e", "98467f6b-e6a1-45c6-ad80-42ec5cf474c1", "b6f6d21f-12ea-40d7-9a22-3b182b08a4f5", "78a6bb53-5c9c-40ac-ad5b-94a6a019ac8c", "73182dc2-7644-42a0-9654-d3f1cbc43100", "cba4d94a-df3a-41b8-b33c-e108217cae72", "cc232171-0890-4b7d-8134-d3ee6e05b419", "a62a0587-b65a-4ad4-9abd-f1042605b8ec", "174b2df9-e099-4211-ace4-ba57daa0e9f5", "5eb6739c-bf4a-4707-b49e-50870f38bc5f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntrials.  The new joint venture will really also aim at accelerati ng drug development and increasing availability and \naccess to clinical trials for community oncology providers and patients, including those patients in underserved \ncommunities.  \n \n This transaction enhances our proposition to biopharma companies and further advances our differentiated \nofferings across the entire pharmaceutical lifecycle. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0ab9ad12-4584-49fb-9fe3-fb3ed3d429aa": {"node_ids": ["828bcf49-3c8f-4eb8-99b6-3b811d87ec7e", "9683624b-4fec-4f16-88e0-da107bce3540", "5fb117ce-5126-480c-9022-a36eb13d954e", "09d53872-5256-47f5-b048-c7ef6bf74d70", "9eaba3b9-009d-4cce-b7b1-12eccdcdb052", "fe4af4a8-24db-456b-81d8-61fdd1fdae34", "05e95049-ed59-486f-a7e6-44cea189deab", "622434c9-071e-4ff9-aa2b-da3b4230aea7", "47e0b962-1ff1-4969-a911-4db2cba6f4be", "297848d1-8949-4952-808c-65a70d8ed085", "0dbe34db-b60a-42d5-bf46-a053eb10be66", "d4dfa8ed-5f14-411e-b586-46e2b512f948", "a77c429a-ba69-4a81-994c-8ccb146bbfa5", "e8685035-4f3f-41ac-a5a1-43418f5aa75e", "fcc51e60-cc80-4d48-b946-a790aa65938a", "ab097267-e0b3-4830-8467-6405848d9600", "d8b07528-d3a7-4fe1-b182-404cf9a42398", "836a9f1d-fe94-4d59-8585-5e5b86007088", "117fc85c-f11a-4c3f-9519-3e20486cbfd0", "278d2b06-10e4-4389-b25e-348cfbbb28d1", "dcb91b59-3e23-4a17-b475-c8f52ad7a3ab", "f5025615-6ff1-4be4-b5be-68c0c57a9975", "790d32c0-a7c5-4250-bb1f-c80f44129cff", "7fad3459-1921-4838-8d6c-02b1d09bde6c", "38d98624-dd10-4f13-b0da-b0080978e474", "cd59befa-21b0-4735-8786-09c9cd8b29cb", "c7d47f5d-ba6e-4777-9a5a-a4c88896eb95", "c3b452bc-227b-4dea-b57c-5bb7b75045ea"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nhas an e xpected close in the second half of our fiscal 2023.  Norway really remains the only country that we have \nnot yet announced an agreement to sell.  \n \n So now, one year after we announced McKesson's strategic intent to exit the European region, we've entered int o \nagreements to sell or we have complete divestitures of the business operations in 11 of the 12 countries in \nEurope. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b2e413e6-6b77-4793-bed9-63c6fcdb07dd": {"node_ids": ["9f2aa3e8-3e65-4e17-9207-e3bc2c298fc8", "e734cdfa-1023-4e61-8af1-13e8d1c442be", "b8247678-97a0-4131-ac6b-3e54d9b0f0f2", "e2b8040e-9f23-4302-acc3-dae612791244", "46e48568-a4b0-43f2-9ba3-0773c11c520f", "b034b5e0-870f-4ac9-b6f5-7ce038427953", "59c9c593-2b1a-4576-b8b2-972b04762429", "235b920b-2d50-48dc-a44f-be7d700bb772", "699c2272-1739-4cfd-bbdb-fcaa7b650556", "5986007f-b30c-4e11-880d-1d7ac8581cb2", "4b4deed6-de40-4e1d-a4bd-1e55e7b162b0", "1f7e3cc9-4ccd-468e-997b-b6176907d07b", "bccbeeb9-17fb-4022-ae6f-98b74369c773", "6d1d55f3-dfee-414e-884e-f2299638372f", "26265ea8-e69b-4e6d-9383-4611c27120fa", "c10f8c20-f4d4-474e-a917-ecb9eeff97e9", "ebe7f705-527b-421b-8d3f-0caf05317b60", "612fc3a8-afb1-4675-a25c-c66a0c8c1510", "79ca684a-7c3d-4f50-bed5-a61dc90ff398", "65b7502b-036d-46f7-a832-84ad3be1086a", "59ff8e31-a4f7-48b1-912b-5198e4f3e73e", "277644bc-5d78-4391-979b-90f89aa3c32c", "f09b6d7b-16cb-4fb9-9034-7b861fb31d25", "ff858c9f-ecb4-4584-86ab-0525c7273aff", "d04067ce-1aff-4a6a-9726-1019a9b4a05c", "1256cb6e-bb0e-44da-86d5-5a2a3186f545", "e6de39b9-d334-42d4-9164-72259947c89e", "fc1c4220-7f1e-4715-8e64-ee7d7918840e", "1a0ce581-819b-43a9-a2a2-0c4cd91e4710", "19ac5f6d-f606-418b-a870-68adf754ea4d", "7a3ebcac-9b94-42cd-a516-221d8f33eb81"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nto the pressu res from cost inflation and supply chain disruption.  The impact from these macroeconomic factors \nwas immaterial in Q1, and we do not anticipate any incremental impact in addition to what was already \ncontemplated in our fiscal 2023 outlook.  \n \n We remain confi dent in our ability to navigate a dynamic economic environment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "acdd98c6-6563-4a6e-b066-86f581f11c88": {"node_ids": ["1899a560-4162-4a44-98f7-cb46072067f5", "2cb24a6d-3b71-4b91-b4d2-bc6e13d914a6", "9892b113-5b2d-407a-a55a-c1b8d8151464", "82156ea0-0724-4dd8-8422-e993de036909", "acc14f00-422f-4934-ae8a-6ed026c6f38f", "a1d3e2e4-9adc-4b2e-a844-1c0f72d06ee5", "f742c09d-4812-435a-8e9b-acccbdfa3c15", "e6eebea9-638e-409d-886d-68725f159695", "75d5c319-ce35-4fee-9c2e-ae1e32ede272", "f10a455d-7792-486f-b65b-0b4f8d5bd831", "c627d022-4964-4c72-a9b4-a37048394f38", "da845238-27c1-456e-89d6-e3dec2cf38e9", "7acd228b-f625-43f5-9521-f954c691a534", "b6756821-2c34-449b-a6f2-6ccb5cdb43bf", "6bf47647-ee3d-4d88-80f6-0aaec72b1991", "70a9bf8e-6e3a-4d96-859e-b0c224a8400d", "3b2a8a11-1844-4e40-99ae-d630baa9c981", "e393ee25-ac0b-48cd-9aa4-add91df17604", "524a8b8d-2afa-41bf-98c3-9581ad5e4800", "37fa92ce-943a-45ef-8c6c-a89d901819ab", "8778d622-64dc-420a-8558-db6b9df538fe", "dfc10eb1-252f-436a-baa5-6026d39e4b2a", "937b3715-4164-44d6-83a0-542ffb9a3f05"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ndedication and the execution from each and every one of our employ ees that's driving McKesson forward and \nultimately helping advance health outcomes for all.  \n \n With that, Britt, why don't you provide some additional color and comments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c29eaffd-9ce2-4a6e-b2b4-58b8bf567fa4": {"node_ids": ["9f2b410a-b583-4eb1-ada4-38f690166acd", "b2a12234-ff10-4715-9e93-e682a8019f96", "a8a35de9-ecf4-4e4a-960d-cb8a24669ca6", "efce78af-7fbe-4f52-b86d-5326fff03f29", "845d4e4f-72cb-4b19-813b-e0b6df9cb377", "0d7a094f-1ef7-4fb1-86cf-29dfb09fad97", "435d3427-9414-49d2-a646-a4ca1853d51d", "197fca61-c016-4809-b584-5b63291c9e86", "57ab07d1-cad1-4552-bde7-729c07500c6c", "216de203-dc90-402c-9045-57c1be875ffb", "f0950528-60c1-4172-a17c-fae3513f111b", "dfe07f87-6403-45fb-9ae0-080a27672c62", "2055d0d8-be83-41ff-a4de-1b0f0aa5e6fb", "4d19dcd6-46e5-4217-af45-ef122418c549", "a77dc1f1-6b0f-4562-8837-bd27d8814d45", "0f563057-2ded-48e7-8892-0339e4355ef3", "34dbd582-5ad7-4716-8417-7ed83bbf7acb", "7a8b53c3-3d2f-40b6-99fa-b25c0be218b8", "b5f3ec4f-e172-408f-9de5-c2476d3b3034", "8a539cf1-12ee-4a83-9693-309d5cd4ad5c", "7c9c3f27-fcdf-469b-9510-1ba20b63f70d", "1a5f685e-083d-4bcc-b5ad-869205e48092", "50e4a36f-8cb7-482f-bfa0-01ff9a483b45", "73fa310e-a499-4926-af74-ad9456ea9f46"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThe combination of these assets complements our existing operations.  It aligns to our strategic growth pr iorities, \nand it supports our vision to improve care in every setting.  The transaction is anticipated to close by the end of \ncalendar year 2022, again subject to regulatory review and approval. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4172e64c-6c9d-43e6-a300-086d5a0a0209": {"node_ids": ["7a57d1ad-16b3-435d-a8e5-44d22bc493b0", "1b635ece-64a4-4ccc-be95-17e1ef3d557d", "dc1afb08-5ede-484b-be20-202066a03e9f", "f627ce10-2aef-42ba-8773-a4d994248e50", "85dc9ee2-c492-430a-852a-d1d07364954e", "7bc9011e-2767-4063-b7d8-144b98bb2830", "0eb1a97f-c35f-4628-a3ff-416e5d27d779", "980d3633-9b27-42ef-bc6d-f99e2db6b61c", "b332e1a4-83a6-40d0-b5d2-1b7688189df3", "e5adc672-7b0b-4972-8f9e-7c8305828ff9", "66485863-969c-47e2-8375-b8718ce44dc5", "5447f708-183d-4d94-91aa-99be4622ef48", "417c575b-c7a6-42e0-9e61-5e5a195aa80c", "3eb3a48b-63c0-45e0-80ca-b1a547c70ca3", "690b3f22-014b-4d1a-8174-ffd7185765bc", "61f5eab5-5a05-4af7-bb3e-4f5b6f29870d", "c1426518-3dea-4330-a19b-221685f7266b", "ccca91bd-e7dc-43e4-93d8-4ba89dd55254", "d53254db-f586-4b7d-8ef5-3631c4da16c4", "2fb9c586-798d-49de-b2c0-557974056f1c", "49b8cc77-f0d6-4417-bda7-b4ec623cfedf", "f235ed21-b917-4ca0-a240-c385fd7d8c4d", "4be4d90d-dc0c-4576-87f6-8208c3d8a83b", "2a0bc333-4464-4171-9203-c1cc04b9e2b3", "4c85e7fe-3225-490b-9473-1b12a55070d9", "14adc5c5-3bbf-43d3-b9a1-0b8095bf8bdc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nThe contribution from our contract with the US government for COVID -19 vaccine distribution provided a benefit \nof approximately $0.18 per share in the quarter , which is compared to $0.30 per share in the first quarter of fiscal \n2022.  Excluding the impact of COVID -19 vaccine distribution, the US Pharmaceutical segment delivered \noperating profit growth of 9%.  Results in the quarter benefited in the timing of gene ric launches and the improved \nperformance of Ontada.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b2cef74e-6340-49bb-bb57-2c460dfee5d1": {"node_ids": ["b8593620-175d-46c7-b052-d9bba51cda99", "a01c12b1-5b24-445f-93e0-9b826509fe71", "6f3fb6f5-9371-4b43-bf66-53adacdc2141", "00c2e69a-06f7-4b7e-8058-460d02ad1d69", "523b0679-382e-478f-ab8d-4f7e747debfe", "b4567667-42bf-4253-977d-a89361b32779", "32e21420-d87e-42d6-971f-577b8bb50c09", "970f9052-0018-48af-9d56-f0bf1b685ecc", "eeffcac5-8152-4d5e-87c8-b1540ea5a7f6", "146d4ba3-43d7-4e50-a6bc-2b7bcf518407", "a3c5fc2d-f79a-4927-8fe5-81c192b8f536", "e48558a8-a525-479a-826f-7f72caf61724", "cd312b3d-55a7-4bab-9243-ea38382edcae", "3fb1dbc8-286c-405e-ae01-533851687a57", "9248b214-925e-4c61-9ff8-fbf5458be95c", "eb2b454d-0217-4d2c-9e3c-d46436320a85", "3bcfbcb4-b014-41d5-b62f-87da7b78fe47", "166eb00b-1774-40a9-99da-54ac0de7b175", "804e60d5-d078-4cfc-8d77-66c10d68e695", "7b15a076-a877-4923-867e-63f1bd864feb", "ed323203-a3b6-4f1a-afff-3a7381e17bff", "08fbcc77-8224-496d-baef-8aa3f7f12dfd", "bc0ef75d-53ca-4c21-a065-8fe084813e6b", "f8e13406-93bd-4639-bb02-2bebbc45b681", "19892139-7960-4077-baf8-ceabcc8f48b9", "f7613544-cea7-4715-b080-01f56703a754", "31c1776c-c4f7-4d5a-9ae6-c484e5f941c2"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a reminder, the impacts on our consolidated results can be influenced by the performance of each individual \ninvestment quarter -to-quarter, and as a result, McKesson's investments may result in gains or losses, the timing \nand magnitude of which can vary for each investment.  It's difficult to predict when gains or losses on McKesson \nVentures' portfolio companies may occur, and therefore our practice has been and will continue to not include \nMcKesson Ventures' portfolio estim ates in our guidance.  \n \n Let me turn to our cash position, which can be found on slide 13. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8bf0574c-99ab-424e-be71-b964b648c234": {"node_ids": ["9850b72b-0794-401c-89d0-bd810ed8df27", "f6fd67a6-b87c-4b62-b6fb-f44de75a50e0", "cb124faa-ea1d-4ab2-ba40-bd52cbfa1aff", "c557e8e1-ec14-49dc-b4f5-b40c25a25f55", "70a1ebe0-7b7f-4b9e-8183-c7e2a37eb66d", "2a12a8bf-26dd-4195-b4f5-bdeb70defb5f", "ab579a46-c3bc-4ecc-a6ff-4b2ad76e4434", "0e852c05-30b3-43d0-86fa-5be7100ada2a", "942b9948-d9af-4b7a-a3bf-4fc9f0a852bd", "2ae8b5c8-09c8-42ee-b627-a769fbd82da7", "4fd7a4e6-9c78-4024-8006-75d281692e33", "e199973e-1dbb-44ea-ac15-97ed694d8347", "9ee7474a-9bd1-4514-aa67-cd3304211d29", "cd55764a-041f-43ea-8f17-efcadc6b3c5a", "d29805d5-d2f8-48aa-960d-279c69cccdc6", "cc7e915d-9dda-47c3-97dd-a6d1325e2817", "7035cf63-5521-42ed-8fc3-c6dc93393c05", "2744b4a5-8d83-4d52-8259-97e16346baaa", "93170ee9-a5a9-45d3-b9d3-90c10467f574", "a0054d63-b886-4feb-b2bf-d88ecfb9fad8", "58e3e786-db30-44a1-a374-eb9d1ad38690", "f5005bc8-ca98-4127-9c77-d6c3e235a943"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nancillary supplies, we are increasing our guidance range for fiscal 2023 to $23.95 to $24.65 from the previous \nrange of $22.90 to $23.60 .  Our fiscal 2023 outlook aligns with the previously communicated long term growth \ntargets, and it demonstrates the commitment to deliver sustainable growth.  \n \n Our revised guidance also includes $0.99 to $1.29 of contribution attributable to the following i tems. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4518dd85-3f7a-4adc-82f3-27f0920d1a72": {"node_ids": ["dc408fa4-995a-48ea-9dc1-1edf55b8ab1b", "09b6a146-042b-41e6-801c-7e792863f9a2", "9f06e1a8-38d3-4e57-a9d0-dd859cea4efe", "7777f1de-81bf-4826-9e5f-44e3fadc84f0", "1e3ae12f-aead-488b-a9dd-7c758e9fb722", "ee887a18-9f61-4f7d-96e4-eff26a04aaae", "37d762d6-8108-4713-a191-9594bfd66277", "337e1084-22a3-4ee4-85dc-a80f60fd2cfe", "83a6836a-35d2-4237-8bdd-8c25d3f529e7", "afb3ef58-2193-409d-b12e-eb01ce794458", "498bccfa-a0c4-4dd1-b304-36200d51308e", "7e35adc5-f39b-46cb-9d22-7a4fe04106bb", "0c062b31-292f-4ec1-811d-cd5831816429", "7d7cbd65-0e68-4425-b4cc-186b6313d676", "a27aec26-3409-4531-8434-b7db57f94d8e", "0a2e21b7-9321-4ec4-97e4-b92c5104f322", "fcad8b29-0bac-4c0f-8be7-a5b38b15198f", "00c31910-950f-4573-bfac-1620b959b963", "3b659ebc-fe60-4fb3-9c2e-f2a26482f027", "6f3a0bef-cfc3-4349-8cd5-5586b86c5aa2", "9e940f77-4cdb-4e9d-af08-c42913b4c402", "9d442ae9-aba3-40aa-8f86-ee746b18780f", "51ee0bb6-79e7-43b2-b10f-7d9d8198bc44", "a97add94-b04b-4f0b-82ca-e3a68212611a", "36503a7a-bab1-4a4c-a8a0-e9489f5b2e91", "865bedc4-f651-4ec9-a5ac-4876e327ad38", "b10d6782-6bc7-40c0-a105-ef39e8848f98", "f7e13ccb-0ecb-4384-b1f8-f8088f1098b7", "dc5f88ec-1b59-48ce-b7f8-3ab8fcbb8fc7", "72d2ac53-2929-48b5-8963-0263132097de", "99050864-04fa-490e-97c1-5ba332e92ea8", "5cb2097f-2350-401c-97c1-39544deb0ad2", "532e37d8-65ab-467f-9edd-5994d2efbde2", "cec87931-ab96-477e-a156-69996a26d650"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAs a result of the share repurchase activity, we estimate weighted average diluted shares outstanding for fiscal \n2023 to be in the range of approximately 142 million to 144 million.  \n \n To wrap up, we are pleased with our solid start to the fiscal year.  We continue to deliver on our growth strategy as \na diversified healthcare services company. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "91497534-9f73-495e-8234-8857f0469491": {"node_ids": ["874237ae-64c3-4f86-9ce3-cce31348227f", "2908f896-0327-453c-8a2b-b4a9a38161a2", "89219999-aca7-4332-8f1d-d43a2821ed14", "250e6ca2-200a-4e20-b10c-63e08b3f632f", "32be5c8a-da6b-4a6e-a7dd-d8129a091024", "83042ad9-ddd8-4693-9338-77c5caf91e5a", "ad680dcb-5766-46ca-a5c1-b7dde3a9532f", "e064b09c-1dd9-4e7b-9ab2-2279e8b83381", "50514a46-142a-4b44-b1b8-cdc814b9e50a", "8406f484-1ca4-445e-9dbc-402b3ba607bd", "4efb4c2b-8318-47ff-872d-55d01ea39f28", "238b2569-729e-4fc5-ae1a-ce04afaf2673", "24c3ab10-00b7-4eab-b139-1bbbbadd049e", "55dde3ff-aacf-4dc8-9069-369e76a9e056", "b2a46f91-3662-4d01-8896-5fea931d9924", "b17a52e6-67e4-47a5-b257-5a3d5cd3c492", "424422c0-ce30-4521-81eb-8dab3e5632b8", "f73b5f4d-2e72-46f7-92ed-133fa5aee23f", "de00843a-66c2-4398-9f0b-aa49c7b1cb5d", "09209a84-99b6-4de4-99f9-410c2a765054", "39a35fde-471e-483c-aad1-2404c4b5181b", "f81bbbf2-e23f-47d4-9347-caa9c9ef659d", "ed0ce3c0-0617-4235-bb38-66a57bb126a7", "25903631-0a63-4213-90ea-4d072bae1002", "2b9d3203-bb73-4411-9c02-9742d7c7a02d", "18b1a0d5-136c-4a8a-95fd-a05e67a9bee1", "ef7447d0-5423-4d6b-b33d-abe6ca1c83a2", "58574996-bef0-444b-aefd-cbee74381dab", "d00eaa23-b6c5-4293-b4c6-53f133254204"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvest or Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fe3783d2-e8d9-41fe-b45f-e75b0ec037d9": {"node_ids": ["f12ec521-5665-4e3b-b506-16844f65d8ea", "1a208041-4887-42a4-973f-c69a8ed78ed5", "27cffdc3-e870-437e-87e9-caa620db432e", "36c02981-8e3c-4e93-86ed-b913d811c0d1", "c8a28949-f56f-4ace-ac6a-a0b9e8c0afa7", "4bb3a59c-2f17-4c67-b5db-cf3ec273da8b", "4715729c-111e-4945-bd8a-3e244b5eec98", "7c62002f-108f-4cf7-910b-953210f6e2e4", "7aee6925-f296-4237-991d-8c530599cb64", "a3dc2fc9-e16f-4522-ac6e-8711f48db93a", "e59e2adb-f0ae-47d0-b634-587d5c622fff", "54f07a9b-bd27-48c4-9913-88a63e527d39", "8cb72f2b-0a05-42e2-94bf-b18f92e29a1e", "75129aca-16eb-4ddd-81a9-9db3f309153f", "047a2b80-2744-4f07-b274-7f91862e3450", "e35bad2a-58d1-438c-9668-4ef2e71612fe", "ee718048-2442-4506-a218-40325ec0af73", "c7d22337-2e04-4326-9018-b9d3091f87a6", "3883e3bb-ced0-4e5a-83e0-5c89fd48dd09", "2c15df65-7aad-4c24-abe9-7f56468041f5", "f8e3c233-9d8f-42ae-a506-b5d72c4e3d1b", "f986e258-fbce-4d60-9e47-c10765ba513f", "32b7315a-a679-49a6-a8e0-141cf8fc5081", "ad041167-1cce-42ed-9f04-21bf9559b536"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nHey, Steven, thanks for the question.  So what we tried to do with that slide is give you the progression, excluding \nsome of the things that we're working through here. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0756e478-fc2c-4319-af5b-383d053c9f26": {"node_ids": ["55ed0b93-f0fe-4b14-90e1-302ff8319b66", "982d19ee-ea81-49a9-a0e5-ac03a5aa7ec9", "adfabef2-fc79-4884-a5d8-12e7903cb5ef", "6eb30b5e-e3c5-40f6-aaf0-b81ac347f729", "a383c03f-bbd9-4f0f-9b22-dd999a5f7969", "b64e020e-cb3e-4909-92e6-23484bb2e49f", "e893593f-f495-4efa-883c-9a91ceec9f07", "9ceea00b-e3ff-4379-9ab9-25f965bcb4e5", "6c3fb57a-1172-4311-b228-ce68fc8e71c7", "cfea3d2f-134d-42f0-83c9-973485af88a7", "09c35a12-1648-48b1-807c-e1a518dc0846", "3232c6bb-3720-49c0-a7a1-84f16e517da8", "4c227e76-536f-42cc-a7d4-6aca10ecbc14", "7fc7cadc-653f-4598-b139-5c17a13d5917", "0f79930d-2662-4d50-b442-fd91f77a66e1", "253620cf-25d7-474b-957b-43be6be68fea", "24968584-4068-42ea-9706-6ca75812f6d8", "05f0fe20-a836-4242-b138-59a06e44ed75", "9879f195-fc95-4647-b260-a239429de9a5", "1f238d41-7a2a-40ec-8a4e-659903a1dd1f", "3b998fc6-4320-421e-ad60-96f62a0d5131", "cca11ec7-9295-4c94-afa1-c08d2685e3d8", "1fb3d9ba-5d6b-4ad6-8e00-ded695865538", "e64df7cc-039f-41ef-ad26-11ddd943ed96", "d705a731-282a-4c64-90bd-3cd8a9b02d0e", "cfcbade4-0043-4233-89e8-479d16a2e4c4", "81ab3ced-249e-4df5-97fe-3756134a7bdc", "452efd88-f1b9-489c-ba51-2ea08021180f", "05b8dd6b-5122-4ee1-a652-2e07e4421d1a", "29c4a902-1cd5-4da5-9170-b31f483af96f", "541d8724-6576-4652-8d03-a87f3b93d257", "0ea841ba-11ef-4e60-a8f7-1459f2c74e2f", "76d4c230-924f-4057-9b76-a675c050ea4f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I think, as it relates to the vaccine, the vaccines themselves, those continue to run through the \ncentralized government model. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "3ea74283-efb4-4b1c-af58-756548490b1d": {"node_ids": ["db068485-9980-4cae-b9d1-3849d6291af3", "3d5ff84e-6ed7-45f6-a979-312da79a2730", "b3a30358-6dd0-4ebb-ab93-e215cea18152", "49fc7e99-248f-4fbf-b0bb-3eeaeca54635", "6e91f949-33a0-47e9-88aa-930923cb992c", "21a34a14-841a-4901-b5ff-22fcd7f48c7c", "d5eb3be2-53ca-4cd9-84d9-8f8561916056", "958d3dd2-0bdc-4c84-8a61-ee685b03ac37", "025da32a-d485-498a-b11b-1b4c1fe13d36", "b0383caf-7345-4df7-9889-380e8fef3df6", "b0a95acf-24c1-4c94-b3d5-a7040067d1e4", "575342f9-635d-4be5-aa23-14b87d38d3d4", "4d64dfb9-373e-48df-9bef-3d4b33b73a9a", "72130b12-70ab-4032-bcd3-fa22e249083e", "798314a9-d05b-4ba5-9ea0-9d9757afa945", "14396577-8bc9-4fbe-b0ba-c6cc0b577bec", "eb99d49b-52dd-491c-a508-87bfbfa0f931", "d885caaf-dac7-4ce4-ba30-7c7612c68f1a", "8da5ad0a-a796-4fca-913c-5544a97fb028", "a6fe85b0-4f15-41e7-9e4d-21f2e2fc3e0e", "8d0601a6-5274-4f5c-9be0-2caeeea67129", "5b61c3a2-978a-477e-8536-43005467df83", "0b1d4ada-a13e-48fc-bcb6-2e8149624779", "ae117dd3-8e67-4d11-8af6-3577b3394ffc", "3795d9cc-4468-4dd5-83c9-b28b30584f1c", "f584a46c-6dd2-4a2d-90f7-4627657ae5ab", "74dab664-dbef-4c04-a317-37a48919990c", "68b834d9-bb9b-4886-9d17-017d414c9575", "24d89fd9-1976-428f-9f05-96f7f1baf912", "0c40338f-315c-4122-b347-22b9ae435bcf", "1a6483b5-4569-463a-b368-3429b70a4038", "c11f9324-2f11-4b9e-88da-3be7bd270c42", "eb949474-6db1-46dc-8906-b9127d2abfd2", "efa6d016-9707-45bc-b266-e52d835a0bf5", "365eb388-026f-456b-9751-0d3252f12268", "072001cd-493b-4ae5-a2be-9bd8d26a2efa"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd then, Ricky, just relative to the distribution of the vaccine itself, I mean, I guess probably best to just  stick to \nthe facts.  We've extended the US government agreement to July of 2023, so to the extent the US government \ncontinues to acquire vaccines and make them available to the public, we will be there, the centralized distributor \nof those vaccines.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "690e83c5-e702-4f38-b4b1-8ffa91f10184": {"node_ids": ["d7745062-43d7-4bbe-bcf9-05d1016992e2", "c2364da4-bb29-47bd-9fb2-e6808f107d3c", "7db0e6b0-9018-4b73-b7fb-ccf0b5298117", "6aad361b-c4ab-47c2-8728-422f1edd33eb", "199dac59-8dfd-4495-b6db-c3ce80f0aaa5", "1447ddd6-0338-4cec-8ea0-a75d69f6c2c6", "111684b4-c497-42d6-80b5-5fd15e7dba3c", "8f4aaa66-fe09-4df9-831d-00993e460428", "2e6231ed-d8da-4cc5-bf24-1029339827b9", "6560cb30-2760-4880-8615-c411cdef42cb", "bed7e969-1f4b-4927-97df-4d2d8fcd13c3", "11cb590a-4709-4722-ad58-99f58d32ea9f", "b9351c92-e520-46ac-9102-08a459e58a24", "cff05a4d-2212-4243-a6f2-7db9871d65e6", "c6b1ef8d-0def-4929-8459-e9d8e6a2e194", "396cdcfe-f7ff-4645-8ca5-fe61c805b83e", "564165c3-9478-485c-8cb3-5fcfa6a73b0c", "bb5eaba2-d061-4574-a521-a3a34f422f67", "8a8249ab-aa78-491a-a4ce-6821ba3ee5c7", "7321422d-2d6e-4ea7-9518-a587a199931f", "2e850790-a896-47ee-bfaa-6922d908cbdb", "df38b331-6406-4701-9ebf-b3057d673bff", "ede6c87f-fd9f-46cc-b911-d9ee750c20e5", "f1dea752-a732-4864-8e70-300f3b3b041a", "7fdd39e7-0b82-42c8-b526-a35b1123c9d6", "f66588c1-3207-456b-9a05-2fe111ba688c", "daee8b5b-7390-4f4e-9374-47bee6515772", "fcaedbc5-4cf7-4052-95a7-c3331455ac78", "6fe1eb9e-0fcb-46f2-8adb-8c934a59e47c", "a967c22f-0802-4331-811b-3fc317305b32", "860abcc1-2130-4c84-9087-b9246700b15a", "14b521f0-a224-45ad-bedd-b75a490a8495", "387d87c5-b879-478e-a637-bb6d724a6ad5", "5881f5e2-2e34-476c-9cf3-6bc59fc35d68", "d8bec91b-9513-430c-9d8f-35ce3f4d8c4f", "3fcfbe1c-94be-4028-bd6c-3182f2447003", "f8bdf535-169a-40ae-90bc-dcf3fd30b7c3"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nflu sales in the quarter.  That was a part of the upside from medical in the first quarter, but overall, it's the primary \ncare business continuing to be quite robust and strong.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a1b4582b-0316-4241-bbf8-f08c2e2dc26a": {"node_ids": ["bd2f80b5-8506-436f-aa99-6d0980bee0ad", "9f3425e5-1503-43b0-9bb7-cf90a13cb0c0", "9febf9b0-10cc-4bda-942b-cbe7f1fccff7", "e75d737c-eb85-4a67-b088-6dac5a057775", "4f6596c0-3509-47a2-904a-106f888325a6", "b0e76304-23bd-41e4-a2cd-29730b0dae13", "eb70b871-2c25-4f3f-a920-227c43c4d404", "60a551fb-28c3-4819-88d6-bf36073c715b", "d9648df9-7289-4b1e-94a8-014f567ed508", "ff23e906-603e-4704-810e-7bf40f95b091", "31208c53-ad50-48c8-8750-2091cd789c2c", "95747fac-5bf5-44e1-947a-6bd677a3325e", "e00ec034-b256-47b4-8ae3-08bec3d0b376", "d5443a84-fb97-4ceb-95ee-35cd1ac5ea8c", "c55a7763-4a39-4d0d-a869-ba239b2dc89b", "3c928566-1139-4ef3-b738-74df3b0e0601", "2f9d9284-e03c-43f9-93ce-f7a5814c80bf", "b6f1b965-a615-418a-b9fa-ec6f509da753", "81de230e-67a6-4a7a-bef2-6bdb62a01019", "3f6515e9-ff0a-4c74-ab5f-52618b45d4ba", "a461b597-b15c-446b-b237-491e89d9ef0e", "b8b6b8da-4b0f-4a6b-a7c6-73b6ef1b030f", "24a0928a-e58f-469c-b6db-f0940086196c", "3acd5945-1f17-4b8b-9378-28701c9540f6", "776ee46f-569e-4ca5-8094-400f8cd40e49", "f9af32a6-223a-4e7f-8a52-83dd516da29a", "087fe0ac-52cd-44a7-9cf3-c0b26e635d28", "c6ed249a-f2fd-4820-8340-17665559fdba", "50844bd4-c826-478a-bdd2-4ec1aa34b25c", "09f29c23-bf45-49c8-bfbb-fcc910b90dee", "a4e5f6d8-ce82-4d19-a22a-0bc850d4e396", "998c2a0f-f7d6-4b4b-8320-fe3fb09d8729", "68ca4f84-708c-4b94-be87-04fbc2133e65"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Charles Rhyee with Cowen.  \n ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "68597756-0004-4e4a-ac4a-afcaac0dccf6": {"node_ids": ["d07af774-624c-4fd1-9814-23c8e2885d61", "d0a67f7f-3301-4d06-b5a5-fbd6b91fb76a", "55f735b3-f8e0-43f3-a48c-6251319179b5", "221479d8-3d82-4fc9-b3dd-2ecc026d9e9e", "672851b2-1ef4-464c-97fd-febf61a3a3b8", "d2816714-a8d1-49fb-b6bc-ad04b833266d", "e8e653d0-98b0-4b23-a5b1-a9b1c160268e", "83d5ccc0-1c04-48bb-b965-ae202b79b888", "a1fe66d9-9751-48e2-84a1-5c55207b2e17", "1a6bd073-8834-432a-ad3c-71f24edaf0e5", "478dfa71-6906-4a7b-aff5-56a8c7efd476", "2275b3c3-ce90-40fa-bc20-07655cb2710d", "0f964c73-514b-420e-a97d-a65e0a9e135a", "52ae7650-4553-430d-a4bf-ff869250ad5a", "568954f7-f269-41a0-a084-fdaf5d1e6dcf", "109b9966-6f40-404d-a8f6-e43e2a2483bf", "ca82a319-7acb-4259-9ebb-3c3d2c34f51b", "f1f45da3-dbf9-468e-80ab-4bd466e26c00", "171dca37-abd8-44a0-97a3-1000be3bb074", "1f150d0a-8140-4927-8138-e03bf163172e", "a6d4c0be-5393-40b6-a272-2d15ff1e2bd0", "73bc9066-0a72-4441-864e-c440f05a803e", "b174f473-1213-45c0-b2ac-27ce5823cc7b", "1ac23be5-0691-47d9-b088-097430717704", "baac0b91-843a-4994-a520-25f504c91cf0", "54bd953c-3b4f-428a-9397-01cda48e94b1", "befa35d5-b0ca-4885-80ae-de55c7d0e32e", "01ff1200-a053-4f82-ba34-f0026995028f", "b941731c-1af4-4a5c-a3c7-eb4184993ff8", "2749ece6-977c-43db-9c95-1e5e2aff33e2", "5da79e79-36d5-44d7-9f05-ac256a1bd5bb"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "473fdb53-3cb8-4ae1-94b3-659842909edd": {"node_ids": ["8d430f65-b1d6-4684-a33e-d8c8282a3389", "e86fe58a-1d5c-46db-b4a5-df6ceb10bedf", "098e8225-81bd-4d13-8cf6-e6e41319659c", "f289b4f9-6fc4-460a-8231-dc5eb450a973", "32beb916-24ba-4b50-86f4-6cd08bbfad93", "680ee8a4-7c2a-464e-a4f7-1afc99e822e7", "926ffa77-8d28-43c8-b4bd-ee8e1138fa1b", "1c1c48a9-31cd-4651-8b3e-1801abed0bb6", "3bff86f8-8b8c-4095-b1ec-ec542ab75298", "e9c5f4fb-69d0-48f7-9fc6-b3c532ae8276", "ea15c294-c572-47c3-9470-2d9e0ec7bbb6", "20f3c70f-36ae-4b9b-986a-c4845235b0e5", "cf6672a9-267d-4204-82fe-8ca4666954ef", "fc57bfb7-50db-4070-871e-06afee1ebb56"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2023 Earnings Call  Corrected Transcript  \n03-Aug-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of a ny \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 370116, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}